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ABSTRACT 
Cutaneous squamous cell carcinoma (cSCC) is an extremely common skin cancer with 
metastatic spread indicated in up to 5 % of cases. Despite cSCC being a significant health 
burden in Australia, the molecular mechanisms underlying metastasis are still largely 
unknown and, consequently, treatment strategies are sub-optimal. Current clinical tools fail to 
adequately stratify a patient’s risk of metastatic disease, and disfiguring surgery and painful 
radiotherapy remain the primary treatment options. Advances in research on metastatic cSCC 
have been slow, partly due to the lack of high-fidelity in vitro models. Due to this, the use of 
contemporary therapies has been limited to small clinical trials and based on efficacy in other 
cancers rather than empirical evidence in cSCC. As a result, no targeted therapies or 
predictive tools for metastatic cSCC (or even high-risk primary cSCC) have yet been fully 
realised. 
This PhD project sought to establish novel patient-derived cell cultures of metastatic cSCC 
and to use these, along with clinical specimens, to help elucidate the unique biological 
properties and drug sensitivities of metastatic cSCC. 
Following numerous attempts, two long-term patient-derived cell cultures (PDCCs) were 
established from lymph node metastases of cSCC and proven to be tumourigenic in mice, 
UW-CSCC1 and UW-CSCC2. A radio-insensitive strain of one was also produced, UW-
CSCC1-R. Extensive genotypic and phenotypic validation was performed on these PDCCs to 
confirm their suitability as models of disease. It was found that, despite downregulation of 
certain pathways and some copy number alterations, little genotypic and phenotypic drift had 
occurred (except for UW-CSCC1-R), particularly for genes of etiological importance. The 
optimal conditions for 2D and 3D experimentation of these PDCCs were also developed. 
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These PDCCs were used in association with clinical (normal skin, primary cSCC that never 
metastasised, primary cSCC that did metastasise, and lymph node metastatic cSCC) to 
identify candidate biomarkers and therapeutic targets. A set of gene lists were derived that 
may serve as the basis of a clinically relevant prognostic test to predict risk of metastasis or to 
guide therapeutic decisions. Of note, factors involved in cellular degradation (particularly via 
matrix metalloproteinases or urokinase plasminogen activation) and PI3K/AKT/mTOR 
signalling (e.g. MET and SRC) were upregulated in metastatic cSCC, representing potential 
biomarkers or therapeutic targets. 
A high-throughput drug screen of over 800 small molecules with known anti-cancer or kinase 
inhibiting effects were assessed using the PDCCs. The results of this assay have revealed a 
suite of efficacious compounds, capable of significantly inhibiting cell growth in this model. 
Potent compounds often targeted cytoskeletal signalling, DNA damage response, 
PI3K/AKT/mTOR signalling, and the cell cycle. The response of some of these compounds 
was also confirmed in a secondary screen, providing IC50 values. Compounds targeting 
PI3K/AKT signalling (e.g. PIK-75) and plasminogen activation (e.g. PAI-2) may prove to be 
of significant benefit in managing metastatic cSCC. Surprisingly, there was little response to 
EGFR or MET inhibitors despite upregulation of the relevant targets both in vitro and in vivo. 
A mechanism of downstream PI3K/AKT/mTOR activation via compensatory signalling of 
EGFR, MET, and SRC is proposed, thus explaining these results. 
In addition, the independent and synergistic effect of carboplatin, a nanoparticle (Tm2O3), and 
external beam radiotherapy were explored using the PDCCs. It was found that the triplet 
combination of these treatments produced a significantly greater overall reduction in 
clonogenic survival than any other combination of the treatments. These data serve as a 
potential representation of expected clinical outcome with combination chemo-radiotherapy in 
treating this disease. 
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In summary, this work has successfully developed reliable novel models of metastatic cSCC. 
These were used in association with clinical specimens to experimentally derive information 
regarding disease biology, including behavioural and molecular characteristics that could be 
exploited for the development of biomarkers or therapeutics to help control this disease.  
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CHAPTER 1: INTRODUCTION TO CUTANEOUS 
SQUAMOUS CELL CARCINOMA (CSCC) & CELL CULTURE 
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1.1 OVERVIEW OF CANCER AND METASTASIS 
Cancer is the term given to a malignant neoplasm/tumour and encompasses a broad group (> 
277 types) of diseases. Cancer arises via progressive genetic mutations resulting in a 
dysregulation of cell growth that ultimately outcompetes or destroys neighbouring tissue 
(Hassanpour and Dehghani, 2017). Specific types of cancer are classified according to their 
anatomical origin (i.e. tissue in which it appeared first) as well as their genetic and phenotypic 
makeup. Carcinogenesis (cancer formation) for every cancer type is established through a 
combination of dysregulated biological capabilities that have come to be known as the 
hallmarks of cancer through the work of Hanahan and Weinberg, (2011), as summarised in 
Figure 1.1. 
 
Figure 1.1 The hallmarks of cancer. Taken from Hanahan and Weinberg, (2011). 
The exact contribution of each of these hallmarks that drive tumour formation and growth can 
vary even between different tumours of the same cancer type. Each hallmark itself is 
underpinned by a plethora of intracellular regulatory oncogenic transformations that 
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culminate into the given capability (Sondka et al., 2018). 
The distant spread of a tumour (metastasis) is estimated to be responsible for approximately 
90 % of cancer deaths (Seyfried and Huysentruyt, 2013; Budczies et al., 2014; Lambert et al., 
2017). For this to occur, amongst the many processes required, cancer cells must undergo 
epithelial-mesenchymal transition (EMT), whereby numerous biological factors are altered, 
permitting the neoplastic cells to traverse tissue and the lymphatic/circulatory system in a 
mesenchymal-like fashion (Thiery, 2002). At the secondary site the cells can form a new 
tumour through a mesenchymal-epithelial transition (MET) (Thiery, 2002). This process is 
summarised in Figure 1.2. 
 
Figure 1.2 The metastatic cascade. Normal epithelium atop a basement membrane can become dysplastic 
through genetic mutation. Further genetic and epigenetic alterations lead to a carcinoma in situ, outlined by an 
intact basement membrane. Events including loss of cell adhesion molecules lead to a mesenchymal phenotype 
which, in association with the secretion of extracellular matrix (ECM) degrading components, allows for the 
dissemination of carcinoma cells through the basement membrane. The invading carcinoma intravasate into 
lymph or blood vessels where they are passively transported to a secondary location. At these secondary sites, 
the carcinoma cells extravasate and can remain as micrometastases, or they revert through a mesenchymal-
epithelial transition (MET), forming a macrometastasis. Taken from Thiery, (2002). 
Whilst much is known regarding key factors attributable to cancer metastasis in general 
(Hassanpour and Dehghani, 2017), critical details that define invasion with specific cancer 
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types remain the least understood aspect of cancer biology and remain an area of intense 
research (Lambert et al., 2017). Knowledge of the chain of events leading to a tumour and its 
metastasis to a secondary site can be applied to design therapies or refine diagnostics (Sondka 
et al., 2018). 
This chapter will first detail current understandings of a common skin cancer, cutaneous 
squamous cell carcinoma (cSCC), and its erratic metastatic propensity, with particular focus 
on aetiology, current therapies, and prognostic capabilities. Secondly, this chapter will 
provide an overview of cell and tissue culture as a tool for advancing diagnostics and 
therapeutics as it pertains to cSCC. This chapter will conclude with a detailing of the aims of 
this PhD project. 
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1.2 EPIDEMIOLOGY AND CLINICAL FEATURES OF CUTANEOUS 
SQUAMOUS CELL CARCINOMA (CSCC) 
1.2.1 Incidence 
Cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer 
(Vasconcelos et al., 2014), making up approximately 30 % of non-melanoma skin cancers 
(NMSCs), with the remaining 70 % of NMSCs attributed to basal cell carcinoma (BCC) and 
other rare skin cancers. An Australian survey from 2002 found the incidence of treated NMSC 
was more than five times the incidence of all other cancers combined (Staples et al., 2006). 
Notably, Australia has the highest rate of cSCC in the world (Australian Institute of Health 
and Welfare & Cancer Australia, 2008). Due to the overwhelming frequency of these cancers, 
they are now considered non-notifiable in Australia, meaning that collection of data into 
national registries, such as the Australian Cancer Database, is precluded for these diseases 
(Australian Institute of Health and Welfare, 2016). As a result, the absolute incidence of 
NMSC in Australia is simply unknown. 
The incidence of NMSC has been steadily increasing over the past few decades with 
incidence per 100,000 estimated to be 555 in 1985; 977 in 1990; 1,109  in 1995; 1,170 in 
2002, and 2,448 in 2011 (Perera et al., 2015). Assuming these more recent estimates and the 
30 % proportion of cSCC, the number of primary cSCC cases per year in Australia could be > 
180,000. Contrastingly, the age-adjusted incidence of NMSC for men and women in Finland 
in 1999 was approximately 6 and 4 per 100,000, respectively (Hannuksela-Svahn et al., 
1999). The increase in estimated incidence may be attributed to higher levels of sun exposure, 
tanning bed use, improved skin cancer detection, and the aging population (Hacker and 
Flowers, 1993; Marks, 1995; Veness et al., 2007; Yanofsky et al., 2011). 
This continued prevalence puts a further burden upon limited resources and the tightly 
budgeted Australian health care system (Doran et al., 2015). The lifetime economic cost of 
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NMSC cases in 2010 in New South Wales alone was estimated at AUD$365 million (Doran 
et al., 2015), making it one of the most expensive type of cancers to treat (Australian Institute 
of Health and Welfare, 2005). Both direct (health care resources) and indirect (sick leave, 
early retirement, premature mortality) costs were considered. This cost is estimated to have 
inflated further in the years since (Fransen et al., 2012), with more recent data suggesting 
$703 million in 2015. More than 2,500 treatments are performed each day in Australia, 
according to annual records of Medicare services used (Australian Institute of Health and 
Welfare, 2016). 
The likelihood of developing SCC is dependent upon exposure to risk factors and specific 
characteristics, such as age, skin type (particularly in Fitzpatrick types I and II), immune 
status, and ethnicity (Marks, 1995; Armstrong and Kricker, 2001; Ashford et al., 2017). As 
this cancer arises primarily from cumulative ultra-violet (UV) radiation damage to the skin, 
most affected individuals are older than 65 (Gray et al., 1997; Australian Institute of Health 
and Welfare, 2016; Garcovich et al., 2017). The incidence of cSCC for those over 80 years of 
age in north Queensland has been reported to be 12,082/100,000 (Buettner and Raasch, 1998). 
In all cases incidence was higher for men than women, likely due to environmental factors 
over biological predisposition. 
Global incidence of cSCC correlates with latitude and melanin composition, with those of 
fair-skin living closer to the equator at greater risk. The high levels of UV radiation 
penetrating Australia, paired with the predominantly Caucasian population, are the driving 
force behind national rates of all skin cancers. Undeniably those with the greatest frequency 
of cSCC are immunosuppressed individuals, especially in the context of organ transplant 
recipients (Brougham et al., 2012). These patients are more than 65 – 250 times more likely 
to develop cSCC than immunocompetent individuals (South et al., 2014; Li et al., 2015; 
Migden et al., 2018). Immunosuppressed individuals not only have an increased risk of 
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primary cSCC, but their rate of metastatic disease is increased ten-fold, due to the decrease in 
immune surveillance and clearance of cancerous cells. Those with inherited disorders such as 
Xeroderma pigmentosum are also greatly predisposed to cSCC formation as are those with 
human papillomavirus (HPV) infection and patients on BRAF inhibitors (Li et al., 2015).  
Metastasis of cSCC is indicated in 1 – 5 % of cases (Joseph et al., 1992; Alam and Ratner, 
2001; Brougham et al., 2012; Karia et al., 2013; Makki et al., 2013; Burton et al., 2016; 
Nelson and Ashton, 2017; Venables et al., 2018) and is met with a poor prognosis. Whilst this 
metastatic sub-group accounts for a minority of NMSC, the overwhelming majority of deaths 
from NMSC are attributed to metastatic cSCC (Brougham et al., 2012; Lambert et al., 2012). 
Assuming the estimated incidence of primary cSCC mentioned above, metastatic disease 
could occur in up to 9,000 cases per year in Australia. Metastatic disease from basal cell 
carcinoma (BCC) is a rare event ranging from 0.0028 to 0.1 % (Paver et al., 1973; Dzubow, 
1986). There were a total of 634 and 1,377 deaths from NMSC and melanoma in Australia in 
2017, respectively (Australian Bureau of Statistics, 2017). 
Despite the comparatively minor differences in mortality between metastatic cSCC and 
melanoma, research efforts for cSCC have remained comparatively slow growing to that of 
melanoma research (Figure 1.3), despite the increasing incidence of disease. 
 
Figure 1.3 Publications per year for research on cSCC and melanoma.  Numbers determined through search 
results on the Web of Science database (http://www.webofknowledge.com; accessed on 19/4/2018). 
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1.2.2 Clinical features 
SCC of the skin can be varied in terms of numbers, location and size of lesions; duration of 
lesions; presence of clinically abnormal lymph nodes; presence of masses on the parotid 
region; presence of recurrence, locoregional metastases, and distant metastases (Vasconcelos 
et al., 2014). The majority of patients present with only one SCC at a time, with very few ever 
presenting with more than three. 
CSCC is the malignancy of neoplastic squamous cells of the skin, growing quickly over 
several weeks or months. These squamous cells form the uppermost layer of the epidermis 
(Figure 1.4), and can be anatomically defined as thin, tightly packed, flat epithelial cells. 
 
Figure 1.4 Anatomy of the skin. Squamous cells are found in the uppermost layer of the epidermis whilst basal 
cells are below, forming part of the basement membrane with the pigment producing melanocytes. Adapted from 
Cancer Council Australia, (2014). 
Compared with their underlying basal counterpart which present macroscopically as a pearly 
bump (Figure 1.5 A), when neoplasms occur in the squamous cells a scaly ulcerative lesion 
typically appears on the surface of the skin (Figure 1.5 B). This lesion may possess the ability 
to invade deeper into tissue. Primary cSCC lesions may often bear a resemblance to actinic 
keratoses which are a lesion also caused from UV damage and can develop into SCC (Marks 
et al., 1988; Lim and Asgari, 2016). Other clinical manifestations of cSCC include papules, 
plaques, nodules, and hyperkeratotic lesions (Lim and Asgari, 2016).  
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Figure 1.5 Non-melanoma skin cancers. A) Basal cell carcinoma presenting as a pearly coloured and dry, flat 
area or lump. B) Squamous cell carcinoma presenting as a red, thickened scaly spot (Cancer Council Australia, 
2014). 
SCC can develop on any cutaneous surface, although it will commonly present itself on the 
head and neck (55 %), as well as the hands and forearms (18 %) (Didona et al., 2018). These 
sites are the most photo-exposed areas, and therefore encounter the greatest cumulative levels 
of UV damage, particularly amongst fair-skinned individuals (Lim and Asgari, 2016). 
Invasive SCC possesses dysplasia across the full thickness of the epidermis and penetrates the 
dermis or deeper tissue. Not all SCC with this aggressive/invasive phenotype are metastatic, 
but their presence is strongly correlated with risk of metastasis, especially if treated late. 
Additionally, several rarer histopathologic variants of invasive SCC exist, including spindle 
cell SCC, acantholytic (adenoid) SCC, clear cell SCC, verrucous, adenosquamous (mucin-
producing) SCC, desmoplastic SCC, and single-cell SCC (Burton et al., 2016; Lim and 
Asgari, 2016). Many of these variants are associated with markedly different clinical 
behaviours and outcomes (Yanofsky et al., 2011). Undoubtedly, with each variant, there are a 
number of unique genetic alterations, further complicating the biological understanding of the 
cSCC as a whole. 
The most frequent site for metastasis of cSCC is to regional lymph nodes; however in rarer 
cases metastasis to distant organs such as the lungs, liver, brain, and bone can occur as well as 
spread to other areas of the skin (Ruzevick et al., 2013). A recent study detected circulating 
tumour cells from regionally metastatic cSCC in pre-operative blood samples (Morosin et al., 
2016), although further work is necessary to determine their clinical significance. Given that 
A) B) 
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the majority of cSCC occurs on the head and neck, there is often a predictable pattern of 
metastatic spread to major draining lymph nodes, with the intraparotid and perifacial lymph 
nodes (Figure 1.6) being the first tier of spread for the majority of cSCC of the scalp and face 
(Forest et al., 2010; Mateus, 2014). The parotid gland is considered the metastatic basin for 
cSCC (O'Brien, 2005; Veness et al., 2007). Metastasis of cSCC is usually discovered when a 
lymph node has become abnormally enlarged. This may have developed rapidly from the 
primary cancer over the course of a few weeks or months, with 95 % of recurrence and 
metastasis occurring within the first five years (Brougham et al., 2012). 
 
Figure 1.6 Routes of lymphatic metastasis. A) Lymph nodes in the head and neck area normally enlarged in 
and associated with cSCC. Major nodes are shown in bold, with the areas draining into these nodal groups 
noted (Vidimos and Stultz, 2015). B) Preoperative photo of a patient with a primary cSCC on the lip and nodal 
metastasis apparent in the submandibular region. Provided with permission by Dr Bruce Ashford (surgeon). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) A) 
Primary 
cSCC 
Nodal 
metastasis 
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1.3 AETIOLOGICAL FACTORS OF SKIN CARCINOGENESIS & 
METASTASIS 
1.3.1 Primary cSCC carcinogenesis 
Ultraviolet (UV) radiation exposure and immunosuppression are the predominant risk factors 
for cSCC, although smoking can also be a significant risk factor for lower lip SCC. 
Additionally, chemical products such as arsenic and polycyclic hydrocarbons, human 
papilloma virus, and chronic ulcerated dermatoses are other less frequent risk factors for the 
development of cSCC (Vasconcelos et al., 2014). 
As the first line of defence, skin accumulates a great deal of trauma over a lifetime. Mutations 
in DNA and the production of reactive oxygen species (ROS) caused from UV-B radiation 
(280 – 315 nm) amass over time, resulting in the unfavourable mutagenic and 
immunosuppressive effects (Veness et al., 2007; Didona et al., 2018). The UV radiation 
stimulates molecules with immunosuppressive properties such as prostaglandins, platelet-
activating factor, and IL-10 (Didona et al., 2018). These factors lead to the formation of a 
primary cSCC lesion, among other keratinocytic malformations. 
As shown in Figure 1.7, the somatic mutation frequency of cSCC is one of the highest of any 
cancer described (Durinck et al., 2011; Pickering et al., 2014; Martincorena et al., 2015; 
Mueller et al., 2019), with the majority of these being C>T mutations resultant from UV 
radiation damage (Mueller et al., 2019). This mutational signature is classified as signature 7, 
and is evident in all cases of cSCC (Helleday et al., 2014). Because of this high mutational 
burden, there can be potentially thousands of mutations per tumour, which makes the task of 
identifying driver mutations particularly difficult (Cammareri et al., 2016). 
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Figure 1.7 Mutation frequencies in cSCC and other cancers. Median value is shown and indicated by the 
horizontal line. Taken from Pickering et al., (2014). 
Loss of function of the transcription factor TP53 is noted in the majority of cancer types and 
is considered the index event for cutaneous malignancy, alongside mutations in NOTCH1/2 
(Durinck et al., 2011; Al-Rohil et al., 2016). This is in line with data obtained from the 
catalogue of somatic mutations in cancer (COSMIC) (Figure 1.8). Asymptomatic normal skin 
carries frequent mutations in TP53 as well as NOTCH, and has been shown 
immunohistochemically to possess detectable clusters of accumulated nuclear p53 protein 
despite the absence of a malignant phenotype (Cancer Council Australia, 2008; Martincorena 
et al., 2015; Cammareri et al., 2016). 
 
Figure 1.8 Top 20 mutations in cSCC. Data obtained from COSMIC: http://cancer.sanger.ac.uk; accessed 
October 2018. 
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Other common genetic aberrations in cSCC development include the inactivation of the 
tumour suppressor gene CDKN2A (via mutation, promoter methylation and/or chromosomal 
loss), as well as mutation and/or amplification of the RAS gene family (Hameetman et al., 
2013; Inman et al., 2018). These gene events along with MYC activation are attributed with 
being amongst the major oncogenic changes associated with the progression from AK to 
cSCC (Hameetman et al., 2013). Inman et al., (2018) similarly observed mutations in the 
aforementioned genes, as well as MAP3K9, PTEN, SF3B1, VPS41, and WHSC1; all of which 
have known genetic alterations in other malignancies. 
Genetic profiling of aggressive or ‘high-risk’ primary cSCC has been performed in a number 
of studies and has consistently revealed a suite of genes to be frequently altered (Pickering et 
al., 2014). Cored formalin-fixed and paraffin embedded (FFPE) samples of high-risk primary 
cSCC that remained non-metastatic at a minimum follow up of 24 months were interrogated 
by Zilberg et al., (2017) using targeted sequencing of 48 relevant genes, finding alterations in 
44 of the 48 genes. TP53 was found to be mutated in all cases (n = 10), whilst the cancer-
associated genes APC, ATM, ERBB4, GNAQ, KIT, RB1, and ABL1 were altered in 60 % of 
tumours. 
Despite their anatomical proximity, BCC and cSCC can vary significantly in their mutational 
profile. Frequent mutations were reported for BCC in NOTCH 1/2, and TP53, although 
PTCH1 was the only gene in BCC found to carry significant functional mutation (Jayaraman 
et al., 2014). Despite PTCH1 mutations in 75 % of BCCs, just 17 % of cSCC tumours 
possessed these mutations (Jayaraman et al., 2014; Pickering et al., 2014). Additionally, the 
gene expression profile of BCC has been found to be dissimilar to that of SCC (Van Haren et 
al., 2009). Pickering et al., (2014) found that the mutational landscape of aggressive cSCC is 
dominated by the same tumour-suppressor genes as those found to be mutated in head and 
neck squamous cell carcinoma (TP53, CDKN2A, NOTCH1, HRAS, CASP8, AJUBA, RASA1, 
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FAT1, and KMT2D). However, additional novel candidate drivers specific to cSCC were also 
identifiable (NOTCH2, PARD3, RASA1) (Pickering et al., 2014). These observations 
demonstrate that it is unreliable to simply infer cSCC biology from the molecular profile of 
cancers with similar primary tissue types. 
1.3.2 Metastasis of cSCC 
1.3.2.1  Genomic factors of cSCC metastasis 
Whilst the aetiological factors underpinning primary lesions are reasonably well understood, 
the biological events that dictate those tumours that metastasise and those that do not are only 
recently coming to light. The few studies that have examined the mutational landscape of 
metastatic cSCC were unable to achieve statistical significance for any particular candidate 
drivers and were clouded by high rates of background mutation (Pickering et al., 2014). 
A study by Li et al., (2015) was the first study to attempt to identify the genetic portrait of 
cSCC nodal metastases. Using 29 FFPE samples against a 504 gene panel, Li et al., (2015) 
attempted to describe key genomic alterations and enumerate potential therapeutic targets. 
They found that multiple genes display recurrent mutation, amplification, and deletion in 
metastatic cSCC, particularly in the TP53 family (79 %), NOTCH 1/2/4 (69 %), and CDKN2A 
(48 %), aligning with alterations found in primary cSCC. This was also shown to be true for 
recurrent and metastatic cSCC samples interrogated by Al-Rohil et al., (2016). Additionally, 
activating alterations were described in the RAS/RTK/PI3K pathways (45 %) which have been 
associated with poorer prognosis. Less frequent activating mutations were also found in 
various tyrosine kinase pathways, upstream of cell survival mediators such as MEK and 
mTOR, including KIT, KRAS, and BRAF (Badlani et al., 2018). Mutations were also observed 
in the tumour suppressor PTEN, a negative regulator of the PI3K/AKT pathway. Whilst the 
study by Li et al., (2015) greatly advanced the genomic observations in cSCC, variant calling 
may have been hampered through the use of FFPE samples as opposed to fresh tumour DNA. 
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Fresh samples of tumour DNA were utilised in a recent study by Inman et al., (2018) which 
presents some of the most extensive genomic observations for metastatic cSCC published to 
date. In addition to the distinct UV-induced C>T mutations, Inman et al., (2018) identified a 
novel mutational signature on the basis of whole-exome sequencing. This signature was 
strongly associated with immunosuppressed individuals with a history of azathioprine 
treatment. Recurrent mutations were identified in the previously implicated genes NOTCH1/2, 
TP53, and CDKN2A. Mutations were also observed by Inman et al., (2018) for HRAS, 
MAP3K9, PTEN, SF3B1, VPS41, and WHSC1. Notably, they found that the majority of the 
significantly mutated genes were caused by azathioprine signature (66 %), with 24.4 % being 
attributed to the UV-driven signature. 
However, as this study focused on whole-exome sequencing, it could be neglecting significant 
genomic aberrations in non-coding regions such as promoter sites. Adjunct studies in our 
laboratory by Dr Bruce Ashford using whole genome sequencing have revealed that the 
majority of mutations in cSCC are contained within introns (Mueller et al., 2019) (Figure 
1.9). 
 
Figure 1.9 Mutations per megabase across fresh-frozen metastatic cSCC. The overwhelming majority of the 
mutations detected are located within the non-coding sections of the genome. Taken from Mueller et al., (2019).  
Due to the success of targeted therapies for melanoma harbouring the BRAF V600E mutation 
and those targeting the hedgehog pathway in BCC, it is hoped that new therapies could be 
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developed for patients with high-risk cSCC through the advent of genomic signatures (Al-
Rohil et al., 2016). 
1.3.2.2 Transcriptomic factors of cSCC metastasis 
Genomic aberrations such as copy number alterations and SNPs do not always result in 
transcriptomic or proteomic significance. As such, a multi-omic approach should be applied 
when attempting to uncover biological characteristics. As cancer cells change their phenotype 
throughout tumour progression (Mitsui et al., 2014), gene expression assays are a great tool to 
identify these changes and reveal biomarkers of disease progression and treatment targets. 
For metastasis to occur there must be numerous variations within the genome and 
transcriptome of primary cSCC compared to metastatic cSCC. Whilst the molecular events 
surrounding the progression of normal skin into primary cSCC (as well as actinic keratoses) 
have been reasonably reported on (Dooley et al., 2003; Kathpalia et al., 2006; Ra et al., 
2011), the gene expression profile that distinguishes metastatic cSCC from primary disease 
has yet to be sufficiently elucidated. Perhaps more importantly, no studies have addressed the 
transcriptomic differences between primaries that never metastasised and those that did. 
In general, cancer cell invasion and metastasis are mediated by processes including 
degradation of the extracellular matrix (ECM) and migration of tumour cells into surrounding 
stroma. The loss of cell adhesion components is greatly associated with metastasis of other 
cancers, resulting from EMT, allowing for migration and invasion (Thiery et al., 2009). Down 
regulation of E-cadherin is a hallmark of EMT, conferring a more invasive phenotype and is 
one of the key steps leading to metastasis. Loss of E-cadherin has been shown to play an 
important role in the progression of head and neck squamous cell carcinoma, demonstrating a 
strong association with lymph node metastasis (Schipper et al., 1991). Loss of membranous 
E-cadherin has been demonstrated in both primary and metastatic cSCC through 
immunohistochemistry (Toll et al., 2013). Transcriptional repressors of E-cadherin, Snail, 
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Slug and Twist, have been shown to be increased in poorly differentiated cSCC relative to 
those that are well differentiated and not as likely to metastasise (Cano et al., 2000; Chen et 
al., 2013). 
Erythropoietin-producing hepatocellular (Eph) receptors are the largest family of receptor 
tyrosine kinases and have roles in numerous biological processes (Farshchian et al., 2015). 
EPHB2 has been shown to be overexpressed in primary and metastatic cSCC and play a role 
in the progression of cSCC, promoting proliferation, migration, and invasion (Farshchian et 
al., 2015). However, expression of EPHB2 has not been observed to be discriminatory 
between primary and metastatic cSCC. 
Gene expression profiling by Mitsui et al., (2014) revealed the similarities and differences 
between actinic keratosis, primary SCC, and SCC that had invaded into the dermis, 
disconnected from the bulk tumour mass (but not yet a fully formed metastatic deposit). As 
shown in Figure 1.10, there are quite strong similarities between the genes that are 
differentially expressed in the various stages of SCC progression, relative to normal 
epidermis. This is particularly true for the probe-sets including S100A, KRT6, and the SERPIN 
families. 
 
Figure 1.10 Region specific gene expression changes in SCC tissues. A Venn-diagram depicts the numbers of 
commonly regulated probe-sets compared to normal epidermis using cDNA microarray data. The numbers in 
red indicate up-regulated probes, whereas those in green indicate down-regulated probes. The top 10 up- and 
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down-commonly regulated probe sets shared by the three stages of SCC progression are shown in a table to the 
right. Adapted from Mitsui et al., (2014). 
In the same study, the authors reported the up- and down-regulated genes specific to invading 
SCC. Genes encoding proteolytic molecules such as MMPs and PLAU were highly-
upregulated relative to normal epidermis. The cell adhesion molecule LAMC2 was also found 
to be up-regulated. Keratinocyte differentiation markers FLG, LOR, and LCE2B were down-
regulated (Mitsui et al., 2014). 
A major problem amongst existing gene expression data relating to cSCC is the lack of any 
real consensus of differentially expressed genes (Hameetman et al., 2013). A review by Van 
Haren et al., (2009) compared six studies investigating differentially expressed genes in cSCC 
(relative to epidermis) and found that of 493 differentially expressed genes reported across the 
studies, only seven genes were found to be dysregulated in the same direction (both 
upregulated or both downregulated) in at least one other study. These differences were 
attributed towards variations in RNA extraction kit, microarray platform, analysis program, 
statistical tests, and the number of samples analysed. None of the studies investigated 
consisted of a cohort larger than eight for any sample type. This is also a criticism of the study 
by Mitsui et al., (2014) as their sample size for invading cSCC was less than five. These 
aspects are concerning given the profound inter-patient heterogeneity observed with cSCC 
(Zilberg et al., 2018). Future efforts require larger sample sizes to account for these variations 
and should utilise newer, more robust gene expression technologies as they arise. As it stands, 
expression analyses on metastatic deposits of cSCC are limited. 
1.3.2.3 Angiogenesis and metastatic cSCC 
The formation of new blood vessels from pre-existing blood vessels (angiogenesis) is critical 
to tumour formation, invasion and metastasis. One of the key factors that stimulate 
angiogenesis is vascular endothelial growth factor (VEGF). Mutations in regulatory regions of 
VEGF and the eventual overexpression of this factor can contribute greatly towards metastasis 
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(Didona et al., 2018). Nie et al., (2016) found an association between specific single 
nucleotide polymorphisms (SNPs) in VEGF and risk of developing primary cSCC, thereby 
warranting the further investigation of these SNPs as genetic markers for determining risk and 
prognosis of cSCC. Alas, no correlation was observed between SNP genotype and lymph 
node metastasis (Nie et al., 2016). 
1.3.2.4 Influence of the tumour microenvironment on metastasis and growth 
It is now well accepted that invasion and metastasis does not depend exclusively on cancer 
cells, but can also be greatly influenced by the tumour microenvironment (TME) (Madar et 
al., 2013; Peng et al., 2013; Kim and Bae, 2016; Hirata and Sahai, 2017). This environment 
consists of cancer cells, the extracellular matrix, and stromal cells including fibroblasts, 
endothelial cells and infiltrating immune cells (Peng et al., 2013; Nunes et al., 2019). Cancer 
cell crosstalk with stroma is simplified in Figure 1.11. 
 
Figure 1.11 Cancer cell crosstalk in the tumour microenvironment. Crosstalk is mediated through cytokines 
and growth factors. Taken from Nunes et al., (2019). 
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Tumour-stroma interaction plays a key role in metastasis for many cancers (Pathak et al., 
2006; Kim and Bae, 2016; Hirata and Sahai, 2017) and cSCC is no different with several 
authors sighting differences in physiology between cSCC and its stromal environment 
(Commandeur et al., 2011; Moussai et al., 2011). Early invasion in SCC is characterized by 
the growth of fibrous tissue. Cancer associated fibroblasts (CAFs) reside within the tumour 
microenvironment as a subpopulation of cells promoting the transformation process by 
encouraging tumour growth, inflammation, angiogenesis, and metastasis (Madar et al., 2013). 
CAFs from cSCC have physiological differences when compared to normal dermal 
fibroblasts, which is unanticipated given the general genetic stability of stromal compartments 
surrounding tumours (Commandeur et al., 2011; Madar et al., 2013). 
Infiltrating immune cells may also have a major impact upon the progression of malignant 
tumours (Peng et al., 2013). Moussai et al., (2011) found CD136+, CD68+, and VEGF-C+ 
cells to be strongly associated with invasive SCC, indicating the mediating role tumour-
associated macrophages may play in lymphangiogenesis. 
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1.4 DIAGNOSIS AND PROGNOSIS OF METASTATIC CSCC 
1.4.1 Prognosis 
The majority of primary cSCC can be cured by cryosurgery, conventional excision or the 
microscopically controlled Mohs’ surgery (Joseph et al., 1992). It is suggested that six-
monthly follow-up for two years should be established to detect new primaries or metastatic 
disease; however, there are currently no strict recommendations for this given the curative 
rates and the burden of incidence. As a result, those with metastatic disease are simply not 
monitored closely enough. Whilst the metastatic form is rare, it is more than often met with a 
poor prognosis and can develop rapidly (Mateus, 2014). Additionally, the rate of metastatic 
cSCC has been shown to increase with the duration of follow-up (Brougham et al., 2012).  
The prognosis of cSCC and its high-risk variants are stratified in Australia according to the 
Cancer Staging Manual published by the American Joint Committee on Cancer (AJCC). From 
this, a nodal (N) system is used to categorise nodal metastasis into one of five tiers (N1, N2a, 
N2b, N2c, and N3). As shown in Figure 1.12, mortality can be reflected by N stage, with the 
lowest branch of nodal metastasis (N1) conferring a five year overall survival rate falling to 
approximately 70 % (Brunner et al., 2015). In cases of multiple lymph node involvement or 
larger deposits, this survival rate falls to 48 % even in the implementation of drastic surgery 
and adjuvant high-dose radiotherapy (Porceddu et al., 2018). N3 is the most clinically 
relevant stage to inform on patient outcome and carries a significantly increased risk of death, 
especially in comparison to N1 (hazard ratio of 2.5, P < 0.001) (Brunner et al., 2015). 
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Figure 1.12 Overall survival by N classification. Taken from Brunner et al., (2015). 
However, there exist concerns over the current staging system as it fails to factor in patient 
details including immunosuppression and tumour recurrence (Burton et al., 2016), and it also 
uses the same nodal staging system for cSCC and mucosal SCC despite different aetiology, 
risk factors, and progression (Moeckelmann et al., 2018). Despite a recent update with the 
release of the 8th edition of the AJCC cancer staging manual, the system is still criticised as 
being a poor prognostic indicator for patients with metastatic cSCC as it fails to adequately 
distinguish unique characteristics from metastatic mucosal SCC (Liu et al., 2018). An 
evidence-based risk stratification system has recently been proposed that incorporates 
immunosuppression data, with the classification system amenable to refinement as new risk-
factors are identified (Baum et al., 2018). 
Early excision of metastases to cervical nodes, prior to extracapsular spread or multiple node 
involvement, provides a survival advantage with disease specific survival greater than 95 % 
(Clark and Soutar, 2008). One study by Joseph et al., (1992) found that patients with operable 
metastases had a mean survival of 53.8 months, whilst those with inoperable disease had a 
dramatically lower mean survival of 12.2 months (P < 0.05). Sentinel lymph node biopsies 
are recommended for high-risk patients as a means of determining metastasis (Samsanavicius 
et al., 2018). However, as primary lesions remain poorly classified, high-risk patients often go 
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unnoticed until secondary tumours have become far too involved with regional structures and 
become unresectable. 
The lack of reliable clinical prognostic markers applicable to primary cSCC and its high-risk 
variants, coupled with the infrequency of patient follow-up, makes it difficult to address those 
at risk. As a result, these patients present with high-grade, late-stage disease and require more 
drastic treatment. As is the case for some other cancers, a biomarker or gene signature specific 
to metastatic cells would inform with a greater degree of certainty on risk.  
1.4.2 Histopathological prognostic factors of metastatic potential 
As it stands, the classification of metastatic risk for cSCC depends mainly on 
histopathological staging as well as clinical features (Petter and Haustein, 2000; Peat et al., 
2012; Vasconcelos et al., 2014; Hirshoren et al., 2017). Table 1.1 details the features of cSCC 
that correlate with high risk for recurrence and metastasis. Lesions on the head and neck, 
particularly the lip and ear, are found to confer a greater risk of recurrence and metastasis and 
should therefore be met with improved follow-up. 
Table 1.1 Features of cSCC that correlate with high risk for recurrence and metastasis. Taken from 
Vidimos and Stultz, (2015). 
 Five-year recurrence rate (%) Five-year metastatic rate (%) 
Clinical features   
Size ≥ 2 cm in diameter 15.2 30.3 
Location   
 Ear 18.7 11.0 
 Lip 10.5 13.7 
 Genitals - 20-60 
Arising within scar, sinus tract, 
chronic ulcer, or burn 
NA 37.9 
Locally recurrent 23.3 30.3 
Immunosuppressed patient NA 12.9 
Rapid growth - - 
Histologic features   
Depth ≥ 4 mm 17.2 45.7 
Poorly differentiated 28.6 32.8 
Perineural involvement 47.2 47.3 
Intravascular invasion - 87.5 
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High metastatic risk is most associated with poor differentiation, perineural/lymphovascular 
invasion, tumour ≥ 20 mm in size and a depth greater than 4 mm. A systematic review by 
Thompson et al., (2016) identified tumour depth as the most informative risk factor for local 
recurrence and metastasis. 
Despite these predictive factors being well recognised and utilised by oncologists, their 
individual value for assessing risk of metastasis appears to be debatable and vary between 
studies, particularly with regards to cellular differentiation (Peat et al., 2012), potentially due 
to subjective pathology reports. These predictive factors also do not necessarily discern 
between metastatic propensity and those with an aggressive phenotype only. Toll et al., 
(2015) remarked that 20 – 30 % of metastatic cSCC cases lack the clinical features purported 
to be indicative of a high-risk lesion. Furthermore, risk of metastasis can only be identified 
from most of these factors at a stage whereby preventative measures may be futile. 
Whilst prognostic information from histological and/or clinical features can be unreliable, it 
can still play a key role when considering preventative measures (Burton et al., 2016). This is 
nonetheless indicative of the need for contemporary molecular biomarkers that can identify 
individuals at a high-risk of developing local recurrence of metastases at early stages of 
cancer development (Toll et al., 2015). 
1.4.3 Molecular prognostic factors of metastatic potential 
Whilst clinical and histological factors may permit the classification of patients into low or 
high risk of recurrence (Mateus, 2014), these predictive factors are not reliable or efficient 
enough for informing on metastatic risk early on. As such, molecular prognostic factors could 
provide valuable data to guide classification for patients that would benefit from the 
implementation of greater surveillance and prophylactic measures (Toll et al., 2015).  
Cancer biomarkers have a key role in cancer detection, prognosis, prevention, and treatment 
(Dawood, 2010). However, few biomarkers have been proposed for informing on cSCC 
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metastasis risk and none are used clinically. As such, molecular prognostic factors posit a 
potential research avenue that could provide valuable data to guide classification in the clinic. 
Components of the plasminogen activation system (PAS) are important determinants of 
metastatic capacity (Stillfried et al., 2007; Mekkawy et al., 2014; Brungs et al., 2017). Two 
significant components of this system are the urokinase plasminogen activator (uPA) and its 
receptor (uPAR) which, when bound, catalyse the cleavage of plasminogen into plasmin. This 
results in a cascade of extracellular matrix degradation, paving the way for metastatic spread 
(Figure 1.13). 
 
Figure 1.13 The mechanism of urokinase activated plasminogen-mediated tumour cell invasion. Pro-uPA 
is converted to active uPA when bound with uPAR. The active uPA subsequently transforms plasminogen into 
the protease plasmin, resulting in ECM degradation and cellular invasion. This process can be inhibited through 
blocking of the active site of uPA through plasminogen activation inhibitor-1 (PAI-1) or plasminogen activation 
inhibitor-2 (PAI-2).  
Expression of uPAR in cSCC has been demonstrated by Rømer et al., (2001), noting a 
particularly high density at the invading front of the tumour. The gene encoding the ligand 
uPA, PLAU, has similarly been found to be overexpressed in invading cSCC, relative to 
normal skin and non-invasive cSCC (Mitsui et al., 2014). Contrastingly, neither uPA nor 
uPAR have been observed in high levels in BCC (Sappino et al., 1991; Miller et al., 1992; 
Rømer et al., 2001). As such, components of this system may be a worthy biomarker of 
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metastatic propensity for cSCC. Serine protease inhibitor A1 (serpinA1) inhibits neutrophil 
elastase which is an inhibitor itself of plasminogen activation. Elevated expression of 
SerpinA1 has been suggested as a novel biomarker for progression of cSCC (Farshchian et 
al., 2011). 
EMT immunohistochemical markers have been investigated as prognostic factors for 
lymphatic metastases in cSCC (Toll et al., 2013). Relative to primary cSCC, metastatic cSCC 
has been found to possess significantly greater levels of nuclear E-cadherin and vimentin 
expression (Toll et al., 2013). Additionally, Twist, Zeb1, nuclear beta-catenin, and podoplanin 
were detected more frequently in metastatic cSCC than primary disease, suggesting potential 
biomarkers. Membranous E-cadherin was found to be a poor immunohistochemical 
prognostic marker of metastatic risk, whilst vimentin was found to be more relevant as a 
biomarker (Toll et al., 2013). A later study by the same authors proposed nuclear active IKK 
as a robust biomarker to predict cSCC outcome (Toll et al., 2015). 
Beyond the gene/proteins mentioned, no further molecular prognostic markers for metastatic 
cSCC have been confidently proposed. Once candidate biomarkers have been identified these 
could be used at a protein level in the form of IHC, or gene expression assays could be 
utilised in the case of multiple biomarkers, serving as a prognostic panel. An example of such 
an expression assay is the Prosigna screening assay which uses a suite of 50 genes with 
known discriminatory power in subtyping breast cancer (Parker et al., 2009; Wallden et al., 
2015). The benefit of such panels is the data can be used in certain cases to predict patient-
response to therapy. 
Clinical, histological, and molecular characteristics that have been identified in various 
studies that potentially distinguish the stages of cSCC are summarised in Figure 1.14. Genes 
noted to have unique alterations in the metastatic setting are limited and largely unsupported. 
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Figure 1.14 Features of normal skin, actinic keratoses, primary cSCC, and metastatic cSCC. Adapted from 
Ratushny et al., (2012). 
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1.5 THERAPEUTICS FOR METASTATIC CSCC 
1.5.1 Surgery 
The reference treatment for primary cSCC is complete surgical excision with 4 – 10 mm safe 
margins (Mateus, 2014; Li et al., 2015). Clinicians may opt for electrodessication or 
cryosurgery, although the pitfall of these destructive methods is that it leaves no tissue for 
pathological examination (Cranmer et al., 2010). These local control methods are often 
curative (Que et al., 2018), although metastases to regional lymph nodes may occur with, but 
not limited to, aggressive cSCC (Moussai et al., 2011). 
As previously stated, metastatic cSCC largely, but not exclusively, involves the head and neck 
(Didona et al., 2018). The surgical treatment for metastatic cSCC is often lymphadenectomy 
of at-risk nodal basins. This may also include resection of salivary glands and lymph nodes, 
dismemberment of facial nerves, removal of anatomical structures such as the mandible, skull 
base, ear, nose, eye, and major neck vascular structures. As shown in Figure 1.15 this 
treatment can be highly invasive. As such, the quality of life for these patients is drastically 
decreased leading to many psychosocial effects and burden. Whilst surgery may likely remain 
the gold-standard for treating metastatic disease, a reduction in tumour size through neo-
adjuvant therapies could potentially decrease the radical nature of surgery, or render 
previously unresectable disease resectable. 
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Figure 1.15 Before and during surgery of metastatic cSCC disease. In this case primary cSCC has spread 
to the left intraparotid lymph node. Surgical excision of the parotid and associated lymph nodes 
performed. Photo provided by Dr Bruce Ashford (Surgeon). 
1.5.2 Radiation therapy 
Radiation therapy (radiotherapy) is an effective therapy when surgery cannot be performed or 
in cases of unresectable disease. For metastatic cSCC, radiotherapy is frequently used in the 
adjuvant setting on a fractionated schedule to treat microscopic deposits of cancer cells 
remaining and tumour unreachable/unresectable during surgery (Reule, 2009; Mateus, 2014; 
Que et al., 2018). Post-operative radiotherapy has been shown to reduce the risk of death in 
patients with lymph node metastasis (Wang et al., 2012; Strassen et al., 2017) and lead to 
significantly improved survival (Figure 1.16), despite more advanced disease (Oddone et al., 
2009; Czerwonka et al., 2017). Prophylactic irradiation of at-risk nodes could reduce future 
recurrence or halt progression, although high-level supportive evidence of this is lacking 
(Veness et al., 2007). 
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Figure 1.16 Survival based on treatment for aggressive cSCC. Taken from Oddone et al., (2009) 
Drawbacks of radiotherapy as a monotherapy for metastatic disease include the lack of 
histologic control of tumour margins and the cocktail of adverse side-effects to the patients, 
including: hair loss, nausea, loss of salivary gland function, skin changes and fibrosis with 
lymphoedema, ulceration, and necrosis (Joseph et al., 1992; Chartier and Asasi, 2016). This 
proves challenging as these effects are worse in the elderly, who represent the primary 
demographic of this disease. Vasculature injury can also be sustained following radiotherapy 
which can lead to an increased risk of stroke (Xu and Cao, 2014). Radiotherapy may also not 
be used on certain sensitive locations, such as eyelids. Paradoxically, exposure to x-rays can 
play a role in the pathogenesis of cSCC and BCC (Didona et al., 2018). Following 
radiotherapy, should cSCC recur there is a greater risk of a highly aggressive tumour forming 
with a high rate of metastasis (Joseph et al., 1992; Cañueto et al., 2018). 
Systemic chemotherapy can be used to radiosensitise tumours, thereby resulting in added 
disease control with concomitant radiotherapy treatment. The approach of adjuvant 
chemoradiotherapy has been reported to significantly improve disease control compared with 
radiotherapy alone for regionally metastatic cSCC (Apisarnthanarax et al., 2011; Tanvetyanon 
et al., 2015), however these studies are limited. Contrastingly, Badlani et al., (2018) stated 
that at present there is no evidence to support the additive effect of chemotherapy to 
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radiotherapy for patients with metastatic cSCC. Further work is needed clarify this 
discrepancy or to identify novel drugs for inclusion in chemoradiotherapy regimens. A recent 
phase III clinical trial evaluating radiotherapy with concomitant carboplatin in patients with 
cSCC lymph node metastases found no additional benefit (Porceddu et al., 2018). Increased 
toxicity through this combined option has also been reported, particularly in the case of 
regimens including cetuximab (Magrini et al., 2016). 
Many of the toxic side effects of radiotherapy stem from x-rays penetrating healthy, disease-
free tissue. Nanoparticles have been gaining research interest for their ability to improve x-ray 
dose-delivery directly to the tumour, sparing healthy tissues. Nanoparticles are small, high-z 
molecules that are biocompatible and readily taken up into the rapidly dividing tumour cells 
(Engels et al., 2016). When interrogated with x-rays, the nanoparticles produce more ROS 
species and localised ionising radiation damage (Engels et al., 2018). The additive effect of 
nanoparticles in depleting cancer burden has been observed in multiple cancer types 
(Jørgensen et al., 2016; Li et al., 2019) and may have a critical role in advancing radiotherapy 
to the head and neck. Nanoparticles such as thulium oxide are also para-magnetic, enabling 
them to also be used for radio-guided imaging of the tumour in real-time (Koehler et al., 
1962; Engels et al., 2018). This level of accuracy is crucial given the at-risk structures (e.g. 
carotid artery) surrounding most metastatic cSCC. A combined approach using 
chemoradiotherapy with nanoparticles has yet to be reported for cSCC and may be found to 
exert a synergistic effect. Nonetheless, further work is needed to identify safer and more 
efficacious chemoradiotherapy regimens as locoregional control on the basis of the current 
approach is insufficient. 
1.5.3 Chemotherapy, targeted therapy, and immunotherapy 
Whilst the majority of cases are treated with surgery and/or radiotherapy, chemotherapy as 
well as targeted therapy or immunotherapy may be sought in cases where locoregional cSCC 
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control has failed by other means, or in the cases of unresectable metastases. Investigations of 
systemic therapy for primary cSCC has been very limited with the literature primarily 
consisting of isolated case reports (Cranmer et al., 2010). Even fewer studies report 
therapeutic efficacy in the metastatic setting, resulting in no solid data to support the use of 
adjuvant systemic chemotherapy in metastatic cSCC (Stratigos et al., 2015). As metastatic 
lesions are the progeny of subpopulations of cells present in the primary tumour, the 
metastatic colonies can be quite different from the primary with regards to their biology 
(Lambert et al., 2017). As such, even systemic therapies approved for primary cSCC have no 
guarantee of efficacy in the metastatic setting. Topical treatments such as imiquimod are 
available for primary cSCC or actinic keratosis (Que et al., 2018), although in some cases 
imiquimod can worsen high-risk cSCC progression through the stimulation and release of 
cytokines (Dika et al., 2018). 
Systemic therapies used for aggressive primary cSCC include cytotoxic chemotherapy (e.g. 
cisplatin, 5-fluorouracil [5-FU], vindesine, methotrexate, bleomycin, and doxorubicin), 13-
cis-retinoic acid (13cRA), immunotherapy (interferon α2a [IFN-α]), and biologics (e.g. 
gefitinib, cetuximab, and erlotinib) (Cranmer et al., 2010). Capecitabine, an oral prodrug of 5-
FU, can be used along with subcutaneous IFN-α to treat advanced primary cSCC (Que et al., 
2018). 
Cisplatin is perhaps the most commonly prescribed chemotherapeutic for treating advanced 
cSCC, owed in part to its use for almost four decades as the standard of care for various forms 
of cancer (Jarkowski et al., 2016; Trodello et al., 2017). Cisplatin operates by introducing 
cross-links into DNA, effecting mitosis. Several signal transduction pathways are also 
activated by cisplatin, leading to apoptosis. It has been shown with mucosal SCC that 
combination concurrent platinum chemotherapy and adjuvant radiotherapy may improve 
disease control and survival for high-risk patients (Veness et al., 2007).  
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Given the majority of patients presenting with this disease are the elderly with many 
comorbidities, therapeutics must be appropriately selected to minimise side-effects that are 
intolerable (Alter et al., 2013). Carboplatin may represent an ideal platinum-based 
chemotherapy agent to be used in this circumstance as many elderly patients will not tolerate 
conventional cisplatin (Trodello et al., 2017). 
Targeted therapies are an alternative approach specifically designed to spare healthy tissue 
and reduce the systemic effects typically seen with cytotoxic agents. Drugs targeting the 
epidermal growth factor receptor (EGFR) represent potential targeted therapies for metastatic 
disease (Nuno-Gonzalez et al., 2012) given the overexpression of EGFR that has been noted 
in metastatic cSCC (Gaffney et al., 2014; Cañueto et al., 2017). However, this expression can 
vary between patients (Joseph et al., 2015) and therefore may only be of benefit to patients 
with high tumour EGFR expression; although this may not always be the case (Kim, 2014). 
Drugs targeting EGFR do so either as anti-EGFR monoclonal antibodies that block ligand 
binding and receptor activation (e.g. cetuximab, panitumumab), or as small-molecule tyrosine 
kinase inhibitors (TKIs) which compete with ATP to bind to the intracellular catalytic 
domain, blocking downstream signalling (e.g. gefitinib, erlotinib, lapatinib) (Figure 1.17) 
(Cranmer et al., 2010; Gaffney et al., 2014). 
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Figure 1.17 Mechanisms of action of anti-EGFR drugs in cancer cells. Taken from Cranmer et al., (2010). 
Cetuximab is a synthetic antibody that has been specifically engineered to bind to EGFR, 
inhibiting downstream signalling for cell growth (Trodello et al., 2017). The most commonly 
reported phase II studies often combine cisplatin with doxorubicin or cetuximab (Cancer 
Council Australia, 2008; Dereure et al., 2016; Trodello et al., 2017). As a monotherapy, 
neither agent has been found to be definitively more effective than the other (Trodello et al., 
2017). Instead, a combined approach has been found to lead to higher response rates for 
metastatic cSCC control (Alter et al., 2013) and may be further improved in conjunction with 
radiotherapy (Samstein et al., 2014). Of note, the presence of EGFR mutations did not 
correlate with response to EGFR-targeting therapy (Alter et al., 2013). However, anti-EGFR 
biologics are only effective in tumours carrying a wild-type RAS genotype. This is owed to 
the fact that mutations in RAS cause the same downstream signalling of EGFR, independent 
of EGFR activation (Figure 1.17) (Zhao et al., 2017). One of the major drawbacks of EGFR 
targeting therapies is the relatively rapid development of resistance. The precise mechanisms 
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of this resistance remain undecided, however it is believed that the tyrosine-protein kinase c-
MET has a role to play (Ribero et al., 2017). 
The relatively recent advent of immunotherapy has resulted in a surge of interest in its 
applicability to advanced or metastatic cSCC, particularly with antibodies directed against the 
programmed cell death-1 protein (PD-1) or its ligand (PD-L1). In this context, blocking of the 
PD-1/PD-L1 pathway increases the T-cell specific immune response. Recent investigations 
using PD-1 inhibitors with cSCC have demonstrated promising preliminary results (Falchook 
et al., 2016; L. Stevenson et al., 2017; Miller et al., 2017; Hermel et al., 2018). Some of the 
most compelling results have been reported by Migden et al., (2018) finding a 50 % response 
rate upon treatment with the PD-1 inhibitor cemiplimab. The dramatic reduction in tumour 
burden after treatment with cemiplimab can be seen in Figure 1.18. There is almost no data on 
either the anti-CTLA4 antibody ipilimumab or anti-PD-1 agents nivolumab or pembrolizumab 
for cSCC (Ribero et al., 2017). 
 
Figure 1.18 Before and after PD-1 therapy. A 62-year-old patient with advanced cSCC at baseline and after 
six weeks of treatment with the PD-1 inhibitor cemiplimab. Adapted from Migden et al., (2018). 
Whilst the exceptional results seen with immunotherapy might suggest an inevitable move 
away from conventional treatment, patients who are immunocompromised are excluded from 
trials using PD-1 or PD-L1 inhibition due to concerns regarding organ rejection, or graft-
versus-host disease (Kittai et al., 2017; Chae et al., 2018). As solid organ transplant recipients 
have a significantly greater risk of developing cSCC than immunocompetent individuals 
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(Migden et al., 2018), it is clear that more work is needed to refine the use of PD-1 inhibitors 
for this demographic. Additional chemotherapeutics/targeted therapies should also be 
concurrently explored. A polychemotherapeutic approach with immunotherapy and/or 
radiotherapy may one day negate aggressive surgery. Nonetheless, other small-molecules 
must continue to be investigated for utility in metastatic cSCC as immunotherapy and targeted 
therapies (to a lesser extent) will remain quite expensive for some time (Ward et al., 2017). 
Due to the success often seen with radiotherapy and surgery, other therapies are not often 
considered as a preferred treatment option for metastatic cSCC. However, clinicians should 
consider the capabilities of therapeutic agents to potentially reduce the dosage of radiotherapy 
used or as a neoadjuvant therapy to minimise the invasiveness and morbidity of surgery. Of 
course, the above mentioned uses of chemotherapy are limited to small case reports and 
therapeutic agents selected on the basis of efficacy in other cancer types rather than empirical 
evidence of benefit in cSCC. As such, there are perhaps many alternative therapeutics which 
simply have yet to be evaluated with metastatic cSCC. Comprehensive genomic and 
transcriptomic analyses may reveal candidate drug targets, whilst high-throughput screening 
of novel and established therapeutics may reveal efficacy with previously unconsidered 
molecules. 
1.5.4 Potential therapeutic strategies 
Genetic information can reveal predictions of drug response in a pre-clinical setting, which 
can greatly influence clinical trial design and foster the emergence of ‘personalised’ medicine 
(Barretina et al., 2012). By establishing what precise mechanisms are being exploited by an 
individual tumour, it may then be possible to specifically target the cancerous cells, leaving 
healthy tissue unimpaired. 
However, care must be taken when deciding on therapeutic targets. For example, despite the 
high frequency of TP53 mutations in cSCC mentioned earlier, there are no approved agents 
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acting directly on TP53 outside of early-stage clinical trials (Al-Rohil et al., 2016). This is 
likely due to the fact that normal skin also carries a high frequency of mutated TP53 
(Martincorena et al., 2015). Such a therapy would be detrimental to healthy tissue as well as 
the cSCC, as would also be the case with NOTCH1 targeting therapies (Cammareri et al., 
2016). 
As noted earlier (section 1.4.3), the urokinase plasminogen activation system may play a key 
role in cSCC progression, given its purported increased activity in metastatic samples. This 
system may be of considerable value in the investigation of novel regimens for metastatic 
cSCC, with its role in other cancers increasingly being identified (Brungs et al., 2017). New 
therapeutics may also be identified through high-throughput screening of novel and 
established compounds against in vitro cell models of cSCC. Molecular data can then be 
cross-referenced with drug response profiles to develop a personalised treatment plan, 
factoring in compensatory signalling. 
  
38 
 
1.6 PATIENT-DERIVED CELL CULTURES AS A MODEL OF 
METASTATIC CSCC 
Cells cultured directly from a tumour are referred to as patient-derived primary cell cultures 
(PDCCs), regardless of whether the tumour itself is from a primary or metastatic site in situ. 
The formation of a tumour cell line from the primary culture in adherent monolayer, 
suspension, or three-dimensional formats occurs once the tumour cells are the predominant or 
only cell type remaining that can be sustained through multiple sub-cultures or ‘passages’ 
(Freshney, 2010; Cree, 2011). Unlike cell lines derived from non-cancerous tissue, cell lines 
derived from cancer specimens are already effectively immortalised through the mutated 
processes inherent in cancer. 
1.6.1 Relevance of PDCCs 
1.6.1.1 The need for PDCCs 
Research of disease biology and development of therapeutics hinges on the acquisition of 
reliable and valid results obtained from robust experimentation. Cell lines, particularly those 
derived from patients, provide a platform for this experimentation whereby tumour biology 
can be replicated and manipulated in vitro. Clinically relevant samples are often formalin 
fixed and paraffin embedded for histological examination. However, this presents a finite 
source of information at a static moment in time and degrades the quality of DNA. Patient-
derived cell cultures (PDCCs) on the other hand, present a continuous stream of cellular 
activity, providing patient-specific information such as proliferation rate, 
genomic/transcriptomic data, metastatic propensity, motility in protein expression, therapeutic 
responsiveness, and much more (Pauli et al., 2017).  
Billions of dollars invested into drug development are lost each year due to failed clinical 
trials. Cell lines offer an animal/patient-free pre-clinical platform for high-throughput 
experimentation informing on tumour biology and drug development. However, clinical 
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efficacy of drug candidates seen in screens with conventionally used immortalised cell lines 
can be poor as they fail to recapitulate key pathophysiological features of the human disease 
(Horvath et al., 2016; Pauli et al., 2017). PDCCs with contemporary culture methods can 
provide a greater mimicry of the tumour, leading to more reliable clinical translatability. 
Patient-dependent tumour variability, deficient cell banks, and disparities in clinical responses 
drive the development of PDCCs (Mitra et al., 2013). The mimicry of host-tumour biology in 
PDCCs results in the generation of high-fidelity data generally translatable to clinical settings, 
more so than ever capable with cell-free assays. 
1.6.1.2 Advantages of PDCCs 
It is widely accepted that PDCCs provide desirable and relevant data, particularly when 
studying physiological interactions (Chi Scientific, 2007; Horvath et al., 2016). PDCCs allow 
the use of a very specific model of diseases of interest rather than just employing the next-best 
commercial cell line. This is becoming ever more important as our collective knowledge of 
cancer grows and subtypes of diseases are identified. 
The establishment of patient-derived cell lines also confers an advantage over commercial cell 
lines by allowing the researcher to know details regarding the tumour or the patient that may 
have not been otherwise available. Perhaps most importantly, tumour-derived primary cell 
cultures provide a robust pre-clinical screening platform for discovering and evaluating the 
efficacy of anticancer therapeutics (Choi et al., 2014). They offer the advantages of being 
affordable, relatively easily grown, and amenable to high-throughput compound screening 
(Goodspeed et al., 2016). 
PDCCs are critical in the shift towards personalised therapy, whereby functional diagnostics 
are performed upon a short-term culture of a tumour biopsy and the therapeutic strategy 
tailored towards the individual (Figure 1.19). 
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Figure 1.19 Current and potential workup for treatment decision. 
1.6.1.3 Disadvantages of PDCCs 
PDCCs however, are not without pitfalls. One of the largest obstacles in generating PDCCs is 
the need for optimisation of culturing conditions. This includes determining the optimal 
conditions for tissue transfer, digestion/homogenisation, purification, culture system surface, 
and growth medium components. Tailoring these aspects to achieve the perfect culturing 
conditions is a laborious and time-consuming process that may deter researchers from 
undertaking some investigations. 
Even when published material is available to guide PDCC development, trialling these 
protocols can be expensive as researchers must purchase and prepare small batches of 
specialty products (Chi Scientific, 2007; Freshney, 2010; Purdie et al., 2011). Additionally, 
rigorous validation of patient-derived primary cell lines (elaborated upon in Chapters 2 and 3) 
is necessary to satisfy the scientific community that the findings observed with these cells are 
reliable. 
Despite cancer therapeutics developing in accordance with our continuing understanding of 
cancer initiation, progression, metastasis, and the tumour microenvironment; drug efficacy 
using cell lines rarely translates into the same in vivo clinical outcome (Mitra et al., 2013; 
Horvath et al., 2016). This low clinical correlation seen with commercial cell lines is observed 
as they can represent a misconstrued model of actual tumour phenotype in vivo. Such cell 
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lines have undergone immortalisation, genetic/phenotypic drift, and are a homogenous supply 
of cells (Pan et al., 2009); yet remain routinely used globally to investigate many aspects of 
cell biology. Contrastingly, tumours in vivo are highly varied between patients, composed of a 
heterogeneous population of cells, and have strong stromal interactions. However, with care 
PDCCs can be quite faithful to their cognate tumour and serve as a strong pre-clinical model. 
1.6.2 Development and validation of PDCCs 
1.6.2.1  Establishment and optimisation 
Viability of tumour cells decreases dramatically with time once removed from the body. 
Therefore, culture establishment can be improved by minimising the time between resection 
in the clinic and dissociation in the laboratory.  
Methods for tissue dissociation will vary depending on the cancer type as well as the integrity 
of the connective tissue encompassing the tumour. As shown in Figure 1.20, these methods 
include enzymatic digestion, chemical dissociation, and mechanical dissociation (Mitra et al., 
2013). Enzymatic dissociation involves the use of various enzymes (e.g. trypsin, papain, 
elastase, hyaluronidase, collagenase, and pronase) to digest tissue into a single-cell suspension 
whilst preserving cell viability. Chemical dissociation is a process where cations involved in 
maintaining cell surface integrity are sequestered, usually through EDTA, to loosen these 
intercellular bonds. Mechanical dissociation involves a combination of physically mincing 
tissue with blades, homogenization, filtration, repeated needle aspiration, vortexing, and other 
methods of tissue shearing. This method can produce low cell viability from the stress 
imparted to the cells. It is suggested that best results may be obtained from using both 
enzymatic and mechanical dissociation, and is the routine in most laboratories developing 
PDCCs (Chi Scientific, 2007). 
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Figure 1.20 Primary tumour processing options to make a cell line. Taken from Freshney, (2010). 
The successful isolation and culture of tumour cells is dependent upon the imitation of in 
vivo-like conditions in vitro (Figure 1.21). Factors which make primary cell culture 
complicated include: i) contaminating non-tumour cells that disrupt tumour cell growth, ii) 
low tumour yield due to necrosis, and iii) stromal cells such as fibroblasts outcompeting 
cancer cells in the long term (Mitra et al., 2013). To increase the success of tumour cell 
isolation, an optimal method of disrupting the ECM is needed whereby the tumour cells are 
not damaged (Mitra et al., 2013). 
43 
 
 
Figure 1.21 In vivo-like conditions needed to obtain improved tumour mimicry. Taken from Choi et al., 
(2014). Additionally, a hypoxic environment is formed naturally in with tumours in vivo due to an oxygen 
diffusion gradient. This is catered for in vitro through a hypoxic atmosphere in the incubator. 
Researchers must optimise the method according to their cell type under investigation. Very 
few methods have been described for establishing cell cultures from primary cSCC (Purdie et 
al., 2011); however, no methods have been published detailing optimal culturing conditions 
for metastatic cSCC. Given the cellular changes experienced through EMT, it is naïve to 
assume metastatic tumour-derived cells would grow optimally under identical conditions to 
their primary, epithelial-like counterpart. 
1.6.2.2 Validation 
The purity and success of a PDCC can be validated through its specific epithelial phenotype 
to exclude contamination by mesenchymal cells such as fibroblasts. This can be best achieved 
using cytokeratin-specific antibodies for epithelial cells (Chi Scientific, 2007; Fuertes et al., 
2013). Complex epithelial cytokeratin (CK) found in the skin include CK5/6, CK10, CK14, 
and CK15 (Fuertes et al., 2013). 
Endothelial cells can be identified using CD31 or factor VIII-related antigen. Positive staining 
of contaminating mesenchymal fibroblasts in cSCC primary cultures is difficult as the 
routinely used mesenchymal marker vimentin is overexpressed in this cell type. Another 
mesenchymal marker α-smooth muscle actin (αSMA) may also be used. A caveat of culturing 
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metastatic PDCCs is they require more thorough validation given the cells have undergone 
processes of EMT/MET and may be harder to differentiate from mesenchymal cells. 
1.6.3 Cell culture techniques 
The successful isolation and survival of PDCCs can hinge upon the technique chosen in the 
beginning for in vitro culture. Ratushny et al., (2012) summarised the strengths and 
weaknesses of common techniques for tumour cell isolation and growth, presented in Figure 
1.22 below. These are discussed in further detail in the following sections. 
 
Figure 1.22 Commonly used cell models for studying cSCC. Adapted from Ratushny et al., (2012). 
1.6.3.1 Two-dimensional (2D) culture systems 
For more than 40 years, in vitro cell growth has been supported in the two-dimensional plane 
typically using polystyrene or glass (Haycock, 2011). Despite the many published studies that 
have relied on these methods, using a cellular monolayer oversimplifies the complexities of 
three-dimensional mammalian physiology. The lack of tissue-architecture found in 2D culture 
abolishes important functions based on this tissue-context (Pan et al., 2009). As this culture 
method is not an accurate representation of the tumour microenvironment found in vivo, 
biological responses may vary greatly between the tissue of origin and the cultured progeny. 
Known differences include altered gene expression profile, metabolic functions, cellular 
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migration, sensitivities toward drugs and physical stimuli, migratory behaviour, and apoptosis 
(Haycock, 2011; Leung et al., 2015). 
Despite this, globally 2D models remain routine practice for maintaining cultures for 
experimentation. For example, 2D cell culture platforms have been the preferred choice for 
high-throughput screening due to their compatibility with robotics, liquid-handling systems, 
and imaging platforms (Leung et al., 2015). Many of these procedures are simply not yet 
compatible with more complex systems. Understandably as a result, researchers will 
frequently opt for the gold-standard 2D system. 
Contrary to a 2D monolayer formed from a single-cell suspension, explant-cell culture 
systems may be utilised with greater success (Mitra et al., 2013). In this system, small pieces 
of tumour tissue (~2 mm3) are cultured on a nutrient-rich medium to achieve an epithelial 
outgrowth from the explant. The benefit of this technique is it facilitates the retention of 
native tissue architecture and microenvironment, whilst the pitfall is the cell lines may 
experience genetic variability and phenotypic drift due to improper topology (Mitra et al., 
2013). 
1.6.3.2 Three-dimensional (3D) culture systems 
A caveat of 2D cell lines is that they may undergo genotypic and phenotypic drift, promoted 
by the loss of host tissue context (Pan et al., 2009). To more accurately reflect the 3D 
spatiality and physiology of tumours in vitro several systems have been developed whereby 
cultured cells can form a 3D mass, with or without the presence of a scaffold, among other in 
vivo-like characteristics. 
A large body of work has emerged in recent years surrounding the advantageous use of 3D 
culture methods (Sharma et al., 2010; Kimlin et al., 2013; Heidari Kani et al., 2017; Nunes 
et al., 2019). Undoubtedly, these advances represent a paradigm shift in not only how 
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experiments are designed moving forward, but also allows doubt to be cast upon prior studies 
relying simply on a 2D plane. For example, poor drug efficacy seen in a 2D culture system 
may have abolished its further investigation, whilst it may have worked in the 3D system, and 
by extension, the clinical setting or vice versa. Researchers may shy from using 3D cultures 
due to the greater amount of labour required, particularly for those involving a scaffold. 
However, the results obtained from using these may be more valid and negate the need for 
unnecessarily high numbers of replicates, as is the case for 2D assays.  
Through the use of non-adherent or ultra-low binding culture vessels, cells can spontaneously 
form aggregates called spheroids (Freshney, 2010). These spheroids come closer to in vivo 
conditions for certain applications. Particularly in cancer research, spheroids are powerful 
tools for examining tumour progression, viability and for conducting drug screening due to 
the hypoxic core which results in greater chemoresistance. Not all tumour cell lines can grow 
in spheroid culture (Sharma et al., 2010), therefore it is important in the early stages of 2D 
cell culture establishment that this ability is assessed. Failure to grow as a spheroid may cause 
cessation of the cell line as a candidate for further pre-clinical research. 
A major downside in using 3D culture systems is their low compatibility with high-
throughput systems of analysis. Leung et al., (2015) attempted to alleviate this concern by 
investigating a 3D collagen cell system on a microscale in a 384-well plate. This allowed for a 
3D cellular environment within a plate capable of interacting with current high-throughput 
system infrastructure. Using this system, the cytotoxic effects of therapeutics against breast 
cancer cells were compared between those in 2D culture and those embedded in 3D 
microgels. Their study indicated that culturing cells in a 3D matrix rather than 2D lead to the 
alteration of cell phenotype and function, particularly differentiation, proliferation and 
survival. Their collagen-embedded cells displayed a substantial decrease in chemosensitivity 
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towards the tested drugs. Utilisation of this method in drug-screening may likely merit 
downstream significance. 
However, there exists a trade-off between in vivo resemblance and reproducibility, as the 
greater complexity with these systems increases the variability in results (Verjans et al., 
2018). 
1.6.3.3 Patient-derived xenografts 
Patient-derived xenografts (PDX), whereby tumour cells are directly implanted into 
immunocompromised mice, may propose a better system to retain original tumour physiology 
(Choi et al., 2014; Goodspeed et al., 2016). The use of direct PDX for metastatic cSCC 
culture is seemingly barren in the literature. 
A study by Dangles-Marie et al., (2007) compared the success rates of establishing human 
colon cancer cell lines from immediate in vitro culture and tumour xenografts. They were able 
to successfully establish 77 % of their tumour specimens in nude mice, of which 47 % led to 
cell lines; whereas only 9.7 % of tumour specimens grew immediately in vitro from the 
primary tumours. Given this, whilst PDX models are not always suitable for high-throughput 
drug screening, they can aid in the establishment of cell lines in the first instance. 
Whilst orthotopic tumour implantation in an animal may confer a greater translational 
advantage due to the tumour developing in the same anatomic microenvironment (Hidalgo et 
al., 2014), this is not feasible with loco-regional cSCC metastases as they are sourced from 
lymph nodes. A lymph node orthotopic model for tumour engraftment would be surgically 
complex and highly subject to failure. 
Sustaining growth through a PDX model is exceptionally costly. To ease the burden, cell lines 
can sometimes be used as an affordable way to store cellular genetic information for eventual 
restoration of phenotype when reimplanted into the animal. This approach is discussed in 
48 
 
greater detail in Chapter 3. Whether the phenotype of metastatic cSCC can be restored from 
cognate cell lines through xenograft has yet to be investigated prior to the current study. 
1.6.3.4 Intermediate tissue culture systems 
It is not always possible to study cell migration in the context of a living organism. Therefore 
intermediate tissue culture systems such as cell-derived matrix, Matrigel®, organotypic 
culture, and organoid culture are useful experimental intermediates (Timpson et al., 2011; 
Mitra et al., 2013). In these systems a faux ECM is created which attempts to mimic that seen 
in vivo, yet allows for experimental manipulation to occur. This further negates the need for 
experiments on living animals.  
Organotypic cultures are one example which can have great utility in understanding cancer 
biology. This technique allows for the investigation of invasion and stromal remodelling in a 
system that better recapitulates the tumour microenvironment (Shamir and Ewald, 2014). In 
this system, tumour cells are seeded onto fibroblast-contracted collagen I matrices (dermal 
equivalents), either as a monolayer or spheroid. The matrices are then exposed to a liquid-air 
interface whereby the tumour cells migrate towards chemo-attractants supplied in the 
underlying growth media (Stark et al., 1999; Timpson et al., 2011), akin to cSCC dermal 
invasion. 
1.6.4 Cell cultures of cSCC 
Cell lines of primary cSCC are abundant in the literature (Kondo and Aso, 1981; Cobleigh et 
al., 1987; Hozumi et al., 1990; Proby et al., 2000; Dooley et al., 2003; Lin et al., 2007; 
Farshchian et al., 2011; Inman et al., 2018), and one commercial cell line named A431 is 
available (Giard et al., 1973). However, A431 originated from the vulva and is not likely to 
have a UV mutational signature definitive of the majority of cSCC cases. Furthermore, A431 
have been shown to not express IL24 even in the presence of a stimulus, despite the fact that 
this gene has been proven to be upregulated in cSCC (Mitsui et al., 2014). Despite these 
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primary cSCC cell lines, there are very few cell lines reported in the literature with their 
origin credited as metastatic cutaneous squamous cell carcinoma (Table 1.2). The American 
Type Culture Collection (ATCC) lists only two commercially available cell lines derived 
from lymph node metastases of cSCC: MS751 and A-388. Both cell lines have been reported 
to form tumours in mice (Fogh et al., 1977), however the specific origin of MS751 is detailed 
as cervix and therefore, similar to A431, very unlikely to carry the distinct UV signature 
associated with sun-exposed symptomatic skin. The primary location from which A-388 was 
derived is not specific in the literature, although given the lymph node deposit was found in 
the neck (Giard et al., 1973), it is reasonable to assume the primary site was proximal to this 
region. Whilst this cell line may seem like a reasonable model of UV-induced metastatic 
cSCC, it was developed in the early 1970’s, prior to our understanding of the importance of 
maintaining a low passage count to prevent genotypic drift. As such, the cells available to 
researchers today have undergone at least 40 passages (Giard et al., 1973; Fogh et al., 1977). 
Basic characterisation of A-388 with its clinical specimen has also not been reported and its 
presence in the literature has faded into obscurity. 
Table 1.2 Reported cell lines derived from cSCC lymph node metastases. Tumour, node, metastasis (TNM) 
staging in accordance to the 7th AJCC cancer staging manual. WD: well differentiated; MD: moderately 
differentiated. 
 Cell line Primary location TNM Histological grade Reference 
UT-SCC-7 Temporal skin T1N0M0 WD Pekkola-Heino, (1992) 
UT-SCC59A Temporal skin T1N3M0 MD Farshchian et al., (2011) 
UT-SCC115 Auricular skin T2N2aM0 MD Farshchian et al., (2011) 
MET4 Skin of hand NA NA Proby et al., (2000) 
IC1MET Temporal skin NA NA Inman et al., (2018) 
 
All of these abovementioned cell lines were cultured in DMEM supplemented with 6 mM L-
glutamine, non-essential amino acids, and 10 % foetal calf serum (FCS), with the exception of 
MET4 and IC1MET which were cultured in accordance to the protocol initially defined by 
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Rheinwald and Green, (1975) with later refinement by Purdie et al., (2011), utilising 
DMEM/F12 supplemented with a mitogen cocktail, 10 % FCS, and human epidermal growth 
factor (hEGF) (after 48 hrs). A search of the literature revealed UT-SCC7, UT-SCC59A, and 
UT-SCC115 have not been validated molecularly as accurate reflections of their originating 
tumour, nor has evidence of tumourigenicity been published. Additionally, the passage 
number of the UT-SCC series have been reported to be comparatively high (up to 25 
passages) by contemporary standards (Pekkola-Heino et al., 1995). MET4 has been 
documented to form a tumour in mice but phenotypic comparisons to its originating tumour 
are limited. Tumourigenicity of IC1MET has not been reported and gene expression assays 
have only compared IC1MET against normal human keratinocytes (NHKs), not against the 
originating tumour. However, mutation signature analysis and whole-exome sequencing have 
revealed the genomic profile of IC1MET and MET4 to be comparable with those of the 
tumour samples (Inman et al., 2018).  
In summation, only a limited number of continuous cell cultures of metastatic cSCC have 
been developed, and none have been sufficiently characterised against their originating 
tumour. Multi-omic technologies are necessary to confirm the suitability of all newly derived 
PDCCs as models of their disease. Whilst this may appear pedantic, the results from a pre-
clinical model can have enormous implications, therefore early characterisation and validation 
is paramount. Even if commercial cell lines of metastatic cSCC were plentiful, it may still be 
necessary to develop new cell lines from primary cell cultures as commercial supplies might 
not always resemble the heterogeneity of a disease correctly. For example, only a fraction of 
non-small cell lung cancer cell lines were found to possess activating mutations in EGFR 
despite the presence of this mutation in some clinical cases (Cree, 2011).  
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1.7 SUMMARY, PROJECT RATIONALE & THESIS AIMS 
Cutaneous squamous cell carcinoma (cSCC) is one of the most common malignancies in 
Australia and is a major health resource burden. Metastasis occurs in up to 5 % of cases and 
can be fatal or greatly impact quality of life. Despite this, cSCC is a grossly understudied 
disease and there remains an unacceptable deficiency in our understanding of the molecular 
foundations that determine the sporadic metastasis of an otherwise docile disease. 
Whilst early treatment for metastatic disease significantly improves mortality, there are no 
definitive prognostic markers of metastatic potential. Novel targets must be identified to 
provide a route for targeted therapy or precision medicine (in accordance to an individual 
tumour’s phenotype). Given the significant genetic variation between cSCC of different 
patients, an extensive archive of metastatic samples must be curated for powerful and deep 
multi-omic analysis. Even upon identification of metastatic disease, the current treatment 
options are highly invasive and significantly impact the quality of life for those affected. As 
such, novel therapeutic strategies must be investigated. The efficacy of platinum 
chemotherapeutics and/or nanoparticles in combination with radiotherapy for treating 
metastatic cSCC must also be empirically defined as this has yet to be substantiated in the 
literature. A laboratory model of the disease is therefore required for pre-clinical assessment. 
Few cell lines of metastatic cSCC exist and their validity as models of this disease is 
questionable. This hampers empirical laboratory-based investigations, such as high-
throughput drug screening, that could otherwise fill these gaps in understanding and 
treatment. As such, the development and validation of continuous patient-derived cell cultures 
of metastatic cSCC is necessary to facilitate our understanding of the disease through 
characterisation and therapeutic screening. Upon establishment and validation of PDCCs, 
these cell models, as well as clinical specimens, can be characterised for traits that endow 
metastatic potential. Significant changes in the expression/activity of associated biochemical 
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pathways may be focused on as a therapeutic target or biomarker of disease, particularly those 
involved in metastatic progression or persistence. Such analyses are critical in developing 
clinical applications that may hold promise for future treatment of metastatic cSCC and 
ultimately improve patient outcome. 
The overall aim of this thesis was to establish patient-derived cell cultures and to use these, 
along with clinical specimens, to help elucidate the unique biological properties and drug 
sensitivities of metastatic cSCC. The specific aims assigned to achieve this were as follows:  
1. Develop 2D and 3D patient-derived cell cultures from fresh nodal metastases of cSCC 
to serve as a model of disease (Chapter 2). 
2. Assess the fidelity of PDCCs with regards to their tumour of origin (Chapter 3). 
3. Identify potential biomarkers and drug targets through genotyping and phenotyping of 
the novel PDCCs as well as clinical specimens of primary cSCC, metastatic cSCC, 
and normal skin (Chapter 4). 
4. Evaluate the inhibitory or cytotoxic efficacy of novel and established therapeutics in 
both 2D and 3D systems, as guided by aim 3 (Chapter 5). 
5. Empirically determine the clonogenic survival of PDCCs in the presence or absence of 
platinum-based therapeutics, nanoparticles, and radiotherapy (Chapter 6). 
These aims will be addressed in the chapters denoted above, with a holistic discussion on the 
significance of this project provided in Chapter 7. Together, the fulfilment of these aims 
through contemporary methodologies has advanced our understanding of metastatic cSCC 
biology.  
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CHAPTER 2: ESTABLISHMENT OF PATIENT-DERIVED 
METASTATIC CSCC CELL CULTURES - BEDSIDE TO 
BENCH 
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2.1 INTRODUCTION 
The isolation and expansion of patient-derived cSCC cell cultures in either two-dimensional, 
three-dimensional, or organotypic formats permits their future use as in vitro models for 
biomarker discovery and rapid pre-clinical drug testing, among many other applications 
(Figure 2.1). 
 
Figure 2.1 Applications of cell lines. Taken from Freshney, (2010). 
In the absence of validated commercial cell lines or researcher stocks of metastatic cSCC cells 
(see Chapter 1, section 1.6.4), PDCCs must be established and validated to further research on 
this disease. Bespoke cell cultures have been created for other cancer types when researchers 
have demanded faithful ex vivo representations of primary tumours, such as those presented 
by Li et al., (2017), Qin et al., (2016), and Wang et al., (2017). Such an undertaking for cSCC 
is immensely easier said than done as keratinocytes are particularly difficult to isolate and 
culture (Chi Scientific, 2007; Rasmussen et al., 2013) and therefore require extensive 
optimisation. Molecularly, cSCC can vary greatly between patients (Ashford et al., 2017; 
Zilberg et al., 2017; Mueller et al., 2019), likely affecting cellular phenotype and 
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consequently the amenability of the cells towards in vitro cell culture. Because of this, the 
techniques that may provide a viable cell culture for one tumour may completely fail for 
another. It is also problematic to fragment a tumour into pieces and expose each to a different 
treatment, for the sake of capturing the optimal growth conditions, as this will inherently 
discard most of the heterogeneity found within the tumour itself. As such, the best current 
approach is to identify a general suite of conditions and techniques that will benefit the 
establishment PDCCs from the majority of cSCC cases. 
Purdie et al., (2011) has published methods for primary SCC keratinocyte isolation, yet 
considering the major differences between cells from primary sites and those that have 
undergone EMT and metastasised, these methods are not guaranteed for developing 
metastatic cell lines. While metastatic cSCC cell lines have been reported, there has yet to be 
any study to date that specifically details the optimal methods needed to establish cultures 
from metastatic cSCC. 
Fibroblast contamination is frequently an issue in early cell cultures whereby they may 
respond to tumour-derived mitogenic factors and eventually outcompete tumour cells (Turin 
et al., 2014). To circumvent this, media composition, incubation oxygen levels, seeding 
density, and other factors must be tailored to retain tumour cell viability and prevent genetic 
drift, whilst depleting fibroblast growth. However, when possible it may also be favourable to 
isolate fibroblasts and culture separately for use as cancer-associated fibroblasts (CAFs) in 
future assays (Kalluri and Zeisberg, 2006; Commandeur et al., 2011; Madar et al., 2013). The 
use of an irradiated feeder-layer of 3T3 fibroblasts to facilitate cSCC cell adhesion has been 
reported (Pourreyron et al., 2011; Purdie et al., 2011), however due to the formulation of 
specialised media, this technique is largely redundant and possesses its own technical 
obstacles. For example, activation of 3T3 cells must be kept under control and contamination 
by viable 3T3 cells must be avoided (Guo and Jahoda, 2009). A cell line of primary cSCC has 
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previously been established by Kondo and Aso, (1981) using 3T3 cells, although this is more 
so a testament to the age of the study and the available technology than an endorsement for 
the contemporary use of feeder layers. 
Purification of epithelial cultures from fibroblasts can be achieved through numerous 
strategies such as: selective killing with geneticin (G418), cell separation using anti-fibroblast 
microbeads, differential trypsinisation, and continuous expansion and passage of cultures 
(Horikawa et al., 1996; Freshney, 2010; Mitra et al., 2013; Kodack et al., 2017). Fibroblasts 
favour high-serum content, although cancer cells can survive lower concentrations when 
supplemented with additional components such as hEGF, non-essential amino acids, insulin, 
transferrin, and cholera toxin. 
Once established, cultures should be validated through positive detection of epithelial or 
cancer-specific markers. This is necessary as cancer cells have undergone EMT, usually 
resulting in a somewhat mesenchymal morphology, similar to fibroblasts, making 
determinations of the cell population by eye difficult. As EMT can also result in lower 
expression of epithelial cell surface markers, multiple markers should be used to confirm the 
nature of the cells. CK-5 is an ideal epithelial marker as it is a routinely used epithelial 
differentiation marker that is complex and found in the skin (Fuertes et al., 2013). Epithelial 
Cell Adhesion Molecule (EpCAM) antibodies can be also be used to positively identify 
epithelial cells (Morosin et al., 2016; Chia et al., 2017; Wang et al., 2017), whereas α-SMA 
can be used to identify mesenchymal cells (Fuertes et al., 2013). 
As a method of confirming parental physiology, the tumourigenicity (ability to form a 
malignant tumour) of cell models can be assessed in mice. This is the gold-standard method 
for proving the culture is derived from tumour cells. Animal models remain crucial to toxicity 
testing of new treatments (Wilding and Bodmer, 2014); therefore if a culture cannot form a 
tumour within an animal model, then it is fundamentally prohibited from progressing most 2D 
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experimental results any further into clinical applications (Sharma et al., 2010). Following 
confirmation of the nature of the cell lines, they must also be assessed for their faithfulness to 
the originating tumour. Significant genotypic or phenotypic drift would similarly result in a 
futile model (Kimlin et al., 2013). Techniques for assessing this fidelity are discussed 
extensively in Chapter 3. Once validated as pure epithelial cultures and characterised as 
faithful representations of their originating tumour, the PDCCs may serve as a model of 
disease providing information on basic biology and therapeutic response via their 
compatibility with high-throughput screening systems. 
Two-dimensional cell culture has attracted much criticism compared to other more 
physiologically relevant in vitro systems such as spheroid culture, organoids, organotypic 
cultures, and other co-culture systems (Haycock, 2011; Kimlin et al., 2013; Ravi et al., 2015). 
Three-dimensional culture is one of the fastest growing experimental approaches in life 
sciences with constant advancements being made in 3D cell culture imaging and analytical 
systems (Tung et al., 2011; Weigelt et al., 2014; Ravi et al., 2015; Heidari Kani et al., 2017; 
Lee et al., 2017). However, for the purpose of high-throughput analyses and preliminary 
investigations of basic cell biology, most 3D systems are currently impractical due to 
incompatibility with high-throughput assays, cost, and labour. 
Nonetheless, due to the above-mentioned benefits of 3D culture, the generation of spheroids, 
organotypic cultures, and animal tumours from a 2D culture is of high importance and should 
be assessed for each new culture. However, this can also be met with many challenges as the 
optimal methodologies for doing this with metastatic cSCC have not yet been published. 
Basic cell biology research on cSCC may be lacking as researchers have been deterred from 
attempting to generate their own cell lines without guidance, and they have simply been 
unable to acquire a validated culture. To fill this void, varied tissue culture processing, 
growth, and purification methods were investigated in the current study to generate a basic 
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protocol for the establishment of 2D and 3D patient-derived cell cultures of cSCC from lymph 
node metastases. In light of the aforementioned issues, the specific aims of the 
experimentation presented in this chapter were to:  
1. Identify the optimal methodology required to establish pure 2D & 3D cultures of 
cSCC metastases. 
2. Validate resulting PDCCs as tumourigenic in mice. 
3. Evaluate the basic characteristics of the resultant PDCCs including morphology, 
growth, and migratory abilities. 
 
 
 
 
 
 
 
 
 
  
59 
 
2.2 METHODS 
2.2.1 Patient characteristics and specimen collection 
Tissue and blood were obtained with written informed patient consent in accordance to the 
declaration of Helsinki and University of Wollongong Human Research Ethics Committee 
(HE14/397) approval. All tissue samples (n=30) for cell culture were collected from 
Wollongong hospital or Wollongong private hospital, Australia. All patient samples of 
metastatic disease were taken from involved lymph nodes, largely within the parotid gland. 
Histological diagnosis of cSCC was confirmed by Dr Ruta Gupta (Staff specialist, 
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 
Camperdown, Australia) and clinical staging of the tumour was performed in accordance to 
the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging manual. 
Tumours destined for cell culture were surgically removed by Dr Bruce Ashford (Illawarra 
and Shoalhaven Local Health District, Wollongong, Australia). For many patients this 
involved radical neck dissections inclusive of parotidectomy and clearance of associated 
lymph nodes. Samples for cell culture were favourably those with a high neoplastic content 
(30 – 90 %) without necrosis, haemorrhage, high keratin content or significant inflammation. 
Under sterile conditions within the operating theatre, resected tumours were placed into 
specimen collection jars containing cold phosphate buffered saline (PBS) supplemented with 
1 % penicillin/streptomycin. Contained samples were immediately placed onto ice and then 
transported to the Illawarra Health and Medical Research Institute (IHMRI) for tissue 
processing. Due to the proximity of the hospital to IHMRI, processing of tumours was able to 
be initialised within 30 minutes post-resection. 
Any resultant patient-derived cell cultures were named in accordance to the guidelines 
stipulated by Geraghty et al., (2014) and Freshney, (2010) to ensure donor anonymity and 
enhance cell line identification for researchers. This format is inclusive of an origin identifier 
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(e.g. UW for University of Wollongong), a tissue identifier (e.g. CSCC), and a number to 
identify the specific cell line in the given series. Any clones/cell line derivations (strains) were 
designated with a suffix to the original designation, e.g. ‘-R’ to denote a radio-insensitive 
strain. At the time of submission, all cell line names presented herein have been confirmed 
through a literature search to be unique from other biological resources. 
2.2.2 Optimisation of tissue processing 
Multiple techniques were employed to identify their effectiveness in successfully establishing 
metastatic cSCC cell cultures. Numerous factors assessed included: homogenisation method, 
basal medium, serum concentration, growth factors and nutrients, attachment substrate, 
incubation conditions, seeding density, and purification strategies. 
Given the large heterogeneity of cells in a tumour, tissue homogenisation is generally 
preferred for cell culture as this gives each cell population the opportunity to clonally expand. 
Tissue can be dissociated into single-cell suspensions by combining mechanical dissociation 
with enzymatic degradation of ECM components. Modifications were frequently employed to 
a standard laboratory protocol to optimise conditions for epithelial isolation, surface 
attachment and competition over fibroblast growth. However, all non-explant methods relied 
upon initial mechanical dissociation using forceps, scalpel or scissors, in the presence of 
dissociative enzymes. Sterility was maintained by performing all direct sample handling 
within a biosafety cabinet. 
Initially, single-cell suspensions were produced using the MACs Miltenyi human tumour 
dissociation kit in conjunction with the gentleMACS dissociator (Miltenyi Biotech, 
Germany), as per the manufacturers’ protocol. This kit is optimised for tumour dissociation 
and preserves cell surface epitopes by utilising a proprietary cocktail of dissociation enzymes, 
inclusive of collagenase. Briefly, excised tumours were minced into 1 – 2 mm3 fragments and 
submerged in an enzyme cocktail. This tumour containing mix was transferred into a C-tube 
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(Miltenyi Biotech, Germany) with additional media and subject to three bouts of 36-second 
mechanical disaggregation (program h_tumour_01) in the gentleMACS dissociator 
interspersed by two 30 minute incubations at 37°C after the first and second disaggregation 
steps. A modification to the protocol involved the manual agitation of C-tubes every 5 
minutes as the recommended MACSmix Tube Rotator was unavailable. The use of the 
gentleMACs dissociator was halted once realised it may be too aggressive for this cell type, 
potentially shearing otherwise viable cells. In response, the majority of subsequent samples 
were incubated for 12 – 18 hours in the enzymatic dissociation mix using a water bath heated 
to 37°C in the absence of homogenisation or agitation. 
In either case, dissociated tissue was passed through a 70 µm MACS SmartStrainer (Miltenyi 
Biotech, Germany) along with 5 mL of cold PBS. The filtrate was centrifuged at 300 × g for 5 
– 7 minutes to form a pellet. Supernatant was discarded, the pellet re-suspended in culturing 
media, and plated onto a culture vessel. Undigested debris caught by the strainer was placed 
directly onto a cell culture vessel with the appropriate media to facilitate growth of any 
undisrupted cells. A cell count was not performed prior to plating as there were too many 
artefacts in the solution to obtain a reliable cell count. 
Due to the continued shortcomings observed with the above approaches, an explant technique 
was also trialled. For the explant strategy, excised tumours were simply washed with PBS, 
dissected into 1 – 2 mm3 fractions and transferred directly onto the surface of a tissue culture 
vessel with the appropriate media. New cultures were monitored closely for the first 72 hours 
to ensure there was sufficient media and growth area. Rather than discarding medium 
containing unattached cells that may grow, at the first medium change this spent media was 
put into a fresh flask. 
2.2.3 Cell culture maintenance 
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2.2.3.1 Two-Dimensional (2D) cell culture 
All samples were firstly attempted to be grown as a monolayer. Culture vessel of choice was 
largely dictated by the abundance of cells present (determined through visual inspection of the 
pellet size), i.e. the more cells, the larger the vessel surface area. Quite often twelve- or six-
well tissue culture treated plates were used in early stages as they provided ample surface area 
for cells to attach and enabled multiple conditions to be trialled within the one plate. Flasks 
larger than 25 cm2 were seldom used for early passages. In one case, plates were coated with 
commercial grade collagen-I at a density 10 µg/cm3 to provide a supportive framework for 
cells to adhere to. These collagen-coated plates were allowed to set overnight in an incubator 
and washed with sterile PBS prior to cell seeding. 
Originally, cells were cultured in either Roswell Park Memorial Institute (RPMI) medium or 
high glucose (4,500 mg/ml) Dulbecco’s Modified Eagle Medium (DMEM), supplemented 
with 10 % heat inactivated FCS. A titration of FCS concentration with these basal media was 
also performed at 1 % and 10 %. For the sake of brevity, all further mentions of DMEM refer 
to DMEM containing 4,500 mg/mL glucose unless otherwise specified. Media formulations 
used are detailed in Appendix A. 
A more complex media formulation, Advanced DMEM/F12 (Gibco™), hereafter ADMEM, 
was used based on a protocol for the establishment of primary cSCC cell lines (Purdie et al., 
2011) which suggested benefit in using this media type. This specialised growth medium 
contains additional amino acids and other growth regulators such as, transferrin, insulin, and 
sodium selenite. This offered enhanced growth nutrients, although required supplementation 
with 4 mM of L-glutamine. These factors allowed for a reduced concentration of serum for 
epithelial cell growth. As such, a concentration range of 1 – 2 % FCS was typically used as 
well as serum-free conditions. Human epidermal growth factor (hEGF; Thermofisher 
Scientific, USA, Cat # PHG0311L) was also added to a final concentration of 20 ng/mL. 
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Cholera toxin was sought for inclusion into media formulations due to its known stimulation 
of epithelial cells, however bureaucratic and fiscal obstacles related to obtaining this toxin in 
Australia prevented its use. 
All trialled media was supplemented with 50 U/mL of penicillin/streptomycin and cells were 
cultured at 37°C under a hypoxic (5 % CO2, 3 % O2) atmosphere. Cells were routinely 
passaged via the addition of 0.05 % trypsin-EDTA, followed by centrifugation and 
resuspension in fresh media. Once established as pure cell lines, cells were typically cultured 
in 75 cm2 tissue-culture flasks (Greiner Bio-One, Austria) and regularly screened for 
mycoplasma contamination using a MycoAlert™ mycoplasma test kit (Lonza Group, 
Switzerland). Cell viability was assessed prior to experimentation via the trypan blue (Sigma-
Aldrich, USA) exclusion method and cell number calculated using a haemocytometer. 
Cell morphology and growth was captured using either the MotiCam 2000 digital camera 
with eyepiece attachment (Motic, Hong Kong) or with the high resolution IncuCyte™ ZOOM 
kinetic imaging system (Essen Bioscience, USA) with parameters adjusted according to the 
experiment. Considering the IncuCyte™ ZOOM was contained within an incubator with 
standard atmospheric O2 levels whilst the cells were culture in hypoxia, imaging within this 
system was limited so as to avoid normoxic-shock and subsequent cell death. 
2.2.3.2 Three-dimensional (3D) cell culture 
3D-spheroid cultures were attempted to observe the propensity for spheroid formation within 
each cell line as well as to provide a 3D platform for downstream experiments. To facilitate 
3D growth, cells were seeded in ultra-low attachment (ULA) plates (Costar® Corning 
Incorporated, USA) and incubated at 37°C in a hypoxic incubator. In later experiments, to 
obtain higher reproducibility in spheroid shape for downstream assays, cells were centrifuged 
in the 96-well ULA plates at 209 × g for 3 minutes after seeding, promoting a central cluster 
of cells. Spheroid formation and growth was monitored every 24 hours at 10× objective using 
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the IncuCyte™ ZOOM kinetic imaging system, with specific attention towards the diameter 
and shape of the spheroid in response to the given treatment. Seeding density in 96-well ULA 
plates was optimised to produce the tightest spheroids by plating cells in varying 
concentrations. The seeding density used for 6-well ULA plates was 0.3 x 106 cells/well. 
Spheroid growth medium was determined by comparing spheroid morphology in DMEM and 
RPMI containing 10 % FCS. A specially formulated media thought to promote spheroid 
growth was also assessed. This media was referred to as ‘spheroid media’ and comprised of 
ADMEM supplemented with L-glutamine (4mM), FCS (1 %), hEGF (20 ng/mL), basic 
fibroblast growth factor (bFGF) (10 ng/mL), penicillin/streptomycin (50 U/mL), 
hydrocortisone (50 nM), and N-2 (1X). Following this, growth in DMEM was also compared 
at concentrations of 10, 5, and 1 % FCS. 
2.2.3.3 Epithelial-Stromal isolation and purification 
To isolate cancerous epithelial cells from competing stromal components, such as fibroblasts, 
a number of techniques were utilised. Initially, the antibiotic G418 (geneticin) was used as 
cancer cell lines tend to be relatively resistant to G418 at low concentrations (25 – 50 µg/mL) 
for a short period of time (3 – 7 days) whilst fibroblasts, among other primary contaminating 
cells, are sensitive to this level of antibiotic and usually die during this incubation period 
(Inagaki et al., 1994; Horikawa et al., 1996; Ji et al., 2000). To determine an optimal 
concentration range, a titration of G418 was performed at concentrations of 50, 25, and 10 
µg/mL in DMEM (10 % FCS/P+S) for 72 hours. The media was subsequently refreshed to 
remove G418 and the cells monitored for viability. 
Human anti-fibroblast microbeads (Miltenyi Biotech, Germany) were also used for fibroblast 
depletion as per the manufactures protocol. Differential trypsinisation was frequently used to 
purify epithelial cells. In this method, 0.05 % trypsin-EDTA was added to the culture vessel 
and incubated in 30 second intervals with frequent checks performed under a light microscope 
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to monitor cell detachment. Using the notion that fibroblasts will detach sooner than epithelial 
cells, media containing serum is added prior to epithelial detachment to quench the effects of 
the trypsin-EDTA and detached cells were discarded or plated into another flask. This 
quenching occurred when epithelial cells appeared rounded and formed a ‘halo’. This was 
performed repeatedly over time to diffuse the fibroblast population, allowing epithelial cells 
to propagate until they represented all of the cell population. In some circumstances, 
fibroblast cultures were also generated by collecting the detached fibroblasts population. 
Isolated fibroblasts were often kept as frozen aliquots for future reference due to the role 
cancer-associated fibroblasts demonstrate in cancer progression (Madar et al., 2013).  
The utility of hEGF and bFGF in supporting epithelial or mesenchymal cell growth was 
briefly assessed in the form of a co-culture experiment, consisting of varying ratios of 
epithelial cells to telomerase immortalised fibroblasts (TIFs) in the presence or absence of 
these growth factors (at 0.01 % concentration). 
2.2.4 Generation of a radio-insensitive population 
Cells were irradiated using a Therapax DXT300 Series 3 Ortho-voltage radiation therapy 
treatment system (Pantak, USA) by Dr Stephanie Corde within the Department of Radiation 
Oncology, Prince of Wales Hospital, Randwick, Australia. A 12.5 cm2 flask containing cells 
under 6 mm of complete medium were irradiated horizontally at a distance of 30 cm from the 
x-ray source using a 6×8 applicator in full scatter conditions, including a solid water 
equivalent of gelatin below (10 cm backscatter) and adjacent to cells. X-rays were generated 
at 125 kVp with a beam current of 20 mA using inherent filtration of 3 mm Be and an 
additional 0.1 mm of copper and 2.5 mm of aluminium (HVL = 6.8 mm Al). These X-rays 
were used to irradiate the cells with a dose rate of 5 Gy/min, totalling a clinically relevant 2 
Gy or 5 Gy dose of orthovoltage radiation, depending on the experiment. Following exposure, 
growth media was refreshed and the cell cultures incubated under hypoxic conditions at 37°C, 
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allowing for the propagation of surviving cells. Growth media was refreshed every day for 
four days to remove debris resulting from dead cells. 
2.2.5 Validation and preliminary characterisation of cell cultures 
2.2.5.1 Immunocytochemistry 
Immunocytochemistry (ICC) was performed to confirm the epithelial nature of the cultures 
using antibodies specific to cytokeratin 4/5/6/8/10/13/18 (pan-cytokeratin CK223, 1:200 
dilution; Abcam, Cat # ab115974) and epithelial cell adhesion molecule (EpCAM, 1:200 
dilution; Abcam, Cat # ab7504), as well as the mesenchymal marker α-smooth muscle actin 
(α-SMA, 1:100 dilution; Abcam, Cat # ab7817) serving as a negative control. Staining was 
also performed on the established breast cancer cell line MDA-MB-231, serving as a positive 
control for epithelial markers. Human skin-derived telomerase immortalised fibroblasts (TIFs) 
were sourced from Dr Paul Timpson of the Kinghorn Cancer Centre, Darlinghurst, Australia, 
to be used as a positive control for mesenchymal markers (Harris et al., 2017). 
For ICC, slides were prepared by either seeding cells directly onto Ibidi™ 8 well µ-slides 
(Ibidi, Germany) at a concentration of 5,000 cells/well or by centrifugation of 5,000 cells onto 
a glass slide using a Cytospin 2 centrifuge (Shandon-Elliott, United Kingdom) for 6 minutes 
at 1,000 rpm. All samples were fixed in 4 % paraformaldehyde (in PBS) for 30 minutes at 
4°C and permeabilised in 0.25 % Triton X-100 for 5 minutes at room temperature prior to 
staining, except in the case of EpCAM-stained samples as this will disrupt the surface-bound 
proteins and produce background overlaying the specific staining. Cells were then blocked 
with 10 % FCS in PBS for 30 minutes at room temperature and washed with PBS. Cells were 
incubated with primary antibodies for 45 minutes at room temperature, washed with PBS, and 
then incubated with the secondary antibody (anti-mouse IgG Alexa-Fluor488, 1:500 dilution; 
Abcam, Cat # ab150101) for 45 minutes at room temperature. All antibodies were diluted in 
10 % FCS in PBS. The nuclear stain RedDot2 was introduced to samples via a 30 minute 
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incubation at room temperature after dilution to 1× in dH2O. Samples were washed again with 
PBS before adding ProLong™ Diamond antifade mountant (Thermo Scientific, USA, Cat # 
P36961) and coating with a coverslip. Fluorescent antibody-labelled cells were imaged using 
a Leica DMI 6000 SP8 laser scanning confocal fluorescence microscope (Leica, Germany) or 
on a Leica DMi8 inverted fluorescence microscope (Leica, Germany). 
2.2.5.2 Growth in immunocompromised mice 
Animal experiments were performed in compliance with the University of Wollongong’s 
Animal Ethics Committee, under ethics approval AE1517. NOD scid gamma (NOD.Cg-
Prkdc<scid>IL2rg<tm1Wjl>/SzJAusb) mice aged 4 – 5 weeks old were obtained from 
Australian Bioresources (Moss Vale, Australia) and were housed in autoclaved individual 
ventilator cages. These mice lack mature T cells, B cells, functional NK cells, and are 
deficient in cytokine signalling. Following a one-week acclimatisation period, mice were 
inoculated subcutaneously with cells on either rear flank via a 21-gauge hypodermic needle 
and syringe. In preparation for injection, cells were detached from the culture vessel with 
PBS-EDTA (to maintain surface receptors) and adjusted to the required concentration in ice-
cold PBS containing calcium and magnesium. To identify the appropriate number of cells 
necessary to form tumours, a concentration gradient of cells were used ranging from 2.5 ×105 
to 2 ×106 cells in a total injected volume of 100 µL per flank. A 10 % excess was used to 
account for loss of volume in transfer. 
2.2.5.3 Population doubling time 
The growth rate of PDCCs in 2D was assessed by seeding 200,000 cells in triplicate into 6-
well tissue culture plates, and counting live cells at 24 hour intervals over 5 days using a 
haemocytometer. Doubling time was calculated using the formula: 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 =
 
𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛∗log (2)
(𝐹𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)−log (𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝐶𝑜𝑛𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
. Only the final four data points were included for 
analysis to capture cells in the log phase of cell growth. 
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2.2.5.4 Hypoxia response 
Initially, the optimal seeding density of the PDCCs across both normoxic (~20 % O2) and 
hypoxic (3 % O2) conditions via a clonogenic survival assay was sought. For this experiment, 
cells were first acclimated for one week in the respective atmosphere and then plated in 
duplicate onto tissue-culture petri dishes (100 mm × 20 mm Falcon BD; Pacific Laboratory 
Products) in 10 mL of DMEM (10 % FCS/P+S) at the following cell densities per dish: 1,000, 
1,500, 2,500, 3,000, and 3,500. The plates were then processed as per the full clonogenic 
assay method described in Chapter 6. In a separate experiment, PDCCs were simply plated 
onto tissue culture flasks at identical densities and exposed to a normoxic or hypoxic 
atmosphere over 72 hours before being imaged to allow for visual comparisons of cell growth. 
2.2.6 Scratch-wound migration assay 
Migratory potential of cell lines was assessed through a 2D random migration assay. 96-well 
ImageLock plates (Essen Bioscience, USA) were coated with 50 µL of 300 µg/mL collagen I 
and incubated overnight at 37°C. Plates were washed in PBS and normoxic acclimated 
PDCCs (see above) seeded at a density capable of producing 100 % confluency overnight (1.1 
×105 cells/cm2). The plates were scratched using a 96-pin Essen Woundmaker™ (Essen 
Bioscience, USA) as per the manufacturers’ instructions, then washed twice with low-serum 
media (DMEM containing 2 % FCS) and then 100 µL of low-serum media added (to 
minimise cell proliferation effects). The plates were incubated in the IncuCyte™ ZOOM 
kinetic imaging system at 37°C, 5 % CO2 and imaged every 3 hours for 24 hours at 10× 
objective to track cell motility and wound width. IncuCyte™ ZOOM software was used to 
analyse wound width reduction over time. 
2.2.7 Organotypic invasion assay 
This assay consists of generating an in vitro replica of human skin. The steps for this detailed 
in the below subsections can simply be summarised in Figure 2.2. 
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Figure 2.2 Preperation and experimental progression of the organotypic invasion assay. A) Initial Collagen 
I extraction from rat tails is performed via tendon dissection, acetic acid extraction, NaCl precipitation and 
dialysis into 17.4 mM acetic acid, at physiological pH 7.4. B – C) Human or murine fibroblasts are co-cultured 
with harvested Collagen I and the matrices are contracted over a pre-determined time course (5 – 12 days). D) 
Contracted matrices are then seeded with cancer cells in 24-well plates and allowed to grow to confluency. E) 
After this time, matrices are partially submerged on top of a stainless steel, sterile grid to create an air/liquid 
interface. The carcinoma cells are then induced to invade into the underlying stroma by the chemo-attractive 
gradient and quantitation of reductions in the extent of invasion can be used as a measure of anti-invasive 
capacity of added compounds. Image adapted from Conway et al., (2014). 
2.2.7.1 Collagen I extraction and purification 
Collagen I was extracted from rat tails to acquire an affordable supply for organotypic matrix 
construction. Rat tails were obtained from the UOW animal facility and soaked in 100 % 
ethanol to aid in removing the surrounding sheath. A scalpel was used to remove the skin of 
the rat tail and toothed forceps were used to pry the tendons away from the tail. The tendons 
were finely minced using scissors and solubilised in 0.5 M acetic acid over 48 hours at 4°C. 
The collagen extract was filtered through wetted paper towel to remove undissolved rat-tail 
tendon. The filtrate was centrifuged at 15,300 × g using a Sorvall RC6+ centrifuge with a J14 
C) 
A) B) 
E) D) 
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rotor installed (Thermo Scientific, USA) at 4°C for 1 hour and the supernatant collected. The 
collagen I was salted out using 10 % (w/v) NaCl and subsequently centrifuged again at 15,300 
× g (using J14 rotor) at 4°C for 30 minutes. The precipitate was resuspended in 0.25 M acetic 
acid and chilled for 24 hours at 4°C. The collagen solution was dialysed over 4 days against 
17.4 mM acetic acid at 4°C, receiving 6 – 8 changes. The dialysed product was centrifuged at 
30,100 × g (using J14 rotor) at 4°C for 1.5 hours. In a biosafety cabinet, the precipitant was 
collected and resuspended in 17.4 mM acid to the desired concentration (generally between 5 
– 8 mg/mL). The purity of the isolated collagen I was verified by performing an 8 % SDS-
PAGE alongside known concentrations of commercial collagen (Sigma-Aldrich, USA). Both 
the commercially available collagen I and in-house rat-tail tendon collagen extract were 
incubated for 10 minutes at 98°C with β-Mercaptoethanol in a loading buffer. Samples were 
run at 80 V for 30 minutes, followed by an additional 60 minutes at 110 V. Gels were stained 
overnight in Coomassie Blue and subsequently de-stained in methanol for imaging. 
Protein concentration cannot be reliably determined with collagen I using the standard Lowry 
method due to its triple helical structure and specific amino acid content. To circumvent this 
issue a modified Lowry protein assay for collagen concentration measurement described by 
Komsa-Penkova et al., (1996) was used. Absorbance readings were taken using the 
SpectraMax Plus 384 microplate reader (Molecular Devices, USA) at 650 nm, and the protein 
concentration of the samples determined by interpretation of the standard curve generated 
from dilutions of the commercial grade collagen I. 
2.2.7.2 Organotypic matrix formation  
Contraction of collagen I matrices using dermally derived telomerase induced fibroblasts 
(TIFs) were performed as previously described (Timpson et al., 2011). Briefly, contraction to 
a 3D matrix was stimulated by mixing a neutralised collagen I cocktail (8.8 % v/v 10× 
minimal essential media [Thermo Scientific, USA]; 75.8 % v/v 2 mg/mL collagen I; 8 % v/v 
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0.22M NaOH [pH 7.4]) with TIFs (1 × 106 per 12 matrices) resuspended in FCS. The TIFs 
used in this assay are required to be quiescent, which was achieved by leaving the cells in 
culture for at least five days after confluency without a change of media. Per 35 mm petri dish 
(Corning, USA), 2.5 mL of the collagen-fibroblast cocktail was dispensed and allowed to 
polymerise for 30 minutes in an incubator at 37°C. Following this, the petri dishes were 
topped with complete media (DMEM/10 % FCS/P+S) and matrices permitted to contract over 
a period of 5 – 12 days to give a diameter no smaller than 1 cm. The media was refreshed 
every 2 – 3 days or as required depending on the state of the colour indicator present within 
the media. 
2.2.7.3 Organotypic invasion assay 
Contracted matrices were moved into 24-well plates (Greiner Bio-One, Austria) and 100 µL 
of complete media containing 3.0 × 105 of the cells under investigation were seeded atop each 
matrix. After 15 minutes in the incubator at 37°C to allow the cells to settle to the matrix, a 
further 900 µL of media was added to each well and left to grow until confluent. The matrices 
were then transferred onto the top of sterile 40 mm mesh screens in 60 mm petri dishes. Fresh 
media was added until surface tension was created between the mesh grid and media, thereby 
creating an air-liquid interface to promote invasion across the chemotactic gradient (in this 
case the underlying media). 
After 7 – 14 days, the matrices were fixed in 4 % neutral buffered formalin for 24 hours 
followed by another 24 hours in 10 % formalin. The fixed samples were dehydrated in 70 % 
ethanol and processed overnight in an ASP200 vacuum tissue processor (Leica Biosystems, 
Germany). Each matrix was then sliced in half dorsoventrally and embedded in paraffin using 
the EG1150 Modular Tissue Embedding Centre and EG1150 Cold Plate (Leica Biosystems, 
Germany). The resultant paraffin-embedded tissue block was sectioned at a thickness of 4 µm 
using a RM2255 Fully-Automated Rotary Microtome (Leica Biosystems, Germany) and 
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transferred onto glass slides by floating sectioned tissue in a dH2O water-bath at 40°C. Slides 
were allowed to dry overnight prior to histological staining. Sectioned tissue was 
deparaffinised in dipentene (POCD Healthcare, Australia) and rehydrated using graded 
ethanol washes (60 – 100 % EtOH). Haematoxylin and Eosin (H&E; POCD Sciences, 
Australia) staining was performed on a LeicaST4020 small linear stainer (Leica Biosystems, 
Germany) and slides mounted with DPX (Sigma-Aldrich, USA). Following an overnight 
drying period, the invasion incurred by the cells was assessed through examination of slides 
under a Leica DM4000 bright-field microscope (Leica Biosystems, Germany). 
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2.3 RESULTS 
2.3.1 Sample size and general characteristics 
In total, 30 samples of metastatic cSCC tumours were processed for this project. Tumours 
generally weighed between 0.25 – 1.2 grams, exhibiting a white to pink colour with an 
occasional yellow hue and often accompanied by blood, fat, and necrotic tissue (Figure 2.3). 
The integrity and coarseness of the tumours varied greatly, ranging from soft and fragile to 
rigid and dense, determined by the degree of fibrosis/necrosis or cancer cellularity. 
  
  
Figure 2.3 Photographs of typical excised cSCC samples. Tumours may possess adipose tissue adjoining the 
tumour (A), necrosis and dense vascularisation (B), or fibrotic and irregular borders (C). For comparison, a 
disease-unaffected lymph node electively removed is shown (D). 
Generally samples would dissociate completely in the enzyme solution except for some 
undigested globules of fat which were separated from single cells using the cell strainer. 
Following centrifugation of the cell suspension, a red pellet containing erythrocytes amongst 
tumour cells would often form. Erythrocyte lysis buffer was not used as it was deemed 
unnecessary given the low downstream impact of the erythrocytes on epithelial plate 
attachment and the relatively low concentration observed. The supernatant of new primary 
cell culture flasks were replenished 24 hours post-seeding and placed into a new flask to 
A) B) 
C) D) 
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culture any unsettled cells. Microbial contamination (including mycoplasma) was not 
encountered with the primary cell cultures.  
Of 30 samples processed, successful continuous cell lines were established from just two 
(6.67 % success). Cancerous epithelial cells were identifiable at high magnification by way of 
evident polyploidy (Figure 2.4). 
 
Figure 2.4 Micrograph image of cSCC in 2D cell culture. Large nuclei can be seen in multiple copies per cell. 
Imaged at 20x objective. Sample ID OT00015175. Large white spheres are the result of glare from bubbles or 
floating cellular debris. 
Despite numerous cultures exhibiting epithelial cells early on (Figure 2.5), with some able to 
be subcultured for up to five passages, the majority succumbed to fibroblast competition or 
entered into sporadic cell cycle arrest and apoptosis. When epithelial cells did grow, their 
morphology was rather varied in each case, demonstrating inter-patient morphological 
heterogeneity, as shown in in Figure 2.5. The degree of fibroblast contamination varied 
greatly between early cultures and appeared to greatly influence epithelial cell growth and 
morphology. Mostly, cultures displayed squamous-like cell morphology, making distinctions 
from fibroblast populations difficult. This discrimination was able to be ascertained by the 
growth patterns of cells; fibroblasts tended to pack together tightly and develop sheaths with a 
Multiple 
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sense of polarity, whereas epithelial cells grew in clusters with no definitive trajectory. In 
some cases, epithelial cells were observed with an atypical squamous morphology, displaying 
poorly defined cell boundaries with large cytoplasm. In some cases, a mixture of cellular 
morphologies could be seen within a single culture (Figure 2.5 F). 
   
   
 
 
 
Figure 2.5 Morphological variation of cSCC in 2D culture. Various low passage PDCCs at low passage 
exhibiting different cell types and morphology. A) 00183729; B) 193958 early; C) 4447; D) 184136 (primary); 
E) 0263859; F) 0296533; G) 0421606; H) 06764418 I) lymph node fibroblasts. 
2.3.2 Optimisation of tissue processing and cell culture 
2.3.2.1 Homogenisation approach 
Initiating a homogeneous cell mixture was initially a key objective in developing primary cell 
cultures of metastatic cSCC. However, it quickly became apparent that a combination of 
mechanical and chemical disaggregation was far too aggressive on this cell type, leading to 
the shearing of otherwise viable epithelial cells. Whilst some epithelial cells would survive 
A) B) C) 
D) E) F) 
G) H) 
300 µm 
I) 
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this process, the mesenchymal fibroblasts were much more resilient and/or abundant and thus 
thrived in culture with little competition. As seen in Figure 2.6, surviving fibroblasts attached 
to the culture vessel surface whilst sheared cells and other debris drifted in solution. 
 
Figure 2.6 Homogenised cSCC 24 hours post-plating. Sample 184136 viewed with 4x objective. Sheared and 
non-adhered cells can be seen floating in solution whilst the slender fibroblasts have adhered. 
As a consequence, use of the gentleMACs™ tissue homogeniser was abandoned to pursue a 
less destructive route, whilst maintaining a homogenous end product. Crude mechanical 
separation using surgical instruments only and enzymatic digestion proved to be less 
deleterious on epithelial cells. To supplement mechanical homogenisation, samples were 
given an extended period of time submerged in the enzyme solution to achieve a single-cell 
suspension. Whilst this proved successful for overall cell viability, the highly competitive 
fibroblast population remained unyielding. Unexpectedly, epithelial cells would often grow 
from preserved undigested material captured by the cell strainer, but inevitably these all failed 
to survive long-term in culture. 
2.3.2.2 Explant approach 
Alternatively, an explant method was investigated to serve as a simple model of cell culture 
whereby the tumour is roughly diced and plated directly onto the tissue culture vessel. With 
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Dead/non-
adherent 
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this, greater successes in establishing early cultures of epithelial cells was observed, but were 
similarly met with great levels of stromal contamination. This method produced dense 
clusters of cells from which a defined epithelial outgrowth was observable (Figure 2.7).  
                    
Figure 2.7 Explant culture of cSCC. Sample 658492 in explant culture 10 days post-plating. Viewed with 4x 
objective. Epithelial outgrowth is observable from the intact explant. 
This clustering seemed to facilitate epithelial cell survival amongst the competing fibroblast 
populations. These competing cell types are visualised in Figure 2.8. This method produced 
greater success in generating early cultures, although this was at the expense of speed. 
Acquiring a confluent monolayer through this method took approximately three times longer 
than the homogenisation approach and was often met with spontaneous cell cycle arrest. 
 
Figure 2.8 cSCC cell and fibroblasts competing in culture. Sample 658492 viewed with 4x objective. 
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2.3.2.3 Collagen coating tissue culture vessels 
Collagen-coating of the cell culture vessel was explored as a means to provide an additional 
attachment surface for cells. As shown in Figure 2.9, over the course of approximately two 
weeks there was no discernible enhancement in cell surface attachment upon using collagen at 
a concentration of 10 µg/cm2. 
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Figure 2.9 Cell attachment in response to collagen coating. Micrograph images of sample 200971 over time 
in the presence or absence of a collagen film coating the plastic. Imaged with 4x objective. 
2.3.2.4 Media optimisation for early culture establishment 
Varying growth medium compositions were tested on fresh specimens to evaluate the optimal 
conditions for early culture establishment. Whilst culture growth of either stromal cells or 
carcinoma was observed in RPMI medium (results not shown), this medium is more aptly 
suited for non-adherent cell lines. As such, DMEM and ADMEM (supplemented with EGF 
and L-glutamine) became the basal media of choice. 
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Given the tenacity of fibroblasts in the presence of high concentrations of FCS, varying levels 
were used with both DMEM and ADMEM, the latter of which is purported to demand less 
FCS without diminishing epithelial growth. As seen in Figure 2.10, both ADMEM containing 
1 % FCS and DMEM containing 10 % FCS demonstrated similar cell growth over time 
despite a 10-fold difference in serum concentration. However, the cultures in both of these 
conditions eventually became overrun with fibroblasts by day 40. Interestingly, the culture 
containing undigested debris in the presence of ADMEM containing 1 % FCS appeared to 
possess high concentrations of epithelial-like cells with minimal fibroblasts detected. This 
culture was still observed to be almost completely comprised of epithelial cells by day 40, 
although growth had slowed and the cells eventually stopped proliferating. 
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Figure 2.10 Sample OT00018498 exposed to various media conditions over time. The right column displays 
the undigested debris caught within the Smartstrainer that was cultured. An image was unobtainable for the 
condition of DMEM 10 % FCS at day 40 due to the culture being overrun with fibroblasts ahead of time. 
Figure 2.11 highlights the influence of high sera (10 %) content in ADMEM, whereby in both 
cases it had the same effect as DMEM + 10 % FCS. As such, it is clearly not necessary to use 
high concentrations of serum with ADMEM to encourage cell growth. Serum-free ADMEM 
was able to facilitate the growth of one sample (Figure 2.11, sample OT00000872), although 
these cells did not proliferate further over time. Additionally, serum-free cultures appeared to 
have numerous floating dead/non-adherent cells, indicating at least some serum is necessary 
for cellular attachment. 
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Figure 2.11 PDCCs in response to various media conditions. Samples 0515757 and 0000872 imaged at 4x 
objective. 
Upon using ADMEM with 1 – 2 % FCS, a notable decrease in the growth of fibroblasts was 
noted over time. However, as a consequence, the epithelial cells often took longer to grow. 
2.3.3 Epithelial-Stromal purification 
For a PDCC to be considered established there had to be no underlying stromal contaminants 
persisting in culture. Whilst an integral part of the tumour microenvironment, these cells 
present a nuisance for epithelial cell culture. Contaminating erythrocytes and leukocytes 
(including lymphocytes) are non-adherent and were able to be washed away through 
refreshing the growth media. Steps to alleviate adherent stromal populations (primarily 
fibroblasts) were often required immediately to ensure the survival and expansion of the 
epithelial cells. The following sections will outline the myriad of techniques employed to 
purify the PDCCs of fibroblasts. The utility of geneticin (G418) in isolating epithelial cells 
was found to be inconclusive and is reported in Appendix B. 
2.3.3.1 Positive selection of fibroblasts through anti-fibroblast microbeads 
Positive selection of the fibroblast populations was attempted using magnetically labelled 
antibodies specific to fibroblasts. When placed in a magnetic field, the labelled fibroblasts 
should remain within the column, allowing the unlabelled epithelial cells to pass through, 
effectively separating the populations. However, there was no identifiable separation using the 
cell mixture and instead all cells were found to be retained within the column despite 
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morphological confirmation that there were both fibroblasts and cSCC present in the culture. 
This suggests that the antibody provided by the manufacturer cross-reacted with the cancer 
cells. As such, this method was deemed unsuitable for isolating fibroblasts from cSCC. 
2.3.3.2 Differential trypsinisation 
Through the process of differential trypsinisation most of the fibroblasts present in culture 
were successfully separated from the epithelial cells (Figure 2.12). By exposing the cultures to 
short rounds of trypsin (approximately 30 – 45 seconds) the fibroblast fraction was able to be 
collected, given fibroblasts adhere looser in culture. Both fractions could be grown and 
differential trypsinisation performed as necessary to completely isolate epithelial cells from 
fibroblasts. 
 
Figure 2.12 Differential trypsinisation on sample 0001517. A) Early-stage culture containing both epithelial 
cells and fibroblasts; B) fibroblasts collected in media after 30 – 45 seconds exposure to trypsin; C) the 
remaining fraction following the short round of trypsinisation. A greater epithelial content was subsequently 
observable; D) a high magnification image of the remaining epithelial fraction (40x objective). The large nuclei 
present in multiple copies confirm these are cancerous cells. 
B) 
D) C) 
A) 
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A pitfall of this technique is the constant exposure to trypsin through repeated attempts which 
can influence the viability and growth of the epithelial cells. Over time, persistent fibroblast 
populations were able to grow whilst epithelial cells were recovering, ultimately leading to 
fibroblast dominance. It was concluded that whilst an effective technique, a complementary 
tactic was needed to facilitate epithelial growth whilst discouraging fibroblastic growth. 
2.3.3.3 Growth factors 
To assess the impact of fibroblast contamination as well as the influence of growth factors in 
enhancing dominance of a given cell type, an experiment was conducted whereby epithelial 
cells and fibroblasts were co-cultured at known ratios in DMEM (10 % FCS/P+S) in the 
presence or absence of growth factors. When epithelial cells were seeded at a 1:1 ratio with 
TIFs, after four days there appeared to be slightly more fibroblasts present in culture (Figure 
2.13). However, when EGF was added to the growth medium, there was a clear domination of 
epithelial cells with very few fibroblasts detectable. When the co-cultured cells at a ratio of 
1:1 were treated with fibroblast growth factor (FGF) in the absence of EGF, the inverse result 
was seen with near complete fibroblast dominance. In the absence of growth factors, epithelial 
cells were observed to dominate over fibroblasts when seeded at a ratio of 3:1. As such, 
surgical specimens containing < 75 % carcinoma cellularity may struggle to survive early 
cultures without growth factors or intervention by other means. This was the rationale behind 
selecting tumours with high neoplastic content from the outset. 
Due to the lengthy process of optimising through intermittent sample provision as well as the 
restricted experimental timeframe available within this project, only a few cultures were able 
to be exposed to the optimal conditions identified above. Greater success was experienced in 
developing early cultures using the refined techniques and it is believed that with more time 
and sample influx, many more PDCCs would have been established using these methods. 
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Figure 2.13 Co-culture of UW-CSCC1 and TIFs. Micrograph images taken over time in response to varying cell type ratios and presence or absence of growth factors. 
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2.3.4 Novel established patient-derived cell cultures  
PDCCs were deemed established as cell lines once 100 % epithelial cellularity was 
determined (via morphological identification with a light microscope) and cells continued to 
proliferate through multiple passages. As indicated above, two (6.67 % of attempts) were able 
to produce long-term bona fide cultures of the carcinoma; one derived using the 
homogenisation approach, the other using the explant approach. A radio-insensitive strain of 
one was also generated. All PDCCs have been sustained long-term and consistently free of 
mycoplasma contamination. These cultures are morphologically distinct and will be described 
in the following sections. 
2.3.4.1 UW-CSCC1 & UW-CSCC1R 
The novel PDCC UW-CSCC1 was derived via mechanical and enzymatic dissociation from a 
nodal cSCC deposit. Full clinical details of this sample are included in Appendix C. These 
cells were cultured in DMEM (10 % FCS/P+S) from the outset with fibroblasts depleted 
through successive rounds of differential trypsinisation. A pure epithelial culture was 
established by passage 13 and has been sustained over 45 passages. Morphologically, the cells 
are approximately 40 µm in diameter and exhibit malignant cytological features including 
pleomorphism as well as large nuclei, often in multiple copies per cell (Figure 2.14). 
Particularly at low seeding densities, these cells often appeared slightly elongated due to their 
squamous cell origin, lacking the more distinct cuboidal or columnar shape seen with 
carcinomas of other tissue types. At a high density, UW-CSCC1 began to resemble a typical 
epithelial phenotype (Figure 2.14 B) forming an epithelial sheet with a stocky morphology. 
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Figure 2.14 Morphology of UW-CSCC1 in 2D culture.  Imaged at 10x objective at A) low density and B) high 
density) in DMEM (10 % FCS/P+S). 
Despite many concurrent attempts at establishing other cell cultures using the homogenisation 
approach, UW-CSCC1 proved to be the only culture capable of proliferating indefinitely and 
free of a fibroblast population via this methodology. A radio-insensitive population of cells 
were established to investigate the influence of radiotherapy upon cancer cell biology. 
Following a one-off treatment of UW-CSCC1 with 2 Gy x-ray radiation, a small population 
of cells were observed to have survived. These cells were allowed to grow to confluency to 
produce a thriving population of ‘radio-insensitive’ cells, designated UW-CSCC1-R. 
Morphologically, UW-CSCC1-R differed only slightly from its cognate PDCC UW-CSCC1, 
possessing a more mesenchymal-like morphology (Figure 2.15). The granularity and size of 
the cytoplasm and sharpness of the cell boundaries in UW-CSCC1-R indicate these cells 
likely have fewer adhesion molecules that would otherwise encourage maximal surface area 
attachment. Cell adhesion and EMT marker expression changes between these cultures are 
detailed in Chapter 3. 
150 µm 
A) B) 
150 µm 
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Figure 2.15 Morphology of UW-CSCC1-R in 2D culture. Imaged at 10x objective at A) low density and B) 
high density in DMEM (10 % FCS/P+S). 
2.3.4.2 UW-CSCC2 
Another PDCC, UW-CSCC2, was able to be derived from a nodal deposit via the explant 
approach. Clinical details of the tumour are provided in Appendix C. Epithelial purification 
was provided through the use of specialised ADMEM and successive differential 
trypsinisation. Once a substantial population of cells was achieved free from fibroblasts, the 
culture was weened onto DMEM 10 % FCS. This patient had a previous history of radiation 
therapy for disease management. These cells appear morphologically distinct from UW-
CSCC1, demonstrating more circular borders and a smaller diameter. High and low seeding 
density micrographs of UW-CSCC2 are shown below (Figure 2.16).  
    
Figure 2.16 Morphology of UW-CSCC2 in 2D culture. A) Low density and B) high density UW-CSCC2 in 
DMEM (10 % FCS/P+S). Imaged at 10x objective. 
A) B) 
150 µm 150 µm 
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2.3.4.3 Proliferation rate of established PDCCs 
As shown in Figure 2.17, there was a small but insignificant difference in doubling time 
between UW-CSCC1 and UW-CSCC1-R, totalling 46.84 and 35.56 hours, respectively. This 
was much faster than UW-CSCC2 which possessed a population doubling time of 81.29 
hours, albeit this was not considered significantly different to either UW-CSCC1 or UW-
CSCC1-R. 
 
Figure 2.17 Growth curve showing PDCC cell count over time. Experimental data for UW-CSCC1 and UW-
CSCC1-R obtained in association with Ms Gretel Major (BSc Honours student). All cultures were grown in 
DMEM supplemented with 10 % FCS and incubated within a hypoxic atmosphere. 
2.3.4.4 Hypoxia response 
Comparisons were made between cells grown in a standard incubator atmosphere and those 
grown in a hypoxic environment, which is thought to be more physiologically relevant for 
tumour-derived cells (Choi et al., 2014). These cells were pre-acclimated in their respective 
atmosphere for at least one week, to account for atmospheric-shock experienced upon 
switching incubating conditions. In the absence of pre-acclimation cells experienced some 
degree of cell death, evident from cellular debris floating in suspension when going into 
normoxic conditions (Appendix D). 
It was found that on the basis of clonogenic survival (methodology described in full in 
Chapter 6), cells seeded and grown in a hypoxic environment produced greater final colony 
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numbers than their normoxic pre-acclimated counterpart (Figure 2.18). Statistically significant 
differences in colonies counted were observed between UW-CSCC1-RHYP and normoxic-
treated cells (P < 0.05). UW-CSCC1HYP did not produce statistically significant differences in 
colony counts compared to the other conditions, however the difference between hypoxic and 
normoxic cultures is apparent nonetheless.  
 
Figure 2.18 Effect of atmosphere on PDCC colony formation.  Colonies determined through a clonogenic 
survival assay after 15 population doublings. 
Additionally, differences in colony numbers between UW-CSCC1 and UW-CSCC1-R were 
evident under hypoxia, especially compared to normoxic conditions. That is, for each seeding 
density within a normoxic atmosphere, there were no significant differences between the cell 
lines, whilst UW-CSCC1-R noticeably produced more colonies in hypoxic conditions. Images 
demonstrating the difference between hypoxic and normoxic atmosphere on colony growth in 
a clonogenic assay are shown in Chapter 6 (section 6.3.2). 
2.3.4.5 Three-dimensional (3D) spheroid culture 
Spheroid cultures were able to be obtained through the use of ULA plates. As shown in 
Figure 2.19 A), simply seeding the cells into ULA plates, resulted in a wide spread of cells 
with smaller aggregates surrounding the central spheroid mass. Brief centrifugation of the 
ULA plates directly after seeding helped to gather the cells and produced a tighter, larger 
sphere (Figure 2.19 B). 
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Figure 2.19 UW-CSCC1 spheroids before and after centrifugation. A) Before and B) following 
centrifugation at 209 x g for three minutes. 
Varying media types were used to determine the optimal growth conditions for cSCC 
spheroids. As seen in Figure 2.20, UW-CSCC1 formed a spheroid best in DMEM (10 % 
FCS/P+S) compared to RPMI (10 % FCS/P+S) or ADMEM (containing growth factors), as 
evident by large aggregates with strongly defined borders. Cells grown in RPMI with 10 % 
FCS possessed less defined borders. In ADMEM supplemented with growth factors purported 
to facilitate spheroid formation and growth (1 % N-2, 0.002 % EGF, 0.01 % bFGF and 1 % L-
gln), multiple smaller spheroids were observed rather than a single mass as seen with DMEM 
and RPMI. Regardless of the media type, UW-CSCC1-R only ever formed loose aggregate-
structures with a large diameter. 
 
Figure 2.20 Optimisation of spheroid culture media. UW-CSCC1 and UW-CSCC-R spheroids grown in 
DMEM supplemented with 4,500 mg/mL glucose, RPMI, or Advanced DMEM with specialised growth factors. 
DMEM and RPMI media also contained 10 % FCS and all media contained 1 % penicillin and streptomycin. 
Cell lines were seeded at 1,000 cells/well into ultra-low attachment, round-bottomed 96-well plates, and imaged 
after 72 h at 10x objective. Representative images are shown of n=5. Fibrous debris surrounding the spheroids 
is a consequence of unfiltered FCS. 
300 µm 300 µm 
A) B) 
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The addition of 1 % FCS to the ADMEM specialised culture media was found to have a small 
effect upon spheroid formation. Cells in serum-free ADMEM again formed multiple 
aggregates, whilst the cells cultured in ADMEM containing 1 % FCS produced fewer 
aggregates, with minor budding off from a single mass (Figure 2.21). This was observed for 
both UW-CSCC1 and another PDCC, 0018498 (which did not survive over sustained 
passage). 
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Figure 2.21 Optimisation of ADMEM spheroid culture media. UW-CSCC1 or 0018498 spheroids grown in 
ADMEM specialised media with 1 % FCS (left) or 0 % FCS (right). Imaged at 10x objective after 48 hours. This 
growth pattern was sustained over 5 days. Representative images are shown of n = 4. 
Given the promising results observed with DMEM (containing 10 % FCS), a titration of 
serum was performed to elucidate at which concentration the spheroids will best aggregate 
within this media type. At lower concentrations of serum, the cells became less tightly bound 
producing a larger yet less dense aggregate (Figure 2.22). As such, the optimal growth 
conditions used for downstream experiments were DMEM containing 10 % FCS. 
300 µm 
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Figure 2.22 Optimisation of spheroid serum concentration. UW-CSCC1 and UW-CSCC-R spheroids grown 
in DMEM with varying percentages of FCS. Cell lines were seeded at 1000 cells/well into ultra-low attachment, 
round-bottomed 96-well plates, and imaged after 72 h at 10x objective. Representative images are shown of n = 
5. Fibrous debris surrounding the spheroids is a consequence of unfiltered FCS. 
The thin strands surrounding the spheroids in the above images are an artefact introduced 
from precipitates found in the unfiltered FCS. In following experiments the FCS was sterile 
filtered to remove these precipitants and improve imaging. 
Adjunct studies in our laboratory by undergraduate student Miss Gretel Major assessed the 
optimal seeding density of UW-CSCC1 and UW-CSCC1-R in ULA plates for growth as a 
spheroid. It was found that densities between 250 and 500 cells/well (~375 cells/well) best 
produced a tight and sufficiently large sphere to mimic the nutrient and oxygen gradient seen 
in tumours (Appendix E1). This was also assessed with UW-CSCC2, revealing an increased 
seeding density of > 500 cells/well to produce tight spheroid cultures (Appendix E2). 
Taking the previous observations into consideration, the resultant spheroids for UW-CSCC1 
and UW-CSCC1-R under optimal conditions is shown below in Figure 2.23. At two days 
post-seeding, a tight sphere was observed for UW-CSCC1, whilst UW-CSCC1-R unavoidably 
continued to produce a loose aggregate with poorly defined borders. Seeding densities for 
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UW-CSCC2 similar to those optimal for UW-CSCC1/-R failed to produce tight spheres, 
instead forming best between 1,000 – 2,000 cells/dish. 
 
Figure 2.23 Spheroid cultures of cSCC PDCCs. Initial seeding density for UW-CSCC1 and UW-CSCC1-R 
was 375 cells/well. Representative spheroids of UW-CSCC2 shown are from initial seeding densities of 2,000 
and 250 cells/well. Imaged at 10x objective 48 hours post-seeding. 
At an initial seeding density of ~ 300 cells/well, UW-CSCC1-R spheroids were observed to 
differ significantly in diameter growth rate compared to both UW-CSCC1 (P < 0.001) and 
UW-CSCC2 (P < 0.01) (Figure 2.24). UW-CSCC1 displayed a practically stagnant diameter 
growth rate of 2.6 µm/day whilst UW-CSCC1-R grew at a rate of 36.7 µm/day. UW-CSCC2 
demonstrated a greater diameter growth rate (10.5 µm/day) than UW-CSCC1, although this 
difference was insignificant. This slightly faster growth rate in 3D for UW-CSCC2 is 
interesting considering its comparatively slower growth in 2D culture.  
UW-CSCC2   250 cells 
300 µm 300 µm 
UW-CSCC2   2,000 cells 
UW-CSCC1     375 cells UW-CSCC1-R    375 cells 
150 µm 150 µm 
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Figure 2.24 Spheroid growth rate. Spheroid growth (µm) over time after initial formation (two days) is shown 
(n = 15). Asterisks indicate significant differences between slopes: *** = P < 0.001; ** = P < 0.01. Experiment 
performed in association with Miss Gretel Major (BSc Honours student).  
2.3.5 Validation of PDCCs as carcinoma 
As cells that have undergone metastasis may not always appear epithelial with respect to their 
morphology, it was necessary to validate the PDCCs as carcinoma through additional means. 
Firstly this was achieved through positive staining of epithelial markers, followed by the 
confirmation of the tumour forming ability in immunocompromised mice. Extensive 
molecular validation was also performed to assess the pre-clinical fidelity of these PDCCs 
which is described in detail in Chapter 3.  
2.3.5.1 Immunofluorescent identification of carcinoma cells 
A pan-cytokeratin epithelial marker was shown to be positive in both UW-CSCC1 and UW-
CSCC2 through immunofluorescent imaging ( 
Figure 2.25 A, B). UW-CSCC1 was also found to be EpCAM positive ( 
Figure 2.25 C); UW-CSCC2 was not stained for this marker. Additionally, UW-CSCC1 and 
UW-CSCC2 were found to be negative for the mesenchymal marker α-SMA (data not 
shown), producing no fluorescent signal. For comparison, TIFs were positive for α-SMA ( 
Figure 2.25 D), as expected, confirming the functionality of the α-SMA antibody. 
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Figure 2.25 Immunocytochemical staining of PDCCs and TIFs. Cultures were stained for cell-type specific 
antibodies (green) and the nuclear stain RedDot2 (red). A) Fixed and permeabilised UW-CSCC1 stained for 
pan-cytokeratin. B) Fixed and permeabilised UW-CSCC2 stained for pan-cytokeratin. C) Non-fixed UW-CSCC1 
stained for Epithelial Cell Adhesion Molecule (EpCAM). D) Fixed and permeabilised TIFs stained for alpha-
smooth muscle actin. 
2.3.5.2 PDCC xenografting to confirm tumourigenicity 
To confirm the tumour forming ability of UW-CSCC1 and UW-CSCC2, cells were inoculated 
subcutaneously into immunocompromised mice. Growth of tumours began very slowly at 
first, with a palpable tumour not detected until just over two months post-inoculation. 
Following this, tumours began to grow exponentially larger at the site of injection (Figure 
2.26 A) and within three months they met the experimental endpoint of 10 mm3 (Figure 2.26 
A, B). Angiogenesis was evident upon dissection of the tumours; however no metastatic 
deposits were found in any organs. A necrotic and nutrient deficient core was observed with 
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resected tumours (Figure 2.26 B). These data confirm that the tumour forming ability has 
been preserved in these PDCCs. 
 
Figure 2.26 Xenograft tumours of cSCC PDCCs. A) Photograph of mouse harbouring UW-CSCC1 derived 
tumour growing subcutaneously on flank. The resultant excised tumour is shown adjacent. B) UW-CSCC1 
derived mouse tumour with associated fat and skin. Evidence of angiogenesis in situ is apparent as well as a 
nutrient deficient core. 
The mouse tumours derived from UW-CSCC1 and UW-CSCC2 subsequently underwent 
histological analysis by our collaborating pathologist Dr Ruta Gupta (Figure 2.27). These 
tumours showed unequivocal squamous epithelial cells in morphology, papilliform 
arrangement, and malignant cytological features including pleomorphism and polyploidy 
(exemplified in Figure 2.27 A). The mouse tumour derived from UW-CSCC1 demonstrated a 
tissue architecture very similar to the originating tumour (193958). Staining of the originating 
tumour (658492) for the UW-CSCC2 derived mouse tumour could not be obtained. 
Nonetheless, H&E staining of the UW-CSCC2 mouse tumour revealed general clinical 
features of cSCC, as noted above. 
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Figure 2.27 H&E stained sections of patient and mouse tumours. A) Clinical tumour (193958). B) UW-SCC1 
(derived from 193958) xenotransplant grown in a NSG mouse. C) UW-CSCC2 (derived from 658492) 
xenotransplant grown in a NSG mouse at 20x objective. D) UW-CSCC2 xenotransplant at 4x objective. The 
interface between the tumour bulk (dense pink/purple mass) and subcutaneous tissue (white, adipose tissue) is 
clear. H&E stained images of the originating tumour for UW-CSCC2 (658492) were unable to be acquired. 
2.3.6 Cell migration and invasion characterisation 
2.3.6.1 Scratch wound healing assays  
The random migratory properties of the PDCCs were compared using the 2D scratch wound 
healing assay. The rate of cell migration into the wound space by UW-CSCC1-R cells at 3.43 
µm/hr was slower than that of UW-CSCC1 at 6.24 µm/hr, although both were slower than 
UW-CSCC2 which migrated at a rate of 9.61 µm/hr. This resulted in a maximum wound 
closure of 21.40 %, 13.20 %, and 32.12 % over 24 hours for UW-CSCC1, UW-CSCC1-R, 
and UW-CSCC2, respectively (Figure 2.28). 
Papilliform  
architecture 
Keratin 
100 µM 400 µM 
A) B) 
C) D) 
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Figure 2.28 Random migration of cSCC PDCCs in vitro. Relative wound width of metastatic cSCC PDCCs 
over 24 h as assessed by a scratch wound assay, n = 3 in duplicate experiments. Error bars represent ± standard 
error. UW-CSCC1 and UW-CSCC1-R data provided by Miss Gretel Major (BSc Honours student). The cultures 
were normoxic acclimated and incubated with ADMEM supplemented with 2 % FCS. 
2.3.6.2 Organotypic invasion assay 
An organotypic mimics the ECM within the skin, making it a perfect candidate for assessing 
the invasive capabilities of the skin cancer derived PDCCs. Firstly, an in-house supply of 
collagen-I from rat tail tendons was made as this represents an inexpensive and accessible 
source of collagen-I. The concentration of collagen-I within the resultant stocks was 
determined through a modified Lowry assay and purity found to be similar to the commercial 
supply via SDS-PAGE (Appendix F).  
The in-house collagen-I was successfully used to prepare fibroblast contracted collagen-I 
matrices. Invasion of the cSCC cells into the matrix was then induced by an air-liquid 
interface. After 4 and 8 days, UW-CSCC1-R had entered the matrix while invasion was only 
evident for UW-CSCC1 after 8 days (Figure 2.29). Longer incubation times may have 
allowed deeper invasion into the matrix, nevertheless it is clear that the migratory and 
invasive potential of these two cell lines has been retained in vitro and that this was enhanced 
in the radio-insensitive strain. Additionally, UW-CSCC1-R cells showed more concentrated 
local invasion of the matrices with limited matrix degradation, while UW-CSCC1 migration 
was diffuse. As such, these cells lines were deemed valid for inclusion in further organotypic 
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invasion assays (see Chapter 4). Hollowed sections of the matrix were evident and are 
believed to be the result of fixation artefacts. 
 
Figure 2.29 Organotypic invasion by cSCC PDCCs. Representative micrographs of sectioned and H&E 
stained organotypic matrices showing UW-CSCC1 and UW-CSCC1-R cellular invasion into fibroblast 
contracted collagen I matrices at four and eight days after being placed onto an air-liquid interface. 
Magnification 20x objective. Dotted arrows show direction of invasion from top of matrix towards the bottom. 
Red arrows indicate areas of matrix degradation by either the cancer cells or formalin fixation. Representative 
images courtesy of Miss Gretel Major (BSc Honours student). 
There remained uncertainty as to the estimated proportions of invading epithelial cells to the 
fibroblasts used to construct the matrix. Generally the telomerase immortalised fibroblasts 
(TIFs) undergo senescence or apoptosis following matrix formation, although some may 
remain active and be stained with H&E. To assess this, a control matrix was prepared by Miss 
Gretel Major whereby no epithelial cells were included; thus revealing only fibroblasts in the 
subsequent H&E stain (data not shown). The findings showed some fibroblasts are still 
detected by the H&E staining process, although their presence is negligible compared to the 
obvious evidence of epithelial migration in other assays. 
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2.4 DISCUSSION 
Following numerous attempts, two cell lines (and a radio-insensitive strain of one) were 
established in 2D and 3D cultures from metastatic cSCC. These PDCCs were validated as 
pure cultures of carcinoma, their tumourigenicity confirmed in mice, and 
migratory/invasiveness evaluated in 2D and 3D in vitro assays. The results of thorough efforts 
for optimisation of this process for metastatic cSCC are a world-first and the significance and 
meaning of these abovementioned results are discussed below. 
2.4.1 Sample size and general characteristics 
The number of samples processed was hampered by both the frequency of surgical cases 
aligning within the inclusion criteria (lymph node metastasis and carcinoma cellularity > 30 
%); as well as the concurrent burden of samples in the laboratory. Quite often there was too 
little tumour for the clinic to spare after biobanking and histology. In other cases there was too 
much stromal infiltrate or necrosis that would make the samples redundant for both cell 
culture and nucleic acid extraction. Geraghty et al., (2014) stated the importance of keeping a 
small portion of the sample in formalin for use in histopathological assessment; ideally by the 
same pathologist reporting on the surgical specimen. The cultured samples reported here were 
carefully harvested amongst the portion that underwent histopathological analysis. Given the 
skill and oversight provided by the collaborating clinicians, we are confident that the sample 
used for cell culture is representative of the surgical specimen. For this investigation, the same 
pathologist (Dr Ruta Gupta) assessed the original tumour, xenograft samples, and organotypic 
sections. 
The relatively low success rate (6.67 %) for establishing continuous cell lines from metastatic 
cSCC is not surprising, considering the poor success rates of developing primary cultures 
from other solid tumours, even with specialised formulations and direct xenograft culturing 
(Verschraegen et al., 2003; Dangles-Marie et al., 2007; Zheng et al., 2011; Turin et al., 2014; 
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Kodack et al., 2017). Verschraegen et al., (2003) reported success rates as low as 16 % for 2D 
ovarian cell cultures, and even 7 and 11 % for subcutaneous and intraperitoneal xenografts, 
respectively. Establishing and propagating a solid tumour through a PDX model would not 
necessarily improve success rates as these generally range from 20 % to 50 %, as reported by 
Wilding and Bodmer, (2014). However, a study by Dangles-Marie et al., (2007) found a 
significant increase in generating successful xenograft cultures (77 %). They also found that 
prior xenograft lead to more efficient cell line establishment (47 %) compared with direct 
establishment from patient tumours (9.7 %). 
These disparities in success rates likely reflect the tissue of origin as the successful 
establishment of a primary cell culture can vary greatly depending on the cancer type. A study 
by Kodack et al., (2017) attempted to generate patient-derived cell cultures from 568 patient 
specimens across multiple malignancies. The authors found that amongst all cancer types, the 
success rate for establishing a finished 2D cell line averaged just 26 %. In this study, a cell 
line was considered finished once it was free of fibroblasts, no longer required a feeder layer, 
and could be re-grown following cryopreservation. Cell lines were considered failed if they 
exhibited no cancer cells after six months of culture. As shown in Table 2.1, the success rates 
by Kodack et al., (2017) varied greatly between tissue types. Rates for head and neck cancer 
and melanoma were 18 % and 14 %, respectively, and represent the closest proxies to cSCC 
available here. 
Table 2.1 Success of cancer cell line establishment by tumour type. Adapted from Kodack et al., (2017). 
Tumour Type 
Cell Lines 
Finished 
Number 
Failed 
Total 
Processed 
Percent 
Successful 
Breast 16 88 104 15 
Colorectal 5 15 20 25 
Endometrial 1 10 11 9 
Head and neck/salivary gland/squamous cell 
carcinoma 
2 9 11 18 
Lung 109 264 373 29 
Melanoma 1 6 7 14 
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Pancreatic/gallbladder 6 10 16 38 
Thyroid 4 10 14 29 
Unknown 4 8 12 33 
Total 148 420 568 26 
 
Kodack et al., (2017) noted the following subjective reasons for cell line failure: no/few 
cancer cells identified after dissociation (77 %), stroma outgrowth (14 %), and cancer cell 
cycle arrest (8 %); aligning with interpretations of our own cSCC culture failures. Much like 
our own study, Kodack et al., (2017) adopted additional techniques as their investigation 
progressed including, specialised growth media and differential trypsinisation. 
It is hypothesised that if such studies are repeated with the optimised methods from the 
beginning, then culture success rates would be greatly improved. Moving forward, the 
optimised methods presented within this chapter should greatly improve the efficiency of 
cSCC sample processing and culture development. 
The extensive morphological variation observed between the early cultures highlights the 
large intra-patient heterogeneity that has been documented elsewhere at a molecular level (Li 
et al., 2015; Ashford et al., 2017; Zilberg et al., 2017) and is discussed in greater detail in 
Chapter 4. Varying morphology could also be a function of the cells at different stages of 
EMT/MET as well as their physical association with stroma. It is not believed that these 
different morphologies are a crude indicator of subtypes (such as spindle cell carcinoma) as 
the clinical specimens were not classified any differently on the basis of histologic 
examination by the pathologist.  
Routine mycoplasma testing was imperative to ensure that these cells remain viable and free 
from contaminants. Over the years, many studies have been rendered useless after the 
revelation of mycoplasma contamination or cell line misidentification (Kaur and Dufour, 
2012; Geraghty et al., 2014).  
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2.4.2 Optimisation of tissue processing 
2.4.2.1 Tissue homogenisation vs tissue explant 
The gentleMACS dissociator method used initially failed to produce sufficient numbers of 
viable epithelial cells following mechanical and enzymatic dissociation. Instead, the tolerant 
fibroblasts persisted. The abovementioned study by Kodack et al., (2017) found that the 
majority of their cell cultures failed due to there being too few cancer cells after dissociation. 
The low success rates observed by Kodack et al., (2017) may be a consequence of their 
similar use of gentleMACS tissue homogenisation. Switching to enzymatic digestion in the 
absence of the tissue dissociator also failed to produce desirable results, likely due to the 
lengthy overnight digestion required causing cellular damage (Chi Scientific, 2007). Other 
studies have found no significant difference in cell numbers or viability between gentleMACS 
dissociated samples and those digested overnight in an enzyme mix (Baldan et al., 2015; 
Emnett et al., 2016). As such, it was concluded that both of these methods of dissociation are 
unsatisfactory for isolating viable epithelial cells from metastatic tumours of cSCC, whether 
used independent of one another or together. 
The practice of explant culture was then adopted and this was met with greater success in 
maintaining viable epithelial cells. Fibroblasts are said to not grow out from adult human skin 
explants until several days after the emergence of keratinocytes (Guo and Jahoda, 2009). 
However, stromal contamination in our cultures was ever-present regardless of 
homogenisation or explant. Nonetheless, future cSCC culture development should utilise a 
tissue explant approach over mechanical and/or enzymatic homogenisation to ensure 
epithelial cell viability and adhesion. 
2.4.2.2 Collagen coating and cell adhesion 
Whilst collagen-coating of tissue culture surfaces is known to enhance cell adhesion (Somaiah 
et al., 2015), no appreciable differences in attachment were observed upon pre-treatment of 
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flasks with collagen. Coating culture surfaces with other extracellular matrix components 
such as laminin and fibronectin are yet another option purported to enhance cell-adhesion and 
should be considered in future investigations. 
The use of a feeder layer of x-ray irradiated 3T3 cells was considered to enhance cell-
adhesion, but due to the formulation of specialised media, this technique is largely redundant 
and possesses its own technical obstacles. For example, contamination by viable 3T3 cells 
must be avoided (Guo and Jahoda, 2009). 
Cell adhesion was not a major concern with the cultures developed in this project; as such 
focus was directed to addressing the high priority issues of cell viability and stroma 
outgrowth, suspending the use of ECM component scaffolding. 
2.4.2.3 Growth media optimisation and the use of specialised media  
Specialised media can often be formulated to encourage the proliferation of specific tissue 
types. Whilst cSCC consists of keratinocytes, it is perhaps short-sighted to assume these cells 
will grow best in a keratinocyte-specific growth medium, given the poor degree of 
differentiation and anatomical positioning within a lymph node as opposed to the skin. As 
such, a simplistic growth medium in the form of DMEM with high glucose content was first 
trialled. A hallmark of cancer is uncontrolled proliferation; therefore the enhanced glucose 
concentration was necessary to avoid starving the cells. As the study progressed, ADMEM 
was also implemented to encourage epithelial growth in general. This was attainable with this 
medium through additional nutrients, enabling less serum to be used (deterring fibroblast 
growth), as well as the addition of EGF. The utility of this was observed in Figure 2.10 
(section 2.3.2.4) whereby cell growth was not impacted between ADMEM 1 % FCS and 
DMEM 10 %, indicating ADMEM can be used to grow cells without encouraging fibroblast 
growth via high sera content. However, serum-free ADMEM is not recommended as at least a 
small amount of serum is required to help cells attach and proliferate. This is echoed by 
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Zheng et al., (2011) who suggested that serum components play an important role in making 
cells attach to a culture dish. Examples of such attachment factors found in serum include 
vitronectin, collagen, and fibronectin (Norris et al., 1990; Howlett et al., 1994). Whilst it is 
possible that cultures may benefit from serum-starvation when fibroblast cells become too 
present, this could also induce cell cycle arrest for epithelial cells and may be too risky a 
procedure for such a precious resource. 
Greater success in generating viable cells was generally observed using specialised media and 
the explant method, although the majority of these cultures succumbed to a fibroblast 
population anyway. The co-culture experiment, whereby fibroblasts and cSCC cells were co-
cultured at known ratios in the presence of absence of growth promoting factors, highlighted 
the influence that carcinoma cellularity can have upon epithelial dominance. The results 
indicate that if the population of adhered cells is less than 75 % epithelial content than there is 
a stronger possibility of inevitable fibroblast domination. The positive influence of EGF for 
epithelial growth was also clearly observed in this assay. Purdie et al., (2011) remarked that 
keratinocytes adhere to plastic better in the absence of EGF, and as such the initial isolation 
and plating should be carried out using EGF-free medium and then switching to medium 
containing EGF after 48 hours. This was not investigated in the current study using metastatic 
cSCC as adherence was generally not an issue, although it may be worthwhile investigating in 
the future to fine-tune cell culture establishment.  
It is concluded that the optimal media conditions for early metastatic cSCC culture 
establishment are likely those containing low amounts of sera in the presence of EGF and 
nutrients to promote epithelial growth, as provided by the ADMEM formulation described 
previously. Understandably, the demands of each culture can vary greatly depending upon the 
tumour carcinoma cellularity and degree of stromal contamination. Therefore, serum content 
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should be increased in the absence of fibroblasts, as to facilitate epithelial adhesion and 
proliferation.  
Keratinocyte-specific media formulations, such as Epilife™ (Gibco, MA, USA), were not 
pursued for cell culture establishment due to the excessive cost and no guarantee of 
translatability for cancerous cells of keratinocyte origin. Given cultures were being generated 
over a long period of time, maintaining a fresh supply of costly specialised media would 
prove uneconomical. Frozen aliquots of Epilife™ basal medium are also prohibited according 
to the manufacturer and supplemented medium stable for only one month.  
In some circumstances the spent media was collected from tissue culture flasks, centrifuged 
and the supernatant added as a component of the renewed media. This media is considered 
‘conditioned’ and contains a variety of cytokines released by the cells which are said to 
enhance proliferation (Walter et al., 2010; Kimlin et al., 2013). No significant improvement 
in cell growth was documented in doing this method (data not shown). To reiterate, cell 
adhesion and proliferation were of low concern compared to stroma outgrowth, which itself 
could equally be as influenced from conditioned media as the epithelial cells would. 
2.4.3 Epithelial-stromal purification – divide and conquer 
The technique of differential trypsinisation was the most effective at controlling fibroblast 
populations in the current study and as reported by numerous researchers (Lin et al., 2007; 
Mitra et al., 2013; García-Inclán et al., 2014; Kodack et al., 2017). Care must be taken to not 
use this technique too many times within the same culture vessel as the process of washing 
with trypsin can alter the surface of the vessel which has been chemically treated to enhance 
cell adhesion. Thus no more than three rounds of differential trypsinisation in the one flask 
are recommended. As the carcinoma cells take some time to recover from over-exposure to 
trypsin it is important to closely monitor the cultures to ensure they receive adequate serum to 
recover (generally 1 – 2 % in ADMEM), whilst preventing residual fibroblasts from thriving. 
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Positive selection of fibroblasts using anti-fibroblast microbeads proved to be a futile 
endeavour, given the cells express the likely targets of the anti-fibroblast beads. Details of the 
antibody are withheld by the manufacturer, however they are theorised to be specific against 
either vimentin or CD29; both of which are traditional mesenchymal markers (Boxall and 
Jones, 2012; Madar et al., 2013; Maleki et al., 2014). However, gene expression data via 
NanoString (methodology described in Chapter 3) demonstrated expression levels of the gene 
coding for CD29 (ITGB1) in cSCC above that of normal skin. Similarly, some level of 
vimentin was identified in the PDCCs (discussed further in section 2.4.5). Due to the apparent 
similarity of cSCC with these ‘anti-fibroblast’ properties this technique was discontinued. 
The molecular data achieved through provision of cell lines and clinical samples may shine 
light onto what pathways could exclusively be exploited to specifically enhance cSCC 
survival, adhesion, and proliferation. Conversely, specific mechanisms could also be 
identified to inhibit fibroblast proliferation. Examples of such a strategy for other cell types 
include using a DNA topoisomerase inhibitor (camptothecin) to eliminate non-neuronal cells 
proliferation in neuron-type primary cell isolation (Andersen et al., 2003), or the use of 
melatonin in melanocyte cultures to potently inhibit fibroblast proliferation (Carossino et al., 
1996). 
Contaminating fibroblasts divide a finite number of times and eventually deplete once the 
inherently immortalised cancer cells take over the culture; however, a high concentration of 
fibroblasts can sequester cancer cells, as was observed in this investigation. A high 
concentration of cancer cells is therefore necessary to compete with fibroblasts. However, 
cancer-associated fibroblasts (CAFs) may also possess mutations in cell cycle regulatory 
genes, leading to their continued survival. Isolated CAFs were often preserved as frozen 
aliquots for future studies due to the emerging evidence regarding their role in the tumour 
microenvironment (Commandeur et al., 2011; Madar et al., 2013; Peng et al., 2013; Erdogan 
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and Webb, 2017). One such study has characterised CAFs isolated from primary cutaneous 
SCCs and compared them to fibroblasts isolated from healthy dermis (Commandeur et al., 
2011). They noted a difference in morphology and increased proliferation and migration in 
CAFs compared to the normal fibroblasts. Their relevance has an impact upon the way in 
which researchers now approach cell culture, calling for the use of co-culture systems, 
organotypic culture, and organoids. 
2.4.4 Establishment of novel PDCCs 
2.4.4.1 UW-CSCC1 & UW-CSCC1-R 
We postulate that success with UW-CSCC1 over other attempts is owed in part to the high 
tumour cellularity present (70 %) in the original specimen. Such a large proportion of 
epithelial cells had the ability to outcompete stroma, even amongst the simplistic medium 
used at the time (DMEM/10 % FCS/P+S). Despite this, the culture was not deemed purely 
epithelial until passage 13, at which point all fibroblasts had either been selectively detached 
through differential trypsinisation or they simply would no longer replicate. As such, the 
number of ‘true passages’ that the carcinoma cells underwent is less. The doubling time 
observed with UW-CSCC1 (47 hours) is similar to the doubling time of the metastatic cSCC 
culture UT-SCC7 (43 hours) (Pekkola-Heino, 1992). 
UW-CSCC1-R represents the surviving fraction of UW-CSCC1 following irradiation. Either 
these cells already possessed characteristics that enabled them to survive the irradiation, such 
as enhancements in DNA damage repair, or the process of radiation treatment has brought 
about new mutations that made the cells more insensitive to the effects of radiation (Pearce et 
al., 2001). It is also possible that these cells were in S phase of the cell cycle and therefore not 
as vulnerable to the effects of radiation. In the case of the former, these resilient cells have 
expanded, passing these genetic traits to their progeny. The cells possess an approximate 30 
% faster proliferation rate than UW-CSCC1. Differences in morphology between these two 
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PDCCs are subtle and likely the result of changes in cell-adhesion genes, affecting attachment 
to both the tissue culture surface and neighbouring cells.  
Spheroid cultures were established to provide a 3D model for downstream experimentation 
such as drug screening. Spheroids were found to best form and proliferate in DMEM 
containing 10 % FCS along with brief centrifugation after seeding to provide consistent 
aggregates. UW-CSCC1-R consistently produced large, dispersed aggregates with a 
significantly increased diameter growth rate compared to UW-CSCC1 and UW-CSCC2. This 
links with the enhanced growth rate seen in the 2D form, although in this circumstance it is 
much more pronounced as the cells are not necessarily growing faster, but rather the loose 
cell-cell contact makes the diameter more dramatic. 
This behaviour is complementary to findings presented in Chapter 3 regarding differential 
expression between these cell lines for cell adhesion genes and stem cell promoting factors. 
These results paired with the morphological differences support a theory of radiation-induced 
EMT, as has been reported in mammary epithelial cells (Mani et al., 2008). This provides an 
explanation for the morphological differences seen in vitro and may help explain the more 
aggressive nature of recurrent cSCC following radiation treatment. Analysis and potential 
knockdown of E-cadherin mediators, Snail and Twist, may be of interest to confirm this EMT 
theory (Batlle et al., 2000; Cano et al., 2000; Mani et al., 2008). 
The enhanced growth rate for UW-CSCC1-R and undefined growth in spheroid cultures may 
also be explained by the formation of cancer stem cell-like populations which maintain tumor 
growth (Reya et al., 2001; Driessens et al., 2012; Rycaj and Tang, 2014). Stem cell associated 
gene expression differences between the PDCCs are described in Chapter 3. 
2.4.4.2 UW-CSCC2 
In contrast to the abovementioned cell lines, UW-CSCC2 was developed via the explant 
approach in ADMEM with low sera, and eventually weaned onto DMEM containing 10 % 
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FCS. A pure culture of epithelial cells was evident by passage two. The different morphology 
of UW-CSCC2 compared to UW-CSCC1 is a testament to the morphological variability of 
cSCC, as highlighted in section 2.3.4.2. UW-CSCC2 is much more of a typical cuboidal 
epithelial phenotype than squamous. The bearing this has upon cell behaviour and therapeutic 
responsiveness remains undetermined. It is inferred that these cells have restored an epithelial 
phenotype following MET yet remain undifferentiated, whereas UW-CSCC1 remains 
mesenchymal-like or at least much more squamous in form. 
The greater population doubling time observed with UW-CSCC2 in contrast to UW-CSCC1/-
R may be due to the cells not being in the log phase of cell growth at the given cell density. 
However, the slow growth of UW-CSCC2 has been consistently noticed through general 
observation during culture. UW-CSCC2 spheroid cultures were established; however they 
required substantially more cells than necessary for UW-CSCC1 at the same time point (48 
hours). This is likely related to the increased population doubling time seen in 2D. 
It is peculiar that UW-CSCC2 had a slightly faster spheroid diameter growth rate compared to 
UW-CSCC1, considering the higher doubling time in 2D culture. A reason for this may 
simply be because the number of cells seeded in the assay was consistent for all cell types, 
even though UW-CSCC2 requires more cells than UW-CSCC1 or UW-CSCC1-R to form 
spheroids best. Therefore, these spheroids may not accurately reflect growth rate in the 
optimal seeding conditions. 
2.4.4.3 Hypoxia as a preferred atmosphere for PDCC culture 
Hypoxia was found to enhance cell attachment and proliferation, supporting the decision to 
culture in a hypoxic atmosphere. Hypoxia inducible factors and their presence between the 
PDCCs is covered in Chapter 3. Spheroids with a hypoxic core are excellent mimics of in vivo 
tumours. Spheroids will naturally develop a hypoxic gradient when larger than 200 µm as 
oxygen diffusion becomes limited beyond this. However, as the UW-CSCC1/-R spheroids 
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were generally only 150 µm in diameter for most experiments, hypoxia from the surrounding 
atmosphere helped to develop this hypoxic core, which was confirmed in adjunct studies by 
BSc (Hons) student Miss Gretel Major. This physiology can have big impacts on drug 
activity, such as in the case of hypoxia-activated cancer pro-drugs (Tung et al., 2011; Thoma 
et al., 2014; Wigerup et al., 2016; Baran and Konopleva, 2017; Mistry et al., 2017). 
2.4.5 PDCCs are pure and genuine cultures of epithelial cells 
Keratinocytes can be characterized based on their epithelial phenotype to exclude 
contamination by mesenchymal cells. This can generally be determined using cytokeratin-
specific antibodies as these are generally specific for epithelial cells. A multi-cytokeratin 
antibody as well as an antibody specific to EpCAM was used in this investigation, powerfully 
identifying the epithelial cells. As the purpose of these antibody-stains were to confirm the 
cell types present in the cultures, UW-CSCC1-R was not stained with these markers as it was 
derived from UW-CSCC1, which was already confirmed to be 100 % carcinoma at the point 
of its inception. However, gene expression of EPCAM and several members of the keratin 
family were found to be significantly downregulated in UW-CSCC1-R. The relevance of 
these findings is discussed in greater detail in Chapter 3. 
Contaminating fibroblasts were evaluated using a mesenchymal marker, α-SMA, proving no 
fibroblasts present in the PDCCs. TIFs as a mesenchymal-positive control helped establish the 
functionality of this antibody. Alternatively, contaminating mesenchymal cells can be 
identified by antibodies against CD31 or factor VIII-related antigen. Vimentin is often used as 
a discriminatory marker between mesenchymal and epithelial cells (Wick and Hornick, 2011), 
although it is not recommended for work involving keratinocytes in vitro as they may initiate 
vimentin synthesis at frequencies that depend on culture conditions (Fearns and Dowdle, 
1992). Vimentin has also been shown to be expressed in other cancers such as non-small cell 
lung cancer (Tadokoro et al., 2016) and oral squamous cell carcinoma (Zhou et al., 2015). 
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Initially vimentin staining was used (data not shown) and displayed no discriminatory power 
between the cSCC cells and fibroblasts despite known co-culture on the basis of morphology. 
A cell model will become largely obsolete if it fails to form tumours in an in vivo system as, 
for the foreseeable future, all toxicity testing of new treatments must be performed in animal 
models (Wilding and Bodmer, 2014). The tumorigenic or malignant capacity of UW-CSCC1 
and UW-CSCC2 has been maintained and the cells readily formed tumours in vivo, provided 
sufficient time and cell numbers (minimum 1 × 106 cells) during inoculation. Moreover, the 
tissue architecture itself has been grossly maintained, closely resembling the original tissue 
with evidence of local invasion into surrounding tissue. This endeavour is the only accepted 
method of confirming malignancy (Freshney, 2010), with the results being crucial towards 
developing a mouse model for therapeutic screening in future experiments. 
2.4.6 Migration and invasion assays 
Daniel et al., (2009) reported on evidence suggesting that the process of establishing 
conventional cell lines can result in the distinct and irreversible loss of important biological 
properties, including the ability to migrate and metastasise. Contradictory to this, our 
organotypic assay has revealed a preservation of invasive potential for UW-CSCC1 and UW-
CSCC1-R. UW-CSCC2 has yet to be assessed. This assay is a robust method of investigating 
invasiveness in vitro by recapitulation of the ECM using a collagen-fibroblast contracted 
matrix. Collagen is the most abundant protein in the human body, particularly within the skin, 
making it a perfect environment to mimic invasion throughout the skin as experienced with 
this disease. The collagen-I preparation derived in-house was found to be of a quality 
comparable to commercial stocks. Given the homology in the amino acid sequence for 
collagen-I between rat and human, rat tails were a suitable source. Fresh adolescent rat tails 
were used because collagen cross-linking is more labile in younger animals (Timpson et al., 
2011), providing higher fidelity for use in an organotypic system. 
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Pores can clearly be seen in the organotypic sections, corresponding to the degradation of 
ECM components, albeit this has been exaggerated from artefacts introduced during tissue 
processing and slide preparation. It is suspected that the samples were not adequately fixed 
using a diluted formalin solution suggested by the obtained protocol. Future fixation should 
be performed using a 10 % formalin solution rather than 4 %. 
Invading carcinoma cells were clearly visible in purple, often traversing the matrix in clusters. 
This provides evidence that this cell culture has on some level retained the ability to transcribe 
ECM-remodelling genes and respond to paracrine signals for migration. At this point the 
fibroblasts used to contract the matrix are thought to have mostly died off, however adjunct 
work by Miss Gretel Major have shown that fibroblasts may persist and be detected upon 
H&E staining. In the future cancer-cell specific markers (e.g. cytokeratin) should be used to 
accurately visualise cancer cell invasion. 
UW-CSCC1 cells tended towards diffuse invasion while UW-CSCC1-R cells had more 
concentrated local invasion. The clustered invasion of UW-CSCC1-R cells could be evidence 
of ‘collective cancer cell invasion’ whereby cells remain loosely attached and invade together 
(Friedl et al., 2012). Molecular evidence to support this theory is described in Chapter 3. 
Commandeur et al., (2011) observed that CAFs produced stronger contraction of collagen 
matrices than normal fibroblasts and released high levels of collagen-I. Importantly, they 
found that CAFs significantly increased tumorigenic characteristics of primary cSCC cell 
lines in an organotypic invasion assay. Future organotypic experiments may better 
recapitulate the tumour microenvironment and extracellular matrix by using CAFs, preferably 
those matching the same patient of origin as the invading carcinoma cells. This was not 
performed within the current investigation due to the additional optimization this would 
demand paired with the timely need to progress with other experimental aims. 
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Interestingly, despite a faster population doubling time, UW-CSCC1-R possessed a slower 
wound healing response. This could be due to the fewer focal adhesions present when in a 
mesenchymal-like state, thereby allowing the ‘sticky’ UW-CSCC1 to readily attach to the 
substrate over UW-CSCC1-R. 
Compared to HaCaT keratinocytes observed by Walter et al., (2010), none of the cSCC cell 
lines were particularly motile in the 2D wound healing assay, likely due to the absence of 
cytokine signalling from fibroblasts. Migration of UW-CSCC1 and UW-CSCC1-R in the 
organotypic, but not in the 2D assay, may be linked to interactions with the fibroblasts in 
culture, as has been suggested by Wang et al., (2012). A 3D in vitro wound healing model 
such as that developed by Iyer et al., (2018) (Figure 2.30) could be utilised in future migration 
experiments alongside organotypic culture to help recapitulate the complex microenvironment 
of healing wounds and invasive cancer cells. 
 
Figure 2.30 Keratinocyte-fibroblast wound healing construct with a fibrin punch. Constructs can be made 
using uniformly dispersed fibroblasts within the collagen matrix or fibroblasts contained within fibrin beads. 
Adapted from Iyer et al., (2018). 
In addition, due to the restriction of the imaging system solely being stationed within a 
normoxic atmosphere, the normoxic acclimated cells used in the scratch assay may not have 
behaved identically to how they would under their regular hypoxic atmosphere. Nonetheless, 
the wound closure observed by UW-CSCC1 at 12 hours matched with that observed by 
Walter et al., (2010) using HaCaT keratinocytes. 
2.4.7 Conclusions and future directions 
Given the difficulty associated with establishing and validating cell lines, particularly with 
keratinocytes, it is understandable that limited progress has been made in this field. Through 
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much trial and error, a suite of conditions or suggested ‘guidelines’ have been identified that 
may aid in the development of future 2D and 3D cell models of metastatic cSCC. Chiefly, the 
optimal strategies are to avoid shearing viable epithelial cells through utilising explant culture 
techniques, and to control competing fibroblasts via differential trypsinisation or reduced sera 
content. 
The morphological variation observed with the metastatic cSCC in this study highlights the 
diversity with which this disease may present, thus explaining why no one specific approach 
to culture delivers consistent results. This notion rationalises the development of metastatic 
cSCC culture ‘guidelines’ rather than a direct protocol. Further attempts should be made to 
purify epithelial cells from fibroblasts as improved techniques become available. 
The establishment of the UW-CSCC series presented herein and their basic characterisation 
have provided the foundations for future in vitro research on this disease that have simply not 
been satisfied elsewhere in the literature. A summary of the basic characteristics observed in 
this chapter for the UW-CSCC cell line series is shown in Table 2.2 below. 
Table 2.2 Novel metastatic cSCC PDCCs and their basic characteristics. 
Identifier Method derived Tumourigenic 
Forms tight 
spheroids 
Doubling time 
(2D) [hours] 
Growth rate 
(3D) [µm/day] 
UW-CSCC1 Homogenisation Y Y 47 2.6 
UW-CSCC1-R Homogenisation Y N 36 36.7 
UW-CSCC2 Explant Y Y 81 10.5 
 
Having confirmed the PDCCs as tumorigenic not only guaranteed that they have retained the 
major proliferative and survival characteristics that define cancers, but also that they are able 
to undergo in vivo pre-clinical screening of therapeutics via engraftment in 
immunocompromised mice. 
The comparisons of basic cell behaviour have revealed the cells to be invasive in an 
organotypic assay, whilst rather stagnant in 2D wound healing assay. This highlights the 
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demand for assays that recapitulate the complexity of the tumour microenvironment, such as 
that in an organotypic invasion assay. As noted in section 2.4.3, co-culture with cancer-
associated fibroblasts can increase cancer cell proliferation and migration. Components that 
seek to mimic the tumour microenvironment in general (e.g. immune cells and ECM-like 
scaffolds) will undoubtedly improve the fidelity of in vitro models of tumours such as cSCC. 
Moving forward, the UW-CSCC series should be attempted to be grown using patient-
matched CAFs, along with other co-culture variables. Co-culture with the monocytic cell line 
THP-1 would allow for immune cell interactions to be restored (Keuper et al., 2011; Chao et 
al., 2018), which could significantly impact cancer cell survival. The ratio of CAFS and 
immune cells relative to cancer cells must also be determined at a range of concentrations to 
determine the optimal or most relevant culture setting. This could be performed both in 
monolayer systems as well as 3D spheroids. If testing in a 3D context, the stiffness of the 
included artificial matrix must be as close to that of in vivo metastatic cSCC as possible. This 
may take considerable experimentation given the presence of CAFs will inherently increase 
the stiffness of the matrix via contraction (Kalli and Stylianopoulos, 2018). Transcriptomic 
analyses presented in Chapter 3 and 4 highlight the impact of an immune cell population on 
cancer cell pathway expression. With the advent of organoids making in vitro cultures ever 
more relevant, the cultures must continue to be refined. However, due to the timely need to 
progress with other aims using these cell lines, complex co-culture systems were not 
implemented. The derivation of organoids from resected metastatic cSCC tissue has not been 
reported in the literature and is itself worthy of an entire PhD project. 
Irradiation of UW-CSCC1 appears to have had a profound effect upon the cells, with UW-
CSCC1-R demonstrating differences in population doubling time, invasiveness, spheroid 
growth, and morphology. These differences may have significant influences on cancer 
recurrence and aggressiveness following radiation. As such, the differences between UW-
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CSCC1 and UW-CSCC1-R were further investigated and are described to a larger scale in the 
following chapters. 
Importantly, the fidelity of these cell lines to their originating tumour is critical in determining 
their worth as models of the clinical disease. Extensive characterisation and validation of 
these cell lines forms the basis of Chapter 3. The utility of these cell lines for therapeutic 
development are subsequently explored extensively in Chapters 5 and 6. 
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CHAPTER 3: MULTI-OMIC CHARACTERISATION AND 
VALIDATION OF CSCC CULTURES 
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3.1 INTRODUCTION 
It is recognised that many genotypic and/or phenotypic changes are often incurred by cells 
taken from an in vivo to in vitro environment (Daniel et al., 2009; Wilding and Bodmer, 
2014). Some changes can be considered to have no significant bearing on the utility of cell 
lines as a model of the disease, whilst others can drastically influence cell behaviour. As such, 
to ensure robust experimentation it is important to determine the major changes incurred 
through cell culture and the ultimate fidelity of a model with respect to its original tumour. In 
the current study, a multi-omic approach utilising whole genome sequencing (WGS) and gene 
expression data was employed to compare molecular characteristics of the novel PDCCs 
under various experimental conditions to their originating tumour. 
Whole genome sequencing of the cell lines and originating tumour were undertaken by fellow 
PhD student Dr Bruce Ashford in fulfilment of his thesis to examine the genomic landscape 
across several lymph node metastatic cSCC samples. Dr Ashford’s WGS data, in association 
with the transcriptomic data presented in this thesis contribute to a larger overall study to 
investigate the biology of metastatic cSCC. This particular project will focus more 
specifically on transcript expression. 
Discovery and quantification of transcripts in a single experiment is possible through the 
high-throughput sequencing assay, RNA-seq (Trapnell et al., 2013). In this assay, a large 
range of gene expression data is available, including the full repertoire of alternative splice 
isoforms in the transcriptome. This is greatly superior to most other expression microarrays. 
However, this scale of information is both a blessing and a curse as the sequencing and 
analysis of the data itself can be complex, misleading, and may require skilled personnel that 
is not available to all laboratories (Ozsolak and Milos, 2011; Hirsch et al., 2015). Users are 
assumed to possess familiarity with UNIX command-line interface, particularly within the R 
programming environment (Trapnell et al., 2012). Furthermore, the financial cost of such a 
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technology can be significant and may not be justifiable for smaller scale experiments or 
those interested in a smaller suite of genes.  
More recently, the Nanostring nCounter platform (NanoString Technologies Inc, USA) has 
been gaining traction as a robust alternative to RNA-seq and other PCR-based gene 
expression assays for directed gene expression analyses (Ozsolak and Milos, 2011; Prokopec 
et al., 2013; Veldman-Jones et al., 2015; Wang et al., 2016). This system utilises a digital 
colour-coded barcode and single molecule imaging technology that is based on direct 
multiplexed measurement of gene expression with high precision and sensitivity levels to 
detect and count hundreds of unique transcripts in a single reaction. In this system, 
NanoString does not rely on synthesis of a cDNA strand or PCR amplification. Instead, 
barcode-labelled probes anneal directly to mRNAs in solution, and the hybrid molecule is 
then immobilised, detected, and counted (Figure 3.1). 
 
Figure 3.1 The principle of gene expression counting with NanoString. Adapted from Tsang et al., (2017) 
Beyond the benefit of avoiding amplification, NanoString assays contain only probes 
determined to be of particular significance to the specific assay. For example, the PanCancer 
progression code-set is specific to genes that mediate aspects of cancer progression including 
angiogenesis, EMT, ECM, and metastasis. 
Through these technologies this chapter aimed to assess the fidelity of PDCCs with regards to 
their tumour of origin. This is necessary to validate the results obtained from assays involving 
the PDCCs and facilitate translatability of these results into clinical applications. 
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3.2 METHODS 
3.2.1 Nucleic acid extraction 
The tumour samples and PDCCs interrogated in this chapter and the passage number (in the 
case of PDCCs) from which nucleic acid was obtained from is presented in Table 3.1. As 
mentioned in Chapter 2, the earliest stock of UW-CSCC1 is passage 13. This is due to the 
procedure of differential trypsinisation required to generate a pure culture from fibroblasts. 
The carcinoma cells themselves have therefore not undergone as many ‘true passages’ as the 
cancerous cells were always preserved, whilst fibroblasts discarded. Nonetheless, passage 
numbering begins at 13 for UW-CSCC1. 
Several derivatives of UW-CSCC1 (described first in Chapter 2) were analysed to investigate 
the effect of particular culture conditions on gene expression. Fresh-frozen samples of 
matched tumours were used for clinical comparisons, along with a few FFPE samples. 
Clinicopathologic details of these tumours are provided in Appendix C. A secondary 2D 
culture was generated from the harvested UW-CSCC1 derived xenograft tumour using the 
same techniques applied for clinical specimens. 
Table 3.1 Samples run on the NanoString nCounter system. The passage number the nucleic acid was 
extracted from for each PDCC is shown. For some UW-CSCC1 derivatives, passage numbering started after 
inception of the derivative. I.e. UW-CSCC1 normoxic was run after 3 subcultures in a normoxic atmosphere 
from a passage 13 culture of UW-CSCC1, thereby gaining the designation 13.03. Passage 13 and 2 are the 
earliest passage at which a pure culture of epithelial cells was confirmed for UW-CSCC1 and UW-CSCC2, 
respectively. 
Sample Passage number 
UW-CSCC1 13 
UW-CSCC1 High passage 41 
UW-CSCC1 Normoxic 13.03 
UW-CSCC1 Spheroid 13.05 
UW-CSCC1 Xenograft - 
UW-CSCC1 Xenograft secondary cell line 2 
UW-CSCC1-R 13.08 
UW-CSCC2 2 
193958 (origin of UW-CSCC1) - 
658492 (origin of UW-CSCC2) - 
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Tumour and PDCC nucleic acids were extracted with assistance from Miss Elahe Minaei 
(research assistant, IHMRI, Australia) using AllPrep DNA/RNA/Protein Mini Kit (Qiagen, 
Germany; Cat no. 80004), according to the manufacturer’s instructions. Blood DNA was 
extracted from whole blood using PureLink Genomic DNA Mini Kit (Invitrogen, Life 
Technologies, USA; Cat no. K18200). All samples were quantified using the NanoDrop 
spectrophotometer (Thermoscientific, USA; Cat no. ND1000) and met the purity 
requirements for downstream applications (A260/280 between 1.7 and 2.3). DNA size and 
quality were tested using gel electrophoresis. Only macrodissected tumour samples confirmed 
to have tumour cellularity > 30 % (as independently reviewed by Dr Ruta Gupta) were 
approved for WGS. Samples were further quality controlled prior to WGS by the sequencing 
facilities. 
3.2.2 Genomic analyses 
3.2.2.1 Whole-genome sequencing 
WGS was performed on Illumina HiSeqX instruments (Illumina, USA) by Genome.One Pty 
Ltd, at the Kinghorn Centre for Clinical Genomics (KCCG), Garvan Institute of Medical 
Research (Australia) and at Macrogen (South Korea). Germline DNA (blood) was sequenced 
to a depth 30 – 45× and the experimental samples to 60 – 90× depending on the sequencing 
provider. 
3.2.2.2 Bioinformatics analysis pipeline 
WGS analyses were undertaken by Dr Bruce Ashford with the assistance of bioinformaticians 
Dr Velimir Gayevskiy and Dr Maely Gauthier (KCCG) and summarised below. Paired-end 
sequencing reads were aligned to the human reference genome NCBI GRC Human Build 37 
(hg19) using the Burrows-Wheeler Aligner (BWA)-MEM v0.7.10-r789 and improved using 
realignment around known indels using Genome Analyser toolkit (GATK) version 3.3.0. PCR 
duplicates were removed using SAMtools v1. The run quality was checked using Picard 
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metrics. Somatic single nucleotide variants (SNVs), including small insertions and deletions, 
were called using Strelka v1.0.15. Somatic allele specific copy number variants (CNVs), 
major structural variants (SVs), tumour cellularity and ploidy were inferred using Sequenza 
2.1.2, Manta 0.27.1 and Purple, a custom-built tool developed by the Hartwig Medical 
Foundation (https://github.com/hartwigmedical/hmftools/tree/master/purity-ploidy-
estimator/src/main/java/com/hartwig/hmftools/purple). SNVs and indels were annotated with 
VEP and Gemini and along with SVs and CNVs, were subsequently filtered and interpreted 
using Seave (https://www.seave.bio) (Gayevskiy et al., 2018). Mutational signature was 
determined for each specimen as per the techniques described by Mueller et al., (2019). 
Genes harbouring exonic variants unique to the PDCCs were interrogated by me using the 
Comparative Toxicogenomics Database (Davis et al., 2017) to identify pathway associations 
across KEGG and REACTOME pathway lists. Somatic variants of interest were verified 
using the Integrated Genomics Viewer (IGV; Broad Institute) to ensure coverage and call 
accuracy. Unique and shared somatic mutation sets were obtained for each sequenced sample 
using Bedtools v2.27.0. Venn-diagram plots were produced using the BioVenn website: 
www.biovenn.nl (Hulsen et al., 2008). 
3.2.3 Transcriptomic analyses 
3.2.3.1 NanoString nCounter and RNA expression analysis 
Total RNA was processed for analysis on the NanoString nCounter SPRINT Profiler using 
the 770 gene PanCancer Pathways panel (606 critical genes from 13 canonical cancer 
pathways, 124 cancer driver genes, and 40 reference genes) and the PanCancer Progression 
panel (770 genes involved in angiogenesis, extracellular matrix remodelling (ECM), 
epithelial-to-mesenchymal transition (EMT) and metastasis, including 30 reference genes) as 
per the manufacturer's instructions (NanoString Technologies, USA). A calibrator sample was 
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included across runs to account for batch-to-batch variabilities between cartridges and code-
sets for the PanCancer progression panel. 
Data was analysed using NanoString’s nSolver™ Analysis Software v4.0 with normalisation 
performed to the geometric mean of spiked-in exogenous positive control genes, and 
hybridisation background subtracted using the spiked-in negative controls. Using the 
geometric mean to calculate normalization factors is recommended to minimize the noise 
from individual genes as well as to ensure that the calculations are not weighted towards the 
highest expression housekeeping targets. It is important to note that some previously-
identified housekeeping genes may, in fact, behave poorly as normalizing targets in particular 
experiments depending on their expression within certain tissue types and certain 
circumstances (Silver et al., 2006). As such, housekeeping genes that possessed a large 
coefficient of variation between samples were manually excluded. Housekeeping genes with 
an average count close to background noise determined by the negative controls were also 
excluded. Differential gene expression was derived using nCounter default settings.  
Quality control steps were performed as per manufacturer’s instructions (Gene expression 
data analysis guidelines, NanoString 2018). Briefly, samples were flagged if 0.5 fM of the 
positive controls were less than or equal to 2 standard deviations above the mean of the 
negative controls. Lanes were also flagged if the mRNA normalisation factor was outside of 
the 0.1 – 10 range, i.e. if a sample fell outside of this range then it had been attributed a >10-
fold normalisation which makes the small differences in precise counts unreliable. Similarly, 
lanes were flagged if the normalisation factor for positive controls fell outside of a 0.3 – 3 
range. Binding density is also a crucial factor to consider, with the acceptable range for the 
SPRINT instrument being 0.1 – 1.8. As recommended, genes whose expression levels were at 
or below the level of the negative controls were removed from the analysis. Genes exhibiting 
fewer than 20 counts were flagged and excluded from analyses unless otherwise determined 
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to be authentic and reliable for inferences. With the remaining list of genes on the panels, a 
filter threshold of fold-change 2 and P < 0.05 was used to identify the significant gene 
expression changes based on the nCounter analysis.  
3.2.3.2 Network visualisation using GeneMANIA 
To permit the visualisation of gene interaction data, genes of interest were queried using the 
GeneMANIA web interface (http://www.genemania.org). This interface generates hypotheses 
about gene function, linking functionally similar genes on the basis of datasets collected from 
GEO, BioGRID, Pathway Commons, and I2D (Warde-Farley et al., 2010). Gene ontology 
was weighted in accordance with biological processes; however branches were later adjusted 
to arbitrary lengths to improve the visualisation of the network maps presented herein. 
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3.3 RESULTS 
3.3.1 Genomic validation of PDCCs  
Extensive analysis of the WGS data across several lymph node metastatic samples and the 
PDCCs has been performed by fellow PhD candidate Dr Bruce Ashford in a complimentary 
study. The implications of the WGS findings pertaining only to the novel PDCCs and their 
matched tumours are presented here. 
Genome-wide molecular characteristics of the PDCCs compared to their clinical tumour of 
origin are globally summarised in the Circos plots shown in Figure 3.2 A-E. Purity adjusted 
allelic frequency of all observed SNV (the second outermost level in the circos plots) for UW-
CSCC1, UW-CSCC1-R, and its clinical tumour are globally similar (Figure 3.2 A-C). The 
cell lines have expressed these frequencies more confidently as expected due to the purity of 
the cultures, whereas the clinical tumour is also calling some stromal contaminant SNVs. Of 
note is the conserved UV-associated (C>T) mutational signature of these SNV, as indicated 
by the red dots. 
The pattern of copy number variants (both gains and losses; indicated by green or red bars, 
respectively) is very well conserved between UW-CSCC1/-R and their originating tumour 
(Figure 3.2 A-C). At most there is a subtle decrease in the PDCCs for the extent of copy 
number variation. This was most notably observed in chromosome 4 of UW-CSCC1-R 
compared to the other samples. Patterns of minor allele copy number were similarly well 
conserved between the UW-CSCC1/-R and the originating tumour. However, reductions in 
minor allele copy number were noticeable in chromosomes 9 and 11 for UW-CSCC1-R. 
As expected with cancer, the originating tumour for UW-CSCC1/-R has a high coding and 
non-coding mutational burden, highlighted by the number of transitions and translocations 
present (Figure 3.2 A-C). Major translocation and transition events appear conserved in the 
cell lines, which themselves present with additional structural variants, likely relating to the 
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purity of the cell line assisting variant detection. Many variants are further detected in UW-
CSCC1-R, and are indicative of additional mutation incurred via irradiation or expansion of a 
previously undetectable subpopulation harbouring this genotype. Either case is consistent 
with the alterations in both major and minor allele copy number. As such, UW-CSCC1-R is 
less faithful to the originating tumour than UW-CSCC1. 
The low cellularity of the tumour 658492 (origin of UW-CSCC2) is obvious by the lack of 
variant calling and copy number variations (Figure 3.2 D), matching instead with the germline 
background signal. As such, WGS data of this sample is detecting and reporting on normal 
skin tissue with sparing detections of cancer-associated genomic aberrations. Therefore 
comparisons cannot be drawn between UW-CSCC2 and its originating tumour. However, 
compared to the other cell lines, UW-CSCC2 does indeed harbour many copy number gains 
and structural variants relative to its germline control (Figure 3.2 E), which at the very least 
supports its validity as a pure culture of cancerous cells. 
Greater than 75 % of mutations in these samples are C>T, typical of a UV-radiation effect 
(Figure 3.2). In vitro cell culture did not appear to drastically affect the distribution of these 
mutational signatures compared to their clinical counterpart. However, signature 58 was not 
called in UW-CSCC1, despite the fact it was called in both the clinical tumour and UW-
CSCC1-R. Additionally, both UW-CSCC1 and UW-CSCC1-R had less of signature 7a than 
the clinical tumour, compensated by a greater detection of signature 7b and 7c; although these 
all represent signature 7 regardless. 
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Figure 3.2 Genomic landscape of PDCCs and matched tumours. Circos plots showing overall pattern of genetic aberrations between A) Tumour 193958, B) UW-CSCC1, 
C) UW-CSCC1-R, D) Tumour 658492, E) UW-CSCC2. Matched tumours and cell lines are indicated by * for tumour 193958 and # for tumour 658492. The layers indicate 
the following: i) The outermost circle shows the chromosomes, with the darker shaded areas representing large gaps in the reference genome due to regions of centromeres, 
heterochromatin, and missing short arms. ii) The second circle shows the purity adjusted allelic frequency of all observed SNV (including introns and intergenic regions). The 
scale is from 0 to 100 % and each variant coloured according to its cosmic signature; red is C>T. iii) The third circle informs on all observed copy number changes; with 
losses indicated in red and copy number gain shown in green. This scale ranges from 0 (complete loss) to 6 (high level gains), with those >6 indicated with a green dot. iv) 
The fourth circle represents the minor allele copy number. Minor allele losses are indicated in orange, whilst blue shows regions of minor allele gain. This scale ranges from 
0 (complete loss of heterozygosity) to 3 (high level gains in both chromosomes). v) the innermost circle displays the observed structural variants within or between the 
chromosomes. Translocations are indicated in blue, deletions in red, insertions in yellow, tandem duplications in green and inversions in black. F) Mutational signature 
frequency of PDCCs and one clinical tumour. Matched pairs indicated by *. 
(D) 658492# (E) UW-CSCC2 (F) Mutational 
signatures 
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Of 3,181 genes containing exonic variants identified in the tumour, 93.7 % of these were 
similarly identified in UW-CSCC1. An additional 1,298 affected genes were identified in 
UW-CSCC1, totalling 4,479 gene variants (Figure 3.3). Similarly, UW-CSCC1-R shared 92.7 
% of the clinical tumour’s genes with variants, with an additional 1,586 mutated genes 
detected, totalling 4,767 genes with variants in UW-CSCC1-R. 
Whilst the cell lines mostly shared the same variants between one another, genes with variants 
unique to either cell line were also identified (Figure 3.3). It is unknown if these additional 
variants are from new mutations manifested through cell culture or whether they already were 
present in the tumour, but their detection masked through stromal interference. Genes 
containing exonic variants private to UW-SCC1-R were most often associated with the 
pathways: immune system (REACT:R-HSA-168256), metabolism (REACT:R-HSA-
1430728), and signal transduction (REAC:R-HSA-12582). 
 
Figure 3.3 Venn-diagram showing overlapping genes with coding variants. The numerical basis for the 
circle proportions are shown and correspond to the number of genes with an exonic variant. Created using 
BioVenn (www.biovenn.nl) (Hulsen et al., 2008). 
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These above molecular data suggest that whilst additional mutations have been called in the 
cell lines, they also faithfully capture the genomic profile of the originating tumour. Major 
CNV and gene mutations appear to be well conserved, indicative of genotypic fidelity. 
3.3.2 RNA expression analysis of PDCCs and matched tumours using NanoString 
In vitro culture environments of PDCCs may impact transcriptomic characteristics and 
potentially invalidate the suitability of PDCCs as models of disease for downstream analyses. 
To evaluate gene expression the PDCCs, along with their experimental derivatives and 
matching clinical specimens, were analysed using two different NanoString cancer gene 
expression panels, each containing 770 cancer-related genes spanning canonical cancer driver 
and progression pathways. 
3.3.2.1 UW-CSCC1, derivatives, and matched tumour - PanCancer Progression panel 
Upon collapsing each of the genes found within the PanCancer progression panel into their 
respective pathway and assigning a gene expression score, unsupervised hierarchical 
clustering analysis produced two major clusters, separating in vitro from in vivo samples 
(Figure 3.4). This heatmap allows a holistic observation of the changes in pathway activity 
rather than single gene differences. Such analyses are important as it is possible that the major 
biological disturbances based on functionality are preserved despite low commonalities at a 
single-gene level. 
The effects of varying culture conditions on pathway gene expression were tested, including 
O2 levels, passage number, growth as a spheroid, and culture as a mouse xenograft. Amongst 
the in vitro PDCC derivatives, there was subtle overall change in expression. Most pathways 
under in vitro conditions were downregulated, with the exception of fibrosis, metastasis 
suppressors, and LOX remodelling which were found to be upregulated relative to the 
xenograft and clinical tumour (Figure 3.4). 
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At a low passage (# 13), UW-CSCC1 displayed an expression profile most akin to the in vivo 
samples than the other in vitro PDCC derivatives, as is supported by its hierarchical 
clustering. Whilst almost all the pathways have been downregulated in UW-CSCC1 compared 
to the clinical tumour, these differences are less evident in comparison to the changes incurred 
through long-term passage (passage # 41), irradiation, or changes to the physiologically 
relevant O2 levels. The spheroid derivative was the next closest in vitro PDCC derivative in 
terms of resembling the originating clinical tumour’s phenotype and may have been even 
greater if a lower passage had been used to generate the spheroids, if not from the beginning. 
 
Figure 3.4 Progression panel pathway scores for UW-CSCC1 culture derivatives. Agglomerative clustering 
of PDCC pathway scores under various conditions is shown following z-score transformation. Yellow indicates 
high scores and blue indicates low scores, with an increased score corresponding to increased expression within 
a given pathway. 
The expression profile of the xenograft across the pathways closely resembled the original 
tumour. Downregulation of gene expression was observed with the xenograft for certain gene 
sets including collagen family, basal lamina, ECM structure, metastasis response, and 
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regulation of angiogenesis. Interestingly, for the xenograft there was an increase in the 
expression of genes associated with cell motility, relative to the clinical specimen. These data 
indicate that in vitro cell lines can preserve genomic information in a resourceful manner that 
can largely be restored to physiological expression levels once re-entered in vivo. 
In addition, it appeared that upon secondary 2D culture of the UW-CSCC1 derived xenograft, 
the phenotype was mostly maintained, even after one passage (Figure 3.5). In fact, some 
pathways (e.g. VEGFA signalling) in the secondary cell line have become even more similar 
to the clinical tumour than the primary xenograft. 
 
Figure 3.5 Pathway scores for xenograft, xenograft derived cell line, and clinical tumour. Following 
removal of the UW-CSCC1 derived tumour from the mouse, it underwent tissue processing as done for clinical 
samples. The resultant 2D culture was subsequently expanded and RNA extracted after one passage. Pathway 
scores are shown having undergone z-score transformation. Yellow indicates high scores and blue indicates low 
scores, with an increased score corresponding to increased expression within a given pathway. 
Expression differences for genes involved in hypoxia inducible factor signalling and stem cell 
associated pathways were determined for UW-CSCC1 under either hypoxic or normoxic 
atmospheric conditions. Most of the genes within these pathways were upregulated in the 
hypoxic-treated UW-CSCC1, with others displaying similar levels to that of the normoxic 
treated cells. Some noteworthy genes within these pathways and their log2 fold-change 
differences are shown in Figure 3.6. The normoxic-acclimated cells were only three passages 
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greater than that tested for the hypoxic UW-CSCC1, and therefore the expression profile 
differences are unlikely to be related entirely to passage number. 
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Figure 3.6 HIF1A and stem cell associated genes for hypoxic vs normoxic treated UW-CSCC1. Log2 ratios 
are shown with the normoxic treated cells as the baseline. 
To quantitatively compare the gene expression differences between UW-CSCC1/-R and the 
clinical tumour, individual genes with a log2 fold-change of ≤ -2 or ≥ 2 were interrogated. 
Between UW-CSCC1 and its matched tumour, 227 (30 %) genes from the panel were 
differentially expressed. The majority of these genes (88 %) displayed downregulation in 
UW-CSCC1 with respect to the tumour. Figure 3.7 compares the top 10 most up- and down-
regulated genes between UW-CSCC1 and the tumour (baseline). Most of the downregulated 
genes related to ECM organisation, whilst the upregulated genes generally had functions in 
cell-cell junction organisation, angiogenesis regulation, and cytokine receptor binding. 
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Figure 3.7 Most differentially expressed genes between UW-CSCC1 and the matched tumour – 
progression panel. Log2 ratios are shown with the tumour as the baseline. 
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Similar to UW-CSCC1, most genes affected in UW-CSCC1-R compared to the clinical 
tumour (as a baseline) were involved in ECM organisation (Figure 3.8), with four of the top 
10 most downregulated genes matching those seen to be downregulated with UW-CSCC1 
(MMP12, CXCL10, SPP1, KRT14), as shown above. Of the topmost upregulated genes in 
UW-CSCC1-R, three match those from UW-CSCC1 (CADM1, CDH2, CXCL8) and the 
majority of functions affected again included cell-cell junction organisation, angiogenesis, 
and cytokine receptor binding. 
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Figure 3.8 Most differentially expressed genes between UW-CSCC1-R and the matched tumour – 
progression panel. Log2 ratios are shown with the tumour as the baseline. 
3.3.2.2 UW-CSCC1, derivatives, and matched tumour - PanCancer Pathways panel 
Unsupervised hierarchical clustering of the samples interrogated with the PanCancer 
pathways panel similarly produced two main clades as above (Figure 3.9). The xenograft 
culture again resulted in a near identical expression profile to the clinical tumour. 
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Figure 3.9 Pathways panel pathway scores. Agglomerative clustering of PDCC pathway scores under various 
conditions is shown following z-score transformation. Yellow indicates high scores and blue indicates low 
scores, with an increased score corresponding to increased expression within a given pathway. 
DNA damage repair gene expression levels in UW-CSCC1 were similar to the clinical 
tumour, whereas gene expression levels in the other in vitro PDCCs were upregulated relative 
to the clinical tumour for this pathway (shown in green box, Figure 3.9). Curiously, UW-
CSCC1 differed more from the clinical tumour than the other derivatives for the majority of 
the other pathways. Notably, the pathway chromatin modification was most strongly 
downregulated in UW-CSCC1, as evident from the bright blue coloured tile (Figure 3.9), 
compared to all other samples. Contrastingly, spheroid culture of the cell line resulted in a 
restored score for chromatin modification, more similar to the xenograft and clinical tumour. 
This is also true to a lesser extent for other pathways (shown in red box, Figure 3.9) with the 
spheroid culture, indicating this form of culture has helped stimulate the cell line closer to the 
in vivo phenotype. For example, Notch related genes have been restored to near-physiological 
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levels in the spheroid, as has been observed elsewhere following transformation to 3D culture 
(Mauretti et al., 2017). However, the influence of the DNA damage repair pathway ultimately 
pushes the spheroid culture further from the clinical tumour upon hierarchical clustering. No 
significant differences in cell adhesion or stem cell related genes (included in the pathways 
panel) were observed in the spheroid derivative over the 2D cell lines. 
The xenograft once again demonstrated a faithful restoration of gene expression. It is clear 
that UW-CSCC1 has retained the genetic information of the tumour and can mostly restore 
physiological mRNA expression via an animal model. When an animal model is not 
available, spheroid cultures appear to potentially be the next best system from the outset, 
alongside using as low of a passage as possible. 
As with the progression panel data, a log2 fold-change threshold of ≤ -2 or ≥ 2 was applied 
and differentially expressed genes determined by the nSolver software. Of the 770 genes 
present in the pathways panel, 76 (9.9 %) were differentially expressed between UW-CSCC1 
and the clinical tumour. The top 20 most dysregulated genes are shown in Figure 3.10. 
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Figure 3.10 Most differentially expressed genes between UW-CSCC1 and the matched tumour - pathways 
panel. Log2 ratios are shown with the tumour as the baseline. 
The significantly downregulated genes shown above are almost all completely linked, sharing 
roles in extracellular matrix organisation, as denoted by red shading in the association data 
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map below (Figure 3.11). The exception lies in SFRP2 which has no direct pathway 
associations with the other genes, although wnt signalling from SFRP2 can interact with ECM 
components. 
 
Figure 3.11 Association data map of downregulated genes. Pathway interaction data of genes downregulated 
in UW-CSCC1 relative to the matched tumour are shown via blue branches of arbitrary length. Genes directly 
involved with ECM organisation are shaded in red. Specific genes of interest are shown by stripes. Image 
created by the GeneMANIA prediction server: biological network integration for gene prioritization and 
predicting gene function (Warde-Farley et al., 2010). 
Contrastingly, the genes with a large positive log2 fold-change in the cell line compared to the 
tumour have very little association with ECM mediating genes and even have fewer 
functional associations with each other. As shown in Figure 3.12, genes significantly 
upregulated in the cell line produced four distinct clusters based on their biological processes, 
compared to the one cluster in Figure 3.11 that holds 90 % of the topmost downregulated 
genes. The most commonly involved functions with the upregulated genes are angiogenesis, 
cytokine receptor binding, and regulation of Wnt signalling. These affiliations are denoted by 
the shading of dark blue, yellow, and purple, respectively, in Figure 3.12. Whilst the 
downregulated genes mostly conform to a similar pathway, the upregulated genes shown here 
appear to be more indiscriminate in their impact. 
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Figure 3.12 Association data map of upregulated genes. Pathway interaction data of genes upregulated in 
UW-CSCC1 relative to the matched tumour are shown via blue branches of arbitrary length. Specific genes of 
interest are shown by stripes. Coloured fractions refer to those genes involved in the functions of angiogenesis 
(dark blue), cytokine receptor binding (yellow), and regulation of Wnt signalling pathway (purple). Image 
created by the GeneMANIA prediction server: biological network integration for gene prioritization and 
predicting gene function (Warde-Farley et al., 2010). 
UW-CSCC1-R exhibited 104 (13.5 %) pathways panel genes that were differentially 
expressed relative to the clinical tumour. Of these genes, all but four demonstrated 
downregulation in the cell line (Figure 3.13).  
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Figure 3.13 Most differentially expressed genes between UW-CSCC1-R and the matched tumour – 
pathways panel. Log2 ratios are shown with the original tumour as the baseline. 
DNA damage repair genes were generally upregulated in UW-CSCC1-R compared to both 
the tumour and UW-CSCC1. Notably, PCNA, MAD2L2, and FEN1 were upregulated in UW-
CSCC1-R and possess important biological roles in DNA damage repair. 
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3.3.2.3 UW-CSCC2 and matched-tumour 
Comparisons of UW-CSCC2 to its clinical sample (658492) are not presented in detail here as 
the latter failed to meet quality control requirements for WGS. Preliminary analyses were 
performed nonetheless and confirmed the low tumour cellularity of the clinical sample 
through the low expression of genes known to be upregulated in cancer. Using the data from 
both panels, hierarchical clustering was performed with UW-CSCC2, its matched clinical 
tumour and normal skin, as well as a separately confirmed metastatic cSCC (193958) for 
comparison. 
Whilst UW-CSCC2 downregulated most pathways compared to the other samples, it 
maintained the expression of a selection of genes compared with the high tumour cellularity 
sample 193958, as highlighted by the red boxes in Figure 3.14. The clinical origin of UW-
CSCC2 (658492) closely resembled the expression profile of the normal skin, and clustered 
with it in both panels. Due to this, it is not possible to validate the fidelity of UW-CSCC2 to 
its originating tumour. 
 
Figure 3.14 Gene expression of UW-CSCC2 with matched tumour and normal skin. These heatmaps of the 
progression panel (left) and pathways panel (right) compare UW-CSCC2 gene expression with its matched 
tumour and normal UV-exposed skin as well as the tumour 193958. Overall normalized data has been further 
scaled to give all genes equal variance, generated via unsupervised clustering. Orange indicates high 
expression; blue indicates low expression. 
Progression Panel          Pathways Panel
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3.3.3 RNA expression profiling of genes with high impact mutations potentially relevant 
to cSCC tumorigenesis 
Differences in the pathway scores between samples using these panels are not necessarily an 
exact determinant of how faithful the PDCCs are to the underlying biology of the disease. 
Some of the altered genes in the aforementioned pathways may not be pivotal with regards to 
cSCC tumorigenesis or therapeutic management. Each cancer type is defined by a unique set 
of mutations that give rise to the disease and allow it to prosper. As such, it is the expression 
of these mutated genes that should be retained in culture for downstream assays to be 
meaningful. Genomic data must be paired with expression data to resolve the impact of 
genetic discrepancies. Proteomic data would add to this, although this goes beyond the scope 
of the current investigation and available resources.  
To further resolve the fidelity of UW-CSCC1 to its originating tumour, differences in the 
expression of genes of potential aetiological significance were investigated. Key short 
variants (KSVs) shared between the samples relative to the germline were determined using 
WGS data. Only those genes included in either of the NanoString panels were interrogated for 
the sake of comparing gene expression. From this, 204 and 143 KSVs were found for the 
progression panel and pathways panel gene lists, respectively. Together, 20 of these KSVs 
carried high impact mutations across 19 genes (Table 3.2). UW-CSCC2 was not analysed due 
to quality control issues in the originating tumour, as mentioned previously.  
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Table 3.2 Key short variants with high impact mutations shared by UW-CSCC1, UW-CSCC1-R, and the matched tumour. Mutation impact classification denoted by 
the following abbreviations: LOF = loss of function; SDV = splice donor variant; SAV = splice acceptor variant; SG = stop gained; FV = frameshift variant. * denotes KSV 
not found in UW-CSCC1-R. 
Gene Impact LOF Exonic Coordinates Resultant protein 
ANPEP* SDV N N chr15:g.90346842C>T Alanine aminopeptidase 
BAD SG Y Y chr11:g.64037723C>T Bcl-2-associated death promoter 
CACNA1C SG Y Y chr12:g.2797646C>T 
 
Calcium channel, voltage-dependent, L type, alpha 1C subunit 
CREBBP SG Y Y chr16:g.3779320G>A CREB-binding protein 
ENO1 SDV Y N chr1:g.8922945C>T Enolase 1 
EP300 FV Y Y chr22:g.41554430ACAGAC>A Histone acetyltransferase p300 (p300 HAT) 
EP300 FV Y Y chr22:g.41554440TG>T Histone acetyltransferase p300 (p300 HAT) 
FUT8 SG Y Y chr14:g.66200010C>T 
 
Alpha-(1,6)-fucosyltransferase 
ITGA5 SG N N chr12:g.54803282C>T Integrin alpha-5 
IL1RAP SG Y Y chr3:g.190373943G>A 
 
Interleukin-1 receptor accessory protein 
NOTCH1 SDV Y N chr9:g.139417301C>T Notch homolog 1, translocation-associated 
NRXN1 SG Y Y chr2:g.50692638C>T Neurexin-1-alpha 
PIK3R5 SAV N N chr17:g.8792271C>T Phopshoinositide 3-kinase regulatory subunit 5 
PTK2 SG Y Y chr8:g.141712701G>A PTK2 protein tyrosine kinase 2 or focal adhesion kinase (FAK) 
PTPRC SAV Y N chr1:g.198710997G>A Protein tyrosine phosphatase, receptor type, C (CD45) 
RB1 SDV Y N chr13:g.48881541TGGTAAGG>T Retinoblastoma protein 
RPA3 SAV Y N chr7:g.7676714C>T 
 
Replication protein A3 
SSX1 SG Y Y chrX:g.48117222G>A 
 
SSX1 
STAB2 SAV Y N chr12:g.103988172G>A Stabilin-2 
TIE1 SG Y Y chr1:g.43774545G>A Tyrosine kinase immunoglobulin-like and EGF-like domains 1 
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Once integrated with gene expression data, only PTPRC, PIK3R5, and TIE1 showed notable 
log2 fold-change differences between UW-CSCC1 and its matched tumour (Figure 3.15). No 
genes with high impact KSVs were found to have a significant (≥ 2 log2 fold-change) 
upregulation in UW-CSCC1. These results demonstrated an appreciable downregulation in 
mRNA expression in only a very few genes of potential aetiologic relevance between the 
PDCC and its originating tumour. The normalised counts of these few genes were found to be 
extremely low (data not shown), aligning with their inactivating mutations listed above. As 
such, subtle differences in count data at such low levels can distort perceived large differences 
in ratios, whilst the expression differences themselves remain functionally irrelevant. 
Therefore, UW-CSCC1 and the originating tumour are genotypically and phenotypically quite 
similar, particularly for these influential genes of tumorigenesis.  
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Figure 3.15 High impact KSVs and gene expression. The log2 gene expression ratios between UW-CSCC1 and 
the matched tumour (baseline) are shown. 
3.3.4 Effect of irradiation on gene expression 
The specific changes incurred through irradiation of UW-CSCC1 were examined more 
discretely using the NanoString data. With respect to the tumour, UW-CSCC1 and UW-
CSCC1-R possessed 227 and 222 differentially expressed progression panel genes, 
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respectively. The PDCCs share 153 of these genes (Figure 3.16), resulting in 74 uniquely 
differentially expressed progression panel genes for UW-CSCC1 and 69 for UW-CSCC1-R. 
 
Figure 3.16 Overlap of differentially expressed genes between the PDCCs compared to the tumour. 
Created using BioVenn (www.biovenn.nl) (Hulsen et al., 2008) with the NanoString progression panel gene list. 
Of the 40 topmost dysregulated genes between these PDCCs (Figure 3.17), most belonged to 
one or more of the following annotations: Epithelial to mesenchymal transition, plasma 
membrane, cell adhesion, and cell proliferation. The upregulated genes in UW-CSCC1 tended 
towards the plasma membrane annotation and cell adhesion, whilst the downregulated genes 
tended towards the ECM structure annotation. 
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Figure 3.17 Most differentially expressed genes in UW-CSCC1 relative to UW-CSCC1-R. Log2 fold-change 
is shown with UW-CSCC1-R as the baseline. 
153 
74 69 
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It is worth noting that of the high impact KSVs identified in section 3.3.3, UW-CSCC1-R 
similarly possessed these KSVs except for the splice donor variant in ANPEP. No additional 
high impact mutations were observed with UW-CSCC1-R. With regards to gene expression 
of ANPEP, UW-CSCC1 and the clinical tumour both shared a similar log2 count of 6.48 and 
6.35, respectively. UW-CSCC1-R however has a lower log2 count of 4.51. As such, it appears 
that the expansion of the radio-insensitive cells has reverted ANPEP back to the genotype of 
the germline. 
Both major and minor alterations in cell adhesion gene expression was notable, with UW-
CSCC1 mostly upregulating these genes (e.g. CDH1 and S100A7) relative to UW-CSCC1-R 
(Figure 3.18). This is reflected physiologically in the inability of UW-CSCC1-R to form tight 
spheroids compared to UW-CSCC1 (Chapter 2). One of the largest differences is with the 
gene S100A7, demonstrating a log2 fold-change of 12 in UW-CSCC1 relative to UW-CSCC1-
R. Some cell adhesion genes were upregulated in UW-CSCC1-R, namely NCAM1. 
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Figure 3.18 Expression of cell adhesion genes between UW-CSCC1 and UW-CSCC1-R. A) Log2 
normalised counts of pathway score for cell adhesion genes. Error bars refer to standard error of the mean. 
Asterisks denote P < 0.001. B) Heatmap of the normalized data for genes included in the cell adhesion pathway, 
scaled to give all genes equal variance via z-score transformation.  
Several genes that mediate ECM degradation have been notably downregulated in UW-
CSCC1 relative to UW-CSCC1-R, including several MMP remodelling genes and PCOLCE, 
which codes for a glycoprotein that drives collagen degradation.  
A) B) 
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Given the differences observed in spheroid formation between UW-CSCC1 and UW-CSCC1-
R shown in Chapter 2 (section 2.3.4.5), and the ability of the UW-CSCC1-R spheroids to 
continue to grow (albeit as loose aggregates), differences in stem cell associated genes were 
also investigated due to their role in maintaining tumour growth. In support of this, 
hyaluronan and proteoglycan link protein 1 (HAPLN1) mRNA expression was significantly 
lower in UW-CSCC1 compared with UW-CSCC1-R. Other indicators of stemness were 
shown by the upregulation of SOX2, CD24, and PROM1 (CD133) in UW-CSCC1-R (data not 
shown). 
It is concluded that irradiation has affected UW-CSCC1 cell adhesion gene expression and 
stem-like properties. This can have influences on cell motility and proliferation, as was seen 
with the cell behaviour differences between the PDCCs addressed in Chapter 2.  
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3.4 DISCUSSION 
Gene expression assays and whole-genome sequencing were implemented to evaluate the 
fidelity of the PDCCs to their originating tumours. The following sections will discuss the 
relevance of the aforementioned results. 
3.4.1 Genetic drift is minimal following 2D culture; increased following irradiation 
At a genomic level, UW-CSCC1 almost completely retained the mutational landscape of the 
clinical tumour, as has been reported for other cell lines (Gazdar et al., 2010). Additional 
variants called in UW-CSCC1 are not explicit evidence of genetic drift, but rather a result of 
the culture purity enhancing variant detection through the elimination of stromal background 
noise. A UV signature was detected in all cases, much like that of Pickering et al., (2014), and 
did not appreciably differ in mutation frequency between tumour or cell line. Comparisons of 
UW-CSCC2 to its clinical tumour were unobtainable given the low tumour cellularity. 
Cell lines which maintain clinically actionable mutations fundamentally retain their sensitivity 
to the targeting agent. This is true within UW-CSCC1, with the exception of some 
adjustments in copy number. However, UW-CSCC1-R presented additional genomic variants, 
likely as a result from DNA damage incurred through irradiation of the parental cell line. It is 
also possible that an initial population of cells harbouring some or all of these mutations 
survived irradiation and were able to expand and become detected. This may also explain why 
the high impact KSV in ANPEP seen in UW-CSCC1 and the clinical tumour is not observed 
in UW-CSCC1-R. In either case, these data highlight the degree of cellular alterations that 
may exist in surviving cells post-radiation therapy. These ‘radio-insensitive’ cells born out of 
such an approach bring the long term unimodal efficacy of radiotherapy into consideration. 
Adjuvant radiotherapy with chemotherapy or radiosensitisers may be necessary to ensure full 
redundancy of the cancerous tissue. Attempts to alleviate these concerns are addressed by the 
aims of Chapter 6. It has also been suggested that radiotherapy can have a range of influences 
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upon the non-cancerous cells in the tumour microenvironment, such as the promotion of 
invasion and metastasis (Barker et al., 2015). However, these claims are largely 
unsubstantiated. 
Given the changes specific to UW-CSCC1-R are mostly associated with the annotations of 
immune system, metabolism, and signal transduction, it is reasonable to expect quite drastic 
changes in physiology. This was already observed in Chapter 2 with stark changes in 
proliferation rate and spheroid growth between UW-CSCC1 and UW-CSCC1-R. The 
influence this has upon response to therapeutics will be discussed in Chapter 5. 
3.4.2 PDCCs downregulate cancer-associated pathways relative to the clinical tumour 
3.4.2.1 Progression panel 
The majority of the pathways analysed displayed downregulation across the PDCCs 
(inclusive of derivatives) with respect to the originating tumour. The differences between 
UW-CSCC1 and the tumour on the basis of the progression panel pathway analysis should not 
immediately disqualify UW-CSCC1 as an accurate model of the tumour as these results 
warrant context. A pathway analysis, whilst providing an overall picture of expression 
differences, can also give an inaccurate drawing of that picture, skewing data and 
interpretations by including outliers or genes with no pathological significance to the disease 
of interest. Stromal and lymphoid gene expression in the original tumour can create large 
differences in gene expression that are not tumour-specific (Daniel et al., 2009) and, as a 
consequence, cloud these interpretations. Furthermore, the probes included in the progression 
panel have a select focus on genes involved in the events that moderate the progression of a 
tumour from its primary site to a metastatic location. As such, a proportion of genes included 
in this panel may have no bearing on the real physiological influence of therapeutics, among 
other characteristics that a cell line attempts to provide a model for. 
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The downregulated pathway profile observed with the cell lines here is unsurprising given 
this effect has been seen in many cell lines of other cancer types (Ertel et al., 2006; Lukk et 
al., 2010). Gillet et al., (2013) surmises that, given the selection for cells that have rapid 
growth, being maintained in growth-promoting cocktails as a monolayer, and in high oxygen 
tension – these conditions undoubtedly select for subpopulations of cells that differ from the 
predominant cells of the original tumour. As such, one should not be surprised that cell line 
expression profiles are different from those of the originating tumour. It is debateable whether 
or not this is grounds to reject such a model – a debate that continues in lieu of the continued 
abundance of publications contributing to scientific understanding and medical practice that 
utilise exactly such models.  
Large scale studies comparing clinical samples with cell lines have similarly observed the 
division into two clades (Lukk et al., 2010; Gillet et al., 2013). Of note, a large-scale gene 
expression analysis conducted by Lukk et al., (2010) revealed that amongst 5,372 human 
samples, most cell lines cluster together rather than with their tissues of origin, with the 
exception of incompletely differentiated cell types (e.g. mesenchymal stem cells). 
Contrastingly, Barretina et al., (2012) observed a positive correlation between 947 cell lines 
and primary tumours, suggesting cell lines possessed many of the genomic aberrations found 
in tumours. They proposed the differences between cell lines and clinical tumours are a result 
of background tumour microenvironment (TME) related gene expression that could be simply 
subtracted, leaving authentic and clinically relevant gene signatures. The TME is inclusive of 
cancer cells, cancer-associated fibroblasts, pericytes, cancer stem cells, and immune cells 
(Figure 3.19); all of which play an important role in vivo, providing crosstalk between the 
tumour and the microenvironment (Goodspeed et al., 2016). Given these interactions with the 
TME will generally be regained in an in vivo model (or in vivo-like models such as 
organoids); it is perhaps fair to neglect this ‘background’ noise for pre-clinical research. 
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Figure 3.19 Components of the tumour microenvironment. Adapted from Hanahan and Weinberg, (2011). 
Genes relating to ECM organisation were often the most downregulated genes in UW-CSCC1 
compared to the tumour, whilst genes involved in cell-cell junction organisation, angiogenesis 
regulation, and cytokine receptor binding were generally upregulated. Differences in all of 
these genes are unsurprising as there are no longer stromal components in 2D culture which 
can influence activation of ECM mediating genes. Additionally, the provision of nutrients and 
oxygen via media and the incubator may affect the expression of genes associated with 
angiogenesis and cytokine signalling whilst the limited cell-cell contact provided in 2D 
culture would activate the expression of cell-cell junction genes (Creighton et al., 2003). 
3.4.2.2 Pathways panel 
The pathways panel produced similar results as with the progression panel, whereby UW-
CSCC1 downregulated genes involved in ECM organisation. However, in the pathway 
analysis, UW-CSCC1 appeared to possess even further downregulation across most pathways 
than other derivatives, including UW-CSCC1-R. This was particularly true for chromatin 
modification. However, UW-CSCC1 maintained expression of DNA damage repair genes 
similar to the clinical tumour and xenograft. As with the progression panel, genes upregulated 
in the cell line appeared to be specific to angiogenesis, cytokine receptor binding, and 
regulation of Wnt signalling. These changes may again be explained by the shift from a 
vascularised system to a 2D monolayer with altered interactions with nutrients (Creighton et 
al., 2003).  
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3.4.3 UW-CSCC1 conserved expression profile for key actionable oncogenic pathways 
For each cancer type there are a particular set of driver mutations that lead to tumorigenesis 
and progression. The preservation of these genes in the cell model is critical to ensure 
translatability of data built by targeting these genes or their respective pathways. 
The 20 key short variants (KSVs) reported in section 3.3.3 were selected for their high impact 
mutations and their expression was found to be mostly retained in UW-CSCC1. UW-CSCC1-
R was not analysed for KSVs as the purpose was to simply validate the relationship between 
UW-CSCC1 and its originating tumour. This was unable to be performed for UW-CSCC2. 
NanoString analyses did reveal large differences in the expression ratios of just a few of the 
high impact KSVs: PTPRC, PIK3R5, and TIE1. Notably, PTPRC (encoding for CD45) 
displayed a log2 fold-change of -6.6 in UW-CSCC1 with respect to the tumour. As CD45 is 
specifically expressed in hematopoietic cells, this reduction indicates a loss of a CD45 
positive cell population in 2D culture. This is unsurprising given  the selectivity for epithelial 
cells with the given culture system. Original tumour expression of PTPRC was not regained 
in the animal model as expected, indicating an irreversible loss of this population.  
Ashford et al., (2017) reported the top 20 mutations in cSCC using COSMIC data 
(http://cancer.sanger.ac.uk), of which there is only one overlap with our high impact KSV 
data: CREBBP. This gene is mutated in approximately 35 % of cSCC (Ashford et al., 2017), 
with both the tumour and UW-CSCC1 falling into this cohort. Given this gene could be of 
significance to disease pathogenesis, large differences in expression in the cell line could be 
dire. However, the log2 ratio between UW-CSCC1 and the tumour was relatively small (-
1.11) and likely carries no significant influence. Nonetheless, this should be considered when 
investigating any downstream products or interactions of CREBBP. 
The PIK3R5 splice acceptor variant present in both UW-CSCC1 and the original tumour is 
non-exonic and results in no loss of function. Therefore, despite a large downregulation in the 
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cell line, the differences in the expression of this gene likely have no downstream tumorigenic 
implications. 
The downregulation of TIE1 can be explained as this gene is specifically expressed in 
developing vascular endothelial cells (Rodewald and Sato, 1996). These cells would be 
detected in the contaminating stroma for the original tumour and absent in the cell line. In 
fact, the impact of the tumour microenvironment can be large, exposing cells to selective 
pressures, which when removed result in a change in expression (Weigelt et al., 2014). As a 
consequence, differences seen may be a result of this rather than inherent clonal selectivity or 
genetic drift. 
When establishing a cell line, one must clearly distinguish between genomic and 
transcriptomic changes incurred through this process relative to the original tumour. It has 
been shown that at the genomic level, driver mutations are mostly retained in other cell lines 
(Gazdar et al., 2010). This is observed too within the current data, except for some copy 
number alterations and SNVs. Nevertheless, both the WGS and NanoString data suggest that 
genes of aetiological relevance included in either of the panels have not been affected 
appreciably by going into 2D culture, thereby qualifying UW-CSCC1 at the very least for 
experimentation as a model of its parental tumour. Limitations of the current study are the fact 
that only key genes involved in cancer progression were analysed and the effect on the 
regulatory regions of these KSVs were unable to be fully examined.  
3.4.4 Culturing conditions and gene expression 
The fidelity of a cell line can vary depending on the culturing conditions it has been subject 
to. Whilst UW-CSCC1 (at a low passage) has been described above to be a reasonably 
faithful model of its parental tumour, retaining key oncogenic pathways, the caveat lies in the 
prolonging of cell culture – inducible of secondary genomic changes such as copy number 
alterations as well as transcriptomic drift. Li et al., (2014) found copy number alterations in 
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HNSCC cell lines that were not present in the original tumours, presumably resulting from 
selection and propagation in vitro. This has likely been the case for the UW-CSCC series as 
well. The impacts of several culturing conditions on gene expression were assessed through 
the provision of UW-CSCC1 derivatives and the findings discussed below. 
3.4.4.1 Xenografting of PDCCs largely restores clinical expression profile 
Critics of in vitro cell lines suggest that cell line establishment results in the distinct and 
irreversible loss of important biological properties. A study by Daniel et al., (2009) attempted 
to compare the expression profiles between non-small cell lung cancer primary tumour 
xenografts, the cell lines derived from these xenografts, and a secondary xenograft created 
from these cell lines. Their experiment found that many of the changes incurred by going onto 
plastic were irreversible, unable to be regained in the secondary xenograft. This is contrary to 
the findings of the UW-CSCC1 xenograft, whereby the majority of examined genes/pathways 
regained the original tumour phenotype for both the progression and pathways panel. 
Unaffected gene annotations included: collagen family, ECM structure, metastasis response, 
and regulation of angiogenesis. This may be due to the mouse stroma accommodating the 
production of ECM components (including collagen) and the provision of a blood supply, 
thereby allowing the cell line to cease transcription of the associated genes. This may also be 
a function of species incompatibility as murine growth factors do not activate certain human-
specific pathways, e.g. human MET (Wilding and Bodmer, 2014; Goodspeed et al., 2016). 
With the PanCancer pathways panel, the UW-CSCC1 xenograft similarly regained expression 
almost identical to that of the clinical tumour, with the exception of the pathways PI3K, 
transcriptional misregulation, and Notch. Again, this is very likely due to subtle differences 
and the interactions with mouse growth factors. 
A similar study by Creighton et al., (2003) compared cell lines with their successive 
xenografts and found a number of gene classes becoming enriched in the xenograft tumours. 
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It is inferred that the restorative ability is cell line dependent, explaining why Daniel et al., 
(2009) did not observe such a response. This restoration of function may suggest that the 
tumorigenic mutations have been retained (genomic stability), despite clonal expansion in 
plastic. This property allows for PDCCs to be derived in vitro in a cost-effective and highly 
reproducible manner for efficient biological assays with the capability of resembling in situ 
tumour biology once given the appropriate environment (Creighton et al., 2003). This confers 
significant advantages over long-term culture through mice. 
NanoString is a highly sensitive technology with great specificity to human tissue. As such, 
practically no mouse stromal tissue would be detected; therefore the expression profile 
observed here is of authentic human carcinoma. Human stroma may be detected in the 
cognate tumour sample to a degree, although given the substantial tumour cellularity; this 
would have a minimal impact. If the xenograft truly has regained important functions, than 
perhaps subtracting the difference between the xenograft profile and that of the original 
tumour may reveal the degree of human stromal contamination. 
Interestingly, upon culture of the harvested xenograft, the expression profile of this 
‘secondary’ cell culture was maintained despite now being in a 2D plane. Albeit, mRNA was 
extracted from a very early passage and therefore the effects of 2D culture may not have 
developed yet. Nonetheless, the sustained expression similar to the clinical tumour adds 
credence to the suggestion that the differences between the clinical tumour, the cell cultures, 
and the xenograft are due to stromal background noise. 
It is recognised that whether an in vitro or in vivo model is used, both are incomplete mimics 
of original tumour physiology (Wilding and Bodmer, 2014). Whilst the in vitro PDCCs are 
missing expression of genes associated with stromal components and immune response, 
xenograft models also fail to express these genes to a human specificity (Wilding and 
Bodmer, 2014). 
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3.4.4.2 Atmosphere 
Given concentrations of oxygen within a tumour are far lower than atmospheric levels, 
ranging from 1-12 % (Goodspeed et al., 2016), all cell lines were cultured in a hypoxic 
atmosphere (3 % O2), with the exception of the normoxic acclimated UW-CSCC1 derivative. 
This derivative sought to showcase the effect of non-physiological levels of oxygen upon 
culture gene expression profile. It was observed in this normoxic derivative that the regulation 
of metabolism and metastasis response were influenced by normoxic-inducible factors. This 
aligns with previous literature reporting on alterations in the above pathways as well as 
angiogenesis and tumour cell growth in response to varied oxygen concentrations (Geraghty 
et al., 2014). This evidence, paired with known physiological oxygen concentrations both 
surrounding, and within cSCC in vivo, reveals the basis for culture in hypoxia. 
3.4.4.3 Spheroid culture 
On the basis of the PanCancer progression panel, the spheroid derivative demonstrated only a 
slight change in expression profile from the other PDCC derivatives. Although, much like a 
study by Kenny et al., (2007), global changes were found to be negligible. However, 
noteworthy alterations were observed, specifically the downregulation of the fibrosis pathway 
and upregulation of metabolism, reverting to a more in vivo tumour physiology. 
The expression profile derived from the PanCancer pathways panel revealed that the spheroid 
culture better resembled the clinical tumour phenotype more than the other derivatives, 
including the low passage UW-CSCC1. The spheroid culture was also found to express the 
stem cell associated gene SOX2 at physiological levels, whilst the other PDCC derivatives 
demonstrated downregulation of this gene. However, SOX2 expression was low even in the 
originating tumour; therefore these differences may not be entirely relevant to physiology. 
With the exception of upregulation of DNA damage repair genes, and the downregulation of 
Hedgehog and TGF-beta genes, the spheroid derivative produced an expression profile akin to 
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the xenograft. These changes are consistent with those reported by Zschenker et al., (2012), 
noting changes in processes associated with immune system responses, tissue development, 
and response to cytokines. 
3.4.4.4 Subculture/Passage number 
The number of times a cell line is subcultured – or passaged – can result in differences in 
expression profiles, with serial passaging causing further genotypic and phenotypic variation 
(Hughes et al., 2007; Kaur and Dufour, 2012). Most pathways in UW-CSCC1 at passage 41 
were significantly downregulated compared to an early passage (# 13) with respect to the 
clinical sample, albeit this was proportionally insignificant compared to the differences seen 
between the cell lines holistically and the tumour. Mouriaux et al., (2016) found that the 
effects of serial passage were most severe in the first four passages, with subsequent passages 
incurring additional, but less dramatic, modifications. This highlights the vulnerability that 
researchers may be facing by using commercial cell lines that may have been serially 
passaged over 100 times under various conditions (Hughes et al., 2007). UW-CSCC2 was less 
burdened by fibroblasts, and a pure culture was reached by passage two. 
3.4.5 The influence of irradiation on cell line gene expression profile 
Radiotherapy is frequently applied as a technique for the management of metastatic cSCC 
(see Chapter 1) and may impact the gene expression profiles of surviving cells. On a global 
level, the gene expression profile of UW-CSCC1-R was different to that of UW-CSCC1, as 
evidenced by further downregulation across most pathways. When looking at individual 
genes, there were in fact more differentially expressed genes (on the basis of ≥2 or ≤-2 fold-
change and P < 0.05) unique to UW-CSCC1 than UW-CSCC1-R, compared to the originating 
tumour. Whilst this would seem contrary to how UW-CSCC1-R clusters further away from 
the clinical tumour than UW-CSCC1 does in a pathways heatmap, this is due to the heatmap 
taking into account the overall pathway scores. Assigning fold-change thresholds such as ± 2 
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also ignores all genes with slightly smaller changes. This is impactful upon our interpretations 
as UW-CSCC1-R possessed a greater number of genes with moderate (yet not significant) 
differences in gene expression, totalling to a larger observable difference in the pathway 
score. 
3.4.5.1 Cell adhesion 
Downregulation of cell adhesion genes was clear in UW-CSCC1-R and corresponds with 
observations in cell culture (Chapter 2). The lower expression of DLC1 in UW-CSCC1-R 
may contribute to reduced cell adhesion as this tumor suppressor is central to the formation of 
focal adhesions (Kim et al., 2007; Tripathi and Lowy, 2017). E-cadherin (CDH1) and 
EPCAM gene expression was significantly lower in UW-CSCC1-R. This gene is responsible 
for adherens junctions between cells and is often used as an epithelial marker (Batlle et al., 
2000; Mani et al., 2008). A loss of E-cadherin expression along with an increase in neural cell 
adhesion molecules (e.g. NCAM1) as shown in UW-CSCC1-R is generally reflective of 
collective migration, also referred to as incomplete EMT (Lee et al., 2006; Lehembre et al., 
2008; Friedl et al., 2012). This aligns with the observations of collective cancer migration 
within the organotypic assay for UW-CSCC1-R (Chapter 2). 
The tumour suppressor gene THY1 is downregulated in UW-CSCC1-R. This gene has been 
shown to mediate melanoma attachment to endothelium (Rege and Hagood, 2006), and as 
such, may be implicated in cell adhesion in cSCC. Additionally, the decreased expression of 
THY1 could be evidence of further tumour suppressor mutation (Abeysinghe et al., 2003), 
enabling UW-CSCC1-R survival and proliferation. 
The largest difference between UW-CSCC1 and UW-CSCC1-R was observed with the gene 
S100A7 whose expression was highly downregulated in the latter, especially compared to the 
tumour (Figure 3.20). Whilst S100A7 expression decreased slightly in UW-CSCC1 compared 
to the originating tumour, complete loss of expression can be seen in UW-CSCC1-R. 
 158 
 
Tumour UW-CSCC1 UW-CSCC1-R
0
5
10
15
L
o
g
2
 c
o
u
n
ts
 
Figure 3.20 Log2 counts of S100A7 between PDCCs and the matched tumour. 
This gene encodes for psoriasin which is overexpressed in skin wounds. Psoriasin is regarded 
as having cell adhesion properties; ergo the loss of gene expression in UW-CSCC1-R aligns 
with observations of other cell adhesion genes. 
Several genes relating to ECM structure were upregulated in UW-CSCC1-R, notably 
PCOLCE. This gene codes for a glycoprotein that drives collagen degradation, thus helping to 
explain the more invasive response observed with UW-CSCC1-R in the organotypic assay 
presented in Chapter 2, section 2.3.6. 
3.4.5.2 DNA damage repair 
DNA damage-repair mechanisms were significantly upregulated in UW-CSCC1-R. This may 
explain how this cell line came to survive irradiation in the first place. It is theorised that a 
subpopulation of cells in UW-CSCC1 possessed elevated DNA damage-repair activity and 
when exposed to irradiation, they were able to utilise this characteristic to survive. Of note, 
PCNA, MAD2L2, and FEN1 were upregulated in UW-CSCC1-R and contribute major roles in 
mediating the DNA damage repair required for the survival of UW-CSCC1-R (Gomes and 
Burgers, 2000; Boersma et al., 2015; Boehm et al., 2016). Further efforts are required to 
dissect the role these DNA damage repair genes play specifically in UW-CSCC1-R. For 
example, knock-down of components of this pathway may result in apoptosis or confer 
greater sensitivity towards additional radiation. 
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3.4.5.3 Stemness 
Cancer stem cells have been well described in the literature for many other malignancies 
following radiation exposure, including squamous skin tumors (Driessens et al., 2012), colon 
cancer (Sahlberg et al., 2014), and breast cancer (Phillips et al., 2006). These populations 
have all demonstrated a faster population doubling time following treatment, like with UW-
CSCC1-R, and likely contribute to the recurrence and rapid spread of disease. 
One of the most upregulated genes in UW-CSCC1-R was HAPLN1, which has been 
documented as a playing a major role in a signaling network which leads to stemness and 
mesenchymal properties in hepatocellular carcinomas (Mebarki et al., 2016). The 
upregulation in UW-CSCC1-R of additional genes generally specific to stem cells, namely 
SOX2, CD24, and PROM1 (CD133), further add to this theory of increased stemness 
following radiation therapy. 
3.4.5.4 Cytoskeletal organisation 
Genes encoding for keratin family proteins, KRT7, KRT14, and KRT19 were downregulated 
in UW-CSCC1-R. These genes encode for proteins that are crucial to cytoskeletal formation 
in keratinocytes. Therefore, the downregulation of these genes relates to the degree of 
differentiation, aligning with morphological observations of the PDCCs (Chapter 2). 
3.4.6 Conclusions and future directions 
Whilst the establishment of the PDCCs are a significant contribution in the journey towards 
understanding metastatic cSCC, they should not be considered as unique, authoritative 
models. Numerous differences between the PDCCs and their clinical counterpart were 
identified, although the impact of these may be insignificant for most relevant cancer research 
purposes, i.e. investigating drug sensitivity. Moving forward with these cell lines, one must 
consider the assay being used and its compatibility with the genomic and transcriptomic 
changes the PDCCs have incurred. Weinstein, (2012) reflected on the words of statistician 
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George Box, “all models are wrong, but some are useful”, a sentiment particularly meaningful 
in cell culture. The novel PDCCs described in this chapter represent the starting pieces of the 
puzzle; whilst far from complete, the first steps have been taken to allow others to fall into 
place – the potential value of which cannot be understated. 
The fact that the majority of pathways are restored in the xenograft demonstrated that the 
PDCCs are at the very least an economic method of preserving genomic information for 
eventual restoration in an animal model. 
Moving forward, animal models with the UW-CSCC series could be developed to validate in 
vitro observations of molecular targets for therapy, prognostic factors, and therapeutic 
responsiveness to novel and established agents (in association with chapter 5). 
As far as 2D cell models go, UW-CSCC1 is just as good, if not better than many other cancer 
models for HTS drug screening. However, given the differences between the cell lines and the 
clinical tumour, it is obvious that cell lines are an unreliable platform for biomarker discovery 
and to a lesser extent, drug target discovery. As such, clinical specimens are required to 
discover candidate biomarkers/drug targets for cSCC, an undertaking presented in Chapter 4 
of this thesis. 
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CHAPTER 4: COMPARATIVE ANALYSES OF CLINICAL 
SAMPLES - BIOMARKER AND DRUG TARGET DISCOVERY 
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4.1 INTRODUCTION 
As covered in Chapter 1, sound efforts have been made into understanding the carcinogenesis 
of primary cSCC, chiefly the role of TP53, NOTCH1/2, CDKN2A, and RAS family proteins. 
However, little is known regarding the specific mechanisms that transform a relatively 
harmless primary cSCC lesion into a life-threatening metastasis. 
Identification of the mechanisms being exploited will facilitate the implementation of targeted 
therapies. Such is the case with basal cell carcinoma (BCC), whereby tumour development 
has been associated with constitutive activation of sonic hedgehog signalling via activating 
mutations in SMO, PTCH1, and SHH (Lupi, 2007). In response, inhibitors of this signalling 
pathway (mostly targeting SMO) have been developed, such as Vismodegib which received 
FDA approval for unresectable BCC in 2012 (Fecher and Sharfman, 2015). Discovering the 
central pathways being utilised by high-risk cSCC to metastasise may highlight drug targets 
and help the development of neo-adjuvant therapies, rather than relying solely on invasive 
prophylactic surgery. 
It is paramount to firstly distinguish between high and low risk lesions. This is currently 
difficult at diagnosis of the primary lesion due to the limited abilities of histological 
examination in distinguishing between the subsets (Prasad et al., 2014). Traditional methods 
of distinguishing cSCC status include H&E staining and immunohistochemistry (IHC) for 
protein expression. However these technologies mostly serve for semi-quantitative 
distinctions and do not always capture at-risk patients (Toll et al., 2015). As it stands, there 
are no clinically useful biomarkers of metastatic risk in primary cSCC (Munguía‐Calzada et 
al., 2018). Farshchian et al., (2011) reported that STAT3, E-Cadherin, SerpinA1, and matrix 
metalloproteinases 13, 12, and 7 are potential biomarkers of cSCC progression. It is becoming 
ever more apparent that molecular biomarkers will play an essential role in the future as part 
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of a comprehensive clinicopathologic classification system to stratify patient prognosis and 
direct optimal treatment strategies. 
Despite the fidelity of the UW-CSCC1 to its originating tumour, as covered in the preceding 
chapter, biomarker discovery benefits from large sample sizes and needs to be as reflective of 
real tumour physiology as possible. Therefore, in this circumstance to identify key drivers of 
metastasis or biomarkers of disease states, the most logical approach is to directly compare 
the multi-omic profiles of available clinical cohorts. In this investigation, these cohorts 
include lymph node metastases, primary cSCC that never metastasise, primary cSCC that did 
metastasise, PDCCs, as well as asymptomatic sun-exposed skin. Ergo, the aim of this chapter 
is to identify potential biomarkers and drug targets through genotyping and phenotyping of 
varied sample types. 
To achieve this, NanoString was further utilised along with other technologies, including 
qPCR and RNA-seq, to reveal the underlying transcriptomic landscape across clinical 
specimens of cSCC and normal UV-exposed skin. The findings of this lay further groundwork 
on identifying high-risk patients as well as potential drug targets. 
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4.2 METHODS 
4.2.1 Samples preparation 
Clinical samples of cSCC and normal skin were processed as described in Chapter 3 for the 
PDCCs and their originating tumours. The DNA/RNA extracted from tumour tissue was 
mostly from fresh-frozen stocks, with others derived from formalin-fixed paraffin embedded 
blocks. Clinical details of the tumour samples used, as well as their storage condition, are 
detailed in Appendix C. 
4.2.2 Quantitative PCR 
Samples of UW-CSCC1, its clinical tumour, and a breast cancer cell line (MDA-MB-231) 
were prepared for qPCR by processing extracted mRNA into cDNA by way of reverse 
transcription-PCR (RT-PCR) and using each template cDNA with the selected qPCR kit 
according to manufacturer’s instructions (see below). Each target and reference reaction 
contained 20 ng and 2 ng of cDNA template, respectively. For each experiment, a standard 
curve was generated using serially diluted MDA-MB-231 template cDNA at known 
concentrations. Samples were incubated with the target primers PLAU (Qiagen, Germany; Cat 
no. QT00013426) and PLAUR (Qiagen; Cat no. QT00076447), as well as reference primers 
specific to the housekeeping genes GAPDH and ACTIN (Qiagen; Cat no. QT00079247, 
QT00095431). Optimisation of annealing temperature was necessary due to variations in 
melting temperature (Tm) between primers. Samples were run in triplicate using a 
LightCycler®480 (Roche, Switzerland) real-time PCR system and analysed using basic 
relative quantification. The basic relative quantification method compares the levels of two 
different target sequences in a single sample and expresses the final result as a ratio of these 
gene levels (e.g. target gene and reference gene). All resultant qPCR products were 
electrophoresed at 90 V for 1 hour on a 2 % agarose gel to confirm gene amplification. In an 
attempt for optimisation of the qPCR kit used, relative expression of PLAUR and GAPDH 
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was compared using qPCR kits from Applied Biosystems, Bioline, and Sigma-Aldrich. The 
results of this are provided in Appendix G, demonstrating the kit provided by Applied 
Biosystems to be the most reliable for accurate gene amplification. For each reaction, a ‘no 
reverse transcriptase’ and ‘no template’ control were included to identify erroneous signals 
due to genomic DNA contamination or cross-contamination of prepared samples. 
4.2.3 RNA-sequencing and analysis pipeline 
RNA harvested from two of the patient samples (181957A and 285248) was subject to library 
preparation and sequencing at the Kinghorn Centre for Clinical Genomics (KCCG), Garvan 
Institute of Medical Research (Sydney, Australia). Preliminary analysis of RNA-Seq data was 
performed to determine differential gene expression between these two samples. Expression 
analyses utilised the ‘Tuxedo protocol’ (Trapnell et al., 2012) via the bioinformatics platform 
‘Galaxy’ (http://galaxy.garvan.unsw.edu.au). The workflow for this protocol is summarised in 
Figure 4.1. Briefly, the RNA-sequence reads were uploaded to Galaxy (hosted on KCCG 
servers) in their native FASTQ format. The reads were then mapped independently to the 
human genome and transcripts assembled. Final transcriptome assembly was obtained by 
merging the two assembled transcripts and differential expression determined by comparisons 
to the mapped reads. The CummeRbund package was utilised in RStudio to visualise RNA-
seq analysis results. Due to quality control issues, these two tumour samples were not 
included in subsequent WGS or NanoString analyses. 
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Figure 4.1 RNA-seq data analysis workflow. Data was analysed using the Tuxedo protocol stipulated by 
Trapnell et al., (2012). 
4.2.4 Immunofluorescent labelling and detection 
4.2.4.1 Immunocytochemical staining and detection with anti-uPAR antibody 
Immunocytochemical staining of PDCCs was performed as described in Chapter 2 (section 
2.2.5.1), with the exception of a 1:200 dilution of anti-uPAR antibody (M7294, Clone 4; 
Dako, USA) used here instead. 
4.2.4.2  Flow cytometric analysis of uPA/uPAR labelled cells 
To preserve cell surface epitopes, cells were detached via incubation with 5 mM EDTA in 
PBS (pH 7.4) at 37°C for 5 minutes. The detached cells were then added to a binding buffer 
solution (9.8 g/L phenol red free HANKS buffered salts; 20 mM HEPES; 1 mM CaCl2; 1 mM 
MgCl2; 5 % BSA; pH 7.4) and a pellet formed by centrifugation at 200 × g for 5 minutes at 
4°C. 
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The cells were then resuspended in ice-cold binding buffer at the desired concentration and 
aliquoted in duplicate into V-bottomed 96-well plates (Greiner Bio-One, Austria). Cells were 
incubated for 10 minutes at 4°C with FcR blocking reagent (Miltenyi Biotech, Germany) to 
improve the specificity of antibody labelling. The cells were centrifuged to form a pellet as 
above, the buffer was removed and the cells resuspended with 100 µL aliquots of diluted 
primary specific antibody, the relevant isotype-matched antibody, or binding buffer alone to 
operate as a negative control and to account for autofluorescence. The APC-bound uPAR 
antibody (Miltenyi Biotech, Germany; Cat no. 130 099 456) was used at a concentration of 10 
µg/mL. A primary antibody specific to human uPA (American Diagnostics Incorporated, 
USA; Cat no. 394) was similarly used at a concentration of 10 µg/mL. Cells were incubated in 
the primary antibody for 45 minutes on ice, pelleted, and washed twice in ice-cold binding 
buffer. All samples excluding those incubated with the APC-bound uPAR were resuspended 
in 100 µL of binding buffer containing the appropriate secondary antibody Alexa488 (Abcam, 
United Kingdom; Cat no. 150101) at a dilution of 1:1000 and incubated for 45 minutes. 
Finally, cells were resuspended in ice-cold PBS and Alexa-fluorescence (515) analysed on a 
BD LSRFortessa™ flow cytometer. 
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4.3 RESULTS 
4.3.1 Samples and quality control 
For qPCR, an annealing temperature of 55°C was found to be optimal (data not shown). For 
RNA-seq, a RNA integrity number (RIN) of 6.6 was found for both tested samples. Whilst 
there is no widely accepted criterion for sample inclusion on the basis of RIN, a cut-off of 
between 6.4 and 7.9 has been proposed (Gallego Romero et al., 2014). As such, the RNA here 
can be considered low quality, potentially leading to underestimates of transcript levels. 
NanoString samples with mRNA content normalisation flags and positive control 
normalisation flags were excluded from further analysis. The number of samples included 
within each NanoString panel and their respective cohort are shown in Table 4.1. The samples 
were sourced from lymph node positive metastatic cSCC (LN MET), normal skin 
(NORMAL), primary cSCC from patients with subsequent metastatic disease (PRIMARY 
MET), and primary cSCC with no subsequent metastasis (PRIMARY NO MET). Normal skin 
samples and primary cSCC were not run on the NanoString PanCancer pathways panel; 
therefore comparisons between the cohorts were limited to the progression panel. 
Table 4.1 Samples included in comparative analyses. The number of samples in each clinical cohort across 
the NanoString panels is shown. 
 
 
Progression 
Panel 
 Pathways 
Panel 
Cohort Cohort annotation Number of samples 
Lymph node metastatic cSCC 
        Calibration samples 
LN MET 
22 
5 
 
4 
0 
Primary cSCC that metastasised  PRIMARY MET 5  0 
Primary cSCC that did not metastasise PRIMARY NO MET 12  0 
Normal skin NORMAL 8  0 
 
4.3.2 Comparative analysis of clinical specimens 
Similar to the PDCCs analyses, the NanoString PanCancer progression panel was utilised to 
reveal differences in gene expression (methodology described in Chapter 3). Hierarchical 
clustering of individual gene expression data revealed a profile in which in all normal skin 
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samples clustered together, whilst both primary and metastatic cSCC samples clustered 
somewhat independent of their assigned cohort (Figure 4.2). Significant variation for 
individual genes was observed between the samples. 
 
Figure 4.2 Overall gene expression of clinical samples. A heatmap shows the overall normalised gene 
expression data from the progression panel, scaled to give all genes equal variance, generated via unsupervised 
clustering. Orange indicates high expression; blue indicates low expression. Sample cohorts are defined by a 
coloured box above each column corresponding to the key. Complete sample identifiers are shown at the bottom. 
The genes were then collapsed into their respective canonical pathway, better revealing major 
differences in pathway regulation between the samples (Figure 4.3). As with above, the 
normal skin samples clustered together whilst the cSCC samples displayed a degree of 
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heterogeneity. Overall, differences between LN MET and PRIMARY NO MET were quite 
varied. Samples of primary cSCC found to possess a subsequent metastasis (PRIMARY 
MET) clustered within one clade (as shown in the red box in Figure 4.3). Of note, PRIMARY 
MET samples tended to upregulate most pathways relative to NORMAL, LN MET, and 
PRIMARY NO MET samples. Evidence of perineural invasion (PNI), as denoted by an 
asterisk in Figure 4.3, was not found to correlate with expression profile. 
 
Figure 4.3 Pathway scores of clinical samples. This plot is a high-level overview of how the pathway scores 
change across samples. Each gene from the progression panel has been collapsed into its relevant canonical 
pathway. Orange indicates high scores; blue indicates low scores. Scores are displayed on the same scale via a 
Z-transformation. Hierarchical clustering was implemented, providing relationships depicted by both row and 
columnar dendrograms. Samples with evidence of extensive perineural invasion (PNI) are denoted with by *. 
The red box showcases the clustering of PRIMARY MET samples in one clade. Complete sample identifiers are 
shown at the bottom. 
A greater score for the cell cycle pathway and metabolic pathways were commonly observed 
amongst the LN MET cohort, whilst the NORMAL cohort possessed a high pathway score for 
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angiogenesis-related pathways and metastasis suppressors. The LN MET cohort appeared to 
mostly have an inverse profile to that of normal skin for the progression panel genes. 
Linear regression analysis revealed that the PRIMARY NO MET cohort had the greatest 
overall similarities with normal skin (R2 = 0.739; Figure 4.4). LN MET and PRIMARY MET 
had weaker correlations with normal skin (R2 = 0.694 and R2 = 0.61, respectively). 
PRIMARY MET gene expression was observed to differ from NORMAL the most. This is 
surprising given the changes hypothesised to occur through EMT would instead suggest the 
LN MET samples to be the most different. 
 
Figure 4.4 Scatter plot of count differences between each cohort relative to normal skin. Genes with 
matching expression will fall directly along the NORMAL line. 
Differential gene expression profiling was performed to compare similarities and differences 
between the states of cSCC relative to normal skin. As shown in the Venn-diagram below 
(Figure 4.5), 95 differentially expressed genes (DEGs) were found in common between the 
cSCC cohorts compared to normal skin using the progression panel (23 downregulated; 72 
upregulated). Of these, 62 genes were found to have noteworthy log2 fold changes of ≤ -2 or ≥ 
2, with particularly dysregulated genes highlighted adjacent to the Venn-diagram (Figure 4.5). 
As a whole, cSCC appeared to dysregulate many genes involved in ECM integrity. 
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LN MET had an overlap of 25 DEGs unique with PRIMARY MET, compared to a unique 
overlap of 31 genes for PRIMARY NO MET. In other words, LN MET share more DEGs in 
common with primaries that never metastasised than those that did. However, the abundance 
of total DEGs increases with cSCC progression: PRIMARY NO MET (162 DEGs), 
PRIMARY MET (192 DEGs), and LN MET (218 DEGs). 
 
Figure 4.5 Differential gene expression profiling by NanoString. A Venn-diagram displays the numbers of 
significantly (P < 0.05) differentially expressed genes for each cohort relative to normal skin. The numbers in 
blue indicate downregulated genes, whereas those in orange indicate upregulated genes. Created using BioVenn 
(www.biovenn.nl) (Hulsen et al., 2008). Some of the most significantly dysregulated genes shared by the cSCC 
cohorts are shown in a table to the right. These genes all displayed a log2 fold-change difference of ≤ -2 or ≥ 2 
relative to normal skin. 
The specific distribution (both significance and log2 fold-change) of differentially expressed 
genes between the cohorts is visualised via volcano plots in Appendix H. One of the largest 
and most significant differences in PRIMARY MET vs PRIMARY NO MET is the 
downregulation of SPINK5, encoding for the serine protease inhibitor of the same name. One 
of the most upregulated genes in PRIMARY MET relative to PRIMARY NO MET is IBSP, 
which has a role in angiogenesis. 
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The results of differential expression testing were summarised at the gene set (or pathway) 
level. Each pathway’s most differentially expressed genes were identified, and the extent of 
differential expression (ignoring whether it was up- or down-regulated) summarised by way 
of a global significance score (Figure 4.6). LN METs displayed extensive differential 
expression relative to normal skin for numerous pathways, particularly for MMP remodelling 
and ECM receptor interaction. The primary cSCC cohorts had fewer differences between each 
other relative to the normal skin; however, further differential expression was evident across 
multiple pathways with PRIMARY MET. Some of the largest differences between the 
primary cohorts were observed with ECM structure, collagen family, cell motility, LOX 
remodelling, and ECM receptor interaction gene sets. 
 
Figure 4.6 Heatmap displaying global significance scores for each cohort. Global significance statistics 
measure the extent of differential expression of a gene set’s genes with a covariate, ignoring whether each gene 
within the set is up- or down-regulated. Orange denotes gene sets whose genes exhibit extensive differential 
expression with the covariate, blue denotes gene sets with less differential expression. 
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4.3.3 Modelling inter-tumour variability through RNA-seq 
Two samples of metastatic cSCC were used for a pilot investigation using RNA-seq. It should 
be noted that WGS data is not available for these specimens and the RNA was of low quality, 
thus only global differences between the specimens were analysed. Inter-patient heterogeneity 
was evident with a large selection of genes also determined to be significantly differentially 
expressed (Figure 4.7 A, B). 
    
Figure 4.7 Overall RNA-seq gene expression differences. Gene expression plots are shown comparing the 
similarities and differences in read counts between metastatic cSCC samples X (ID 181957A) and Y (ID 
285248). FPKM, fragments per kilobase of transcript per million fragments mapped. A) Simple scatter plot 
highlighting general similarities and specific outliers between the two samples. A mostly positive correlation of 
log10FPKM between the two samples was evident, although big differences for particular genes were present. 
Genes with matching expression will fall directly along the dashed line. B) Volcano plot identifying differentially 
expressed genes between samples. Red dots indicate genes significantly differentially expressed. 
Histological slides of the RNA-seq interrogated samples (Figure 4.8) highlight how these big 
differences in gene expression cannot be easily determined through simple morphological 
examination due to gross similarities. Even with specialist skills, histology can only grade 
tumours to a certain extent, thereby limiting accurate subtyping.  
   
Figure 4.8 Images of H&E stained lymph node involved cSCC. Sample 181957 (A) and 285248 (B) showcase 
morphological similarities despite gene expression differences. The green arrow indicates a poorly differentiated 
cancer cell. The blue arrow indicates an interspersed lymphocyte. The green lines and text specify the length of 
the perimeter of the invasive front of the tumour and were for the pathologist’s reference only.  
A) B) 
A) B) Lymphocyte 
cSCC 
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4.3.4 Biomarker and therapeutic target discovery 
Informed by the previous gene expression profiles, individual genes or gene lists were 
investigated for use as potential clinical biomarkers of metastatic risk or to serve as a highly-
specific drug target. This was achieved using a combination of techniques mentioned 
previously, as well as immunofluorescent technology. Genes discussed in the following 
section were determined either through notable fold-changes in mRNA expression and the 
significance of those changes on the basis of P value, or they their known influence in other 
cancer types. In the interest of brevity, only key genes will be discussed. 
4.3.4.1 Urokinase Plasminogen Activation System (uPAS) 
Regulators of the urokinase plasminogen activation system were investigated due to their 
known role in promoting cancer metastasis in other cancers (Dass et al., 2008). The relative 
expression of the gene PLAUR – encoding the urokinase plasminogen activation receptor 
(uPAR) – was determined through qPCR for a metastatic cSCC sample (193958) and the 
breast cancer cell line MDA-MB-231, which is purported to overexpress PLAUR. As shown 
in Figure 4.9 A), the clinical tumour expressed PLAUR at a level similar to MDA-MB-231. 
Given such a small difference, it is reasonable to conclude that PLAUR is overexpressed in 
this metastatic cSCC sample. 
Expression of plasminogen activation system components between two samples of metastatic 
cSCC were analysed via RNA-seq (Figure 4.9 B). As only one treatment type (metastatic 
cSCC) was analysed, conclusions cannot be drawn on expression relative to other tissue 
types. Rather, this data allows for the comparison of uPAS component variability amongst 
patient tumours. There were notable differences in expression of PLAU and SERPINB2 
(encoding for an inhibitor of this system) between the samples, with a greater number of 
transcripts being detected in sample 181957. On the other hand, PLAUR maintained a similar 
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expression between the two patients. This low variance is essential if uPAR is to be 
considered as either a clinical marker of disease or a therapeutic target.   
 
Figure 4.9 Gene expression of components of the plasminogen activation system. A) Relative expression of 
PLAUR mRNA between the cell line MDA-MB-231, cSCC tumour 193958, and its resultant PDCC UW-CSCC1, 
as assessed by qPCR using a kit provided by Applied Biosystems. MDA-MB-231 is a breast cancer cell line 
known to overexpress uPAR. The ratio scores displayed on the y-axis are relative, dimensionless numbers that 
are meaningful only when compared between samples. B) Heatmap using RNA-seq FPKM data. FPKM refers to 
the Fragments Per Kilobase of transcript per million Mapped reads. These values are necessary as in RNA-seq 
the relative expression of a transcript is proportional to the number of cDNA fragments that originates from it. 
Using NanoString, gene expression of PLAU and PLAUR was found to be significantly 
elevated in all tested cSCC relative to normal skin (P < 0.001). Expression of PLAU between 
the cSCC cohorts did not significantly differ. However, PLAUR expression was significantly 
greater (P < 0.05) in PRIMARY MET compared to PRIMARY NO MET. Furthermore, 
expression was maintained in the PDCC (Figure 4.10). 
 
Figure 4.10 Box plots of mRNA expression for PLAU and PLAUR across cohorts. Log2 counts are shown. 
Significance is denoted by asterisks: * = P < 0.05; *** = P < 0.001. 
A) B) 
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The expression levels presented in the above results were confirmed at a protein level through 
immunofluorescent assays and IHC staining. A strong positive fluorescence signal 
corresponding to uPAR was detected for UW-CSCC1 by immunocytochemistry (Figure 4.11 
A). This signal was comparable to that experienced with MDA-MB-231 cells (Figure 4.11 B). 
 
Figure 4.11 Immunocytochemical images of cell lines expressing uPAR. Detected uPAR-specific antibodies 
are shown in green and the nuclear stain RedDot2 is shown in red. A) Fixed and permeabilised UW-CSCC1. B) 
Fixed and permeabilised MDA-MB-231. Cells imaged at 40x objective. 
Flow cytometry data on UW-CSCC1 similarly revealed a positive signal for uPAR. A positive 
shift in fluorescence intensity was evident (Figure 4.12), with uPAR antibody-treated cells 
exhibiting an enhanced geometric mean away from the control and isotype-treated cells. 
 
Figure 4.12 uPAR flow cytometry data on UW-CSCC1. Treated samples were incubated with either uPAR 
primary antibody or an isotype control. All samples were incubated with FcR block. Fluorescence intensity is 
shown between control, isotype, and uPAR treated cells. GM = Geometric Mean. 
A) B) 
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Adjunct studies in our laboratory by honours student Miss Gretel Major have also confirmed 
uPAR and uPA protein expression via western blot. Expression of uPAR on invasive UW-
CSCC1 within an organotypic culture was also determined via IHC (Figure 4.13).  
 
Figure 4.13 Anti-uPAR stained organotypic section. Positive staining of uPAR can be seen in UW-CSCC1 
cells within and atop the collagen-contracted fibroblast matrix. Note that areas of matrix degradation could be 
due to either invasion or simply be an artefact from fixation errors. Imaged at 17.5x objective. 
These data confirm that, at the very least, uPAR is overexpressed in both clinical samples and 
the cell line. The little variance in uPAR gene expression between the samples permits further 
investigations into its use as either a clinical marker of disease or a therapeutic target. 
4.3.4.2 Proto-oncogene c-SRC & protein tyrosine kinase MET 
c-SRC is a non-receptor tyrosine kinase oncogene implicated in the development of cancers 
including cSCC (Matsumoto et al., 2003; Ayli et al., 2008). Given this and the reported 
activity of SRC-targeting drugs against cSCC (see Chapter 5), the gene SRC was analysed 
specifically. It was found that SRC expression is upregulated in cSCC relative to normal skin 
and is particularly upregulated in metastatic cSCC relative to primary disease (Figure 4.14 A). 
c-MET, also called hepatocyte growth factor receptor (HGFR) is a tyrosine protein kinase 
encoded by MET. This gene was targeted due to reported expression in cSCC (Szabo et al., 
2011; Cataisson et al., 2016; Bonan et al., 2019) as well as its purported elevation following 
resistance to EGFR-tyrosine kinase inhibitors (Huang and Fu, 2015). Like SRC, elevated 
expression of MET was observed in metastatic and primary cSCC relative to normal skin 
(Figure 4.14 B). 
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Figure 4.14 Relative mRNA expression of SRC and MET. Box plots demonstrating log2 counts of gene 
expression between samples of metastatic cSCC, primary cSCC, and normal skin. Significance is denoted by 
asterisks: * = P < 0.05; ** = P < 0.01; *** = P < 0.001; ns = non-significant. 
4.3.4.3 Matrix metalloproteinases (MMPs) 
Numerous MMPs were found to be upregulated in cSCC, particularly in primaries that 
metastasised. MMP gene expression was considerably lower in normal skin than with any of 
the cSCC cohorts (Figure 4.15). PRIMARY MET generally had the greatest expression of the 
interrogated MMPs. Some of these genes may prove as valuable biomarkers of 
aggressiveness, with those prone to metastasis expressing a degree of MMP expression. 
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Figure 4.15 NanoString mRNA expression data for matrix metalloproteinase coding genes. 
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4.3.4.4 Disease profiling using gene lists 
A gene list was ultimately developed as no one gene can be relied upon for absolute 
predictive power. To develop a robust screening panel, gene expression data was compared 
between the cohorts and genes with a significance of P < 0.05 and log2 fold-change ratios ≥ 2 
or ≤ -2 were selected. 
To determine which molecular traits increase an individual’s risk of developing metastatic 
disease, it was considered most effective to compare the gene expression profiles of primaries 
that do metastasise from those that do not. Significant dysregulation of a particular gene (or 
gene set) in the primaries that do metastasise could also inform on drug targets to control 
disease prior to metastasis. 
After filtering for genes with the most significant expression differences between the primary 
cohorts, a selection of genes was found to mostly separate the two cohorts into a specific 
expression profile (Figure 4.16). The low sample size of PRIMARY MET may prohibit more 
accurate gene selection, although given the heterogeneity mentioned earlier (section 4.3.3); it 
is unsurprising that finding an authoritative predictor of metastasis is difficult. Some genes 
found to be universally upregulated in the PRIMARY MET cohort, whilst downregulated in 
the PRIMARY NO MET cohort, should be investigated further, potentially via IHC, to 
determine their prognostic capabilities. Such genes include FN1, INHBA, BGN, and ITGB3. 
 181 
 
 
Figure 4.16 Screening profile to differentiate between level of primary cohorts. The heatmap displays 
mRNA expression of genes found to be most differentially expressed between primary cSCC never metastasised 
and those that did. Count data has undergone z-score transformation to give equal mean and variance across 
the samples. Orange indicates a higher score, blue indicates a lower score. 
Significant gene expression differences between all cohorts were tabulated, resulting in a list 
of 86 discriminatory genes (Appendix I). All cohorts were subject to the bespoke gene panel 
to produce Figure 4.17. This heatmap visualises the gene expression signatures that best 
discriminate between all the cohorts. 
     
Figure 4.17 Screening profile to differentiate between all cohorts. This heatmap displays mRNA expression of 
genes found to be most significantly differentially expressed between all the cohorts. All samples have been 
condensed into their respective cohort to yield a group gene expression signature. Count data has undergone z-
score transformation to give equal mean and variance across the samples. Orange indicates a higher score, blue 
indicates a lower score. 
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To identify drug targets for patients already exhibiting metastatic disease, it is most effective 
to identify which genes have been dysregulated most in the metastatic cSCC cohort relative to 
both normal skin and primary cSCC. Like above, significant differences between the cohorts 
were tabulated, resulting in a list of significantly differentially expressed genes in metastatic 
cSCC relative to both primary cSCC and normal skin (Table 4.2). Given it is these genes that 
distinguish metastatic cSCC from the other cohorts most; they may be worthy biomarkers or 
drug targets for further investigation. 
Table 4.2 Topmost differentially expressed genes between LN MET and other cohorts. The top 11 
upregulated genes and top 4 downregulated genes are shown 
LN MET vs NORMAL LN MET vs PRIMARY NO MET LN MET vs PRIMARY MET 
Gene Log2 Fold-change Gene Log2 Fold-change Gene Log2 Fold-change 
MMP1 8.37 PLA2G2D 2.79 PLA2G2D 4.9 
MMP12 7.57 MMP12 2.46 CXCL10 4.56 
MMP13 8.14 HOXB13 2.31 SPINK5 4.37 
MISP 6.5 SPOCK3 2.26 GATA4 4.5 
CDKN2A 6.43 ANGPTL4 2.18 HKDC1 4.1 
POPDC3 6.37 HKDC1 2.16 ISL1 4.25 
MMP10 6.95 CXCL10 2.16 ITGB7 3.82 
MMP13 6.94 CCL7 2.03 OCLN 3.47 
IL11 5.47 TSPAN1 2.26 PPL 3.35 
HKDC1 5.08 ITGA5 1.56 SLPI 4.08 
PLAU 4.32 PRSS22 1.65 CHP2 3.81 
EMILIN3 -7.16 CMA1 -4.66 ITGA11 -4.23 
MYH11 -6.12 EMILIN3 -3.77 CCL11 -4.21 
CMA1 -5.7 PITX2 -3.38 IBSP -3.59 
TNXB -5.85 TWIST2 -1.79 HAS1 -3.77 
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4.4 DISCUSSION 
Multi-omic technologies were implemented here to help identify potential biomarkers/drug 
targets to test using large cohorts of clinical specimens across the spectrum of cSCC disease 
(from asymptomatic sun-exposed skin to metastatic cSCC). Actinic keratoses were not 
considered for this experiment. Due to the volume of data achieved through these methods, 
only the most statistically significant differences have been reported upon, or those considered 
functionally relevant to the question under investigation. 
4.4.1 Samples and quality control 
Given the impact of downstream results, it was critical to ensure samples met stringent quality 
control standards. Whilst the RIN numbers for the samples that underwent RNA-seq can be 
considered low, their suitability for analyses is not entirely compromised. Gallego Romero et 
al., (2014) were able to identify differentially expressed genes between individuals using 
samples with RIN scores of 4. A wide range of RIN cut-offs have been arbitrarily 
implemented by individual researchers, ranging from 3.95 (Weis et al., 2007) to 8 (Imbeaud 
et al., 2005), but even this fails to account for differences in transcript-specific decay rates. As 
such, a low RIN may not have such a dramatic impact upon specific transcripts. 
Gallego Romero et al., (2014) stated that rather than decreasing experimental power by 
excluding potential samples, it may be better to include all samples regardless of quality and 
apply a model for RNA quality and globally correcting for RIN values in the analysis. This 
theory was utilised in NanoString, whereby the nSolver software performed a series of quality 
control checks and normalisation procedures. A caveat of the NanoString system is that it can 
struggle to accurately compare FFPE samples with fresh-frozen samples. This caveat did not 
appear to be of a significant influence in the current study; however its existence should be 
noted to explain differences that may be observed in future experiments with datasets 
consisting of solely FFPE or solely fresh-frozen samples. 
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A benefit of possessing both WGS and NanoString data is samples with questionable results 
in one platform could be informed by the other. For example, several samples were excluded 
as WGS revealed a low tumour cellularity which was confirmed by the profile revealed in 
NanoString by unsupervised hierarchical clustering. I.e. samples with low tumour cellularity 
(and therefore higher normal tissue/fibroblasts from lymph nodes) would cluster closely with 
normal skin (dermal fibroblasts) samples rather than metastatic cSCC. 
The choice of nucleic acid extraction kit can contribute towards variation in gene expression 
data between studies on cSCC (Van Haren et al., 2009). The current study utilised the AllPrep 
nucleic acid extraction kit by Qiagen. This kit has been found to be the most suitable for 
working with FFPE samples due to its yield, quality and ability to purify RNA and DNA from 
the same samples (Patel et al., 2017). These qualities make it ideal for a biomarker study. For 
downstream application in NanoString, Patel et al., (2017) found no significant difference in 
total signal counts between the common DNA/RNA extraction kits. In addition, Patel et al., 
(2017) found that NanoString assays using AllPrep nucleic acids extracted independently by 
three laboratories produced highly correlated results. These data highlight both the high-
fidelity and reproducibility of both the AllPrep kit and NanoString. 
One major point of consideration amongst the tested samples is what constitutes ‘normal’ 
skin. Martincorena et al., (2015) noted that aged, sun-exposed skin is not homogenous, but 
rather a patchwork of thousands of evolving clones. They found that over a quarter of 
‘normal’ skin cells carry cancer-causing mutations, while maintaining the physiological 
functions of the epidermis. The genes mutated in normal skin are said to often match those 
mutated in cSCC (but not so much BCC or melanoma), namely NOTCH1, NOTCH2, 
FAT1, and TP53 all being significantly mutated. There were more NOTCH1 mutations in just 
5 cm2 of aged, sun-exposed skin analysed in the Martincorena et al., (2015) study than have 
been identified in more than 5,000 cancers sequenced by TCGA. Approximately 20 % of 
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normal skin cells carried NOTCH1 mutations, compared to 60 % of cSCC. Therefore, 
NOTCH1 targeted therapies could have considerable collateral damage to asymptomatic skin. 
(Martincorena et al., 2015). Nonetheless, the normal samples profiled in this project revealed 
strong similarities with each other and differed substantially from the cSCC samples. 
4.4.2 Choice of profiling platform – targeted vs broad 
For assays investigating either DNA or RNA, researchers have the choice to utilise targeted 
panels or to take a broader approach. Whole-genome sequencing was selected for this project 
by Dr Bruce Ashford to align with the investigatory aspects of his concurrent PhD project. 
Given the WGS data presented within this thesis was used for more basic comparisons of the 
PDCCs with their parental tumours, a smaller gene panel or whole-exome sequencing may 
have sufficed. However, as recently published by Dr Ashford and the research group (Mueller 
et al., 2019), the overwhelming majority of mutations specific to metastatic cSCC are 
contained within the introns. As such, the comparisons made using WGS have captured all 
genomic events that may have occurred in going from in vivo (tumour) into in vitro (onto 
plastic) environments. 
With regards to gene expression profiling, RNA-seq was utilised as part of a pilot study 
investigating the transcriptomic landscape of metastatic cSCC. The emerging medium-
throughput NanoString gene expression platform was subsequently opted for ease of use and 
data analysis, with the preliminary RNA-seq data used as an example of inter-patient 
heterogeneity. Trapnell et al., (2012) reflected that whilst the volume of data from RNA-seq 
provides enormous insight, it is often burdensome. However, as sequencing costs become 
more affordable and informatics skills more commonplace, future RNA-sequencing of all 
samples run on the NanoString platform should inevitably be explored. This will help directly 
cross-reference mutations observed in the genomics data with transcriptomic implications. 
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A major benefit of the NanoString panels utilised in this study is that they have been carefully 
curated to encompass genes (or gene families) that have a noteworthy function in cancer 
progression. Whilst this could also be achieved through qPCR to a degree, NanoString panels 
provide neither too few nor too many genes to analyse, whereas to analyse the same number 
of genes via qPCR would be a laborious undertaking (Prokopec et al., 2013; Veldman-Jones 
et al., 2015). Nevertheless, qPCR was used for a small number of genes prior to NanoString 
to compare gene expression differences between the tumour and UW-CSCC1. 
A major drawback of qPCR is the multitude of variables that can influence output and 
reproducibility. To submit qPCR data for publication in a scientific journal, researchers are 
expected to adhere to the guidelines set out by Bustin et al., (2009). These guidelines compel 
researchers to address up to 83 variables that can affect the data. Also, each qPCR experiment 
will generally consist of 1 – 3 reference genes, which is insufficient as the validity of a single 
reference gene cannot be determined. Contrastingly, NanoString uses 30 – 40 reference genes 
in every experiment. Dijkstra et al., (2014) assessed all qPCR colorectal cancer publications 
over a seven-year period for the number of reference genes used and whether they had been 
validated. They found that 92 % of publications used only a single reference gene, and 70 % 
of the total publications used just one of three reference genes (ACTB/GAPDH/18S). The 
validity of 97 % (173/179) of the publications could not be assessed. Ergo, multiple validated 
reference genes, such as in the case of NanoString, are necessary to improve the reliability of 
RNA quantification assays. More recently, Bustin and Nolan, (2017) heavily criticised the 
ongoing use of qPCR, stating that the majority of qPCR data published is likely just technical 
noise. They regard the apparent simplicity of qPCR to conceal a complexity that extends to 
every step of the workflow. Nevertheless, while only two reference genes were used in the 
qPCR experiments presented in this thesis (the abovementioned overused GAPDH and 
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ACTB), the gene expression differences noted were reflected in both the NanoString data and 
IHC for the specific gene PLAUR. 
4.4.3 Comparative analysis reveals mechanisms of cSCC tumourigenesis 
When looking at all genes in the overall heatmap, large differences in gene expression were 
evident, even amongst samples of the same cohort. These differences between individual 
samples of metastatic and primary cSCC are further proof of inter-patient heterogeneity, 
which is discussed further in section 4.4.4. These differences became less pronounced once 
the samples were analysed according to pathway scores. There was no apparent association 
between extensive perineural invasion (PNI) and gene expression profile amongst these 
samples. 
Given the progression panel has been designed with probes specific to genes involved in 
cancer progression, it is fair to deduce that normal skin would possess a low score for every 
pathway. However, there was significant upregulation of pathways including: angiogenesis, 
TGFB signalling, metastasis response, VEGFA signalling, cell proliferation, transcription 
factor and cellular growth factor. This may be primarily because normal epidermis increases 
skin angiogenesis and VEGF expression in response to UV irradiation (Kosmadaki et al., 
2003; Zhu et al., 2013). This process is mediated through cytokine release and transcription 
factor activation – thus explaining some of the other upregulated pathways in normal skin. 
Expression of these pathways was lowest for metastatic cSCC, which in turn has experienced 
the greatest degree of neoplasia and therefore is less likely to behave like normal dermis. 
PRIMARY MET samples and some PRIMARY NO MET samples were found to also 
upregulate these angiogenic pathways which is unsurprising given the demand for 
oxygenation and nutrients as a growing primary tumour (Hillen and Griffioen, 2007). This is 
less of a demand in the metastatic setting given the continued nutrient supply via the 
lymphatics and existing vasculature (Bielenberg and Zetter, 2015). 
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Relative to normal skin, cSCC (both primary and metastatic) was found to upregulate most of 
the progression pathways. Strong pathway scores were most evident with MMP remodelling, 
cell motility, ECM receptor interaction, and metabolic gene sets. These are unsurprising and 
align with the widely agreed upon hallmarks of cancer (Hanahan and Weinberg, 2011). Scores 
for these pathways was most often higher in metastatic samples. 
It was interesting to note that, on the basis of linear regression analysis, PRIMARY MET 
differed from normal skin more than LN MET did. This suggests that PRIMARY MET are 
endowed with characteristics that aid rapid tumour progression, whilst LN MET are 
downregulating these genes as these traits are no longer necessary in the secondary site. 
However, subsequent differential expression analyses revealed that DEGs correlated with 
pathological state, with LN MET exhibiting the most DEGs. The DEGs shared between all 
three cSCC cohorts represent the most common differentially expressed cancer progression 
genes in the cSCC samples. The upregulation of MMPs, PLAU, FN1, PDPN, and LAMC2 in 
cSCC was similarly observed by Mitsui et al., (2014). Targeted therapy specific to these 
genes and/or their pathways may assist in the control of this disease. 
Of the differences between primaries that did metastasise and those that did not, SPINK5 and 
IBSP were the most notable (Appendix H). As SPINK5 encodes for a serine protease inhibitor 
(LEKTI), the downregulation of this gene (as shown in PRIMARY MET compared to 
PRIMARY NO MET) results in greater protease activity, leading to ECM degradation 
(Mitsudo et al., 2003). Of note, this protease inhibitor works against plasmin, halting its 
proteolytic abilities. As already determined, activators of plasmin PLAU and PLAUR are 
overexpressed in the cSCC samples; therefore, in the absence of SPINK5, there is little 
stopping ECM degradation via plasmin. Accompanying this, PRIMARY MET significantly 
upregulated IBSP compared to PRIMARY NO MET, resulting in enhanced angiogenesis. 
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These may be key determinants in delineating what enables some primary cSCC to 
metastasise from those that do not. 
E-cadherin (CDH1) gene expression was not found to significantly differ between the 
metastatic cSCC and normal skin (Figure 4.18), perhaps as the metastatic cSCC has 
undergone MET and restored part of its epithelial phenotype. A large variation was evident 
amongst LN MET samples, potentially reflecting samples at different stages of MET. Both 
primary cohorts did significantly decrease CDH1 compared to normal skin and metastatic 
cSCC (Figure 4.18). A decrease in CDH1 was also notable for primaries that did metastasise 
compared to those that did not. This aligns with previous reports in cSCC (Koseki et al., 
1999) as well as in head and neck squamous cell carcinoma (Schipper et al., 1991), whereby 
decreased expression of E-cadherin in the primary lesion correlated with nodal metastasis. 
This is in contrast to Toll et al., (2015) who suggested that E-cadherin is a poor prognostic 
marker of metastatic risk, on the basis of IHC. This may be an example of how differences at 
an mRNA level may not necessarily translate into significant protein-level findings. To 
complement the gene expression findings here and the observations by Toll et al., (2015), 
IHC could be performed on preserved slides of the corresponding patient’s tumour. 
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Figure 4.18 Relative mRNA expression of CDH1 across clinical cohorts. Log2 count data shown. 
Significance denoted by asterisks: * = P < 0.05; ** = P < 0.01; *** = P < 0.001. 
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Comparisons in this project are also limited as no samples are matched, i.e. the normal skin, 
primary cSCC, and metastatic cSCC are all from different patients. Analyses using matched 
samples are currently being performed by other members of the laboratory and may yield 
more informative data regarding individual patient’s gene expression profile throughout 
disease progression. 
4.4.4 Inter-patient heterogeneity 
Several authors have remarked on the genomic and transcriptomic heterogeneity found 
between samples of cSCC (Pickering et al., 2014; Li et al., 2015; Harwood et al., 2016; 
Yesantharao et al., 2017). The gene expression profiling of clinical samples presented in this 
thesis supports the mutational variability presented by others (Li et al., 2015; Mueller et al., 
2019), revealing a range of profiles. Whilst these cSCC samples mostly clustered within their 
own cohort, the range of expression for any one given gene within the cohort was 
considerable. This was not just a phenomenon seen within the NanoString panels, but RNA-
seq data similarly revealed heterogeneity across the entire transcriptome, albeit the RNA-seq 
sample size was considerably limited (n = 2). 
These differences may be due to varying levels of tumour cellularity between the patients 
resulting in varying levels of background noise. To test this theory, LN MET samples 
underwent supervised clustering, whereby the samples were reordered based on percentage 
tumour cellularity (Figure 4.19). This rearrangement produced no clearer associations, still 
showcasing the large variation in gene expression profile between samples. 
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Figure 4.19 Metastatic cSCC gene expression with supervised clustering according to tumour cellularity. 
Nonetheless, if interference of stromal cells is an issue, single-cell transcriptomics could be 
utilised to extract information from cancerous cells only. Such an approach was utilised by 
Zhang et al., (2016) to characterise the heterogeneous gene expression profiles within 
squamous cell carcinoma of the urinary bladder. 
It is unsurprising that patients exhibited quite a variation as there are multiple processes that 
can become damaged and lead to tumorigenesis. Rodríguez-Paredes et al., (2018) found two 
distinct subgroups of cSCC that are defined by stem cell-like and keratinocyte-like 
methylation patterns. I.e. prior to cSCC development, actinic keratoses that form from well 
differentiated and keratinised epithelial cells provide a separate profile to those that arose 
from more stem-like epithelial cells. 
Whole-genome sequence analysis revealed the tumour mutation burden (mutations/Mb) of the 
metastatic cSCC samples to be some of the greatest of any cancer type (Mueller et al., 2019) 
(Appendix J). A large degree of variation in mutation burden was evident with samples 
ranging from 44.8 to 468.8 mutations/Mb. 
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In his analyses, fellow PhD student Dr Bruce Ashford found that despite a wide range in 
mutational burden between the samples tested, there existed strong commonalities for select 
genes. For example, high impact TP53 variants were found in 100 % of all analysed samples 
and 93 % of the samples harboured AHNAK and SYNE1 variants (Appendix J). These genes 
with high impact variants were similarly observed by Pickering et al., (2014) and 
consequently, may be of prognostic or therapeutic interest. 
4.4.5 Biomarker and therapeutic target discovery 
A number of genes were found to be uniquely dysregulated between the cohorts. Genes 
discriminatory between primaries with subsequent metastases from those without may serve 
as candidate biomarkers of metastatic risk. The following will discuss some genes worthy of 
further experimental consideration. 
4.4.5.1 Plasminogen activation system 
Components of the urokinase mediated plasminogen activation system are gaining momentum 
as candidate biomarkers in other cancer types (Brungs et al., 2017). Within the current study, 
both PLAU and PLAUR were found to be upregulated in a manner consistent with disease 
progression, as similarly reported by others (Rømer et al., 2001; Mitsui et al., 2014; Garcia-
Diez et al., 2019). Due to this, PLAU and/or PLAUR may be worthy biomarkers of disease 
progression. At the very least, these data suggest the continued investigation of the role of 
uPAS components in cSCC metastasis. 
Notwithstanding the potential prognostic capabilities, uPAR and/or uPA may serve as 
important therapeutic targets (Ulisse et al., 2009; Montuori et al., 2016; Su et al., 2016; 
Buckley et al., 2018). The activation of this system is crucial towards invasion and metastasis 
of cSCC. Given the metastatic process is the critical dilemma in cSCC, determining therapies 
that target this process is paramount. Such potential therapies are explored briefly in Chapter 
5. 
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4.4.5.2  c-SRC 
The findings of SRC expression in the current study align with those of Ayli et al., (2008) 
who observed SRC family kinases to be activated in cSCC relative to normal epidermis on the 
basis of IHC. Matsumoto et al., (2003) found in an animal model that overexpression of 
human c-SRC led to enhanced tumour promotion and the rapid conversion of papillomas to 
cSCC with a metastatic phenotype. Activation of SRC family kinases has also been reported 
to be co-localised with invasive tumour fronts in oral squamous cell carcinoma (Cheng et al., 
2012). Given the greater levels of SRC detected in metastatic cSCC than primary cSCC, it 
also appears in the current study that SRC expression correlates with invasive tissue. SRC 
family kinases have been observed to be a novel predictor of recurrence in cervical squamous 
cell carcinoma patients (Hou et al., 2013). Pharmacological targeting of SRC may have 
therapeutic benefit for cSCC via downregulating the cellular activity of downstream growth-
regulatory molecules (Ayli et al., 2008). As such, SRC inhibitors could be a worthy treatment 
for primary and metastatic disease. However, it has been noted that prolonged inhibition of 
SRC family kinases leads to tumour cell survival through altered JAK/Stat3 interaction (Nam 
et al., 2013). To compensate for this, a duel inhibitor of JAK family members and SRC may 
be necessary. 
4.4.5.3 EGFR and c-MET 
Whilst EGFR is reported to be overexpressed in cSCC (Yanagi et al., 2018), only a modest 
increase in expression relative to normal skin was observed across both metastatic and 
primary samples included in this study. Contrastingly, MET overexpression positively 
correlated with disease progression. The protein c-MET offers bypass signalling of the EGFR 
pathway by way of PI3K/AKT activation. Zhang et al., (2012) remarked that profiling of 
bypass genes for the EGFR pathway may help predict response to EGFR therapies. 
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4.4.5.4  Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of endopeptidases that are capable of 
degrading the majority of ECM components (Johansson et al., 1997), thereby promoting 
invasion and metastasis. MMPs can also cleave TGFβ precursors to generate active cytokines 
that regulate proliferation and apoptosis (Roy et al., 2009; Radisky et al., 2017). MMPs 
(particularly MMP-9) have been exploited as biomarkers of disease progression and 
metastasis for numerous other cancers (Sawaya et al., 1996; Papathoma et al., 2000; Tutton et 
al., 2003; Fernandez et al., 2005; Tian et al., 2008; Zhang et al., 2008). The presence of 
MMPs in cSCC has been reported by multiple authors (Airola et al., 1997; Johansson et al., 
1997; Kerkelä et al., 2001; Kerkelä and Saarialho-Kere, 2003; Ala-aho et al., 2004; Ahokas et 
al., 2005; Gialeli et al., 2011; Kivisaari and Kähäri, 2013; Zheng et al., 2017), and expression 
has been found to generally correlate with the transformation and invasiveness of cSCC cells. 
The results of the current study similarly revealed the upregulation of MMP genes in cSCC 
relative to normal skin. The majority of MMPs analysed displayed the highest expression with 
the PRIMARY MET cohort, followed by LN MET, then PRIMARY NO MET. The weakest 
differences were observed with MMP14 and to a lesser extent, MMP9. In fact, MMP9 was 
found to have a relatively high expression in normal skin, making it a poorer biomarker of 
disease diagnosis or prognosis, despite its frequent use for such purposes as mentioned above. 
Between PRIMARY MET and PRIMARY NO MET, MMP10 was found to provide one of 
the most powerful differentiators of metastatic risk. 
4.4.5.5 Disease profiling using gene lists 
Two gene lists were created to help discriminate between the cohorts. The first of these 
sought to delineate primaries that do metastasise from those that do not. The resultant list of 
genes (Table 4.3) separated the samples quite well and may be the most deterministic of 
metastatic risk. With further refinement through larger sample sizes this gene list could 
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potentially serve as a valuable addition to current staging methods. Additionally, these genes 
may suggest therapeutic targets to treat high-risk primaries. 
Table 4.3 Promising biomarkers of cSCC metastasis Genes were selected based on their high differential 
expression (DE) between the primaries that did metastasise from those that did not.DE ratio based on log2 
normalised counts. 
PRIMARY MET vs PRIMARY NO MET 
Gene DE ratio  Gene DE ratio 
MMP10 7.05  SPINK5 -13.18 
IBSP 5.29  S100A7 -11.48 
MMP13 4.41  CLDN4 -9.77 
ADAMTS8 4.32  PPL -8.84 
MMP9 4.14  SCNN1A -4.99 
BAI1 4.12  CXCL10 -4.79 
ISLR 3.75  ITGB7 -4.77 
BGN 3.72  IL18 -3.78 
COL1A2 3.68  EREG -3.65 
INHBA 3.54  ITGA8 -3.21 
POSTN 3.53  DSC2 -3.16 
ITGB3 3.51  ARAP2 -3.02 
EMILIN1 3.38  NOX5 -2.93 
ITGA11 3.08  FUT3 -2.9 
FN1 2.66  CHI3L1 -2.24 
PRKCG 2.38  CXCL11 -2.02 
COMP 2.07  MS4A6A -1.59 
FGF18 1.98  ISL1 -1.33 
NRXN3 1.47  HOXA5 -1.32 
 
Promising biomarkers are usually classified according to their phase in the development 
pipeline, being: exploratory, assay development and validation phase, retrospective validation 
studies, and prospective validation studies. The research presented within this thesis is 
confined to the first of those phases: exploratory. Moving forward, the above mentioned genes 
should be progressed into validation studies incorporating clinical values. IHC on preserved 
samples of affected patients with varying degrees of pathology is the next logical step towards 
achieving this. It is difficult to determine the robustness of any singular gene as a biomarker 
of cSCC metastasis given the significant degree of inter-patient heterogeneity, therefore the 
utility of the genes must be examined synergistically. Regardless, in the absence of clinical 
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values, the diagnostic and/or prognostic implications of these biomarkers are yet to be 
determined. Once this data becomes available the quality of the selected biomarkers can be 
assessed on the basis of the criteria formulated in either the Reporting Recommendations for 
Tumour Marker Prognostic Studies (REMARK) guidelines or the Standards for Reporting of 
Diagnostic Accuracy (STARD) (Hussein et al., 2018). 
The second gene list (Table 4.2) sought to identify the biggest differences between all of the 
cohorts. This provided a view of some of the most significant differences across cSCC disease 
pathology. Importantly, the differences in the metastatic cohort from others shed light on 
potential therapeutic targets for those already suffering from metastatic disease. 
Whilst NanoString is a highly powerful tool for simple visualisation of gene expression, the 
development of biomarkers should ideally utilise higher power technologies such as RNA-seq 
or mRNA microarray to uncover as many novel biomarkers as possible. Subsequently, 
NanoString may be useful for analysing samples with a smaller biomarker gene panel first 
determined via RNA-seq. 
Future investigations should utilise an expanded gene list as some genes of interest identified 
in the literature were absent from either of the panels used. For example, it may be worth 
investigating genes encoding E2F family proteins such as E2F7 as this gene plays an essential 
role in the regulation of cell cycle progression, keratinocyte proliferation, and has been shown 
to contribute to drug resistance in head and neck squamous cell carcinoma (Jones et al., 1997; 
Hazar-Rethinam et al., 2011). E2Fs are also indirectly involved in modulating the activity of 
important pathways such as MAPK, p38 and PI3K/AKT through transcriptional regulation of 
upstream pathway components (Hazar-Rethinam et al., 2011). Given the importance of the 
PI3K/AKT pathway in cSCC identified in this thesis and elsewhere (Lin et al., 2007; Janus et 
al., 2017; Ding et al., 2018), E2F proteins may be of considerable insight. 
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Recently Toll et al., (2015) discovered that high levels of IKK-α in primary tumours is 
predictive of cSCC metastatic capacity. However, the relevant gene (CHUK) is absent from 
the progression panel, therefore the predictive power of this could not be determined. 
Similarly, EGR3 was shown to be closely associated with the occurrence of cSCC by Wei et 
al., (2018), yet is absent from the progression panel. This gene can stimulate MAPK and 
NFKB signalling pathways and may prove to be a valuable therapeutic marker for cSCC, 
assuming the findings of Wei et al., (2018) can be substantiated in other samples of cSCC. 
4.4.6 Conclusions and future directions 
Comparative analysis of these clinical samples has provided essential foundations on which to 
base novel prognostic and therapeutic strategies for cSCC. The major pathways that define 
primaries that do eventually metastasise from those that do not have been investigated, as well 
as those that discriminate metastatic cSCC from normal skin. The individual aspects that 
differ between these cohorts are numerous and are best summarised in Figure 4.20 A & B. 
These networks highlight the major pathways affected that contribute towards the given 
pathology. 
The gene lists created to distinguish the cohorts resulted in uniquely identifiable expression 
profiles. Whilst the sample size of primaries with subsequent metastases was admittedly low, 
many of the genes listed may prove to be powerful in their ability to inform on metastatic risk. 
As more samples are processed, the statistical power of each gene in its discriminatory 
abilities will become clearer. 
Factors involved in cellular degradation (MMPs and PLAU) and PI3K/AKT/mTOR signalling 
(MET and SRC) were particularly upregulated and represent candidate biomarkers and/or 
therapeutic targets. The advent of the novel cell lines established and validated in this project 
(Chapters 2 and 3) has enabled the testing of candidate therapeutics such as these. The results 
of such an endeavour are presented in the following chapter.  
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Figure 4.20 Differential expression of the pathways in cancer. A) PRIMARY MET vs PRIMARY NO MET. B) LN MET vs NORMAL. In these analyses, genes within the 
NanoString progression panel have been mapped to their given pathway and differential expression information overlaid. Pathway nodes shown in white have no genes in the 
panel that map to them. Pathway nodes in grey have corresponding genes in the panel, however no significant differential expression is observed. Nodes in blue denote 
downregulation relative to the selected baseline, whereas nodes in orange denote upregulation relative to the selected baseline. Image rendered by NanoString’s pathview 
function in nSolver 4.0 using data from KEGG (Kanehisa et al., 2017). 
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CHAPTER 5: PRE-CLINICAL SCREENING OF 
ESTABLISHED AND NOVEL THERAPEUTICS FOR CSCC – 
BACK TO THE BEDSIDE 
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5.1 INTRODUCTION 
No targeted therapies are routinely administered to relieve metastatic cSCC tumour burden, 
and those that are sparingly used have very little empirical evidence supporting their use in 
this disease. Outside of some platinum therapeutics and cetuximab, the use of 
chemotherapeutics to treat metastatic cSCC has largely been disregarded due to the lack of 
evidence and thus has never been given serious attention. 
Recently immunotherapy has been gaining traction as a therapy for cSCC given positive 
response rates (Falchook et al., 2016; L. Stevenson et al., 2017; Miller et al., 2017; Hermel et 
al., 2018). However, response to immunotherapy is not 100 %, varying greatly between 
patients and giving unique patterns of clinical benefit (Emens et al., 2017). Advances in 
chemotherapy on cSCC have been stagnant; therefore, additional therapies must continue to 
be sought after to complement advances in targeted/immuno-therapy. 
As stated in Chapter 1, there are many acquired biological capabilities, or hallmarks, that 
define a given cancer. Consequently, successful therapies for a cancer exploit the contribution 
of these hallmarks either alone or in combination (Figure 5.1). A deep understanding of the 
mechanisms being exploited by a cancer allows us to also identify how best to attenuate these 
mechanisms to our advantage. For example, cancers that sustain proliferative signalling 
through overexpression of epidermal growth factor (EGF) or its receptor (EGFR) will 
generally benefit from EGFR inhibitors (Uribe and Gonzalez, 2011). 
By such logic, the findings of Chapter 4 propose therapeutic efficacy against cSCC with 
agents targeting ECM remodelling mediators (e.g. plasminogen activation system and 
MMPs), c-SRC, c-MET, EGFR, PI3K/AKT, and JAK/STAT signalling pathways. 
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Figure 5.1 The hallmarks of cancer with relevant therapeutics. Taken from Hanahan and Weinberg, (2011). 
Therapies targeting EGFR (e.g. cetuximab) have previously shown promising results for SCC 
(Yanagi et al., 2018). However, the use of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) 
such as gefitinib can lead to resistance via activation of bypass signalling (Huang and Fu, 
2015; Morgillo et al., 2016; Zhao et al., 2017). One such mechanism of resistance to EGFR-
targeting therapies in cSCC is the overexpression of hepatocyte growth factor (HGF) and/or 
its receptor c-MET (Cataisson et al., 2016). Activation of c-MET restores phosphorylation of 
downstream PI3K/AKT pathways (Huang and Fu, 2015). Chapter 4 found that both EGFR 
and c-MET were upregulated in metastatic disease. Therefore, optimal therapy may consist of 
EGFR-targeted therapies + c-MET inhibitors, as has been proposed by others (Huang and Fu, 
2015; Yap et al., 2017). 
The provision of cell culture enables the rapid accumulation of drug sensitivity data which 
may begin to shift the paradigm for the standard of care of metastatic cSCC. Screening of 
diverse small molecule libraries against known targets or disease-specific pathways can 
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facilitate the discovery of candidate therapies (Goktug et al., 2013). With the establishment of 
novel metastatic cSCC PDCCs (Chapter 2) and their validation (Chapter 3), large scale 
therapeutic screening of this disease became possible.  
Novel and established chemotherapeutics, guided by the volume of candidate drug targets 
identified in Chapter 3 and 4, were tested against the PDCCs by their inclusion in 2D high-
throughput screening (HTS) libraries with over 840 small-molecules. Lead compounds 
identified from the HTS were subsequently analysed in secondary screens to a greater depth 
using smaller-scale dose-response assays to elucidate half maximal inhibitory concentration 
50 (IC50) values. IC50 values refer to the concentration of an inhibitor required to halt a 
response (generally proliferation or cell viability) by 50 % in comparison to untreated cells. 
There are multiple benefits to obtaining IC50 values, one of which is the ability build 
chemogenomic analyses (Kalliokoski et al., 2013), whereby the exact molar potency of a 
given drug can be related back to transcriptomic or genomic aberrations. This is particularly 
useful in comparisons of prior irradiation (modelled by UW-CSCC1-R) upon response to 
therapies. 
This chapter will present the results of these drug assays and discuss the relationship between 
drug response and expression of the target. The utility of 3D therapeutic screening assays was 
also briefly investigated, including limited analyses of drugs in the setting of an organotypic 
invasion assay. 
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5.2 METHODS 
5.2.1 Therapeutic selection 
To gain meaningful drug-response data against cSCC cultures, compounds with known roles 
in mediating cancer growth and survival were selected. Two HTS screening panels were 
utilised, consisting of molecules curated for their known or promising roles in controlling 
cancer. The distribution of the multiple pathways targeted by the drugs for both screening 
libraries is shown below (Figure 5.2). 
 
Figure 5.2 Pathways targeted by the small molecule screening libraries. A) anti-cancer library. B) kinase-
inhibitor library. 
Compounds for dose-response screening were chosen based on either: efficacy in the HTS 
screen, enhanced expression of the drug target (as determined in Chapters 3 or 4), or for their 
known use in managing other cancer types. Most compounds used for dose-response assays 
were kindly donated by Dr Phillip Clingan (Southern Medical Day Care Centre, Wollongong, 
Australia) and stored as per manufacturer instructions. 
Inhibition of plasminogen activation was explored using 6-subtituted hexamethylene 
amiloride (HMA) analogues, BB2-30F and HM2-74, developed in-house by collaborator Dr 
Benjamin Buckley. These 6-HMA analogues have shown nanomolar potency against uPA 
(Buckley et al., 2018). These drugs, along with plasminogen activator inhibitor-2 (PAI-2) and 
A) B) 
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an inactive PAI-2 mutant (PAI-2 ΔR380A), were interrogated in organotypic invasion assays 
to reveal their influence in ECM remodelling and epithelial invasion. 
5.2.2 High-throughput screening 
5.2.2.1 Cells and plate preparation 
Metastatic cSCC cell cultures UW-CSCC1 & UW-CSCC1-R (passage 14) were brought up 
from frozen in complete media under hypoxic conditions (5 % CO2, 3 % O2) at the National 
Cancer Centre, Singapore. UW-CSCC2 had not yet been generated at this point in time and 
therefore could not be assessed. Once expanded, 1,000 cells/well were seeded into white-
opaque 384-well plates (PerkinElmer, USA; Cat no. 6007558), leaving a border of two wells 
around the sides of the plate to prevent evaporation. The two cell lines were tested against two 
screening libraries (with each library spanning two plates) in triplicate, giving a total of 24 
plates prepared for screening. Wells were made up to 50 µL with growth medium. A 
transparent plate was also prepared to monitor cell growth prior to drug addition. 
5.2.2.2 Drug addition 
At 24 hours post-seeding, cells were screened using the anti-cancer (Cat no. L3000) and 
kinase-inhibitor (Cat no. L1200) libraries (SelleckChem, USA). These assays encompass 416 
and 420 small molecules, respectively, and target a range of pathways at low nanomolar 
potency. Screening assays were performed at the Centre for High Throughput Phenomics at 
the Genome Institute of Singapore. Using the Bravo automated liquid handling platform 
(Agilent Technologies, USA), drugs were added to the plates at a concentration of 1 µM and 
mixed gently on an orbital shaker. DMSO internal controls were included within each 
replicate. Plates were subsequently incubated at 37°C for three days in a hypoxic atmosphere. 
5.2.2.3 Viability assay and digital analysis 
Following incubation, cell viability by way of ATP activity was measured using the CellTiter-
Glo® Luminescent assay as per manufacturer’s instructions. For efficient querying and 
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analysis of the data generated from the screening assays, a web portal developed by the 
Genome Institute of Singapore was utilised. Screening data was uploaded onto the database 
portal and processed to generate normalised scores and various plots for visualising data. For 
each replicate, percentage viability was calculated relative to the average DMSO reading 
(
𝐷𝑟𝑢𝑔
𝐷𝑀𝑆𝑂 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 × 100 %). Triplicates were then averaged and arranged by percentage 
inhibition. Normalised data was presented using the plots generated by the web portal, or 
scores were retrieved and interpreted using Graphpad Prism 6.0. 
5.2.3 Two-dimensional dose-response assays 
In vitro cytotoxicity of a smaller selection of compounds at a titrated range was performed to 
elucidate the half maximal inhibitory concentration (IC50) values. Into 96-well microplates 
(Greiner Bio-One, USA), 10,000 cells were seeded per well and incubated overnight in a 
hypoxic atmosphere (5 % CO2, 3 % O2). Cells were then incubated with serial dilutions of 
each drug in triplicate for 72 hours with drug vehicle dilution (water or DMSO depending on 
the compound) kept constant across all drug concentrations and controls. Drug concentration 
ranges were selected appropriately to give a large order of magnitude, with reported IC50 
values against head and neck squamous cell carcinoma (HNSCC) occasionally used as a point 
of reference. 
The metabolic activity of cells was determined using CellTitre 96® Aqueous One Solution 
Cell Proliferation Assay (Promega, USA, Cat no. G3581) using a Spectromax 250 UV plate 
reader in association with the Softmax Pro software (Molecular Devices, USA). It should be 
noted that this technique measures the relative abundance of ATP, and as such informs on 
metabolic activity rather than cell death precisely. The raw data of treated cells was 
normalised against vehicle controls with background absorbance values subtracted. IC50 
values were derived within GraphPad Prism 6.0 using a logarithmic sigmoidal dose–response 
curve with the variable slope parameter. 
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5.2.4 Three-dimensional dose-response screening 
5.2.4.1 Spheroid cytotoxic assay 
Cytotoxicity assays were undertaken using spheroid cultures as a more physiologically 
relevant system compared to 2D culture. Spheroids/aggregates were allowed to form over 48 
hours (as described in Chapter 2). Serial dilutions of a given drug were added to each 
spheroid-containing well and incubated for 72 hours. An acid phosphatase assay (APA) 
protocol (Friedrich et al., 2007) was used to determine spheroid viability. In accordance with 
this protocol, spheroids were incubated at 37°C for 1.5 hours in an acid phosphatase buffer 
(0.1 M sodium acetate [pH 5.5]; 0.1 % v/v Triton-X-100; 2 mg/mL p-nitrophenyl phosphate). 
To stop the reaction, 1 M NaOH was added and absorbance measured at 405 nm using a 
Spectromax 250 UV plate reader in association with the Softmax Pro software (Molecular 
Devices, USA). 
5.2.4.2 Organotypic invasion assay 
Organotypic cultures were developed as described in Chapter 2 (section 2.2.7). To assess 
inhibition of invasion in an organotypic system, several compounds were added to the 
underlying media during the air-liquid interface step. The drug-infused media was refreshed 
every 2 – 3 days during the experiment, depending on colour change. Vehicle controls of 0.2 
% DMSO were also included. Organotypic cultures were subsequently processed as described 
in Chapter 2. 
5.2.5 Drug-treated scratch-wound migration assay 
A scratch-wound migration assay was performed on UW-CSCC2, as per the methodology 
described in Chapter 2, section 2.2.6. However, in this circumstance following the initial 
scratch the cells were incubated with 200 ng/mL high molecular weight uPA (Sapphire 
Bioscience, Australia; Cat no. UPA-HTC) or 50 ng/mL hEGF (Thermofisher Scientific, USA; 
Cat no. PHG0311L). 
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5.3 RESULTS 
5.3.1 High-throughput screening 
Screening libraries of anti-cancer and kinase-inhibiting compounds were used with UW-
CSCC1 and UW-CSCC1-R to identify candidate drugs for further investigation. 
5.3.1.1 Reliability and compound distribution 
Correlation plots (Figure 5.3) demonstrate the high fidelity of the experimental replicates, 
displaying strongly positive Pearson correlation scores. These scores in conjunction with the 
plethora of internal controls highlight the validity of these data and permit further analyses. 
 
Figure 5.3 Correlation plots of anti-cancer and kinase-inhibitor library replicates for the PDCCs. 
Of the compounds tested in the anti-cancer library, 85 (20.4 %) were shown to inhibit UW-
CSCC1 cell viability by at least 50 % at 1 µM (Figure 5.4 A); falling to 82 against UW-
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CSCC1-R. More compounds were highly effective (≥ 70 % inhibition) against UW-CSCC1-R 
(69 compounds) compared to UW-CSCC1 (63 compounds). 
Of the kinase-inhibitors, 51 (12.1 %) and 47 (11.2 %) compounds inhibited UW-CSCC1 and 
UW-CSCC1-R cell viability by at least 50 %, respectively. However, the proportion of highly 
effective compounds (≥ 70 % inhibition) against UW-CSCC1 (21) was smaller than against 
UW-CSCC1-R (32) (Figure 5.4 B). 
 
Figure 5.4 Distribution of HTS small molecules with respect to percentage inhibition of PDCCs. All 
compounds tested at 1 µM). Percentage inhibition scores of 50 % and 70 % are shown by dashed lines. A) Anti-
cancer library. B) Kinase-inhibitor library. 
The distribution of compound effects can also be viewed in a scatter plot to reveal how each 
compound behaved between the two interrogated cell lines. A bimodal distribution was 
evident for the anti-cancer library, as shown in Figure 5.5 A), in which most drugs were either 
strongly potent or very mild/ineffective. Contrastingly, the data was more spread in response 
to the kinase-inhibitors (Figure 5.5 B). Linear regression analysis revealed that for the anti-
cancer library, a strong positive correlation between the cell lines was evident (r2 = 0.87), 
whilst for the kinase-inhibitor library a weaker correlation was found (r2 = 0.68). Clearly the 
alterations brought about by irradiation highlighted in Chapter 3 have led to a change in 
response towards some kinase-inhibitors. 
B)      Kinase-inhibitor library A)      Anti-cancer library 
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Figure 5.5 Scatter plots comparing individual compound inhibition between the PDCCs. A) anti-cancer 
and B) kinase-inhibitor libraries. Negative inhibition implies a pro-proliferative event has occurred. Line of best 
fit and coefficient of determination are shown. 
Most of the samples included in either panel are purported to possess low nanomolar potency 
against their respective targets. As such, this HTS at the comparatively potent 1 µM has 
revealed distinctly those compounds that are either effective or ineffective against these cell 
lines, and therefore those worth considering in future investigations. 
5.3.1.2 Potent metabolic inhibitors 
The top 20 most potent drugs against UW-CSCC1 and UW-CSCC1-R across both screening 
libraries are shown in Table 5.1 and Table 5.2, respectively. An expanded list of the top 40 
most potent compounds against each cell line across both libraries is provided in Appendix K, 
detailing percentage inhibition, effected pathway and specific targets. 
Table 5.1 Topmost potent anti-cancer and kinase-inhibiting compounds against UW-CSCC1 at 1 µM. 
 
 
Anti-cancer library   Kinase-inhibitor library 
Compound Pathway 
 % 
Inhibition 
 Compound Pathway 
 % 
Inhibition 
Flavopiridol Cell cycle 98.20  PIK-75 PI3K/Akt/mTOR 97.85 
Daunorubicin 
HCl 
DNA damage 97.61 
 
BGT226 PI3K/Akt/mTOR 97.62 
Elesclomol Angiogenesis 97.60  Dinaciclib Cell cycle 96.02 
MLN2238 Proteases 97.18  SNS-032 Other 95.90 
Bortezomib Proteases 97.15 
 Flavopiridol 
HCl 
Cell cycle 95.63 
Topotecan HCl DNA damage 96.98 
 
Staurosporine TGF-beta/Smad 94.90 
PIK-75 PI3K/Akt/mTOR 96.96 
 
CUDC-907 
Cytoskeletal 
signalling 
94.81 
Flavopiridol HCl Cell cycle 96.69  Flavopiridol  Cell cycle 93.60 
B) 
Kinase-inhibitor Anti-cancer 
r2 = 0.87 r2 = 0.68 
A) 
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MLN9708 Proteases 96.66  AZD7762 Cell cycle 89.55 
SNS-032 Other 96.53  KX2-391 Angiogenesis 88.63 
Doxorubicin  DNA damage 95.71  Torin 2 PI3K/Akt/mTOR 85.43 
Triptolide Other 95.48  Hesperadin Cell cycle 81.40 
Gemcitabine  DNA damage 95.30  CHIR-124 Cell cycle 77.59 
Clofarabine DNA damage 94.78  AT7519 Cell cycle 77.38 
Disulfiram Other 94.68  VE-822 PI3K/Akt/mTOR 77.22 
Ganetespib Other 94.52  Rigosertib Cell cycle 76.97 
Romidepsin  
Cytoskeletal 
signalling 
94.32 
 
PHA-793887 Cell cycle 74.79 
Mitoxantrone 
HCl 
Other 94.23 
 
FIIN-2 
Protein tyrosine 
kinase 
73.99 
MK-1775 Cell cycle 94.09 
 JNK Inhibitor 
IX 
MAPK 72.68 
Mitoxantrone Cell cycle 94.03 
 
PF-3758309 
Cytoskeletal 
signalling 
72.26 
 
Table 5.2 Topmost potent anti-cancer and kinase inhibiting compounds against UW-CSCC1-R at 1 µM. 
 
 
Anti-cancer library   Kinase-inhibitor library 
Compound Pathway 
 % 
Inhibition 
 Compound Pathway 
 % 
Inhibition 
Flavopiridol  Cell cycle 98.32  PIK-75 PI3K/Akt/mTOR 98.43 
MLN9708 Proteases 98.28  SNS-032 Other 97.94 
AZD7762 Cell cycle 97.95  BGT226 PI3K/Akt/mTOR 97.84 
Daunorubicin 
HCl 
DNA damage 97.89 
 
VE-822 PI3K/Akt/mTOR 97.36 
MLN2238 Proteases 97.66  Dinaciclib Cell cycle 97.17 
PIK-75 PI3K/Akt/mTOR 97.55  LY2603618 Cell cycle 97.07 
Elesclomol Angiogenesis 97.47  CHIR-124 Cell cycle 96.93 
Bortezomib  Proteases 97.41 
 Flavopiridol 
HCl 
Cell cycle 96.75 
Clofarabine DNA damage 97.00  AZD7762 Cell cycle 96.64 
Flavopiridol  
HCl 
Cell cycle 96.96 
 
Staurosporine TGFO-beta/Smad 96.42 
Topotecan HCl DNA damage 96.88  Flavopiridol Cell cycle 95.26 
Doxorubicin  DNA damage 96.84 
 
CUDC-907 
Cytoskeletal 
signalling 
95.15 
MK-1775 Cell cycle 96.72  KX2-391 Angiogenesis 95.09 
Gemcitabine  DNA damage 96.61  PF-477736 Cell cycle 94.94 
Vinorelbine 
Tartrate 
Cytoskeletal 
signalling 
95.99 
 
MK-8776 Cell cycle 92.22 
LY2603618 Cell cycle 95.93  Torin 2 PI3K/Akt/mTOR 91.96 
Teniposide  Other 95.88  AZ20 PI3K/Akt/mTOR 90.96 
Mitoxantrone 
HCl 
Other 94.96 
 
PF-3758309 
Cytoskeletal 
signalling 
90.13 
Triptolide Other 94.65  GSK461364 Cell cycle 90.00 
CYT997  
Cytoskeletal 
signalling 
94.24 
 
Ro3280 Cell cycle 88.91 
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It should be noted that some drugs overlap between the two screening libraries, such as PIK-
75. Whilst small differences in inhibition by PIK-75 were noticed between the panels, this is 
due to minor biological fluctuations or technical differences, and the degree of difference is 
negligible. 
For each of the potent anticancer compounds tabulated above, the median difference in 
percentage inhibition between the PDCCs was 0.48 %. The most notable difference in the 
anti-cancer library was with the compound LY2603618 (rabusertib) which was more potent 
against the irradiated UW-CSCC1-R (96 % inhibition) compared to UW-CSCC1 (65 % 
inhibition). 
There was much more variability in response profiles of kinase-inhibitors between the cell 
lines, with a median change in response of 5.8 % for the compounds tabulated above. AZ20 
and MK-8776 displayed the greatest difference in response between the cell lines (~60 %). 
The altered genotype in UW-CSCC1-R does not appear to have created any change in overall 
drug resistance or susceptibility, rather the differences between the cell lines appear specific 
to individual targets or pathways.  
5.3.1.3 Topmost effected pathways 
The variance in metabolic inhibition for potent drugs between the two cells lines across both 
screening libraries can be seen in Figure 5.6. The drugs that produced ≥ 70 % inhibition (i.e. 
potent) between both cell lines are shown according to their relevant pathway target and 
reveal a poor correlation between the cell lines (anti-cancer - R2 = 0.5703; kinase-inhibitor – 
R2 = 0.3055). The anti-cancer library possessed 52 compounds in this cohort of potent 
inhibitors, whilst there were only 18 highly effective compounds from the kinase-inhibitor 
library.  
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Figure 5.6 Scatter plots of metabolic inhibition between the PDCCs. Cultures were treated with anti-cancer 
agents or kinase-inhibitors at a concentration of 1 µM. Only highly efficacious (≥ 70 % inhibition) are shown 
and compounds are classified according to the pathway they target. 
The frequency of a given pathway being targeted by a potent inhibitor (≥ 70 %) is shown in 
Figure 5.7. It was apparent that drugs targeting the cell cycle were commonplace as potent 
inhibitors between both libraries. Compounds contained within the anti-cancer library 
targeting cytoskeletal signalling were particularly abundant as potent inhibitors. 
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Figure 5.7 Pathways implicated in potent metabolic inhibition and their frequency.  The compounds across 
both screening libraries that exhibited greater than 70 % inhibition were classified according to their target. 
The frequency of these pathways being targeted in this highly potent range is shown. 
For the anti-cancer library, agents in the category of ‘other’ had the second largest number of 
potent compounds (12), however this is somewhat proportional to the large number of 
compounds placed within this category (113 total) and their diverse targets. On the other 
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hand, 8 drugs targeting the cell cycle pathway were found to be potent (≥ 70 % inhibition) 
despite a total count of only 20 drugs targeting this pathway in the whole library. Therefore, 
40 % of drugs targeting the cell cycle were notably potent compared to just 10.6 % of the 
drugs within the ‘other’ cohort. Similarly, 66.67 % of the drugs targeting cytoskeletal 
signalling were contained within the highly potent cohort. 
In summary, for the anti-cancer library many of the effective drugs targets involved cell cycle, 
cytoskeletal signalling, DNA damage, and proteases. Looking more specifically into these 
pathways, many of the efficacious compounds are inhibitors of topoisomerase II (e.g. 
topotecan, doxorubicin) or cyclin dependent kinases (CDK) (e.g. flavopiridol, SNS-032). 
Efficacious compounds in the kinase-inhibitor library largely pertained to targeting the cell 
cycle (particularly via CDKs) or PI3K/AKT/mTOR pathway (e.g. PIK-75). 
Targets involving the pathways protein tyrosine kinase, apoptosis, MAPK, and JAK/STAT 
were mostly ineffective. Apart from pelitinib, no EGFR-TKIs (e.g. erlotinib, gefitinib, 
lapatinib, afatinib) produced greater than 50 % cell inhibition for both cell lines. 
5.3.2 Two-dimensional dose-response screening 
Dose-response screening was performed on compounds commonly used in the clinical setting 
to treat a range of cancers. Many of these were also present in the single-concentration HTS 
screen. PIK-75 was assessed via dose-response analysis as it was a top hit in the HTS screen 
and the role of PI3K signalling as uncovered in Chapter 4. Whilst absent from the HTS 
screen, AMG337 (a c-MET inhibitor) was assessed due to the significance of c-MET 
uncovered in Chapter 4. Sigmoidal dose-response curves generated from the data allowed for 
determinations of IC50 values, thereby providing a more quantitative assessment than single 
concentration screens. The full list of screened compounds and their IC50 values are 
summarised in Table 5.3 alongside IC50 values pertaining to HNSCC cell lines for 
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comparison. All compounds except for PIK-75 and AMG337 were exclusively screened using 
UW-CSCC1. 
Table 5.3 IC50 values of chemotherapeutic agents against UW-CSCC1. Compounds are listed in order of 
lowest IC50. The geometric mean IC50 for head and neck squamous cell carcinoma (HNSCC) are shown where 
possible. These geometric means were derived from www.cancerrxgene.org and consist of oral, mucosal, and 
some cutaneous SCC calculated across multiple experiments from different institutions and cell lines with 
varying culture conditions. 
 Compound Drug class 
UW-CSCC1 
IC50 (µM) 
HNSCC                       
IC50 (µM) 
Gemcitabine* Antimetabolite < 22 nM 0.105 
Docetaxel* Microtubule targeting < 4 nM 0.0015 
Pemetrexed† Antimetabolite 0.025 - 
Mitoxantrone Anthracyclines 0.027 - 
Paclitaxel Microtubule targeting 0.031 0.095 
Etoposide Topoisomerase inhibitors 0.098 4.29 
PIK-75 PI3K inhibitor 0.110 - 
Mitomycin-c† Alkylating agent 0.503 0.448 
Doxorubicin Anthracycline 0.586 0.151 
Methotrexate Antimetabolite 1.252 0.904 
Oxaliplatin Platinum analogue 3.154 - 
5-Fluorouracil Antimetabolite 4.470 62.3 
Cisplatin† Platinum analogue 15.26 12.4 
Carboplatin† Platinum analogue 22.40 - 
Cyclophoshamide Alkylating agent 40.92 - 
Panitumumab**† Monoclonal antibody - - 
Cetuximab**† Monoclonal antibody - - 
AMG337**† c-MET inhibitor - - 
*  IC50 not determined by lowest drug concentration tested. 
** Compound had a cytostatic effect within the concentrations tested. I.e. no cytotoxic effect. 
† Compound not present in HTS drug screen 
         
Morphological changes were consistent with the MTS assay results, whereby increasing 
concentration of drug caused further cellular degradation and apoptosis (Figure 5.8), except in 
the case of panitumumab, cetuximab, and AMG337 which exhibited no response. 
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Figure 5.8 UW-CSCC1 morphology in response to mitoxantrone. Cells imaged at 20x objective after a 72 
hour incubation with mitoxantrone at 0 µM (control), 0.044 µM, and 44.996 µM. 
No one drug class appeared to be uniformly superior to another, however the platinum 
analogues mostly demonstrated higher IC50 concentrations. These drugs may not be 
particularly cytotoxic at low concentrations as they are more often intended as 
radiosensitising agents as opposed to straight-forward cytotoxins. The monoclonal antibodies 
were unable to provide a cytotoxic effect. 
Several of the IC50 values found against UW-CSCC1 were similar to those observed against 
HNSCC cell lines. This was evident for docetaxel, mitomycin, methotrexate, and cisplatin. 
Contrastingly, a big difference was observed with UW-CSCC1 in response to 5-fluoruracil 
(Table 4.3), exhibiting a much stronger positive response than with HNSCC cells. 
UW-CSCC1 and UW-CSCC1-R sensitivity to PIK-75 did not differ substantially, with IC50 
values being 0.110 µM and 0.151 µM (not shown in Table 5.3), respectively. However, PIK-
75 was more potent against UW-CSCC2 compared to the other cell lines, exhibiting an IC50 
of 0.044 µM (not shown in Table 5.3). The effect of increasing concentration of PIK-75 on 
cell morphology/viability can be seen in Figure 5.9. 
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Figure 5.9 PDCCs in response to PIK-75. Cells imaged at 20x objective after a 72 hour incubation with 
increasing concentrations of PIK-75. 
The c-MET inhibitor AMG337 was also assessed against all three cell lines due to both the 
upregulation of its target, MET (Chapter 4), and the observed resistance to EGFR therapies 
noted in the abovementioned assays, despite upregulation of EGFR in metastatic cSCC 
(Chapter 4). This is suggestive of sustained signalling downstream of EGFR. As a single-
agent, AMG337 exhibited no cytotoxic effect against the cell lines (Figure 5.10) and therefore 
IC50 values could not be determined. 
 
Figure 5.10 Dose-response curves for AMG337 against cSCC PDCCs. The lack of effect on cell survival as 
measured by metabolic inhibition by AMG337 made determinations of IC50 impossible. 
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To determine the impact that passage number had on therapeutic efficacy, IC50 values from 
four different drugs against UW-CSCC1 were compared between a comparatively low 
passage (# 15) and a high passage (# 32). These experiments were performed together with 
Miss Gretel Major. It was found that whilst small differences in IC50 were found between the 
passages (data not shown); overall there was a similar drug-response profile. The influence 
that passage number had on gene expression was previously determined in Chapter 3. It 
appears however that these gene expression changes had little effect upon cell drug-response 
profiles. Nonetheless, all therapeutic screening was performed at no greater than passage 20 to 
limit the possibility of variance occurring. 
5.3.3 Three-dimensional therapeutic screening 
Screening of candidate therapeutics in a 3D format was only briefly investigated in this PhD 
project and mostly sought to optimise the assays with the UW-CSCC cell line series. More 
comprehensive analyses of 3D drug screening were performed by Miss Gretel Major as an 
honours project of mine and Professor Ranson’s design and supervision, and as such will not 
be presented in any detail here. 
5.3.3.1 Spheroid cytotoxic screening 
Several chemotherapeutics were assessed against spheroid cultures of UW-CSCC1 and UW-
CSCC1-R. Results from an acid phosphatase assay were somewhat ambiguous with large 
standard errors between replicates. It was observed that doxorubicin, mitoxantrone, paclitaxel, 
and gemcitabine failed to produce a dose-response against UW-CSCC1 at the concentrations 
tested (Figure 5.11). 
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Figure 5.11 Dose-response curves of UW-CSCC1 spheroids against conventional chemotherapeutics. 
Due to the irregularities in results seen with the above viability assays, further spheroid 
screening of these cell lines was assessed by Miss Gretel Major via morphological 
examination as well as calcein AM/PI staining to determine the proportion of live:dead cells 
in the spheroid/aggregate. This approach more clearly demonstrated the effect of 
chemotherapeutics on spheroid viability (Appendix L).  
5.3.3.2 Pilot organotypic invasion assays 
Organotypic invasion assays were utilised in pilot studies to assess the ability of candidate 
therapeutics in controlling cell invasion into an in vitro dermal equivalent. It was observed 
that, compared to the control, inclusion of plasminogen activator inhibitor-2 (PAI-2) into the 
underlying media reduced UW-CSCC1 invasion and collagen degradation after 14 days. This 
can be seen in Figure 5.12, whereby the control sample displayed cells spread throughout the 
matrix accompanied by pores in the matrix surrounding the cells. Contrastingly, PAI-2 treated 
matrices displayed fewer cells spread throughout the matrix and those that did invade appear 
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thinner. Additionally, PAI-2 treated matrices demonstrated little evidence of collagen 
degradation as compared to the control treated matrices. To demonstrate this response as a 
bona fide product of PAI-2 functionality, an inactive mutant of PAI-2 (ΔR380A) was also 
assessed. This mutant PAI-2 failed to produce a noticeable effect upon invasion, resembling 
the control treated matrices instead, therefore confirming the specific activity of PAI-2 on 
uPA mediated invasion. 
   
Figure 5.12 Representative H&E stained sections of anti-uPA treated 3D organotypic cultures. UW-CSCC1 
(purple) were seeded onto fibroblast contracted collagen-I matrices (pink) and allowed to invade over 14 days 
(arrow indicates the direction of invasion). Each treatment was performed in quadruplicate. Control treated 
organotypics were exposed to media containing PBS as a vehicle control. Drug-treated matrices were exposed 
to media containing either 500 nM of PAI-2 or 500 nM of the inactive PAI-2 mutant R380A. Poor stain quality is 
due to early attempts at H&E staining, prior to the development and implementation of an optimised protocol. 
Similarly, inhibition of invasion was observed slightly with in-house anti-uPA/NHE1 
amiloride derivatives HM-74 and BB2-30F at 10 µM (Figure 5.13). Non-cytotoxic 
concentrations of drug were first determined through an MTS assay (Appendix M). A 
sublethal dose was needed as the organotypic seeks to assess the influence on cellular 
invasion, not viability. A defined monolayer of cells atop the matrix for drug-treated samples 
was observed, with little matrix degradation and fewer invading cells compared to the control. 
  
Figure 5.13 Representative H&E stained sections of anti-uPA/NHE1 treated organotypic cultures. UW-
CSCC1 (purple) were seeded onto human dermal fibroblast contracted collagen-I matrices and allowed to 
invade over 14 days (arrow indicates the direction of invasion). Each treatment was performed in quadruplicate. 
Control treated organotypics were exposed to media containing 0.2 % DMSO as a vehicle control. Drug-treated 
matrices were exposed to media containing 10 µM of anti-uPA/NHE1 amiloride derivatives HM-74 or BB2-30F. 
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5.3.4 Scratch-wound migration assay with uPA and EGF 
Incubation with exogenous high molecular weight uPA was not observed to significantly 
affect the rate of wound closure over 24 hours (9.95 µm/hr) for UW-CSCC2 compared to 
untreated cells (9.61 µm/hr) (Figure 5.14). However, upon addition of EGF, the rate of wound 
closure significantly increased, totalling a rate of 700.76 µm/hour (Figure 5.14). This resulted 
in a maximum wound closure of 32.12 %, 37.41 %, and 99.23 % over 24 hours for untreated, 
uPA-treated, and EGF-treated UW-CSCC2, respectively (Figure 5.14). 
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Figure 5.14 Random migration of UW-CSCC2 in vitro in response to uPA and EGF. Relative wound width 
of UW-CSCC2 over 24 h as assessed by scratch wound assay in the presence of uPA (200 ng/mL) or EGF (10 
µg/mL), as well as an untreated control. Asterisks represent significant differences, P < 0.0001. Error bars 
represent ± standard error. 
Representative micrographs of UW-CSCC2 closing the scratch-wound over time are shown in 
Figure 5.15. It is worth noting that EGF-treated cells may not only have enhanced motility, 
but they may also be closing the gap through faster cell proliferation. 
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Figure 5.15 Representative images of UW-CSCC2 wound closure in response to uPA and EGF over time. 
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5.4 DISCUSSION 
Cell lines are useful high-throughput tools to predict clinical response to pharmacological 
agents (Weigelt et al., 2014; Niu and Wang, 2015). The establishment of UW-CSCC1, and its 
derivatives, has enabled the screening of a large panel of compounds, revealing efficacious 
agents and drug classes that will direct the focus of future investigations. 
The introduction of variables and selected clones such as UW-CSCC1-R has allowed the 
investigation of mutations and drug responses that are impossible to perform in humans, and 
as such offer valuable pre-clinical tools.  
5.4.1 High-throughput screening reveals hit compounds against PDCCs 
Given the sheer volume of drugs analysed it is impractical to present an explanation for every 
single compound. As such, the following will discuss only those compounds that displayed a 
noteworthy potency or those that warranted investigation on the basis of efficacy in related 
cancers as well as molecular findings from Chapter 3 or 4. Whilst this approach may overlook 
negative results that further characterise these cell models (and therefore to an extent cSCC 
itself), these inefficacious compounds will continued to be studied in future investigations. 
5.4.1.1 Compound distribution 
The HTS data revealed that for both UW-CSCC1 and UW-CSCC1-R, the majority of the 
tested compounds were ineffective at 1 µM, despite the low nanomolar potencies against the 
relevant targets in cell-free assays purported by the screening library manufacturer 
(SelleckChem, USA). This is not entirely surprising given the screening libraries intentionally 
include compounds targeting a broad range of targets. If a given cancer does not rely upon a 
specific pathway entirely for survival or proliferation, then all the relevant compounds 
specific to that pathway would likely be ineffective in causing any significant change. A 
smaller bimodal response was seen with the kinase-inhibitor library as those compounds 
targeting kinases were mostly ineffective at inhibiting cell viability. 
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A weak correlation in overall response was seen between the PDCCs against the kinase-
inhibitor library. This correlation was further weakened when comparing the topmost potent 
compounds between the cell lines. For example, both MK-8776 and AZ20 had differences of 
~60 % between the cell lines. These drug-response differences between UW-CSCC1 and 
UW-CSCC1-R suggest that the alterations derived through the initiation and propagation of 
irradiated cells has had a profound effect upon therapeutic response to these drugs. However, 
the total number of compounds exhibiting > 50 % inhibition between the cell lines was mostly 
unchanged. This likely indicates that whilst irradiation has changed the response to a given 
drug between the cell lines, the newly acquired physiology has also made it more or less 
susceptible to inhibition by other compounds. Nonetheless, a history of radiotherapy for 
disease management may be crucial information in the future when developing a personalised 
treatment plan, especially in the context of recurrent disease. 
Of the potent compounds, the most commonly targeted pathways were cytoskeletal signalling, 
DNA damage response, PI3K/AKT/mTOR, and the cell cycle. This aligns well with the role 
of these pathways in the cell lines (Chapter 3) and the clinical specimens (Chapter 4). For 
example, mediators of PI3K/AKT activation (MET, SRC, and EGFR) were shown to be 
overexpressed and thus explain the survival advantage of targeting this pathway. Surprisingly, 
drugs targeting MAPK and JAK/STAT were mostly ineffective despite known activation of 
these pathways in cSCC (Janus et al., 2017). Drug responses may be better explained on a 
case by case basis, relating each drug with its particular target. 
5.4.1.2 Cyclin dependent kinase (CDK) inhibitors 
Several of the efficacious cell cycle targeting compounds were cyclin dependent kinase 
(CDK) inhibitors. CDK inhibitors were amongst the most potent compounds for both cell 
lines; however many CDK inhibitors also demonstrated weak potencies.  
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The CDK inhibitor flavopiridol (alvocidib) (and its HCl formulation) exhibited inhibition of 
greater than 95 %. Flavopiridol activity is strongest against CDK1, CDK2, CDK4, CDK6, and 
CDK9, although the cytotoxic activity of flavopiridol is not limited to cycling cells, and may 
also kill resting cells (Sedlacek, 2001). Inhibition of these CDKs results in cell cycle arrest 
and eventual apoptosis (Gallorini et al., 2012). Outside of haematological malignancies, 
flavopiridol efficacy has only been assessed in limited cases (Srikumar and Padmanabhan, 
2016). Multiple phase 1/2 trials are in progress to assess the efficacy of flavopiridol as a 
monotherapy or in combination with other chemotherapeutics against a range of solid tumours 
(NCT00003690; NCT00003004; NCT00003256). 
Dinaciclib was also found to potently inhibit PDCC metabolic activity. This drug is similarly 
a pan-CDK inhibitor, potently inhibiting CDK1, CDK2, CDK5, and CDK9, and exhibits an 
improved therapeutic index in preclinical studies over flavopiridol (Bose et al., 2013). This 
compound has also shown success in treating haematological malignancies and is in phase III 
clinical trials for chronic lymphocytic leukaemia (CLL) (NCT01580228). More recently 
dinaciclib was shown to inhibit thyroid cancer proliferation in both in vitro and in vivo assays 
(Lin et al., 2017). As it stands, there are no ongoing clinical studies on the efficacy of CDK4 
and CDK6 inhibitors in cSCC (Kalu and Johnson, 2017). 
Significant efficacy was observed with SNS-032, a novel inhibitor of CDKs 2, 7, 9, and to a 
lesser extent CDKs 1 and 4 (Bose et al., 2013). This compound is currently still undergoing 
phase I clinical trials for solid tumours and lymphoma following its strong and selective 
inhibitory activity for CDK2 (Chen et al., 2009). The current study is the first to report 
efficacy of SNS-032 against cSCC, the positive results of which support its continued 
investigation. 
Some CDK inhibitors did not vary greatly in drug-response between the cell lines, these 
being: flavopiridol, SNS-032, CHIR-124, and dinaciclib. Variation in drug response up to 28 
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% was observed with CDK inhibitors PHA-793887, PHA-848125, AT75, and AT7519. 
Potency of these inhibitors was greater in UW-CSCC1 than UW-CSCC1-R except in the case 
of PHA-848125 (UW-CSCC1: 53 %; UW-CSCC1-R: 75 %). 
Expression differences for CDK2 and CDK6 between the PDCCs were negligible; whilst 
UW-CSCC1-R appeared to upregulate CDK4. These differences in CDK4 expression did not 
positively correlate with the differences observed in drug response. This is unsurprising given 
the multi-CDK mechanism of action for most of these inhibitors. Furthermore, PHA-848125 
exhibited a great difference in drug response between the PDCCs despite the conserved gene 
expression of its selective target, CDK2. A potential reasoning for this difference may be due 
to the fact that PHA-848125 competes with ATP to bind to CDK2; and given the enhanced 
proliferation rate and metabolic activity of UW-CSCC1-R, there may be less intracellular 
ATP available to compete with the drug, thereby resulting in a greater drug-response. 
In summary, many CDK inhibitors were potent against metastatic cSCC cell lines, although 
some displayed a great degree of variation in drug response whilst others had no effect. This 
range in response is perplexing given the general multi-CDK selectivity of the CDK inhibitors 
as well as the conserved gene expression of CDK2 and CDK6. It has been suggested that 
benefits of CDK inhibitors will be achieved through combination with immunotherapy or 
low-dose chemotherapy (Kumar et al., 2015; Kalu and Johnson, 2017). Moving forward, 
dinaciclib is a strong candidate therapeutic for cSCC given the efficacy revealed here, its 
tolerability over other CDK inhibitors, as well as the fact that it is in phase III clinical trials 
for other cancers. Flavopiridol was not considered for secondary screening despite its strong 
potency as more targeted therapies were sought. 
5.4.1.3 PI3K/AKT/mTOR inhibitors 
Activating mutations have been shown in cSCC for signalling pathways involving 
PI3K/AKT/mTOR (Li et al., 2015; Harwood et al., 2016; Ashford et al., 2017; Janus et al., 
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2017), and the upregulation of gene expression (namely MET, SRC, and EGFR) relating to 
these pathways is noted in Chapter 4. PIK3CA in particular has been observed to frequently 
carry activating mutations in metastatic cSCC samples (Li et al., 2015; Janus et al., 2017). 
In UW-CSCC1, UW-CSCC1-R, and their originating tumour, six single nucleotide 
polymorphisms were identified in PI3KCA, however these were intronic, non-coding, and 
carried a low impact. Nonetheless, copy number gain was evident within these samples 
compared to the germline, with total copy number being five for UW-CSCC1/-R and four for 
the tumour. 
On an expression level, PIK3CA was overexpressed in all cSCC clinical samples and cell 
lines tested relative to normal skin. Pre-clinical results and small clinical trials have shown 
great promise with inhibitors specific to these pathways (Massacesi et al., 2016), although 
none of these inhibitors are under clinical trial specifically for cSCC, metastatic or otherwise 
(Harwood et al., 2016; Janus et al., 2017). PI3K/AKT/mTOR targeting compounds found to 
be potent against the cell lines are summarised in Table 5.4 below. 
Table 5.4 Efficacy of PI3K/AKT/mTOR targeting compounds towards the novel PDCCs. Percentage 
inhibition is shown along with the specific target(s). 
 Compound 
 % inhibition 
UW-CSCC1 
 % inhibition 
UW-CSCC1-R 
Target 
BGT226 (NVP-BGT226) 97.6 97.8 mTOR/PI3K 
PIK-75 97.0 97.6 PI3K 
CUDC-907 94.8 95.2 HDAC/PI3K 
Torin 2 89.9 93.6 mTOR 
GSK2126458 (Omipalisib) 80.8 80.5 mTOR/PI3K 
VE-822 77.2 97.4 ATM/ATR 
INK 128 (Sapanisertib) 73.5 67.1 mTOR 
AZD8055 72.2 65.1 mTOR 
GSK1059615 64.3 67.6 mTOR/PI3K 
PF-04691502 61.0 58.3 Akt/mTOR/PI3K 
WYE-125132 (WYE-132) 56.8 52.7 mTOR 
Dorsomorphin 43.3 53.9 AMPK 
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BGT226 was particularly potent and is currently in phase I/II clinical trials for treatment of 
advanced solid tumours including head and neck squamous cell carcinoma (Simioni et al., 
2015). PIK-75 was also quite potent against the cell lines. The selective target of PIK-75 is 
p110α, the catalytic subunit of PI3K, which is encoded by the frequently activated and 
overexpressed PIK3CA. Due to this, PIK-75 efficacy was further assessed in a dose-response 
cytotoxic assay, discussed further in section 5.4.2.5. The current study appears to be the first 
to demonstrate the in vitro efficacy of many of these inhibitors (inclusive of the highly 
efficacious BGT226, PIK-75, and CUDC-907) against cSCC. 
The range of responses to PI3K inhibitors may relate to the fact that there are eight distinct 
PI3K isoforms that exist and each inhibitor may be targeting a specific isoform (Janus et al., 
2017). The PI3K/AKT targeting compounds GDC-0941 (pictilisib) and GSK690693 were 
found to exhibit a very mild effect (data not shown) upon PDCC metabolic inhibition. The 
Genomics of Drug Sensitivity in Cancer database (https://www.cancerrxgene.org/) revealed 
that the potency of these compounds to other cancers is dependent upon the presence of 
activating mutations in PIK3CA. Therefore, the absence of such a mutation in the cSCC cell 
lines may explain the low potency. This further highlights the power of molecular data as 
predictors of drug response. A novel PI3K-mTOR dual inhibitor (GDC-0084) has recently 
been reported by Ding et al., (2018) to inhibit primary cSCC cell growth both in vitro and in 
vivo (tumour xenograft assay). PI3K/AKT/mTOR inhibitors such as those mentioned are 
clearly a step in the right direction for treating cSCC. 
5.4.1.4 Matrix metalloproteinase inhibitors 
The HTS consisted of only one compound that explicitly targeted MMPs, SB-3CT. This drug 
is an effective and selective gelatinase inhibitor, targeting MMP-2 and MMP-9. In the current 
study SB-3CT inhibited only ~10 % of metabolic activity at 1 µM. This is not entirely 
surprising given that the expected effect of this compound is to inhibit invasion, rather than to 
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elicit a cytotoxic response. This compound should be further assessed in a migration assay 
with the novel cSCC PDCCs. 
SB-3CT has been observed in murine models to reduce liver metastasis of T-cell lymphoma 
and bone metastasis of prostate cancer (Kruger et al., 2005; Bonfil et al., 2006). MMP 
inhibitors (specifically SB-3CT) were selected by Bonfil et al., (2006) on the rationale that 
MMP-2 and MMP-9 have been associated with prostate cancer metastasis. Similarly, success 
may be found in reducing cSCC metastasis with MMP inhibitors due to the role of MMPs in 
cSCC uncovered in Chapter 4 and elsewhere (Kerkelä and Saarialho-Kere, 2003; Prasad et 
al., 2014). Other MMP inhibitors such as nobiletin, marimastat, batimastat, and ilomastat 
should be investigated in future drug screens/migration assays due to their broader MMP-
targeting spectrum. Unfortunately, phase III clinical trials using MMPs including marimastat 
and batimastat against advanced cancers have been disappointing (Kerkelä and Saarialho-
Kere, 2003). This was possibly due to the fact that MMPs are most influential during the early 
stages of tumour progression and therefore may not be useful as therapy in the metastatic 
setting. Benefit may instead be seen with patients with early stage tumours. Perhaps patient 
selection for MMP inhibiting therapy could be determined on the basis of MMP expression in 
the primary tumour. 
Whilst MMPs may be promising targets for cSCC therapy, MMP inhibitors have largely 
failed clinical trials due to toxicity and negligible clinical outcomes (Roy et al., 2009; 
Nissinen et al., 2016; Radisky et al., 2017). Poor efficacy of MMP inhibitors may be linked to 
their inhibition of cancer-protective MMPs (e.g. MMP-8). However, highly selective 
inhibitors could resolve these issues, such as that of disulfiram which inhibits MMP-2 and 
MMP-9 specifically (Shian et al., 2003; Cho et al., 2007; Roy et al., 2009). 
Disulfiram was included in the HTS and demonstrated a remarkable potency (~92 % 
inhibition) against the PDCCs. This compound is conventionally used to treat alcoholism, but 
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has shown anti-cancer properties through inhibition of MMP activity via chelation (Wiggins 
et al., 2015) as well as inhibition of transcription factor/cyclic-AMP-responsive element 
binding protein activity (Cho et al., 2007). Ixazomib (MLN9708) and bortezomib, both 20S 
proteasome inhibitors, were also extremely potent against both cell lines. These compounds 
may be worthy candidates for further investigation against invading cSCC in 
migration/invasion assays. 
5.4.1.5 BRAF & MEK inhibitors 
Compounds targeting MAPK signalling were generally ineffective at inhibiting cell viability 
for either of the PDCCs. Vermurafenib (zelboraf) displayed no inhibition against either cell 
line. This compound is a novel and potent BRAF inhibitor with an IC50 of 31 nM in cell-free 
assays. It is currently approved for use as a monotherapy to treat late-stage metastatic 
melanoma in patients possessing the common V600E mutation (Bollag et al., 2012). 
Paradoxically, vermurafenib and other BRAF or broad-spectrum kinase inhibitors have been 
shown elsewhere to instigate the manifestation of primary cSCC lesions in patients receiving 
systemic therapy (Arnault et al., 2009; South et al., 2014). Another specific inhibitor of 
BRAFV600E, dabrafenib, also displayed low potency against UW-CSCC1 (3.82 %) and UW-
CSCC1-R (0 %). Upon interrogation of WGS data for the cell lines and the originating 
tumour, no significant mutations were found in either BRAF or MAP2K (MEK). This 
information paired with the results of the drug screen inform against the use of vermurafenib 
and dabrafenib in treating this patient’s cancer, and potentially other metastatic cSCC. 
Additional RAF/MEK inhibitors included in the panel showing little efficacy were: 
RO5126766 (phase I), AZ628, GDC-0879, and SB590885.  
Contrastingly, trametinib displayed 63.1 % and 46.4 % inhibition against UW-CSCC1 and 
UW-CSCC1-R respectively. This compound is a MEK inhibitor that has been shown to 
effectively treat metastatic melanoma carrying the V600E mutation in BRAF. Trametinib is 
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may be used in conjunction with dabrafenib to overcome resistance to BRAF inhibitors. 
Despite no mutations identified in either BRAF or MAP2K for the tested PDCCs, trametinib 
was mildly effective, suggesting a potential off target effect. 
It should be noted that compounds targeting downstream of Ras should be investigated in 
combination with inhibitors of PI3K, EGFR, SRC, MET, or mTOR to alleviate compensatory 
increases in PI3K-AKT signalling (Harwood et al., 2016). 
5.4.1.6  Cell cycle checkpoint inhibitors 
MK-8776 and LY2603618 (rabusertib) demonstrated markedly increased potencies against 
UW-CSCC1-R than UW-CSCC1. These compounds are cell cycle checkpoint inhibitors 
specific to CHK1 (Le et al., 2015). It is theorised that upon irradiation of UW-CSCC1, CHK1 
has become activated to allow the cancer cells to repair the damaged DNA. Constitutive 
activation of CHK1 may be necessary in UW-CSCC1-R to manage the heavily mutated 
genome and enable tumour growth (Zhang and Hunter, 2014). Therefore, inhibition of CHK1 
may make UW-CSCC1-R more susceptible to replicating defunct DNA, resulting in cell 
death (Zhang and Hunter, 2014). However, no notable differences in CHK1 expression 
between the cell lines were evident within the NanoString analyses, yet the DNA damage 
repair pathway was shown to be upregulated in UW-CSCC1-R (Chapter 3, section 3.3.2.2). 
 Events governing activation and phosphorylation as well as post-translational modifications 
of CHK1 in either cell line should be investigated in future efforts to elucidate the cause of 
such differences in drug-response. Oddly, other CHK1 inhibitors included in the libraries 
(AZD7762 and PF-477736) had no appreciable difference in potency between the cell lines. 
In general, checkpoint inhibitors do not seem to be ideal candidates for treating cSCC, 
although use in cases of prior irradiation may be worth considering. 
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5.4.1.7 Tyrosine kinase inhibitors (TKIs) 
5.4.1.7.1 Proto-oncogene c-SRC 
In the previous chapter the role of SRC as a potential biomarker and/or drug target was 
discussed. By virtue of the size of the screening library, six SRC inhibitors were evaluated at 
1 µM: ponatinib, saracatinib, dasatinib, KX2-391, DCC-2036 (rebastinib), and bosutinib. 
DCC-2036 and bosutinib had only a small effect upon cell viability. Saracatinib and dasatinib 
exhibited a mild potency against both cell lines (~30 – 45 % inhibition). One other study to 
date (Farshchian et al., 2017) has assessed the efficacy of dasatinib in the treatment of cSCC. 
Similar to the current study, their metastatic cell lines UT-SCC7 and UT-SCC59A displayed 
inhibition of ~30 – 40 % with 1 µM dasatinib. Dasatinib is in clinical trial for unresectable or 
metastatic cSCC (Harwood et al., 2016) and should be investigated further, perhaps as part of 
a combinatorial regiment. 
Ponatinib had a large difference in response between UW-CSCC1 and UW-CSCC1-R, 
demonstrating 42 % and 6 % inhibition, respectively. These differences in drug response did 
not correlate with differences in SRC expression. 
KX2-391 produced an extremely potent response of 87 – 91 % inhibition across the cell lines. 
KX2-391 is the first clinical SRC inhibitor (peptidomimetic class) that targets the peptide 
substrate site of SRC. In pre-clinical animal models of cancer, orally administered KX2-391 
has shown to inhibit primary tumour growth and to suppress metastasis (Fallah-Tafti et al., 
2011). KX2-391 is currently in phase II clinical trials for several malignancies 
(NCT03285477, NCT00658970) and may offer a therapeutic avenue for patients with high 
risk cSCC, given the association between gene expression of SRC and disease progression 
(Chapter 4). SRC targeting therapies may be favourable as SRC is upstream of PI3K-AKT, 
MAPK, FAK, and STAT3 signalling (Zimmer and S Steeg, 2014), as depicted in Figure 5.16. 
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Figure 5.16 Overview of the effects of SRC activation. 
5.4.1.7.2 EGFR TKIs 
EGFR has been implicated as a strong therapeutic target in advanced cSCC (Gaffney et al., 
2014).  However, none of the Therapeutic Goods Administration (TGA) approved anti-EGFR 
TKIs were able to inhibit cell growth by more than 10 % in this experiment, despite purported 
low nanomolar potency. Admittedly, EGFR was not as abundant in expression in the cell lines 
as in their clinical counterpart, and therefore may contribute to the reduced effect seen here. 
However, response to EGFR inhibitors does not always depend on expression status, with 
reports of objective response rates in patients with EGFR-undetectable tumour types having 
been reported (Alter et al., 2013; Gaffney et al., 2014; Kim, 2014).  This is due to differences 
in drug bypass signalling as well as genetic variations of drug target (Zhang et al., 2012). Due 
to bypass signalling in samples with mutant RAS, anti-EGFR biologics are only effective in 
those samples without the mutation. However, both the cell lines and originating tumour 
tested carried wild-type RAS; therefore this does not explain the results. 
Silva-Oliveira et al., (2017) observed that inhibition of the AKT pathway can overcome 
resistance to anti-EGFR TKIs. As mentioned in Chapter 4 (section 4.4.5.3), profiling of 
EGFR pathway bypass genes may facilitate better predictions of response to EGFR targeted 
therapies than those focusing solely on EGFR expression (Zhang et al., 2012). 
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A response was observed for at least one EGFR targeting compound, pelitinib. This 
compound is a potent, irreversible, and selective inhibitor of EGFR under development and 
was found to produce a noteworthy response of > 50 % inhibition for both cell lines. An 
advantage of pelitinib over other EGFR inhibitors is its oral bioavailability as opposed to the 
intravenous administration required by antibody-targeted EGFR inhibitors (Yoshimura et al., 
2006). Additionally, pelitinib binds irreversibly compared to other reversible EGFR 
inhibitors, thus conferring a prolonged effect against the target. 
Given the response seen with pelitinib, it is not theorised that the reduced expression of EGFR 
in the cell lines is the cause for poor inhibition with other EGFR inhibitors, but rather that 
downstream signalling may still be activated through alternative pathways such as c-MET 
activation. It is now realised that despite targeting the same functional molecule, EGFR-TKIs 
work via different mechanisms (Gaffney et al., 2014). For example, pelitinib is also capable 
of inhibiting Erb2, SRC, CDK4, c-MET, Raf, and MEK/ERK, effecting potential EGFR 
bypass signalling and thus explaining the efficacy of pelitinib over other EGFR-TKIs. 
Beyond pelitinib, it appears that anti-EGFR inhibitors are mostly ineffective as single-agent 
therapies for the metastatic cSCC cell models. Greater success may be seen in combination 
with compounds that target EGFR-bypass mechanisms (Harwood et al., 2016). 
5.4.2 Two-dimensional dose-response screening 
Dose-response screening was performed on several compounds, many of which are clinically 
relevant to cSCC. This was done to ascertain IC50 values which are necessary to compare the 
potencies of these drugs between cSCC and other cancers. These results also validate the 
sensitivity of the cell lines towards these compounds, thereby qualifying their continued 
investigation as candidate therapeutics for metastatic cSCC. Many of these chemotherapeutics 
remain systemically delivered and are met with toxic side effects; however, their use should 
still be considered in the absence of validated targeted therapy or in cases of resistance. 
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5.4.2.1 Microtubule targeting agents 
Of the microtubule targeting agents, docetaxel was shown to be more potent than paclitaxel 
against UW-CSCC1. A similar trend was observed with HNSCC datasets. This aligns with 
previous reports of docetaxel being at least twice as potent as paclitaxel due to a higher 
affinity to microtubules (Verweij et al., 1994). Both compounds were also present in the HTS 
and demonstrated remarkable potency at 1 µM, which is not surprising given the extremely 
low nanomolar potency demonstrated here. Docetaxel requires further investigation with UW-
CSCC1 at a diluted concentration to elucidate a reliable IC50 value. Nonetheless, these drugs 
appear very potent against cSCC cell models and their use should be considered for systemic 
therapy in the absence of targeted therapy. 
5.4.2.2 Topoisomerase inhibitors and anthracyclines 
Etoposide, a topoisomerase II inhibitor demonstrated an IC50 of 0.098 µM in the dose-
response assay, yet in the HTS assay it demonstrated only ~23 % inhibition despite a 
significantly greater concentration of 1 µM. The geometric mean IC50 of etoposide against 
HNSCC (taken from www.cancerrxgene.org) was 4.28 µM. Whilst these are different 
diseases, this is suggestive that the HTS results may be more accurate than the dose-response 
data. Potential reasons for this variation may stem from the fact that the stocks of etoposide 
used in the dose-response assay were leftover solutions provided by a cancer clinic. As such, 
the etoposide present in the solution may have degraded prior to use in the assay. However, 
this would explain the results only in the case that potency decreased in the dose-response 
assay, not increase as it did. Etoposide is poorly soluble in water and has a limited stability in 
solution; therefore it is often resuspended in a solution containing Tween, polyethylene 
glycol, benzyl alcohol, anhydrous citric acid and absolute alcohol (Slevin, 1991). It is 
therefore possible that these additional chemicals (particularly the ethanol) present in the 
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clinical supply have contributed towards cell death. Further testing may be necessary to 
confirm the results with fresh, research grade etoposide. 
The anthracyclines doxorubicin and mitoxantrone demonstrated extreme potencies which are 
supported by the similarly high potencies in the HTS assay at 1 µM. Mitoxantrone should be 
considered preferentially over doxorubicin given its greater potency against cSCC here as 
well as its improved tolerability than doxorubicin noted in the clinic (Evison et al., 2016).  
5.4.2.3 Antimetabolites 
The antimetabolites tested varied considerably in their IC50 values. Gemcitabine was 
extremely potent against UW-CSCC1 and requires further dilution to elucidate IC50 values. 
The response to gemcitabine was similarly observed in the HTS screen at 1 µM. 5-
fluororuacil demonstrated a potency in the low micromolar range, similar to those 
documented for HNSCC. Whilst both are pyrimidine antagonists, gemcitabine and 5-FU have 
different mechanisms of action and therefore the combination of these drugs could 
theoretically result in a higher activity. This has been seen for pancreatic cancer (Cascinu et 
al., 1999; Gennatas et al., 2006; Heinemann et al., 2008) whilst others have suggested no 
added benefit to the combination of gemcitabine with other cytotoxins (Sohn et al., 2015). 
Nonetheless, such a regimen may facilitate greater response rates in cSCC. 
Pemetrexed was a more potent folate inhibitor compared to methotrexate. These folate 
antagonists operate by inhibiting folate-dependent enzymes necessary for cancer cell growth. 
Clinically, high doses of methotrexate are required to facilitate diffusion of the drug into the 
core of solid tumour where carrier mediated transport might be compromised (Visentin et al., 
2012). To protect the patient from the systemic toxicity of these high doses, they must receive 
subsequent administration of leucovorin. Given the greater effect of pemetrexed observed 
here, as well as the fact that tumours can develop resistance to methotrexate (Visentin et al., 
2012), future studies should perhaps focus on pemetrexed over methotrexate. 
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5.4.2.4 Alkylating agents and platinum analogues 
The alkylating agents mitomycin-c and cyclophosphamide demonstrated a large difference in 
their potencies, although neither were particularly potent inhibitors. Mitomycin-c is well 
known to produce severe side effects (Verweij and Pinedo, 1990) and has been superseded by 
other therapeutics for the treatment of most cancers. 
The low potency of cyclophosphamide is reflective of its historical use as part of a 
polychemotherapeutic approach over monotherapy. Of note, cyclophosphamide only becomes 
activated once processed in the liver, hence in vitro studies may not be indicative of clinical 
response if this activation has not occurred. In future, research grade stocks of the active 
metabolites of cyclophosphamide should be used to investigate efficacy against cSCC rather 
than remaining clinical reserves. However, the alkylating agents produced underwhelming 
potencies in general and may not be ideal candidates for treating cSCC. 
Whilst the platinum analogues also exhibited potencies in the high micromolar range they 
may be useful therapeutics for cSCC as radiosensitisers or in combination therapy. Nakamura 
et al., (2013) reported the synergistic effect of platinum analogues with anthracyclines against 
advanced cSCC. Carboplatin produces fewer toxic side effects than cisplatin (Adams et al., 
1989) and is preferentially used to manage cSCC. The high proton number of the platinum 
molecules enables directing of x-rays towards the tumour, sparing healthy tissue. The synergy 
of carboplatin with x-rays against cSCC is elaborated upon in Chapter 6. 
5.4.2.5 Targeted therapies 
IC50 values were not able to be determined for either of the monoclonal antibodies cetuximab 
or panitumumab as no response was apparent at the tested concentrations. These compounds 
specifically bind to the EGFR receptor, blocking signalling for downstream processes. It is 
possible no effect was observed as EGFR was downregulated in the cell line compared to the 
clinical specimens; thereby other processes were responsible for cancer cell survival and 
 239 
 
therapies specific to EGFR would have no effect, as was seen with the EGFR-TKIs. Other 
possibilities include inadequate concentration of drug tested or the short-term MTS assay 
being an inappropriate assay to test such a drug. Testing at higher concentrations or in the 
form of an organotypic assay may yield more informative results on the use of these therapies 
in metastatic cSCC. Tumours harbouring PIK3CA amplifications and mutations have shown 
association with cetuximab resistance and therefore may benefit from PI3K inhibitors such as 
PIK-75 (Massacesi et al., 2016). Future efforts should combine these anti-EGFR therapies 
with those blocking bypass signalling such as c-MET or PI3K inhibitors.  
PIK-75 was revealed to be a potent inhibitor against cSCC in the HTS screen and its 
nanomolar potency determined in the dose-response screen. Given the potency of PIK-75 
elucidated here against cell lines that do not even bear the PIK3CA activating mutations, this 
may be a very attractive drug to consider for aggressive/metastatic cSCC. 
The c-MET inhibitor AMG337 was investigated here as a monotherapy but produced no 
effect on UW-CSCC1, UW-CSCC1-R, or UW-CSCC2 metabolic activity. In contrast, 
AMG337 has shown to inhibit proliferation in MET-dependent cell lines by Hughes et al., 
(2016). These data suggest that EGFR and MET are compensatory for one another through 
downstream signalling (Figure 5.17). PI3K signalling feeds into many cancer pathways, 
therefore inhibition of this complex alone by PIK-75 is still capable of reducing overall cell 
viability. A comprehensive treatment plan for metastatic cSCC using the inhibitors shown in 
Figure 5.17 may result in an enhanced response. The influence of each inhibitor will be 
affected by the abundance of the target which can vary between patients. As such, precise 
combinations of these inhibitors may need to be determined based on target expression. Anti-
HGF/anti-MET monoclonal antibodies are still undergoing clinical development (Lee et al., 
2015). The specificity of targeted therapy is particularly advantageous in this disease as it can 
help reduce tumour burden surrounding at-risk structures. 
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Figure 5.17 Crosstalk of HGF-MET and EGF-EGFR signalling pathways. Key points of signal inhibition 
are shown along with suggested inhibitors. Blocking of EGFR signalling is compensated through a MET 
signalling cascade activating both PI3K and RAS. Similarly, inhibition of MET signalling is bypassed via 
activation of PI3K by EGFR signalling. 
5.4.3 Three-dimensional therapeutic screening 
For unknown reasons, the assay used to determine spheroid cell viability produced 
inconclusive results despite morphological differences in spheroid integrity. The concept of 
resistance is unlikely given the extreme potency of gemcitabine in the 2D assays as well as 
the morphological changes in the spheroid. Subsequently, calcein AM/PI staining was used to 
differentiate the live:dead cells following treatment. This proved successful in the attempts 
made by Miss Gretel Major and should be used in future experiments with these PDCCs. 
These above-mentioned difficulties are a testament to the problems experienced with scaling 
3D assays into high-throughput formats. Thankfully, advancements are being constantly made 
to increase the compatibility of spheroids with high-throughput screening. For example, 
multiparametric scoring systems have been developed with 3D imaging systems (Kessel et 
al., 2016; Cribbes et al., 2017) and 384-well 3D collagen cell systems (Leung et al., 2015). 
The organotypic invasion assays revealed that agents targeting the uPA system may be 
effective in controlling cSCC cell invasion. Notably, PAI-2 selectively reduced cSCC cell 
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invasion whilst the in-house anti-uPA/NHE1 amiloride derivatives produced less of an effect. 
This system is highly useful for demonstrating the clinical utility of non-cytotoxic 
therapeutics in controlling disease progression. Inhibiting invasion may be most important in 
the primary context rather than metastatic (as it has already spread), therefore targeting 
components of the uPA system may be well suited for patients identified as high risk and/or 
high expressers of uPA/R. 
5.4.4 Effect of exogenous uPA and EGF on cell migration 
An excess of exogenous uPA did not increase random cell migration as measured in a wound-
healing assay despite the purported effects (Chandrasekar et al., 2003; Hildenbrand et al., 
2008). It is perhaps unsurprising that no significant change in random migration was noted as 
uPA specifically effects directed migration through degraded ECM. As the ECM was not 
mimicked in this particular scratch-wound assay, any migration is considered random and 
therefore does not necessarily confirm the specific migratory influence of uPA. Treatment of 
organotypics that mimic the ECM with uPA is therefore more likely to confer meaningful 
data on the influence of uPA on cell migration/invasion. Conversely, a significant influence 
upon random cell migration was observed with EGF, suggesting that inhibition of the 
associated pathway may be efficacious as a therapy. 
5.4.5 Conclusions and future directions 
In summary, the provision of the novel cell lines enabled the first ever HTS of metastatic 
cSCC, revealing a multitude of efficacious and inefficacious compounds. Across two 
screening libraries, the most potent compounds were found to be those targeting cytoskeletal 
signalling, DNA damage response, PI3K/AKT/mTOR signalling, and regulators of the cell 
cycle. Contrastingly, compounds targeting MAPK and JAK/STAT were mostly ineffective. 
EGFR-TKIs produced only a moderate response, yet anti-EGFR therapies are one of the few 
chemotherapeutics prescribed to patients with advanced cSCC. Together, both expression data 
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and drug-response data imply EGFR and MET signalling are compensatory in cSCC. As 
such, combination therapy is necessary to block potential bypass signalling. Compounds 
targeting the CDKs (especially dinaciclib) and components of PI3K/AKT/mTOR were 
particularly efficacious, owed to the fact that these proteins are regulatory bottlenecks. 
Therefore, the inhibition of these can have a widespread effect. Nonetheless, larger sample 
sizes of cell lines are necessary to capture responder subsets and confirm these observations. 
Oncogenic addiction postulates that whilst cancers may arise due to a multitude of genetic 
mutations, tumours may ultimately rely only on a select few genes for continued growth and 
survival (Torti and Trusolino, 2011). The tumours are, in essence, ‘addicted’ to these 
oncogenes. The dramatic effect seen with PI3K/AKT/mTOR targeting compounds adds 
credence to this theory, suggesting the PI3K pathway as the ‘Achilles heel’ of metastatic 
cSCC. Small interfering RNAs are one way in which PI3K ‘addiction’ could be determined, 
thus supporting PI3K targets as a therapeutic option. A major problem however is the bypass 
mechanisms by which a tumour may initiate when targeted with a therapeutic specific to the 
pathway in question. This can arise due to the genomic instability of cancers, allowing them 
to escape from one state of oncogenic addiction to another. Intra-tumour heterogeneity also 
plays a role as subpopulations of a tumour may have different genes to which they are 
‘addicted’ to. Weinstein and Joe, (2008) therefore recommend combination therapy to still be 
required. Pagliarini et al., (2015) found that in prostate cancer, a cycle exists whereby 
inhibition of oncogenic PI3K or AR activation results in feedback upregulation of the other. 
Similarly, Saito et al., (2019) found that targeting NOTCH in glioblastoma transfers the 
oncogene addiction from the NOTCH pathway to the PI3K pathway. These findings are 
relevant to our own study due to the role PI3K appears to play and the observed compensatory 
signalling provided by growth factors that feed into the PI3K pathway. This knowledge of 
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feedback pathways may aid in the rational development of therapeutic combinations to 
conquer resistance.  
The results observed with UW-CSCC1-R suggest that the physiological changes incurred via 
irradiation of UW-CSCC1 have led to varying degrees of changes in drug sensitivity and 
resistance. This would imply that those with recurrent disease following radiotherapy should 
not simply have treatment determined on the basis of primary tumour pathology. 
Dose-response screening of many clinically used chemotherapeutics was performed and 
mostly validated their continued or future use against cSCC. Alkylating agents (particularly 
cyclophosphamide) and platinum analogues were found to require high concentrations to 
achieve metabolic inhibition, and therefore may serve better as part of a combined regimen 
with other chemotherapeutics and/or radiotherapy. Many of these drugs are systemically 
delivered, have varying rates of success, and produce toxic side effects in comparison to more 
targeted therapies. The EGFR targeting cetuximab and panitumumab along with the MET 
inhibitor AMG337 produced no dose-response at the tested concentrations, likely due to 
compensatory. PIK-75 was extremely potent and should be investigated further as either a 
monotherapy or as part of a combination involving anti-EGFR and anti-MET inhibitors. 
Inhibitors of PI3K/AKT/mTOR in general may prove to be worthy therapeutics for cSCC 
(Hafner et al., 2010). 
Menyhárt et al., (2016) stressed that functional assays should be selected based on the 
hallmark of cancer being investigated. Organotypics were therefore deemed more relevant to 
study drugs targeting the hallmark of ‘activating invasion and metastasis’. The organotypic 
assays provided a physiologically relevant model of dermal invasion by cSCC, revealing 
potential benefit in using anti-uPAS agents to mediate ECM degradation. More work is 
required to determine the ideal concentration of anti-uPAS agent necessary to produce 
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maximal inhibition of invasion. Combination treatment or monotherapy with MMP inhibitors 
should also be evaluated in this model system. 
Moving forward, much more work is needed to evaluate other hit compounds from the HTS 
in the form of a dose-response assay, both in 2D and 3D formats. Optimisation of 3D drug 
screening by Miss Gretel Major (Appendix L) has made such analyses possible and was 
necessary to progress candidate drugs further in pre-clinical work. Co-culture experiments 
with tumour microenvironment components in vitro may also prove to further these findings 
and provide more reliable pre-clinical results. A limitation of MTS assays is that they cannot 
discriminate between a reduction in metabolic or proliferative activity per cell and a reduced 
number of cells (Freshney, 2010). Therefore, any noteworthy observations should be 
confirmed through additional means such as live cell imaging or clonogenic survival assays. 
Further work should also be conducted to better correlate drug response with gene expression 
data. These results are of course limited to a handful of cell lines. Given the significant 
variability in the mutational landscape of cSCC (Hanna et al., 2016) and no predominant 
defect (unlike hedgehog in BCC or BRAF in melanoma), optimal molecular therapy for cSCC 
may need to be tailor-made to the individual. Whilst this experiment compared drug responses 
against only two cell lines (except for PIK-75 and AMG337 dose-response screens), these 
provide the first account of HTS on metastatic cSCC. Continued cell line generation and drug 
response analysis will allow for greater statistical power, capturing responder subsets and 
highlighting the benefit of incorporating molecular data with drug response profiling.  
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CHAPTER 6: EFFICACY OF COMBINATION CHEMO-
RADIOTHERAPY AGAINST CSCC (IN VITRO) 
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6.1 INTRODUCTION 
Radical surgery is currently the gold-standard for treatment of metastatic cSCC, usually 
paired with adjuvant radiotherapy (Cañueto et al., 2018). Radiotherapy operates by 
interrogating tumours with ionised external beam radiation, which in turn damages DNA 
preferentially in rapidly dividing cells. In developed countries, radiation is used to treat half of 
all cancer patients (Baskar et al., 2012). The total dose of radiation is delivered in a 
fractionated schedule to amplify the survival advantage of normal tissue over cancerous cells, 
due in part to the better sublethal damage repair of radiation damage in normal cells. 
Radiation to the undissected neck for metastatic cSCC is generally given as a total of 50 Gy 
over 25 fractions, equating to 2 Gy per fraction (Harwood et al., 2016). As the damaging 
effects of radiotherapy are experienced during the proliferative phase of the cell cycle, 
fractionation ensures all cells within the tumour are irradiated at some point during their 
proliferative stage. However, radiotherapy is not infallible as has been observed through 
varied response rates and the abundance of recurrence (Pearce et al., 2001). The tumours of 
those patients experiencing local recurrence following radiotherapy are generally more 
aggressive and resistant to further treatment. This would suggest that a population of cancer 
cells survived the irradiation process (through various biological mechanisms) and may have 
acquired (or innately possessed) genetic/epigenetic alterations that contributed to a more 
aggressive phenotype. This was observed with UW-CSCC1-R relative to UW-CSCC1 in the 
previous chapters. 
Chemotherapy may be prescribed as an adjuvant systemic therapy or to assist in radio-
sensitisation of cancer cells. Platinum-based therapeutics such as cisplatin or carboplatin has 
been traditionally used as chemoradiosensitising agents (Cranmer et al., 2010; Samstein et al., 
2014). The use of combined chemo-radiotherapy in the context of metastatic cSCC has little 
empirical data regarding candidate drugs and their efficacy in combination with radiation to 
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reduce tumour burden. As a result, patients may be receiving taxing treatments in vain, or 
conversely they may be neglected from optimal therapies. 
To prevent damage to healthy tissue, care is taken to deposit the therapeutic dose specifically 
to the tumour (Cañueto et al., 2018). High-Z nanoparticles (E.g. Ta2O5, Tm2O3, Bi2O3) are 
increasingly being studied on other cancer types as they offer the primary benefit of 
enhancing local tumour radio-sensitivity and dose conformity. These compounds are 
biocompatible, capable of permeating the cell membranes due to their small size, and can be 
engineered to target certain tumours (Engels et al., 2018). The dose-enhancement abilities of 
nanoparticles had yet to be tested with cSCC in any capacity prior to the current study. 
A study focusing on the effective combination of radio-sensitisers (chemotherapy and 
nanoparticles) against cSCC is necessary to develop improved techniques that assist clinical 
practice. An increase in x-ray dose-enhancement to the tumour through a combination of 
these radiosensitising agents may negate the adverse side effects observed from scattered x-
rays being delivered to healthy tissue, as detailed in Chapter 1, section 1.5.2 (e.g. damage to 
arteries). If this can be attained, then lower dosages or fractionation of radiotherapy could be 
administered to the patient whilst maintaining a strong response against the cancer. 
Considering this, the overall objective of this chapter was to evaluate the efficacy of platinum-
based chemotherapeutics, nanoparticles, and radiotherapy either as a mono-, doublet-, or 
triplet-therapy against metastatic cSCC cell models. Clonogenic survival assays were used as 
the biological endpoint to determine the efficacy of each therapeutic approach. The influence 
of hypoxia on in vitro clonogenicity was also investigated.  
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6.2 METHODS 
6.2.1  Nanoparticle preparation & cytotoxicity 
Thulium (III) oxide (Tm2O3) nanoparticles (99.9 % trace metals basis) were kindly provided 
by Dr Moeava Tehei and Miss Elette Engels, whom obtained the nanoparticles from Sigma-
Aldrich (USA) in the first instance. Miss Engels prepared the nanoparticle solution by 
crushing the thulium nano-powder sample with mortar and pestle, then sonicating in 
ethanol/water for 40 minutes. Full characterisation of the Nanoparticles was performed by 
Tehei and Engels to confirm nanoparticle size (Engels et al., 2018). Before use, the 
nanoparticles were sonicated using a Bransonic® M ultrasonic bath (Branson Ultrasonics, 
USA) for 30 minutes in PBS to resuspend the particles and the sample was then diluted to a 
final concentration of 5,000 µg/mL. 
Prior to treatment with radiation, cytotoxicity of the nanoparticle to our PDCCs was first 
determined using the CellTiter 96® Aqueous One Solution cell proliferation assay, as per 
other compounds detailed in Chapter 5, section 5.2.3. UW-CSCC1, UW-CSCC1-R, and the 
established breast cancer cell line MDA-MB-231 were treated in this instance with a 
2
3
: 1 
titration of nanoparticle, starting with 500 µg/mL (1.296 nM) and diluted in H2O. Following 
incubation in a hypoxic atmosphere for 72 hours, metabolic inhibition was determined using 
the proliferation assay stated above. The cytotoxicity of carboplatin was similarly investigated 
and is reported upon in Chapter 5, section 5.3.2 and reiterated in section 6.3.1 of this chapter. 
6.2.2  Clonogenic survival assay 
Clonogenic survival, or ‘colony forming’, assays were performed to elucidate the survival and 
proliferation of cells following a given treatment (McDonald et al., 2018). Through this 
method, single colonies representing expansion of a single cell were counted and compared to 
the number of cells that were initially seeded to provide the plating efficiency (PE). For each 
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group, the surviving fraction (SF) was calculated by taking the ratio of the PE of the treated 
cells to the PE of the untreated cells. 
UW-CSCC1 and UW-CSCC1-R were exposed to their respective treatment, and then plated 
in duplicate (at a minimum) onto tissue-culture petri dishes (100 mm x 20 mm Falcon BD; 
Pacific Laboratory Products) in 10 mL of DMEM (10 % FCS/P+S) at a density dependent 
upon the individual experiment. UW-CSCC2 was not investigated in this chapter as it had not 
yet been established during the time of experimentation. After 15 doubling times 
(approximately three weeks for these cell lines), petri dishes were washed with PBS 
(containing Mg2+ and Ca2+) and the cell colonies fixed and stained with a 1:3 (v/v) solution of 
crystal violet:absolute ethanol. The crystal violet solution was derived from a 2.3 % crystal 
violet stock (Sigma-Aldrich, USA). After 10 minutes incubation at room temperature, the 
stain was removed, dishes washed with distilled water, and allowed to air-dry upside down 
overnight. Colonies were manually counted the next day and were only considered if they 
consisted of ≥ 50 cells (Menyhárt et al., 2016). This data was tabulated and interpreted using 
GraphPad Prism v6.0. A one-way ANOVA with Tukey’s multiple comparisons test was 
applied to determine significant changes between treatments. ImageJ v1.51 j8 was initially 
used in an attempt to automate counting of the numerous colonies, although this was forwent 
as the grooves present within the dishes as well as other artefacts caused unreliable counts 
with densely populated dishes, thereby rendering its utility moot. 
6.2.3  Clonogenic survival assay optimisation 
6.2.3.1 Determination of optimal seeding densities 
Initially, the optimal seeding density of UW-CSCC1 and UW-CSCC1-R had to be identified 
for use in this assay in the absence of therapeutics. Seeding number must be adjusted 
depending on the plating efficiency observed following a given treatment. For example, if 
cells were to be seeded at a low density following a treatment that results in a low plating 
 250 
 
efficiency, then resulting colonies (if any) may be too few to provide reliable comparisons. 
Once the optimal seeding density for the control samples was identified, this served as the 
guide for plating controls in subsequent experiments. The influence of a hypoxic atmosphere 
on colony formation was also investigated in comparison to normal atmospheric oxygen 
levels. Cells were pre-acclimated to the given atmospheric condition (as per Chapter 2, 
section 2.2.5.4) and assessed in duplicate as per the clonogenic assay above at five cell 
densities: 1,000, 1,500, 2,500, 3,000, and 3,500 cells/dish. The results of this were presented 
briefly in Chapter 2, section 2.3.4.5. 
Following identification of the baseline seeding density and atmospheric conditions for 
untreated cells, the optimal seeding density in this assay was investigated for cells pre-treated 
with carboplatin as well as that for those treated with radiation alone. For identification of the 
former, UW-CSCC1 and UW-CSCC1-R were pre-treated with 0, 1, or 5 µM of carboplatin 
for 72 hrs (with the 0 µM treatment serving as an additional replicate of the previous control 
experiment). These concentrations of carboplatin were selected as they are well below the 
lethal dosage previously identified (Chapter 5). This was important as identifying the 
chemoradiosensitisation of carboplatin was the aim rather than to achieve cell death through 
cytotoxicity. The carboplatin-treated cells were seeded for the clonogenic assay in duplicate at 
densities of 300, 500, 1,000, and 1,500 cells/dish. Whichever density produced plates with 
neither too many nor too few colonies was determined to be the optimal seeding density for 
that given treatment. 
The optimal seeding density for UW-CSCC1 treated with radiation alone was also determined 
by exposing UW-CSCC1 in 12.5 cm2 flasks to doses of 2 Gy and 5 Gy radiation (method 
described in Chapter 2, section 2.2.4) and subsequent plating at densities of 400, 650, and 900 
cells/dish for 2 Gy treated cells, and 700, 1,400, and 2,100 cells/dish for 5 Gy treated cells. 
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Optimal seeding conditions following exposure to the nanoparticle alone were the same as the 
no-treatment control due to the sublethal concentration used, as determined by the results of 
the cytotoxicity assay (section 6.3.1). 
6.2.3.2 Chemoradiosensition and irradiation 
To assess which modality of therapeutics would provide the greatest degree of cell death, a 
series of conditions were trialled in combination or as a monotherapy. These treatments and 
their respective seeding densities for the clonogenic assay are shown in Table 6.1. Cells were 
first seeded onto 12.5 cm2 flasks at a density of 2.8 × 104 cells/cm2. The following day the 
carboplatin (5 µM final concentration) and and/or Tm2O3 (50 µg/mL final concentration) 
were added to the cells and incubated for 72 hours. Vehicle control (PBS) was similarly added 
to the control flasks. All treatments were performed in triplicate. Due to the length of time 
required to detach, count, and plate the cells, two flasks of controls were prepared. One 
control was the first flask to undergo processing, whilst the other was the last. This allowed 
for comparisons of any cell death overtime to be monitored and factored into analyses. 
Table 6.1 Therapeutic modality performed and seeding density for the clonogenic survival assay. Some 
treatment types were assessed at multiple seeding densities. Carboplatin and Tm2O3 were incubated with the 
cells for 72 hours prior to commencement of the clonogenic assay. 
Treatment Seeding density 
Control start 500 
Control end 500 
2 Gy only 900 
Carboplatin only 800 
Carboplatin + 2 Gy 800/1300/1800 
Carboplatin + 5 Gy 1400/2800/4200 
Tm2O3 only 500/1000 
Tm2O3 + 2 Gy 1000/1800 
Tm2O3 + Carboplatin 800/1300 
Tm2O3 + Carboplatin + 2 Gy 1500/2200 
 
After the incubation period, all flasks were transported to the Department of Radiation 
Oncology, Prince of Wales Hospital for exposure to x-rays as detailed in Chapter 2, section 
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2.2.4. To account for the potentially damaging effects incurred through transport and the 
lengthy departure from an incubator, the control flasks were also transported. The beam 
effective energy was chosen to better target the maximum in mass energy absorption 
coefficient of platinum relative to water (Figure 6.1). 
 
Figure 6.1 The ratio of the mass energy absorption coefficients of platinum to water. This figure was 
generated using XmuDat: Photon attenuation coefficients (v1.0.1) in association with absorption coefficient data 
derived from Boone and Chavez, (1996). 
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6.3 RESULTS 
6.3.1  Therapeutic cytotoxicity 
The cytotoxicity of Tm2O3 and carboplatin towards UW-CSCC1 and UW-CSCC1-R were 
determined through a cell proliferation assay to identify the ideal concentration for use in 
subsequent experiments. The breast cancer cell line MDA-MB-231 was also compared to 
demonstrate the cytotoxicity of these compounds in other cancers. Across all cell lines, 
Tm2O3 had little to no effect upon cell viability at concentrations less than 150 – 200 µg/mL 
(Figure 6.2). Above this concentration, a downward trend in cell viability was evident, with 
the highest concentration tested (500 µg/mL) inhibiting cell viability by approximately 25 %. 
IC50 values were unobtainable as no concentration tested surpassed the 50 % metabolic 
inhibition required for such determination. 
 
 
Figure 6.2 Cell viability in response to Tm2O3. The non-linear regression of cell viability for UW-CSCC1, 
UW-CSCC1-R, and MDA-MB-231 is shown in response to increasing concentrations of Tm2O3 following a 72-
hour incubation with the compound. 
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All cell lines demonstrated a sigmoidal dose-response to carboplatin (Figure 6.3), and the 
average IC50 of the PDCCs determined to be 22.4 µM. 
 
Figure 6.3 Cell viability in response to carboplatin. The non-linear regression of cell viability for UW-
CSCC1, UW-CSCC1-R, and MDA-MB-231 in response to increasing concentrations of carboplatin following 
72-hour incubation with the compound. 
6.3.2  Optimal seeding density/conditions of cSCC PDCCs in clonogenic survival assays 
6.3.2.1 Untreated control seeding density and atmosphere 
A clonogenic survival assay was performed on cultures in the absence of any chemo/radio-
treatment to elucidate the optimal seeding density for control samples in this assay. The 
influence of O2 concentration was also assessed to determine the ideal conditions (normoxic 
vs hypoxic) to encourage colony formation. Resultant colonies were counted and their PE 
determined. As previously presented in Chapter 2 (section 2.3.4.5), the cells seeded and 
grown in the hypoxic atmosphere were observed to produce more colonies than the standard 
atmospheric conditions. The impact of this can be visualised further in Figure 6.4, whereby 
representative images of the resulting stained colonies demonstrate that at both seeding 
densities, more colonies were evident in the hypoxic-treated cultures for both cell lines. 
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Figure 6.4 Crystal violet stained untreated PDCC colonies. The colonies resultant from clonogenic expansion 
of UW-CSCC1 and UW-CSCC1-R single cells cultured in hypoxic and normoxic conditions is shown. 
Representative plates for two of five seeding densities are shown. 
From gross observation of the plate, it is obvious that seeding the cells at 3,500 cells/dish 
resulted in numerous colonies, making counting difficult as some colonies began to merge 
with neighbouring colonies. This is particularly true for UW-CSCC1-R cultured in hypoxia. 
UW-CSCC1-R also produced slightly larger colonies than those of UW-CSCC1, attributable 
to its faster growth rate (Chapter 2, section 2.3.4). Plates with seeding densities of 1,000 
cells/dish in hypoxic conditions contained a reasonable number of colonies, although better 
determinations and ease of counting would be enhanced at a slightly lower seeding density. 
Counts between 150 and 400 are generally manageable and do not overcrowd the plate, nor 
produce too few colonies required for statistical power. A seeding density of approximately 
500 – 750 cells/dish (6.37 – 9.55 cells/cm2) for non-treated cells cultured in hypoxia is 
recommended based on these results, depending on whether UW-CSCC1 or UW-CSCC1-R 
are used. However, this recommendation is refined in the following section due to additional 
data. 
The average PE for the normoxic cultures was calculated to be 14 %, in contrast to the 
hypoxic cultures which displayed an average PE of 36 %. This represents an almost 2.6-fold 
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increase in PE for hypoxic cultures over those cultured in standard atmospheric conditions. 
The average PE for UW-CSCC1 and UW-CSCC1-R in hypoxia was found to be 33 % and 38 
%, respectively. 
6.3.2.2 Carboplatin-treated cell seeding density 
Given the above identification of the optimal seeding density and atmospheric conditions for 
control plates, as well as determinations of carboplatin cytotoxicity against the PDCCs, the 
optimal seeding density in a clonogenic assay for cells pre-treated with carboplatin was 
investigated. These preliminary investigations were not attempted using the nanoparticle 
given its negligible cytotoxicity at the dosage set to be used in subsequent assays, and the 
presumed null effect in general in the absence of radiation. 
Cultures were pre-incubated for 72 hours with sublethal concentrations of carboplatin: 0, 1, 
and 5 µM. The 0 µM treated cultures served as additional replicates of the above control 
samples, however lower plating densities (300, 500, 1,000, and 1,500 cells/dish) were used in 
this instance. Upon using these lower seeding densities, the average PE of control dishes in 
hypoxia was found to be higher (UW-CSCC1: 68 %; UW-CSCC1-R: 86 %) than the previous 
experiment (UW-CSCC1: 33 %; UW-CSCC1-R: 38 %), perhaps attributable to less 
overcrowding allowing for more accurate counts. This notion is supported when the plating 
efficiencies for each seeding density are compared (Figure 6.5), revealing a downward trend 
in plating efficiency as seeding density increased. Differences in PE for equivalent seeding 
densities across the two experiments were unexpected and demonstrate the range of PE 
variation between experiments. To keep in line with achieving between 150 – 400 colonies for 
PE’s from either experiment, control dishes should be seeded with approximately 300 – 500 
cells (3.8 – 6.37 cells/cm2). 
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Figure 6.5 Plating efficiency in response to seeding density for untreated cells. Comparisons are shown for 
UW-CSCC1 and UW-CSCC1-R under hypoxic conditions. Experiment 1 pertains to the results presented in 
section 6.3.2.1, whereas experiment 2 refers to the results of the 0 µM carboplatin experiment. 
Unlike with the control dishes above, changes in the seeding density following exposure to 
carboplatin had no consistent impact upon PE for either culture (Figure 6.6), again likely 
because of the comparatively low and similar seeding densities analysed. 
 
Figure 6.6 Plating efficiency in response to seeding density for carboplatin-treated cells. Comparisons are 
shown for UW-CSCC1 and UW-CSCC1-R treated with 1 or 5 µM of carboplatin under hypoxic conditions. 
Crude examination of the crystal violet stained dishes revealed that a seeding density of only 
300 cells/dish resulted in too few colonies, particularly for those treated with 5 µM 
carboplatin (Figure 6.7). Conversely, at 1,500 cells/dish there were too many colonies (Figure 
6.7). 
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Figure 6.7 Crystal violet stained carboplatin treated PDCC colonies. The colonies resultant from clonogenic 
expansion of UW-CSCC1 and UW-CSCC1-R following treatment with either 1 or 5 µM of carboplatin is shown. 
Representative plates for two of four seeding densities are shown. 
Due to the impact that 5 µM carboplatin had upon PE, and therefore the surviving fraction, it 
would have become difficult in subsequent experiments to elucidate dose-enhancement at 
such low values. This would be particularly challenging once the effects of radiation and/or 
the nanoparticle are accounted for. As such, subsequent experiments utilised a carboplatin 
concentration of 1 µM. In keeping with the 150 – 400 colonies/dish range specified earlier, 
and assuming a PE range of 40 – 60 % with 1 µM carboplatin, a seeding density between 400 
– 1,000 cells/dish (5.1 – 12.74 cells/cm2) should provide reliable counts. 
6.3.3  Therapeutic radio-sensitisation 
As this was a pilot investigation the following experiments were performed using UW-
CSCC1 only. These experiments sought to determine the efficacy of combinatorial therapy 
and at this stage not be conflated with whatever implications prior exposure to radiotherapy 
(as in the case of UW-CSCC1-R) may hold upon response to secondary exposure. The above 
optimisation of UW-CSCC1-R has nonetheless provided a basis for such investigations in the 
future. 
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6.3.3.1 Optimising x-ray dosage 
Whilst repeated doses (fractions) of 2 Gy is the clinical norm for treating cSCC (Harwood et 
al., 2016), the current study exposed UW-CSCC1 to both 2 and 5 Gy radiation. This was 
performed to decipher from clonogenic survival which dosage will provide clearer 
information on dose-enhancement with carboplatin and/or the nanoparticle. At the end of the 
clonogenic assay, the PE of each treatment was normalised to the control to quantify the 
surviving fraction (Figure 6.8). It was found that 2 Gy radiation resulted in a significantly 
lower median surviving fraction of 66 % (P < 0.001), relative to the untreated cells. Exposure 
to 5 Gy radiation resulted in a surviving fraction of 10 %, significantly lower than the control 
as well as 2 Gy-treated cells (P < 0.001). 
 
Figure 6.8 Percentage survival of UW-CSCC1 in response to increasing dosage of radiation. Cells were 
irradiated using kilovoltage radiation under hypoxic conditions (5 % CO2, 3 % O2). Stained colonies were 
counted, plating efficiency determined and normalised to the control to provide a quantification of percentage 
survival. Significance denoted by asterisks: P < 0.001. 
As per the reasons mentioned earlier regarding the response to 5 µM carboplatin (section 
6.3.2.2), 2 Gy radiation was chosen over 5 Gy to better elucidate dose-enhancement with 
either carboplatin and/or the nanoparticle. 
6.3.3.2 Monotherapy vs combination therapy using carboplatin, Tm2O3, and radiation 
Combining the above mentioned optimal seeding densities, drug concentrations, and x-ray 
dosage, the efficacy of each treatment as either monotherapy or combination therapy were 
determined via a clonogenic survival assay under hypoxic conditions (Figure 6.9). It was 
found that single-agent addition of Tm2O3 to the cells produced no significant reduction in 
 260 
 
cell survival as expected. The addition of Tm2O3 with carboplatin resulted in a statistically 
significant reduction in clonogenic survival relative to the control (P < 0.001), although this 
effect would be attributed to the carboplatin only as the identical response was also seen with 
carboplatin alone. Compared to carboplatin alone, 2 Gy of radiation alone produced an even 
further decrease in clonogenic survival (P < 0.01). The combination of carboplatin with 2 Gy 
of radiation produced no additive benefit compared to 2 Gy of radiation alone. Contrastingly, 
the combination of Tm2O3 with 2 Gy of radiation resulted in a very significant reduction in 
clonogenic survival (P < 0.001) compared to treatment with 2 Gy alone. The combination of 
carboplatin with Tm2O3 and 2 Gy of radiation resulted in an even further reduction in 
clonogenic survival compared to any other combination treatment (P < 0.001). These data 
clearly demonstrate the additive benefit of combination therapy and the dose-enhancement 
properties of these chemo-radiosensitisers. 
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Figure 6.9 Percentage survival of UW-CSCC1 following exposure to various treatments. Treatments 
included single or combinatorial treatment of Tm2O3 at 50 µg/mL, carboplatin at 1 µM, and 2 Gy of radiation. 
Surviving fractions were normalised to the control. Significance denoted by asterisks: ns = P > 0.05, * = P ≤ 
0.05, ** = P < 0.01, *** = P < 0.001. 
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6.4 DISCUSSION 
This is the first study to provide empirical in vitro data on the efficacy of radiation therapy 
with high-z nanoparticles for the management of metastatic cSCC. Whilst the clinical efficacy 
of radiotherapy against lymph node metastases of cSCC has been previously determined 
(Wang et al., 2012; Strassen et al., 2017), the advent of the PDCCs in these clonogenic 
survival assays allows for pre-clinical investigations of novel combination therapies, such as 
those tested here. 
6.4.1  Optimisation of treatment dosage and seeding density 
Through the results gathered, the clonogenic survival assay with UW-CSCC1 and UW-
CSCC1-R was optimised, accounting for seeding density, O2 levels, and non-cytotoxic drug 
concentrations. Evaluation of the cytotoxicity of both Tm2O3 and carboplatin towards both 
cell lines allowed for sublethal dosages to be determined, thereby allowing changes in 
survival within the subsequent clonogenic assays to be reflective of dose-enhancement rather 
than inherent cytotoxicity. The ideal number of colonies to count was ultimately determined 
to be between 1.9 – 5.1 colonies/cm2. Plating efficiencies for each treatment were therefore 
used as a reference point for seeding density to achieve the ideal final number of colonies. 
Complementary to the observations presented in Chapter 2 (section 2.3.4), hypoxia enhanced 
plating efficiency as well as colony formation, whilst UW-CSCC1-R also produced larger 
colonies of due to differences in growth rate. The positive influence of hypoxia on clonogenic 
survival was similarly reported by Kim et al., (2018), noting a ~35 % increase in surviving 
fraction compared to that of normoxic cells. Kim et al., (2018) remarked that the ability of 
tumour cells to form single colonies is related to stemness properties and found that hypoxia 
increased CD44 expression. This protein is a putative marker of cancer stemness and mRNA 
expression was similarly found to be upregulated in UW-CSCC1 following hypoxia (Chapter 
3, section 3.3.2). In fact, many hypoxia inducible factor signalling and stem cell associated 
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genes were observed to be upregulated in the hypoxic-treated UW-CSCC1 compared to the 
standard atmospheric O2 levels (Chapter 3, section 3.3.2). 
6.4.2  Combination chemoradiotherapy trumped monotherapy 
Combination therapy generally has a pattern of synergy, resulting in a greater response than 
observed with single-agent alternatives (Veness et al., 2007; Bayat Mokhtari et al., 2017). Of 
the tested combinations, all but two treatments resulted in enhanced cell death over their 
monotherapy counterpart. The addition of carboplatin with Tm2O3 produced no significant 
reduction in clonogenic survival, as expected. As mentioned in the introduction, the role of 
nanoparticles is to enhance x-ray beam delivery to the tumours; therefore no response is 
generally expected in the absence of radiation. Whilst some nanoparticles such as gadolinium 
can be mildly toxic and even exacerbate or create skin lesions (Iordache et al., 2019), the 
MTS assay on Tm2O3 confirmed its non-cytotoxicity at assay-relevant concentrations in vitro.  
Both carboplatin alone and radiation alone produced significant reductions in clonogenic 
survival relative to both the untreated samples and those treated with Tm2O3 alone. The effect 
of 2 Gy of radiation alone was more profound than the carboplatin alone, as expected due to 
the sublethal dose of carboplatin used. 
There was also no statistically significant benefit in the addition of 1 µM carboplatin to 2 Gy 
of radiation. This is surprising considering the routine clinical use of such a regimen to 
patients with advanced cSCC (Pekkola-Heino, 1992; Samstein et al., 2014; Yanagi et al., 
2018). Carboplatin is generally used on the basis that elderly patients (the majority of cSCC 
sufferers) are unlikely to tolerate cisplatin (renal and ototoxicity) due to pre-existing co-
morbidities (Veness and Howle, 2016).  
Very recently, a randomised controlled study (Trans-Tasman Radiation Oncology Group 
05.01 trial; POST study) sought to determine whether the addition of concurrent weekly 
carboplatin to post-operative radiotherapy improved loco-regional control in patients with 
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high-risk cSCC (Veness and Howle, 2016; Porceddu et al., 2018). No benefit was observed 
with the addition of carboplatin in this post-operative setting (Porceddu et al., 2018). 
However, this does not rule out its inclusion as a concurrent treatment modality with neo-
adjuvant radiation therapy to control disease progression prior to surgery. Whilst the 
clonogenic survival assay data similarly suggested no benefit in the combination of 1 µM of 
carboplatin with 2 Gy of radiation, a statistically significant decrease in clonogenic survival 
was noted upon the addition of carboplatin to a Tm2O3 plus 2 Gy radiation treatment. This 
indicates that carboplatin could operate synergistically in such a regimen. 
Even in the absence of carboplatin, a combination of the Tm2O3 with 2 Gy of radiation 
produced far more benefit than any form of monotherapy as well as the combination of 2 Gy 
of radiation with carboplatin. Of course these in vitro findings are simplistic, but nonetheless 
suggest that carboplatin may still hold relevance as part of a chemoradiation management plan 
for advanced cSCC. 
Whilst generally more physiologically relevant (Choi et al., 2014), hypoxic culturing 
conditions may be influencing the radiosensitivity of the cells following exposure to x-rays. 
This may explain why the cell death with 2 Gy radiation only was somewhat underwhelming, 
considering this is the standard of care. Oxygen increases the cytotoxicity of radiation 
substantially, therefore the hypoxic conditions used theoretically conferred a degree of radio-
resistance (Moeller and Dewhirst, 2006; Stewart et al., 2010). However, as tumours possess 
an oxygen-gradient across their radius (Choi et al., 2014), it is believed that culture in hypoxia 
still represents the most physiologically relevant context for this assay. 
6.4.3  Conclusions and future directions 
This chapter has, for the first time, reported the efficacy of Tm2O3 in improving x-ray induced 
damage to metastatic cSCC cells. By virtue of the novel cell lines established in this PhD 
project, the cytotoxicity of the nanoparticle has been determined along with its ability to 
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significantly reduce clonogenic survival in association with radiation [2 Gy] ± carboplatin [1 
µM]. 
Due to the high-z number, biocompatibility and small size of < 100 nm, Tm2O3 is efficiently 
taken up by tumours and consequently provides a contrast that can guide imaging (Andras et 
al., 2014; Engels et al., 2018). The para-magnetism of Tm2O3 also enables it to be used with 
MRI as well as CT scanning technologies (Koehler et al., 1962). The utility of Tm2O3 for 
image-guided radiotherapy with rats harbouring malignant glioma was recently demonstrated 
by Engels et al., (2018). The less biocompatible nanoparticle gadolinium is currently used to 
visualise perineural invasion in patients with cSCC (Reule, 2009); Tm2O3 may offer an 
alternative to this with the added benefit of localising x-rays to the affected tissue. Engels et 
al., (2018) stated that accurate imaging is as equally important as the treatment itself as it 
provides information for diagnosis and radiotherapy planning. Given the abundance of at-risk 
structures in the head and neck (the most common sites of cSCC metastases), this 
enhancement in imaging and beam delivery is of considerable clinical value. For these 
reasons, Tm2O3 should continue to be investigated with cSCC. Chiefly, the response with 
additional cSCC cell lines (e.g. UW-CSCC1-R and UW-CSCC2) should be determined. 
Concomitant carboplatin and radiotherapy demonstrated no significant benefit in reducing 
clonogenic survival than either treatment as a monotherapy. These in vitro results corroborate 
clinical observations that have found a similar null effect (Porceddu et al., 2018). Regardless, 
due to the enhancement seen upon addition of carboplatin to the combination of Tm2O3 plus 
radiation, carboplatin should continue to be analysed as part of a combinatorial regimen for 
advanced cSCC. This regimen could be assessed in a clinical trial similar to the POST-study 
mentioned previously (Porceddu et al., 2018). Much like the in vitro experimentation 
performed in this project, such a clinical trial would compare patients receiving standard 
postoperative radiotherapy with those receiving the addition of concurrent carboplatin as well 
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as individuals receiving concurrent carboplatin and Tm2O3. An additional cohort receiving 
only radiation therapy and the Tm2O3 should also be analysed, given concurrent carboplatin 
was not found to have a significant impact in the POST-study. The study populations could 
include not only those presenting with high-risk nodal disease, but also those containing high-
risk local cSCC (histologically proven to be cSCC) as well as those with advanced primary 
disease found to be in-transit. Ideally the study population would not include those taking 
immunosuppressant drugs, although given this population is most often at risk, such an 
investigation would be worthwhile pending the results with non-immunocompromised 
individuals. Furthermore, to decrease the likelihood of targeting a radio-resistant population, 
study participants should have no previous radical radiotherapy to the affected sites. As most 
participants would be the elderly and some presenting with comorbidities, freedom from 
locoregional relapse and disease-free survival are perhaps greater indicators of efficacy than 
overall survival. Such a trial may restore any faith lost from the POST-study regarding 
concurrent therapy to treat advanced cSCC. 
Thorough optimisation of the clonogenic assay was performed to identify the plating 
efficiencies following a given treatment, and therefore the optimal seeding densities for 
subsequent experimentation. This optimisation was necessary to ensure accurate count data 
was obtained. Using this information, this assay could be up-scaled and utilised with systems 
such as the Oxford Optronix ColCount colony counter (Dahle et al., 2004) to increase 
throughput. Further treatment combinations should be investigated as well as variations in 
beam energies (megavoltage rather than orthovoltage) or in beam width. This was briefly 
investigated with UW-CSCC1 by Miss Elette Engels using synchrotron microbeam activated 
radiation therapy at the Australian Synchrotron (Victoria, Australia). Following treatment 
with 2 Gy microbeam radiation, UW-CSCC1 death was substantial, resulting in a PE < 4 % 
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(data not shown). Similar results have been reported by Engels et al., (2016) with another 
nanoparticle (Ta2O5) against 9L gliosarcoma cells. 
Together, these promising results further demonstrate the utility of the newly established cell 
lines. Their existence has enabled cSCC to be modelled in a clonogenic survival assay and 
therefore offer another pre-clinical tool to screen potential therapeutics. Due to the laborious 
undertaking of comparing so many conditions in the final assay, only UW-CSCC1 was 
analysed. Efforts should be made in the future to also interrogate UW-CSCC1-R with 
radiation as this would determine if the increase in DNA damage repair associated gene 
expression present in this culture have endowed a greater resistance to radiation. In such cases 
of DNA damage repair activation, combination therapy with CDK inhibitors may prove 
beneficial in compensating for such resistance.  
Targeted chemotherapeutics identified in the previous chapters may also be assessed in a 
clonogenic survival assay as single-agents or as part of a combination regimen with other 
chemotherapeutics, immunotherapy, nanoparticles, and/or radiation. Together with better 
surveillance (attributed to better prognostic markers such as those identified in Chapter 5), 
perhaps such regimens could be used in the neo-adjuvant setting and lessen the severity of 
surgical intervention, if not substitute it entirely. 
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CHAPTER 7: THESIS CONCLUSIONS AND FUTURE 
DIRECTIONS 
In the complex web of biological capabilities that lead to cancer formation, the route to 
metastasis remains largely uncharted. The aims set out in this thesis attempt to contribute to a 
larger overall study born out of this uncertainty – to understand the diverse landscape of 
metastatic cSCC biology. To achieve this, cell cultures were developed to enable in vitro 
investigations of cSCC biology. In vitro cell cultures are undoubtedly powerful tools able to 
identify biomarkers for prognosis and have been widely used to integrate genomic and 
transcriptomic data with pharmacological profiles to predict clinical response (Weigelt et al., 
2014; Niu and Wang, 2015). Through the trials and tribulations that accompanied the 
optimisation of a standardised protocol for the establishment of metastatic cSCC cell cultures, 
a set of suggested guidelines were ultimately developed. Due to the substantial heterogeneity 
between metastatic cSCC tumours, these ‘guidelines’ aimed to cater to the general demands 
of metastatic cSCC in culture. Namely, the use of hypoxia and specialised (although not 
overly complex) media formulations including hEGF and low sera were determined to 
contribute to greater short-term culture establishment. As a result of numerous attempts, two 
long-term cultures were established, UW-CSCC1 and UW-CSCC2. A radio-insensitive strain 
of UW-CSCC1 was also developed, named UW-CSCC1-R. Spheroids were able to be 
produced using UW-CSCC1 and UW-CSCC2, whilst UW-CSCC1-R formed loose 
aggregates. Long-term establishment of both cell lines was derived using differential 
trypsinisation to deplete fibroblast contamination. It is believed that if additional samples 
were acquired and subject to these techniques, then the chance of successful culture 
establishment would have increased significantly from what was obtained. 
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The shortcoming of many studies using cell lines to predict clinical response to therapies are 
deficient cell line numbers which limit the statistical power for identifying responder subsets 
due to genomic diversity. This is of particular relevance to cSCC, given the heterogeneity 
present within this disease, leading to responder subsets to therapy and variation in the 
applicability of prognostic molecular markers. Early cell line panels for drug discovery sought 
to bypass the large variation seen in response rates to chemotherapy; however, these panels 
were still relatively small (6 – 9 per tumour-type), and with the advent of –omic technologies 
the need for larger panels became apparent (Gillet et al., 2013). Barretina et al., (2012) 
compared 24 anticancer drugs across 479 cancer cell lines and found strong correlates 
between molecular subtypes and drug sensitivity. They concluded that cell lines may provide 
representative proxies of the tumour type from which they originate, given ample cell line 
numbers. The establishment of novel PDCCs in this PhD project are an attempt to fulfil this 
requirement, allowing for the continued generation of models for experimentation. The 
suggested culturing conditions would also help for the development of short term cultures for 
rapid drug testing to personalise the treatment administered to the patient. Importantly, UW-
CSCC1 and UW-CSCC2 were found to be tumourigenic in mice, thereby allowing future in 
vivo work to be conducted using these cell lines. Moving forward, additional metastatic cSCC 
cultures should be generated to satisfy a reasonable coverage of biological variability. 
The two major issues prohibiting the advancement of cancer treatment are: technical concerns 
– sensitivity and specificity of the gene expression profiling assays; and biological concerns – 
clinical relevance of the in vitro models used (Gillet et al., 2013). In the current study, the 
establishment of novel PDCCs, and their integration with contemporary gene mutation/gene 
expression technologies attempt to address these issues. The technologies used in this 
investigation (namely whole genome sequencing and NanoString) proved fruitful, 
immediately highlighting poor quality samples and confidently reporting on good quality 
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samples. The depth to which the WGS was performed was more than sufficient to detect 
variants, although the stroma did potentially mask some carcinoma cell variants that were 
later called in the cell lines. NanoString proved to be robust and produced plots containing 
only high quality data for comparisons. Nevertheless, potential genes of importance may have 
been neglected from the NanoString panels. RNA-seq should be performed on the samples to 
ensure complete coverage, taking into consideration the full scope of the transcriptomic 
landscape. Such an effort is in early development by the group and it will be rewarding to 
compare the observations seen in NanoString with those from RNA-seq. Proper integration 
with the genomic data is also incredibly valuable to explain the cause of any gene expression 
changes. 
Molecularly, UW-CSCC1 was revealed to be a reasonably faithful model of the originating 
tumour, at least for aspects considered to be of value in studying this disease (e.g. high impact 
key short variants). Unfortunately, UW-CSCC2 could not be molecularly validated against its 
originating tumour, although its gene expression profile was somewhat similar to UW-
CSCC1. Whilst many cancer progression pathways were downregulated in UW-CSCC1 
compared to its clinical counterpart, these differences are suggested to be a result of 
background ‘noise’ caused from the stroma present within the originating tumour. As a 
rudimentary assessment of this, one of the preserved stocks of matched cancer-associated 
fibroblasts (i.e. the fibroblasts detached during differential trypsinisation) could be run on 
NanoString. The gene counts of these stromal cells could theoretically be related back to the 
tumour’s count data to reveal the authentic expression of the carcinoma cells, aligning more 
with the profile of the cell lines. This was not pursued as it was believed that such a simplistic 
approach would ignore other biological complexities that are in play and the methodology to 
achieve this was unfamiliar territory. Additional variants and gene expression changes were 
evident in UW-CSCC1-R, particularly in DNA damage repair genes. This raises a point of 
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concern over the unimodal efficacy of radiation therapy in treating metastatic cSCC. 
However, this was only a single observation and requires far more work to be done to support 
to such a statement. 
On the basis of the pathways panel, it was found that it may be better to culture cells as a 
spheroid, perhaps preferably from the outset. Steps were taken by Miss Gretel Major to 
optimise spheroid cultures for drug screening through the use of live:dead fluorescent 
imaging. This work should be expanded upon by interrogating all of the lead compounds 
identified in 2D with the 3D spheroids. In fact, even drugs observed to be non-efficacious in 
2D should be considered for investigation in 3D as they may present a different response in 
the latter. Furthermore, spheroids embedded in organotypics may also yield informative 
results following exposure to certain therapies. The advent of the novel PDCCs has made 
such investigations possible. 
Between the clinical cohorts a series of differentially expressed genes were identified that 
may serve as candidate biomarkers or highlight potential therapeutic targets. Factors involved 
in cellular degradation (MMPs and PLAU) and PI3K/AKT/mTOR signalling (MET and SRC) 
were particularly overexpressed in metastatic cSCC and represent candidate biomarkers 
and/or therapeutic targets. However, it has been noted that between the few studies that have 
profiled the transcriptome of cSCC relative to normal skin, there is often very little overlap in 
the precise differentially expressed genes (Hameetman et al., 2013). Nonetheless, some 
similarities were determined from the current study with that of Mitsui et al., (2014), namely 
the upregulation of MMPs, PLAU, FN1, PDPN, and LAMC2 in cSCC relative to normal skin. 
Moving forward, candidate biomarkers should be assessed using patient samples at a protein 
level to determine their actual value in distinguishing between cSCC phenotypes. This is 
currently being explored by other members of the research group with preserved slides of 
various cSCC pathologies using anti-body staining specific to uPAR (encoded by PLAUR). It 
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is hoped that elevated protein expression of uPAR is associated with primaries that were 
known to result in metastases, thereby validating the mRNA observations and supporting its 
use as a prognostic biomarker. 
A functional genomics tactic should be utilised further to compare genomic observations of 
candidate biomarkers/drug targets with gene expression and drug response. For example, 
response to anti-EGFR therapies following knock-down of MET would confirm the theory of 
compensatory signalling. Such determinations will better encapsulate the value of a given 
gene as a biomarker or therapeutic target. 
A proto-type gene signature panel was developed based on differentially expressed genes with 
the intention of efficiently discriminating between the clinical cohorts. Theoretically, such a 
panel could be used to screen primary cSCC for metastatic risk on the basis of the resultant 
gene expression profile belonging to either a ‘NO MET’ or ‘MET’ category. In the event of a 
profile indicative of aggressive or metastatic cSCC, the appropriate course of treatment can be 
applied, such as prophylactic surgery, radiotherapy, or improved surveillance. Conversely, if a 
lesion is determined to be of low risk, then the general standard of care can be applied, 
thereby reducing healthcare resource consumption whilst alleviating the psychological burden 
upon the patient. Gene expression profiles may also assist in the development of tailor-made 
therapies for each given profile. 
As the cost of gene expression assays continuously reduce, there may come a time when 
every suspicious skin lesion (be it actinic keratoses or cSCC) is biopsied, sequenced, and 
subject to such a panel to determine risk. This could even be performed non-invasively using 
mRNA obtained via adhesive patch-based skin biopsies (Yao et al., 2017). However, for now 
the statistical power of the custom gene panel must be enhanced through expanding the 
number of samples analysed and further refining the predictive power of each gene. 
Additional cohorts such as actinic keratoses and cSCC implicated in different degrees of 
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perineural invasion should also be investigated along with matched-patient normal skin, 
primary cSCC, and metastatic cSCC. 
Drug screening of UW-CSCC1 and UW-CSCC1-R was performed in both 2D and 3D 
formats. A high throughput screen was utilised to efficiently determine effective and 
ineffective drugs against these PDCCs. The results of this indicated particular susceptibility to 
compounds targeting cytoskeletal signalling, DNA damage response, PI3K/AKT/mTOR 
signalling, and regulators of the cell cycle. Notably, across both the HTS and dose-response 
screens, inhibitors of EGFR, MET, and SRC were found to be mostly ineffective despite the 
upregulation of the targets in both the clinical samples and the cell lines relative to normal 
skin. From this, it is proposed that the downstream activation of these proteins is sustained via 
compensatory signalling, particularly the continued activation of PI3K/AKT/mTOR. Further 
evidence to support this was found in the efficacy of selective PI3K/AKT/mTOR inhibitors 
against the PDCCs, both in the HTS and dose-response screens. These data suggest clinical 
benefit in either combinatorial therapy using inhibitors for both EGFR and MET (among 
other growth factor receptors), or the use of selective PI3K/AKT/mTOR inhibitors such as 
PIK-75. To reiterate, without the generation of the novel PDCCs this data would not exist. 
To complement the broad suite of pathways targeted by compounds within the HTS, the 
candidate therapeutics identified from the gene expression data should be investigated further. 
Particularly, MMP inhibitors should be investigated in organotypic invasion assays to observe 
their influence upon invasion. Such an approach was performed using inhibitors of the 
urokinase plasminogen activation system, revealing a mild effect upon invasion. It is the 
ability to invade that makes this cancer deadly compared to its comparatively docile primary 
counterpart, therefore if invasion can be controlled, then the disease may be more effectively 
managed. 
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The empirical data regarding the efficacy of carboplatin as therapy for metastatic cSCC 
supports its frequent use in the clinical setting with radiation therapy. However, it was 
identified that this efficacy can be enhanced in association with other agents. This project has, 
for the first time, investigated the x-ray dose-enhancement capabilities of Tm2O3 against 
cSCC. This was met with overwhelming success in so far as the triplet combination of 
radiotherapy, Tm2O3, and carboplatin produced the greatest decrease in cell survival 
compared to the other mono- or doublet therapies tested. Given the associated benefits of 
using nanoparticles in radiotherapy mentioned throughout Chapter 6, this nanoparticle should 
be pursued further. The results reported so far have been limited to 2D cultures only. As such, 
future experiments involving radiation should also include spheroid cultures with  clonogenic 
survival being determined via a 3D colony forming assay, such as that attempted by 
Zschenker et al., (2012). Following investigations in 3D and animal models, this combined 
approach using nanoparticles should be investigated in a clinical trial such as that proposed in 
Chapter 6. If positive results are observed, this would represent one of the largest strides 
forward in post-operative care of this disease. Future combinatorial drug studies involving 
radiotherapy should include CDK inhibitors such as dinaciclib. The reasoning for this is 
dinaciclib can inhibit DNA damage repair mechanisms that can be overexpressed in radio-
resistant cells, thereby restoring susceptibility to radiation damage. Comparisons of UW-
CSCC1 and UW-CSCC1-R in response to such a treatment may highlight the efficacy of this. 
The positive role of immunotherapy as a cancer treatment is increasingly becoming 
understood. However, immunotherapy was not evaluated within the current study as this 
would be incompatible with the current cell line model given the absence of immune cells. 
Similarly, immunotherapy agents could not be utilised with the xenograft model, given the 
lack of a functioning immune system in the immunocompromised mice. Humanised mice 
models have been developed to circumvent this issue (Emens et al., 2017), however their 
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predictive ability of a response in the clinic remains unknown. An issue associated with 
immunotherapy for cSCC patients is that it cannot be safely administered to 
immunocompromised patients, whom represent a large proportion of sufferers of metastatic 
cSCC. Evidently more work is required to determine a method to make such treatment 
tolerable for this demographic. Because of this, other chemotherapeutics must still be 
determined in lieu of immunotherapy, highlighting the relevance of the results determined in 
this thesis. 
It is hoped that the data provided within this thesis will aid other researchers in their own 
investigations on this insidious disease. The establishment of the novel PDCCs (and the 
suggested culture guidelines) allowed for efficient experimentation that was previously not 
possible. In addition, the candidate biomarkers and therapeutics discovered within provide a 
starting point for further investigation on how to identify and treat at-risk or already suffering 
individuals. Taken together, these data are believed to contribute at least one further piece of 
the puzzle in a complex disease. 
  
 275 
 
LIST OF REFERENCES 
Abeysinghe, H. R., Q. Cao, J. Xu, S. Pollock, Y. Veyberman, N. L. Guckert, P. Keng and N. Wang. (2003). 
Thy1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genetics and 
Cytogenetics 143: 125-132. 
Adams, M., I. J. Kerby, I. Rocker, A. Evans, K. Johansen and C. R. Franks. (1989). A comparison of the toxicity 
and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The swons gynaecological cancer 
group. Acta Oncolologica 28: 57-60. 
Ahokas, K., T. Skoog, S. Suomela, L. Jeskanen, U. Impola, K. Isaka and U. Saarialho-Kere. (2005). Matrilysin-2 
(matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin 
carcinogenesis. Journal of Investigative Dermatology 124: 849-856. 
Airola, K., N. Johansson, A.-L. Kariniemi, V.-M. Kähäri and U. K. Saarialho-Kere. (1997). Human collagenase-
3 is expressed in malignant squamous epithelium of the skin. Journal of Investigative Dermatology 109: 
225-231. 
Al-Rohil, R. N., A. J. Tarasen, J. A. Carlson, K. Wang, A. Johnson, R. Yelensky, D. Lipson, J. A. Elvin, J. A. 
Vergilio, S. M. Ali, J. Suh, V. A. Miller, P. J. Stephens, P. Ganesan, F. Janku, D. D. Karp, V. Subbiah, 
M. C. Mihm and J. S. Ross. (2016). Evaluation of 122 advanced-stage cutaneous squamous cell 
carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. 
Cancer 122: 249-257. 
Ala-aho, R., M. Ahonen, S. J. George, J. Heikkilä, R. Grénman, M. Kallajoki and V.-M. Kähäri. (2004). 
Targeted inhibition of human collagenase-3 (mmp-13) expression inhibits squamous cell carcinoma 
growth in vivo. Oncogene 23: 5111. 
Alam, M. and D. Ratner. (2001). Cutaneous squamous-cell carcinoma. New England Journal of Medicine 344: 
975-983. 
Alter, M., I. Satzger, A. Mattern, A. Kapp and R. Gutzmer. (2013). Treatment of advanced cutaneous squamous 
cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology 227: 289-294. 
Andersen, P. L., J. R. Doucette and A. J. Nazarali. (2003). A novel method of eliminating non-neuronal 
proliferating cells from cultures of mouse dorsal root ganglia. Cellular and Molecular Neurobiology 23: 
205-210. 
Andras, P., D. Tapas, C. Sudipta, K. Reka, D. Gabriella, J. R. Peter, J. Csaba, T. Julianna, P. Zita, H. Veronika, 
J. Gergely, J. G. A., P. M. R.A. and B. Lajos. (2014). Thulium-170-labeled microparticles for local 
radiotherapy: Preliminary studies. Cancer Biotherapy and Radiopharmaceuticals 29: 330-338. 
Apisarnthanarax, S., N. Dhruva, F. Ardeshirpour, J. E. Tepper, C. G. Shores, J. G. Rosenman, W. W. Shockley, 
M. C. Hayward and D. N. Hayes. (2011). Concomitant radiotherapy and chemotherapy for high-risk 
nonmelanoma skin carcinomas of the head and neck. International Journal of Surgical Oncology 2011: 
464829. 
Armstrong, B. K. and A. Kricker. (2001). The epidemiology of uv induced skin cancer. Journal of 
Photochemistry and Photobiology B: Biology 63: 8-18. 
Arnault, J. P., J. Wechsler, B. Escudier, A. Spatz, G. Tomasic, V. Sibaud, S. Aractingi, J.-D. Grange, V. Poirier-
Colame, D. Malka, J.-C. Soria, C. Mateus and C. Robert. (2009). Keratoacanthomas and squamous cell 
carcinomas in patients receiving sorafenib. Journal of Clinical Oncology 27: 59-61. 
Ashford, B. G., J. Clark, R. Gupta, N. G. Iyer, B. Yu and M. Ranson. (2017). Reviewing the genetic alterations 
in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic 
targets. Head & Neck 39: 1462-1469. 
Australian Bureau of Statistics. (2017). "3303.0 - causes of death, australia 2017."   Retrieved 13/03/2019, 2019, 
from http://www.abs.gov.au/causes-of-death. 
Australian Institute of Health and Welfare. (2005). "Health system expenditures on cancer and other neoplasms 
in australia 2000-01."  Cancer series no. 29. Retrieved March 23, 2016, from 
http://www.aihw.gov.au/publication-detail/?id=6442467719. 
Australian Institute of Health and Welfare. (2016). "Skin cancer in australia." 
Australian Institute of Health and Welfare & Cancer Australia. (2008). "Non-melanoma skin cancer: General 
practice consultations, hospitilisation and mortality."  Cancer series no. 43. Retrieved March 23, 2016, 
from http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442454591. 
Ayli, E. E., W. Li, T. T. Brown, A. Witkiewicz, R. Elenitsas and J. T. Seykora. (2008). Activation of src-family 
tyrosine kinases in hyperproliferative epidermal disorders. Journal of Cutaneous Pathology 35: 273-
277. 
Badlani, J., R. Gupta, J. Smith, B. Ashford, S. Ch'ng, M. Veness and J. Clark. (2018). Metastases to the parotid 
gland - a review of the clinicopathological evolution, molecular mechanisms and management. Surgical 
Oncology 27: 44-53. 
 276 
 
Baldan, V., R. Griffiths, R. E. Hawkins and D. E. Gilham. (2015). Efficient and reproducible generation of 
tumour-infiltrating lymphocytes for renal cell carcinoma. British Journal of Cancer 112: 1510. 
Baran, N. and M. Konopleva. (2017). Molecular pathways: Hypoxia-activated prodrugs in cancer therapy. 
Clinical cancer research : an official journal of the American Association for Cancer Research 23: 
2382-2390. 
Barker, H. E., J. T. E. Paget, A. A. Khan and K. J. Harrington. (2015). The tumour microenvironment after 
radiotherapy: Mechanisms of resistance and recurrence. Nature Reviews. Cancer 15: 409-425. 
Barretina, J., G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehar, G. V. 
Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, 
A. Korejwa, J. Jane-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. 
Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi, M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, 
E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. 
Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. 
Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. 
R. Sellers, R. Schlegel and L. A. Garraway. (2012). The cancer cell line encyclopedia enables 
predictive modelling of anticancer drug sensitivity. Nature 483: 603-307. 
Baskar, R., K. A. Lee, R. Yeo and K.-W. Yeoh. (2012). Cancer and radiation therapy: Current advances and 
future directions. International journal of medical sciences 9: 193-199. 
Batlle, E., E. Sancho, C. Francí, D. Domínguez, M. Monfar, J. Baulida and A. García de Herreros. (2000). The 
transcription factor snail is a repressor of e-cadherin gene expression in epithelial tumour cells. Nature 
Cell Biology 2: 84. 
Baum, C. L., A. C. Wright, J.-C. Martinez, C. J. Arpey, J. D. Brewer, R. K. Roenigk and C. C. Otley. (2018). A 
new evidence-based risk stratification system for cutaneous squamous cell carcinoma into low, 
intermediate, and high risk groups with implications for management. Journal of the American 
Academy of Dermatology 78: 141-147. 
Bayat Mokhtari, R., T. S. Homayouni, N. Baluch, E. Morgatskaya, S. Kumar, B. Das and H. Yeger. (2017). 
Combination therapy in combating cancer. Oncotarget 8: 38022-38043. 
Bielenberg, D. R. and B. R. Zetter. (2015). The contribution of angiogenesis to the process of metastasis. Cancer 
journal (Sudbury, Mass.) 21: 267-273. 
Boehm, E. M., M. S. Gildenberg and M. T. Washington. (2016). The many roles of pcna in eukaryotic DNA 
replication. The Enzymes 39: 231-254. 
Boersma, V., N. Moatti, S. Segura-Bayona, M. H. Peuscher, J. van der Torre, B. A. Wevers, A. Orthwein, D. 
Durocher and J. J. L. Jacobs. (2015). Mad2l2 controls DNA repair at telomeres and DNA breaks by 
inhibiting 5' end resection. Nature 521: 537-540. 
Bollag, G., J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, K. Nolop and P. Hirth. (2012). Vemurafenib: The first drug 
approved for braf-mutant cancer. Nat Rev Drug Discov 11: 873-886. 
Bonan, N. F., D. Kowalski, K. Kudlac, K. Flaherty, J. C. Gwilliam, L. G. Falkenberg, E. Maradiaga and K. L. 
DeCicco-Skinner. (2019). Inhibition of hgf/met signaling decreases overall tumor burden and blocks 
malignant conversion in tpl2-related skin cancer. Oncogenesis 8: 1. 
Bonfil, R. D., A. Sabbota, S. Nabha, M. M. Bernardo, Z. Dong, H. Meng, H. Yamamoto, S. R. Chinni, I. T. Lim, 
M. Chang, L. C. Filetti, S. Mobashery, M. L. Cher and R. Fridman. (2006). Inhibition of human prostate 
cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based 
selective gelatinase inhibitor. International Journal of Cancer 118: 2721-2726. 
Boone, J. M. and A. E. Chavez. (1996). Comparison of x-ray cross sections for diagnostic and therapeutic 
medical physics. Medical Physics 23: 1997-2005. 
Bose, P., G. L. Simmons and S. Grant. (2013). Cyclin-dependent kinase inhibitor therapy for hematologic 
malignancies. Expert opinion on investigational drugs 22: 723-738. 
Boxall, S. A. and E. Jones. (2012). Markers for characterization of bone marrow multipotential stromal cells. 
Stem Cells International 2012: 12. 
Brougham, N. D., E. R. Dennett, R. Cameron and S. T. Tan. (2012). The incidence of metastasis from cutaneous 
squamous cell carcinoma and the impact of its risk factors. Journal of Surgical Oncology 106: 811-815. 
Brungs, D., J. Chen, M. Aghmesheh, K. L. Vine, T. M. Becker, M. G. Carolan and M. Ranson. (2017). The 
urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-
analysis. Oncotarget 8: 23099-23109. 
Brunner, M., B. C. Ng, M. J. Veness and J. R. Clark. (2015). Assessment of the new nodal classification for 
cutaneous squamous cell carcinoma and its effect on patient stratification. Head & Neck 37: 336-339. 
Buckley, B. J., A. Aboelela, E. Minaei, L. X. Jiang, Z. Xu, U. Ali, K. Fildes, C.-Y. Cheung, S. M. Cook, D. C. 
Johnson, D. A. Bachovchin, G. M. Cook, M. Apte, M. Huang, M. Ranson and M. J. Kelso. (2018). 6-
substituted hexamethylene amiloride (hma) derivatives as potent and selective inhibitors of the human 
urokinase plasminogen activator for use in cancer. Journal of Medicinal Chemistry. 
 277 
 
Buckley, B. J., U. Ali, M. J. Kelso and M. Ranson. (2018). The urokinase plasminogen activation system in 
rheumatoid arthritis: Pathophysiological roles and prospective therapeutic targets. Current Drug 
Targets. 
Budczies, J., M. von Winterfeld, F. Klauschen, M. Bockmayr, J. K. Lennerz, C. Denkert, T. Wolf, A. Warth, M. 
Dietel, I. Anagnostopoulos, W. Weichert, D. Wittschieber and A. Stenzinger. (2014). The landscape of 
metastatic progression patterns across major human cancers. Oncotarget 6: 570-583. 
Buettner, P. G. and B. A. Raasch. (1998). Incidence rates of skin cancer in townsville, australia. International 
Journal of Cancer 78: 587-593. 
Burton, K. A., K. A. Ashack and A. Khachemoune. (2016). Cutaneous squamous cell carcinoma: A review of 
high-risk and metastatic disease. American Journal of Clinical Dermatology 17: 491-508. 
Bustin, S. and T. Nolan. (2017). Talking the talk, but not walking the walk: Rt-qpcr as a paradigm for the lack of 
reproducibility in molecular research. European Journal of Clinical Investigation 47: 756-774. 
Bustin, S. A., V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M. W. Pfaffl, 
G. L. Shipley, J. Vandesompele and C. T. Wittwer. (2009). The miqe guidelines: Minimum information 
for publication of quantitative real-time pcr experiments. Clinical Chemistry 55: 611-622. 
Cammareri, P., A. M. Rose, D. F. Vincent, J. Wang, A. Nagano, S. Libertini, R. A. Ridgway, D. Athineos, P. J. 
Coates, A. McHugh, C. Pourreyron, J. H. S. Dayal, J. Larsson, S. Weidlich, L. C. Spender, G. P. 
Sapkota, K. J. Purdie, C. M. Proby, C. A. Harwood, I. M. Leigh, H. Clevers, N. Barker, S. Karlsson, C. 
Pritchard, R. Marais, C. Chelala, A. P. South, O. J. Sansom and G. J. Inman. (2016). Inactivation of tgfβ 
receptors in stem cells drives cutaneous squamous cell carcinoma. Nature Communications 7: 12493. 
Cancer Council Australia (2008). Basal cell carcinoma, squamous cell carcinoma (and related lesions) – a guide 
to clinical management in australia. Australian Cancer Network. Sydney. 
Cancer Council Australia (2014). Understanding skin cancer: A guide for people with cancer, their families and 
friends. A. Burgess. 
Cano, A., M. A. Perez-Moreno, I. Rodrigo, A. Locascio, M. J. Blanco, M. G. del Barrio, F. Portillo and M. A. 
Nieto. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing 
e-cadherin expression. Nature Cell Biology 2: 76-83. 
Cano, A., M. A. Pérez-Moreno, I. Rodrigo, A. Locascio, M. J. Blanco, M. G. del Barrio, F. Portillo and M. A. 
Nieto. (2000). The transcription factor snail controls epithelial–mesenchymal transitions by repressing 
e-cadherin expression. Nature Cell Biology 2: 76. 
Cañueto, J., E. Cardeñoso, J. L. García, Á. Santos-Briz, A. Castellanos-Martín, E. Fernández-López, A. Blanco 
Gómez, J. Pérez-Losada and C. Román-Curto. (2017). Epidermal growth factor receptor expression is 
associated with poor outcome in cutaneous squamous cell carcinoma. British Journal of Dermatology 
176: 1279-1287. 
Cañueto, J., A. Jaka and A. Toll. (2018). The value of adjuvant radiotherapy in cutaneous squamous cell 
carcinoma: A review. Actas Dermo-Sifiliográficas (English Edition) 109: 476-484. 
Carossino, A. M., A. Lombardi, M. Matucci-Cerinic, A. Pignone and M. Cagnoni. (1996). Effect of melatonin 
on normal and sclerodermic skin fibroblast proliferation. Clinical and Experimental Rheumatology 14: 
493-498. 
Cascinu, S., R. R. Silva, S. Barni, R. Labianca, L. Frontini, E. Piazza, G. Pancera, P. Giordani, L. Giuliodori, M. 
A. Pessi, V. Fusco, G. Luporini, R. Cellerino and G. Catalano. (1999). A combination of gemcitabine 
and 5-fluorouracil in advanced pancreatic cancer, a report from the italian group for the study of 
digestive tract cancer (giscad). British Journal of Cancer 80: 1595-1598. 
Cataisson, C., A. M. Michalowski, K. Shibuya, A. Ryscavage, M. Klosterman, L. Wright, W. Dubois, F. Liu, A. 
Zhuang, K. B. Rodrigues, S. Hoover, J. Dwyer, M. R. Simpson, G. Merlino and S. H. Yuspa. (2016). 
Met signaling in keratinocytes activates egfr and initiates squamous carcinogenesis. Science Signaling 
9: 62-62. 
Chae, Y. K., C. Galvez, J. F. Anker, W. T. Iams and M. Bhave. (2018). Cancer immunotherapy in a neglected 
population: The current use and future of t-cell-mediated checkpoint inhibitors in organ transplant 
patients. Cancer Treatment Reviews 63: 116-121. 
Chandrasekar, N., S. Mohanam, M. Gujrati, W. C. Olivero, D. H. Dinh and J. S. Rao. (2003). Downregulation of 
upa inhibits migration and pi3k/akt signaling in glioblastoma cells. Oncogene 22: 392-400. 
Chao, T.-L., T.-Y. Wang, C.-H. Lee, S.-J. Yiin, C.-T. Ho, S.-H. Wu, H.-L. You and C.-L. Chern. (2018). Anti-
cancerous effect of inonotus taiwanensis polysaccharide extract on human acute monocytic leukemia 
cells through ros-independent intrinsic mitochondrial pathway. International journal of molecular 
sciences 19: 393. 
Chartier, T. K. and S. Z. Asasi. (2016). Treatment and prognosis of cutaneous squamous cell carcinoma. 
Uptodate. R. S. Stern and J. K. Robinson. UpToDate, Waltham, MA. (Accessed on April 4, 2016). 
 278 
 
Chen, H., M. Takahara, L. Xie, S. Takeuchi, Y. Tu, T. Nakahara, H. Uchi, Y. Moroi and M. Furue. (2013). 
Levels of the emt-related protein snail/slug are not correlated with p53/p63 in cutaneous squamous cell 
carcinoma. Journal of Cutaneous Pathology 40: 651-656. 
Chen, R., W. G. Wierda, S. Chubb, R. E. Hawtin, J. A. Fox, M. J. Keating, V. Gandhi and W. Plunkett. (2009). 
Mechanism of action of sns-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic 
leukemia. Blood 113: 4637-4645. 
Cheng, S. J., S. H. Kok, J. J. Lee, M. Yen–Ping Kuo, S. L. Cheng, Y. L. Huang, H. M. Chen, H. H. Chang and 
C. P. Chiang. (2012). Significant association of src protein expression with the progression, recurrence, 
and prognosis of oral squamous cell carcinoma in taiwan. Head & Neck 34: 1340-1345. 
Chi Scientific. (2007). Handbook of primary cell culture: A practical manual to the labtoratoty. Maynard, 
Massachusetts. 
Chia, S., J.-L. Low, X. Zhang, X.-L. Kwang, F.-T. Chong, A. Sharma, D. Bertrand, S. Y. Toh, H.-S. Leong, M. 
T. Thangavelu, J. S. G. Hwang, K.-H. Lim, T. Skanthakumar, H.-K. Tan, Y. Su, S. Hui Choo, H. 
Hentze, I. B. H. Tan, A. Lezhava, P. Tan, D. S. W. Tan, G. Periyasamy, J. L. Y. Koh, N. Gopalakrishna 
Iyer and R. DasGupta. (2017). Phenotype-driven precision oncology as a guide for clinical decisions 
one patient at a time. Nature Communications 8: 435. 
Cho, H.-J., T.-S. Lee, J.-B. Park, K.-K. Park, J.-Y. Choe, D.-I. Sin, Y.-Y. Park, M. Yong Suk, K.-G. Lee, J.-H. 
Yeo, S.-M. Han, Y.-S. Cho, M.-R. Choi, N.-G. Park, Y.-S. Lee and Y.-C. Chang. (2007). Disulfiram 
suppresses invasive ability of osteosarcoma cells via the inhibition of mmp-2 and mmp-9 expression. 
Journal of Biochemistry and Molecular Biology 40: 1069-1076. 
Choi, S. Y. C., D. Lin, P. W. Gout, C. C. Collins, Y. Xu and Y. Wang. (2014). Lessons from patient-derived 
xenografts for better in vitro modeling of human cancer. Advanced Drug Delivery Reviews 79: 222-237. 
Clark, R. R. and D. S. Soutar. (2008). Lymph node metastases from auricular squamous cell carcinoma. A 
systematic review and meta-analysis. Journal of Plastic, Reconstructive & Aesthetic Surgery 61: 1140-
1147. 
Cobleigh, M. A., J. L. Kennedy, A. C. Wong, J. H. Hill, K. M. Lindholm, J. E. Tiesenga, R. Kiang, E. L. 
Applebaum and W. P. McGuire. (1987). Primary culture of squamous head and neck cancer with and 
without 3t3 fibroblasts and effect of clinical tumor characteristics on growth in vitro. Cancer 59: 1732-
1738. 
Commandeur, S., S. H. Ho, F. R. de Gruijl, R. Willemze, C. P. Tensen and A. El Ghalbzouri. (2011). Functional 
characterization of cancer-associated fibroblasts of human cutaneous squamous cell carcinoma. 
Experimental Dermatology 20: 737-742. 
Conway, J. R. W., N. O. Carragher and P. Timpson. (2014). Developments in preclinical cancer imaging: 
Innovating the discovery of therapeutics. Nature Reviews Cancer 14: 314. 
Cranmer, L. D., C. Engelhardt and S. S. Morgan. (2010). Treatment of unresectable and metastatic cutaneous 
squamous cell carcinoma. The Oncologist 15: 1320-1328. 
Cree, I. A. (2011). Principles of cancer cell culture. Methods in Molecular Biology 731: 13-26. 
Creighton, C., R. Kuick, D. E. Misek, D. S. Rickman, F. M. Brichory, J.-M. Rouillard, G. S. Omenn and S. 
Hanash. (2003). Profiling of pathway-specific changes in gene expression following growth of human 
cancer cell lines transplanted into mice. Genome Biology 4: R46. 
Cribbes, S., S. Kessel, S. McMenemy, J. Qiu and L. Chan. (2017). A novel multiparametric drug-scoring method 
for high-throughput screening of 3d multicellular tumor spheroids using the celigo image cytometer. 
SLAS discovery 22: 547-557. 
Czerwonka, L., R. J. De Santis, G. Horowitz, M. Hong, M. Orsini, D. Enepekides, D. P. Goldstein, J. Dort and 
K. Higgins. (2017). Staging cutaneous squamous cell carcinoma metastases to the parotid gland. 
Laryngoscope2063-2069. 
Dahle, J., M. Kakar, H. B. Steen and O. Kaalhus. (2004). Automated counting of mammalian cell colonies by 
means of a flat bed scanner and image processing. Cytometry A 60: 182-188. 
Dangles-Marie, V., M. Pocard, S. Richon, L.-B. Weiswald, F. Assayag, P. Saulnier, J.-G. Judde, J.-L. Janneau, 
N. Auger, P. Validire, B. Dutrillaux, F. Praz, D. Bellet and M.-F. Poupon. (2007). Establishment of 
human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell 
line features. Cancer Research 67: 398-407. 
Daniel, V. C., L. Marchionni, J. S. Hierman, J. T. Rhodes, W. L. Devereux, C. M. Rudin, R. Yung, G. 
Parmigani, M. Dorsch, C. D. Peacock and D. N. Watkins. (2009). A primary xenograft model of small 
cell lung cancer reveals irreversible changes in gene expression imposed by culture in-vitro. Cancer 
Research 69: 3364. 
Dass, K., A. Ahmad, A. S. Azmi, S. H. Sarkar and F. H. Sarkar. (2008). Evolving role of upa/upar system in 
human cancers. Cancer Treatment Reviews 34: 122-136. 
 279 
 
Davis, A. P., C. J. Grondin, R. J. Johnson, D. Sciaky, B. L. King, R. McMorran, J. Wiegers, T. C. Wiegers and 
C. J. Mattingly. (2017). The comparative toxicogenomics database: Update 2017. Nucleic Acids 
Research 45: 972-978. 
Dawood, S. (2010). Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics 10: 581-
590. 
Dereure, O., H. Missan, C. Girard, V. Costes and B. Guillot. (2016). Efficacy and tolerance of cetuximab alone 
or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: 
An open study of 14 patients. Dermatology 232: 721-730. 
Didona, D., G. Paolino, U. Bottoni and C. Cantisani. (2018). Non melanoma skin cancer pathogenesis overview. 
Biomedicines 6. 
Dijkstra, J. R., L. C. van Kempen, I. D. Nagtegaal and S. A. Bustin. (2014). Critical appraisal of quantitative pcr 
results in colorectal cancer research: Can we rely on published qpcr results? Molecular Oncology 8: 
813-818. 
Dika, E., P. A. Fanti, M. Lambertini, F. Scarfì, G. M. Ravaioli, G. Veronesi, C. Baraldi, A. Guglielmo and A. 
Patrizi. (2018). Cutaneous squamous cell carcinoma progression during imiquimod treatment. Journal 
of the American Academy of Dermatology 79: 11-12. 
Ding, L.-t., P. Zhao, M.-l. Yang, G.-z. Lv and T.-l. Zhao. (2018). Gdc-0084 inhibits cutaneous squamous cell 
carcinoma cell growth. Biochemical and Biophysical Research Communications 503: 1941-1948. 
Dooley, T. P., S. P. Reddy, T. W. Wilborn and R. L. Davis. (2003). Biomarkers of human cutaneous squamous 
cell carcinoma from tissues and cell lines identified by DNA microarrays and qrt-pcr. Biochemical and 
Biophysical Research Communications 306: 1026-1036. 
Doran, C. M., R. Ling, J. Byrnes, M. Crane, A. Searles, D. Perez and A. Shakeshaft. (2015). Estimating the 
economic costs of skin cancer in new south wales, australia. BMC Public Health 15: 952. 
Driessens, G., B. Beck, A. Caauwe, B. D. Simons and C. Blanpain. (2012). Defining the mode of tumour growth 
by clonal analysis. Nature 488: 527. 
Durinck, S., C. Ho, N. J. Wang, W. Liao, L. R. Jakkula, E. A. Collisson, J. Pons, S. W. Chan, E. T. Lam, C. Chu, 
K. Park, S. W. Hong, J. S. Hur, N. Huh, I. M. Neuhaus, S. S. Yu, R. C. Grekin, T. M. Mauro, J. E. 
Cleaver, P. Y. Kwok, P. E. LeBoit, G. Getz, K. Cibulskis, J. C. Aster, H. Huang, E. Purdom, J. Li, L. 
Bolund, S. T. Arron, J. W. Gray, P. T. Spellman and R. J. Cho. (2011). Temporal dissection of 
tumorigenesis in primary cancers. Cancer discovery 1: 137-143. 
Dzubow, L. M. (1986). Metastatic basal cell carcinoma originating in the supra-parotid region. Dermatologic 
Surgery 12: 1306-1308. 
Emens, L. A., P. A. Ascierto, P. K. Darcy, S. Demaria, A. M. M. Eggermont, W. L. Redmond, B. Seliger and F. 
M. Marincola. (2017). Cancer immunotherapy: Opportunities and challenges in the rapidly evolving 
clinical landscape. European Journal of Cancer 81: 116-129. 
Emnett, R. J., A. Kaul, A. Babic, V. Geiler, D. Regan, G. Gross and S. Akel. (2016). Evaluation of tissue 
homogenization to support the generation of gmp-compliant mesenchymal stromal cells from the 
umbilical cord. Stem Cells International 2016: 1-9. 
Engels, E., S. Corde, S. McKinnon, S. Incerti, K. Konstantinov, A. Rosenfeld, M. Tehei, M. Lerch and S. 
Guatelli. (2016). Optimizing dose enhancement with ta2o5 nanoparticles for synchrotron microbeam 
activated radiation therapy. Physica Medica 32: 1852-1861. 
Engels, E., M. Westlake, N. Li, S. Vogel, Q. Gobert, N. Thorpe, A. Rosenfeld, M. Lerch, S. Corde and M. Tehei. 
(2018). Thulium oxide nanoparticles: A new candidate for image-guided radiotherapy. Biomedical 
Physics & Engineering Express 4: 1-11. 
Erdogan, B. and D. J. Webb. (2017). Cancer-associated fibroblasts modulate growth factor signaling and 
extracellular matrix remodeling to regulate tumor metastasis. Biochemical Society Transactions 45: 
229-236. 
Ertel, A., A. Verghese, S. W. Byers, M. Ochs and A. Tozeren. (2006). Pathway-specific differences between 
tumor cell lines and normal and tumor tissue cells. Molecular Cancer 5: 55-55. 
Evison, B. J., B. E. Sleebs, K. G. Watson, D. R. Phillips and S. M. Cutts. (2016). Mitoxantrone, more than just 
another topoisomerase ii poison. Medicinal Research Reviews 36: 248-299. 
Falchook, G. S., R. Leidner, E. Stankevich, B. Piening, C. Bifulco, I. Lowy and M. G. Fury. (2016). Responses 
of metastatic basal cell and cutaneous squamous cell carcinomas to anti-pd1 monoclonal antibody 
regn2810. Journal for immunotherapy of cancer 4: 70-70. 
Fallah-Tafti, A., A. Foroumadi, R. Tiwari, A. N. Shirazi, D. G. Hangauer, Y. Bu, T. Akbarzadeh, K. Parang and 
A. Shafiee. (2011). Thiazolyl n-benzyl-substituted acetamide derivatives: Synthesis, src kinase 
inhibitory and anticancer activities. European Journal of Medicinal Chemistry 46: 4853-4858. 
Farshchian, M., A. Kivisaari, R. Ala-aho, P. Riihilä, M. Kallajoki, R. Grénman, J. Peltonen, T. Pihlajaniemi, R. 
Heljasvaara and V.-M. Kähäri. (2011). Serpin peptidase inhibitor clade a member 1 (serpina1) is a 
 280 
 
novel biomarker for progression of cutaneous squamous cell carcinoma. The American Journal of 
Pathology 179: 1110-1119. 
Farshchian, M., L. Nissinen, R. Grénman and V.-M. Kähäri. (2017). Dasatinib promotes apoptosis of cutaneous 
squamous carcinoma cells by regulating activation of erk1/2. Experimental Dermatology 26: 89-92. 
Farshchian, M., L. Nissinen, E. Siljamäki, P. Riihilä, M. Toriseva, A. Kivisaari, R. Ala-aho, M. Kallajoki, E. 
Veräjänkorva, H.-K. Honkanen, R. Heljasvaara, T. Pihlajaniemi, R. Grénman, J. Peltonen, S. Peltonen 
and V.-M. Kähäri. (2015). Ephb2 promotes progression of cutaneous squamous cell carcinoma. Journal 
of Investigative Dermatology 135: 1882-1892. 
Fearns, C. and E. B. Dowdle. (1992). The desmoplastic response: Induction of collagen synthesis by melanoma 
cells in vitro. International Journal of Cancer 50: 621-627. 
Fecher, L. A. and W. H. Sharfman. (2015). Advanced basal cell carcinoma, the hedgehog pathway, and 
treatment options - role of smoothened inhibitors. Biologics: targets & therapy 9: 129-140. 
Fernandez, C. A., L. Yan, G. Louis, J. Yang, J. L. Kutok and M. A. Moses. (2005). The matrix 
metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor 
growth and is present in the urine of breast cancer patients. Clinical Cancer Research 11: 5390-5395. 
Fogh, J., J. M. Fogh and T. Orfeo. (1977). One hundred and twenty-seven cultured human tumor cell lines 
producing tumors in nude mice. Journal of the National Cancer Institute (Bethesda) 59: 221-226. 
Forest, V. I., J. J. Clark, M. J. Veness and C. Milross. (2010). N1s3: A revised staging system for head and neck 
cutaneous squamous cell carcinoma with lymph node metastases: Results of 2 australian cancer centers. 
Cancer 116: 1298-1304. 
Fransen, M., A. Karahalios, N. Sharma, D. English, G. G. Giles and R. Sinclair. (2012). Non-melanoma skin 
cancer in australia. Med J Aust 197: 565-568. 
Freshney, R. (2010). Culture of animal cells: A manual of basic technique and specialized applications, sixth 
edition. 
Friedl, P., J. Locker, E. Sahai and J. E. Segall. (2012). Classifying collective cancer cell invasion. Nature Cell 
Biology 14: 777-783. 
Friedrich, J., W. Eder, J. Castaneda, M. Doss, E. Huber, R. Ebner and L. Kunz-Schughart. (2007). A reliable tool 
to determine cell viability in complex 3-d culture: The acid phosphatase assay. Journal of Biomolecular 
Screening 12: 925-937. 
Fuertes, L., C. Santonja, H. Kutzner and L. Requena. (2013). Immunohistochemistry in dermatopathology: A 
review of the most commonly used antibodies (part i). Actas Dermo-Sifiliográficas (English Edition) 
104: 99-127. 
Gaffney, D. C., H. P. Soyer and F. Simpson. (2014). The epidermal growth factor receptor in squamous cell 
carcinoma: An emerging drug target. Australasian Journal of Dermatology 55: 24-34. 
Gallego Romero, I., A. A. Pai, J. Tung and Y. Gilad. (2014). Rna-seq: Impact of rna degradation on transcript 
quantification. BMC Biology 12: 42-42. 
Gallorini, M., A. Cataldi and V. di Giacomo. (2012). Cyclin-dependent kinase modulators and cancer therapy. 
BioDrugs 26: 377-391. 
Garcia-Diez, I., I. Hernandez-Munoz, E. Hernandez-Ruiz, L. Nonell, E. Puigdecanet, M. Bodalo-Torruella, E. 
Andrades, R. M. Pujol and A. Toll. (2019). Transcriptome and cytogenetic profiling analysis of 
matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients. Genes 
Chromosomes Cancer 58: 164-174. 
García-Inclán, C., A. López-Hernández, M. Alonso-Guervós, E. Allonca, S. Potes, S. Melón, F. López, J. L. 
Llorente and M. Hermsen. (2014). Establishment and genetic characterization of six unique tumor cell 
lines as preclinical models for sinonasal squamous cell carcinoma. Scientific Reports 4: 4925. 
Garcovich, S., G. Colloca, P. Sollena, B. Andrea, L. Balducci, W. C. Cho, R. Bernabei and K. Peris. (2017). Skin 
cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging and disease 8: 643-
661. 
Gayevskiy, V., T. Roscioli, M. E. Dinger and M. J. Cowley. (2018). Seave: A comprehensive web platform for 
storing and interrogating human genomic variation. Bioinformatics 35: 122-125. 
Gazdar, A. F., B. Gao and J. D. Minna. (2010). Lung cancer cell lines: Useless artifacts or invaluable tools for 
medical science? Lung cancer (Amsterdam, Netherlands) 68: 309-318. 
Gennatas, C., V. Michalaki, D. Mouratidou, N. Tsavaris, C. Andreadis, A. Photopoulos and D. Voros. (2006). 
Gemcitabine combined with 5-fluorouracil for the treatment of advanced carcinoma of the pancreas. In 
Vivo 20: 301-305. 
Geraghty, R. J., A. Capes-Davis, J. M. Davis, J. Downward, R. I. Freshney, I. Knezevic, R. Lovell-Badge, J. R. 
Masters, J. Meredith, G. N. Stacey, P. Thraves and M. Vias. (2014). Guidelines for the use of cell lines 
in biomedical research. British Journal of Cancer 111: 1021-1046. 
Gialeli, C., A. D. Theocharis and N. K. Karamanos. (2011). Roles of matrix metalloproteinases in cancer 
progression and their pharmacological targeting. Febs j 278: 16-27. 
 281 
 
Giard, D. J., S. A. Aaronson, G. J. Todaro, P. Arnstein, J. H. Kersey, H. Dosik and W. P. Parks. (1973). In vitro 
cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. Journal 
of the National Cancer Institute (Bethesda) 51: 1417-1423. 
Gillet, J.-P., S. Varma and M. M. Gottesman. (2013). The clinical relevance of cancer cell lines. Journal of the 
National Cancer Institute 105: 452-458. 
Goktug, A. N., S. C. Chai and T. Chen. (2013). Data analysis approaches in high throughput screening. Drug 
discovery. H. A. and El-Shemy, IntechOpen. 
Gomes, X. V. and P. M. Burgers. (2000). Two modes of fen1 binding to pcna regulated by DNA. Embo j 19: 
3811-3821. 
Goodspeed, A., L. M. Heiser, J. W. Gray and J. C. Costello. (2016). Tumor-derived cell lines as molecular 
models of cancer pharmacogenomics. Molecular Cancer Research 14: 3-13. 
Gray, D. T., V. J. Suman, W. P. Su, R. P. Clay, W. S. Harmsen and R. K. Roenigk. (1997). Trends in the 
population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 
1992. Archives of Dermatology 133: 735-740. 
Guo, A. and C. A. Jahoda. (2009). An improved method of human keratinocyte culture from skin explants: Cell 
expansion is linked to markers of activated progenitor cells. Exp Dermatol 18: 720-726. 
Hacker, S. M. and F. P. Flowers. (1993). Squamous cell carcinoma of the skin. Will heightened awareness of 
risk factors slow its increase? Postgraduate Medicine 93: 115-121. 
Hafner, C., M. Landthaler and T. Vogt. (2010). Activation of the pi3k/akt signalling pathway in non-melanoma 
skin cancer is not mediated by oncogenic pik3ca and akt1 hotspot mutations. Experimental 
Dermatology 19: 222-227. 
Hameetman, L., S. Commandeur, J. N. B. Bavinck, H. C. Wisgerhof, F. R. de Gruijl, R. Willemze, L. 
Mullenders, C. P. Tensen and H. Vrieling. (2013). Molecular profiling of cutaneous squamous cell 
carcinomas and actinic keratoses from organ transplant recipients. BMC cancer 13: 58-58. 
Hanahan, D. and Robert A. Weinberg. (2011). Hallmarks of cancer: The next generation. Cell 144: 646-674. 
Hanna, G. J., E. S. Ruiz and J. H. Lorch. (2016). Management of widely metastatic and unresectable cutaneous 
squamous cell carcinoma. High-risk cutaneous squamous cell carcinoma: A practical guide for patient 
management. C. D. Schmults. Berlin, Heidelberg, Springer Berlin Heidelberg. 213-222. 
Hannuksela-Svahn, A., E. Pukkala and J. Karvonen. (1999). Basal cell skin carcinoma and other nonmelanoma 
skin cancers in finland from 1956 through 1995. Arch Dermatol 135: 781-786. 
Harris, N. L. E., C. Vennin, J. R. W. Conway, K. L. Vine and M. Pinese. (2017). Serpinb2 regulates stromal 
remodelling and local invasion in pancreatic cancer.  36: 4288-4298. 
Harwood, C. A., C. M. Proby and S. T. Arron. (2016). Genomics of scc: Tumor formation, progression, and 
future therapeutic implications for high-risk cutaneous squamous cell carcinoma. High-risk cutaneous 
squamous cell carcinoma: A practical guide for patient management. C. D. Schmults. Berlin, 
Heidelberg, Springer Berlin Heidelberg. 67-102. 
Harwood, C. A., C. M. Proby, G. J. Inman and I. M. Leigh. (2016). The promise of genomics and the 
development of targeted therapies for cutaneous squamous cell carcinoma. Acta Dermato-
Venereologica 96: 3-16. 
Hassanpour, S. H. and M. Dehghani. (2017). Review of cancer from perspective of molecular. Journal of Cancer 
Research and Practice 4: 127-129. 
Haycock, J. W. (2011). 3d cell culture: A review of current approaches and techniques. 3d cell culture: Methods 
and protocols. W. J. Haycock. Totowa, NJ, Humana Press. 1-15. 
Hazar-Rethinam, M., L. Endo-Munoz, O. Gannon and N. Saunders. (2011). The role of the e2f transcription 
factor family in uv-induced apoptosis. International journal of molecular sciences 12: 8947-8960. 
Heidari Kani, M., E. C. Chan, R. C. Young, T. Butler, R. Smith and J. W. Paul. (2017). 3d cell culturing and 
possibilities for myometrial tissue engineering. Annals of Biomedical Engineering 45: 1746-1757. 
Heinemann, V., S. Boeck, A. Hinke, R. Labianca and C. Louvet. (2008). Meta-analysis of randomized trials: 
Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced 
pancreatic cancer. BMC cancer 8: 82-93. 
Helleday, T., S. Eshtad and S. Nik-Zainal. (2014). Mechanisms underlying mutational signatures in human 
cancers. Nature reviews. Genetics 15: 585-598. 
Hermel, D. J., O. M. Ragab, S. Higgins, A. Wysong and G. K. In. (2018). Pd-1 inhibition in cutaneous squamous 
cell carcinoma (cscc). Journal of Clinical Oncology 36: e15100-e15100. 
Hidalgo, M., F. Amant, A. V. Biankin, E. Budinská, A. T. Byrne, C. Caldas, R. B. Clarke, S. de Jong, J. Jonkers, 
G. M. Mælandsmo, S. Roman-Roman, J. Seoane, L. Trusolino and A. Villanueva. (2014). Patient 
derived xenograft models: An emerging platform for translational cancer research. Cancer discovery 4: 
998-1013. 
Hildenbrand, R., M. Gandhari, P. Stroebel, A. Marx, H. Allgayer and N. Arens. (2008). The urokinase-system-
role of cell proliferation and apoptosis. Histology and Histopathology 23: 227-236. 
 282 
 
Hillen, F. and A. W. Griffioen. (2007). Tumour vascularization: Sprouting angiogenesis and beyond. Cancer 
metastasis reviews 26: 489-502. 
Hirata, E. and E. Sahai. (2017). Tumor microenvironment and differential responses to therapy. Cold Spring 
Harbor Perspectives in Medicine 7. 
Hirsch, C. D., N. M. Springer and C. N. Hirsch. (2015). Genomic limitations to rna sequencing expression 
profiling. The Plant Journal 84: 491-503. 
Hirshoren, N., J. Danne, B. J. Dixon, M. Magarey, S. Kleid, A. Webb, A. Tiong, J. Corry and D. Gyorki. (2017). 
Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head & 
Neck 39: 772-778. 
Horikawa, T., D. A. Norris, T. Zekman and J. G. Morelli. (1996). Effective elimination of fibroblasts in cultures 
of melanocytes by lowering calcium concentration in tpa depleted medium following geneticin 
treatment. Pigment Cell Research Supplement 9: 58-62. 
Horvath, P., N. Aulner, M. Bickle, A. M. Davies, E. D. Nery, D. Ebner, M. C. Montoya, P. Östling, V. 
Pietiäinen, L. S. Price, S. L. Shorte, G. Turcatti, C. von Schantz and N. O. Carragher. (2016). Screening 
out irrelevant cell-based models of disease. Nature Reviews Drug Discovery 15: 751. 
Hou, T., J. Xiao, H. Zhang, H. Gu, Y. Feng and J. Li. (2013). Phosphorylated c-src is a novel predictor for 
recurrence in cervical squamous cell cancer patients. International journal of clinical and experimental 
pathology 6: 1121-1127. 
Howlett, C. R., M. D. M. Evans, W. R. Walsh, G. Johnson and J. G. Steele. (1994). Mechanism of initial 
attachment of cells derived from human bone to commonly used prosthetic materials during cell culture. 
Biomaterials 15: 213-222. 
Hozumi, Y., S. Kondo, T. Shimoura and K. Aso. (1990). Human squamous cell carcinoma from skin: 
Establishment and characterization of a new cell line (hsc-5). Journal of Dermatology 17: 143-148. 
Huang, L. and L. Fu. (2015). Mechanisms of resistance to egfr tyrosine kinase inhibitors. Acta Pharmaceutica 
Sinica B 5: 390-401. 
Hughes, P., D. Marshall, Y. Reid, H. Parkes and C. Gelber. (2007). The costs of using unauthenticated, over-
passaged cell lines: How much more data do we need? Biotechniques 43: 575-577. 
Hughes, P. E., K. Rex, S. Caenepeel, Y. Yang, Y. Zhang, M. A. Broome, H. T. Kha, T. L. Burgess, B. Amore, P. 
J. Kaplan-Lefko, J. Moriguchi, J. Werner, M. A. Damore, D. Baker, D. M. Choquette, J. C. Harmange, 
R. Radinsky, R. Kendall, I. Dussault and A. Coxon. (2016). In vitro and in vivo activity of amg 337, a 
potent and selective met kinase inhibitor, in met-dependent cancer models. Molecular Cancer 
Therapeutics 15: 1568-1579. 
Hulsen, T., J. de Vlieg and W. Alkema. (2008). Biovenn – a web application for the comparison and 
visualization of biological lists using area-proportional venn diagrams. BMC Genomics 9: 488. 
Hussein, A. A., T. Forouzanfar, E. Bloemena, J. de Visscher, R. H. Brakenhoff, C. R. Leemans and M. N. 
Helder. (2018). A review of the most promising biomarkers for early diagnosis and prognosis prediction 
of tongue squamous cell carcinoma. British Journal of Cancer 119: 724-736. 
Imbeaud, S., E. Graudens, V. Boulanger, X. Barlet, P. Zaborski, E. Eveno, O. Mueller, A. Schroeder and C. 
Auffray. (2005). Towards standardization of rna quality assessment using user-independent classifiers 
of microcapillary electrophoresis traces. Nucleic Acids Research 33: 56. 
Inagaki, T., S. Matsuwari, R. Takahashi, K. Shimada, K. Fujie and S. Maeda. (1994). Establishment of human 
oral-cancer cell lines (kosc-2 and -3) carrying p53 and c-myc abnormalities by geneticin treatment. 
International Journal of Cancer 56: 301-308. 
Inman, G. J., J. Wang, A. Nagano, L. B. Alexandrov, K. J. Purdie, R. G. Taylor, V. Sherwood, J. Thomson, S. 
Hogan, L. C. Spender, A. P. South, M. Stratton, C. Chelala, C. A. Harwood, C. M. Proby and I. M. 
Leigh. (2018). The genomic landscape of cutaneous scc reveals drivers and a novel azathioprine 
associated mutational signature. Nature Communications 9: 3667. 
Iordache, A. M., A. O. Docea, A. M. Buga, R. Mitrut, D. Albulescu, O. Zlatian, S. Ianosi, G. Ianosi, D. Neagoe, 
M. Sifaki, O. C. Rogoveanu, D. E. Branisteanu and D. Calina. (2019). The incidence of skin lesions in 
contrast media-induced chemical hypersensitivity. Experimental and Therapeutic Medicine 17: 1113-
1124. 
Iyer, K., Z. Chen, T. Ganapa, B. M. Wu, B. Tawil and C. S. Linsley. (2018). Keratinocyte migration in a three-
dimensional in vitro wound healing model co-cultured with fibroblasts. Tissue Eng Regen Med 15: 721-
733. 
Janus, J. M., R. F. L. O'Shaughnessy, C. A. Harwood and T. Maffucci. (2017). Phosphoinositide 3-kinase-
dependent signalling pathways in cutaneous squamous cell carcinomas. Cancers 9: 86. 
Jarkowski, A., 3rd, R. Hare, P. Loud, J. J. Skitzki, J. M. Kane, 3rd, K. S. May, N. C. Zeitouni, J. Nestico, K. L. 
Vona, A. Groman and N. I. Khushalani. (2016). Systemic therapy in advanced cutaneous squamous cell 
carcinoma (cscc): The roswell park experience and a review of the literature. American Journal of 
Clinical Oncology 39: 545-548. 
 283 
 
Jayaraman, S. S., D. J. Rayhan, S. Hazany and M. S. Kolodney. (2014). Mutational landscape of basal cell 
carcinomas by whole-exome sequencing. The Journal of Investigative Dermatology 134: 213-220. 
Ji, Z. W., N. Oku and T. Komori. (2000). Establishment of a novel human squamous cell carcinoma cell line 
from oral primary tumor by geneticin treatment. Kobe J Med Sci 46: 137-145. 
Johansson, N., K. Airola, R. Grenman, A. L. Kariniemi, U. Saarialho-Kere and V. M. Kahari. (1997). Expression 
of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. The 
American Journal of Pathology 151: 499-508. 
Jones, S. J., A. J. Dicker, A. L. Dahler and N. A. Saunders. (1997). E2f as a regulator of keratinocyte 
proliferation: Implications for skin tumor development. The Journal of Investigative Dermatology 109: 
187-193. 
Jørgensen, J. T., K. Norregaard, P. Tian, P. M. Bendix, A. Kjaer and L. B. Oddershede. (2016). Single particle 
and pet-based platform for identifying optimal plasmonic nano-heaters for photothermal cancer therapy. 
Scientific Reports 6: 30076. 
Joseph, M. G., W. P. Zulueta and P. J. Kennedy. (1992). Squamous cell carcinoma of the skin of the trunk and 
limbs: The incidence of metastasis and their outcome. Australian and New Zealand Journal of Surgery 
62: 697-701. 
Joseph, S., L. Endo-Munoz, D. Gaffney, N. Saunders and F. Simpson. (2015). Dysregulation of epidermal 
growth factor receptor in actinic keratosis and squamous cell carcinoma. Current Problems in 
Dermatology 46: 20-27. 
Kalli, M. and T. Stylianopoulos. (2018). Defining the role of solid stress and matrix stiffness in cancer cell 
proliferation and metastasis. Frontiers in oncology 8: 55-55. 
Kalliokoski, T., C. Kramer, A. Vulpetti and P. Gedeck. (2013). Comparability of mixed ic50 data - a statistical 
analysis. PLoS ONE 8: 61007-61007. 
Kalluri, R. and M. Zeisberg. (2006). Fibroblasts in cancer. Nature Reviews. Cancer 6: 392-401. 
Kalu, N. N. and F. M. Johnson. (2017). Do cdk4/6 inhibitors have potential as targeted therapeutics for 
squamous cell cancers? Expert opinion on investigational drugs 26: 207-217. 
Kanehisa, M., M. Furumichi, M. Tanabe, Y. Sato and K. Morishima. (2017). Kegg: New perspectives on 
genomes, pathways, diseases and drugs. Nucleic Acids Research 45: 353-361. 
Karia, P. S., J. Han and C. D. Schmults. (2013). Cutaneous squamous cell carcinoma: Estimated incidence of 
disease, nodal metastasis, and deaths from disease in the united states, 2012. Journal of the American 
Academy of Dermatology 68: 957-966. 
Kathpalia, V. P., E. N. Mussak, S. S. Chow, P. H. Lam, N. Skelley, M. Time, R. J. Markelewicz, D. Kanduc, L. 
Lomas, Z. Xiang and A. A. Sinha. (2006). Genome-wide transcriptional profiling in human squamous 
cell carcinoma of the skin identifies unique tumor-associated signatures. The Journal of Dermatology 
33: 309-318. 
Kaur, G. and J. M. Dufour. (2012). Cell lines: Valuable tools or useless artifacts. Spermatogenesis 2: 1-5. 
Kenny, P. A., G. Y. Lee, C. A. Myers, R. M. Neve, J. R. Semeiks, P. T. Spellman, K. Lorenz, E. H. Lee, M. H. 
Barcellos-Hoff, O. W. Petersen, J. W. Gray and M. J. Bissell. (2007). The morphologies of breast 
cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Molecular 
Oncology 1: 84-96. 
Kerkelä, E., R. Ala-aho, J. Lohi, R. Grénman, V. M-Kähäri and U. Saarialho-Kere. (2001). Differential patterns 
of stromelysin-2 (mmp-10) and mt1-mmp (mmp-14) expression in epithelial skin cancers. British 
Journal of Cancer 84: 659-669. 
Kerkelä, E. and U. Saarialho-Kere. (2003). Matrix metalloproteinases in tumor progression: Focus on basal and 
squamous cell skin cancer. Experimental Dermatology 12: 109-125. 
Kessel, S., S. Cribbes, O. Déry, D. Kuksin, E. Sincoff, J. Qiu and L. Chan. (2016). High-throughput 3d tumor 
spheroid screening method for cancer drug discovery using celigo image cytometry. Journal of 
laboratory automation 22. 
Keuper, M., A. Dzyakanchuk, K. E. Amrein, M. Wabitsch and P. Fischer-Posovszky. (2011). Thp-1 
macrophages and sgbs adipocytes - a new human in vitro model system of inflamed adipose tissue. 
Frontiers in Endocrinology 2: 89-89. 
Kim, J. and J. S. Bae. (2016). Tumor-associated macrophages and neutrophils in tumor microenvironment. 
Mediators of inflammation6058147. 
Kim, M.-C., S.-H. Hwang, N.-Y. Kim, H.-S. Lee, S. Ji, Y. Yang and Y. Kim. (2018). Hypoxia promotes 
acquisition of aggressive phenotypes in human malignant mesothelioma. BMC cancer 18: 819-819. 
Kim, T. W. (2014). Egfr status is not a reliable biomarker to select patients suitable for cetuximab-based therapy. 
Clinical Colorectal Cancer 13: 3-4. 
Kim, T. Y., J. W. Lee, H. P. Kim, H. S. Jong, T. Y. Kim, M. Jung and Y. J. Bang. (2007). Dlc-1, a gtpase-
activating protein for rho, is associated with cell proliferation, morphology, and migration in human 
hepatocellular carcinoma. Biochemical and Biophysical Research Communications 355: 72-77. 
 284 
 
Kimlin, L. C., G. Casagrande and V. M. Virador. (2013). In vitro three-dimensional (3d) models in cancer 
research: An update. Molecular Carcinogenesis 52: 167-182. 
Kittai, A. S., H. Oldham, J. Cetnar and M. Taylor. (2017). Immune checkpoint inhibitors in organ transplant 
patients. Journal of Immunotherapy 40: 277-281. 
Kivisaari, A. and V.-M. Kähäri. (2013). Squamous cell carcinoma of the skin: Emerging need for novel 
biomarkers. World journal of clinical oncology 4: 85-90. 
Kodack, D. P., A. F. Farago, A. Dastur, M. A. Held, L. Dardaei, L. Friboulet, F. von Flotow, L. J. Damon, D. 
Lee, M. Parks, R. Dicecca, M. Greenberg, K. E. Kattermann, A. K. Riley, F. J. Fintelmann, C. Rizzo, Z. 
Piotrowska, A. T. Shaw, J. F. Gainor, L. V. Sequist, M. J. Niederst, J. A. Engelman and C. H. Benes. 
(2017). Primary patient-derived cancer cells and their potential for personalized cancer patient care. 
Cell Reports 21: 3298-3309. 
Koehler, W. C., J. W. Cable, E. O. Wollan and M. K. Wilkinson. (1962). Magnetic structures of thulium. 
Physical Review 126: 1672-1678. 
Komsa-Penkova, R., R. Spirova and B. Bechev. (1996). Modification of lowry's method for collagen 
concentration measurement. Journal of Biochemical and Biophysical Methods 32: 33-43. 
Kondo, S. and K. Aso. (1981). Establishment of a cell line of human skin squamous cell carcinoma in vitro. 
British Journal of Dermatology 105: 125-132. 
Koseki, S., T. Aoki, S. Ansai, Y. Hozumi, Y. Mitsuhashi and S. Kondo. (1999). An immunohistochemical study 
of e-cadherin expression in human squamous cell carcinoma of the skin: Relationship between 
decreased expression of e-cadherin in the primary lesion and regional lymph node metastasis. The 
Journal of Dermatology 26: 416-422. 
Kosmadaki, M. G., M. Yaar, B. L. Arble and B. A. Gilchrest. (2003). Uv induces vegf through a tnf-alpha 
independent pathway. Faseb j 17: 446-448. 
Kruger, A., M. J. Arlt, M. Gerg, C. Kopitz, M. M. Bernardo, M. Chang, S. Mobashery and R. Fridman. (2005). 
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Research 65: 3523-
3526. 
Kumar, S. K., B. LaPlant, W. J. Chng, J. Zonder, N. Callander, R. Fonseca, B. Fruth, V. Roy, C. Erlichman, A. 
K. Stewart and C. Mayo Phase. (2015). Dinaciclib, a novel cdk inhibitor, demonstrates encouraging 
single-agent activity in patients with relapsed multiple myeloma. Blood 125: 443-448. 
L. Stevenson, M., Q.-F. Wang, M. Abikhair Burgo, N. Roudiani, D. Felsen, J. G. Krueger, A. C. Pavlick and J. 
Carucci. (2017). Expression of programmed cell death ligand in cutaneous squamous cell carcinoma 
and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol 153. 
Lambert, A. W., D. R. Pattabiraman and R. A. Weinberg. (2017). Emerging biological principles of metastasis. 
Cell 168: 670-691. 
Lambert, S. R., C. A. Harwood, K. J. Purdie, A. Gulati, R. N. Matin, M. Romanowska, R. Cerio, D. P. Kelsell, I. 
M. Leigh and C. M. Proby. (2012). Metastatic cutaneous squamous cell carcinoma shows frequent 
deletion in the protein tyrosine phosphatase receptor type d gene. International Journal of Cancer 131: 
216-226. 
Le, Q.-T., H. Shirato, A. J. Giaccia and A. C. Koong. (2015). Emerging treatment paradigms in radiation 
oncology. Clinical Cancer Research 21: 3393-3401. 
Lee, D., E.-S. Sung, J.-H. Ahn, S. An, J. Huh and W.-K. You. (2015). Development of antibody-based c-met 
inhibitors for targeted cancer therapy. ImmunoTargets and therapy 4: 35-44. 
Lee, J. M., S. Dedhar, R. Kalluri and E. W. Thompson. (2006). The epithelial-mesenchymal transition: New 
insights in signaling, development, and disease. J Cell Biol 172: 973-981. 
Lee, S. H., K. Y. Shim, B. Kim and J. H. Sung. (2017). Hydrogel-based three-dimensional cell culture for organ-
on-a-chip applications. Biotechnology Progress 33: 580-589. 
Lehembre, F., M. Yilmaz, A. Wicki, T. Schomber, K. Strittmatter, D. Ziegler, A. Kren, P. Went, P. W. Derksen, 
A. Berns, J. Jonkers and G. Christofori. (2008). Ncam-induced focal adhesion assembly: A functional 
switch upon loss of e-cadherin. Embo j 27: 2603-2615. 
Leung, B. M., C. Moraes, S. Cavnar, K. E. Luker, G. D. Luker and S. Takayama. (2015). Microscale 3-d 
collagen cell culture assays in conventional flat-bottom 384-well plates. Journal of laboratory 
automation 20: 138-145. 
Li, H., J. S. Wawrose, W. E. Gooding, L. A. Garraway, V. W. Lui, N. D. Peyser and J. R. Grandis. (2014). 
Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: A rational 
approach to preclinical model selection. Molecular Cancer Research 12: 571-582. 
Li, J., Y. Mitani, P. H. Rao, L. Perlaky, B. Liu, R. S. Weber and A. K. El-Naggar. (2017). Establishment and 
genomic characterization of primary salivary duct carcinoma cell line. Oral Oncology 69: 108-114. 
Li, K., E. Hong, B. Wang, Z. Wang, L. Zhang, R. Hu and B. Wang. (2019). Advances in the application of 
upconversion nanoparticles for detecting and treating cancers. Photodiagnosis and Photodynamic 
Therapy 25: 177-192. 
 285 
 
Li, Y. Y., G. J. Hanna, A. C. Laga, R. I. Haddad, J. H. Lorch and P. S. Hammerman. (2015). Genomic analysis 
of metastatic cutaneous squamous cell carcinoma. Clinical Cancer Research 21: 1447-1456. 
Lim, J. L. and M. Asgari. (2016). Clinical features and diagnosis of cutaneous squamous cell carcinoma (scc). 
Uptodate. R. S. Stern and J. K. Robinson. UpToDate, Waltham, MA. (Accessed on March 22, 2016). 
Lin, C. J., J. R. Grandis, T. E. Carey, S. M. Gollin, T. L. Whiteside, W. M. Koch, R. L. Ferris and S. Y. Lai. 
(2007). Head and neck squamous cell carcinoma cell lines: Established models and rationale for 
selection. Head & Neck 29: 163-188. 
Lin, N., Y. Moroi, H. Uchi, N. Fukiwake, T. Dainichi, S. Takeuchi, M. Takahara, Y. Tu, M. Furue and K. Urabe. 
(2007). Significance of the expression of phosphorylated-stat3, -akt, and -erk1/2 in several tumors of 
the epidermis. Journal of Dermatological Science 48: 71-73. 
Lin, S.-F., J.-D. Lin, C. Hsueh, T.-C. Chou and R. J. Wong. (2017). A cyclin-dependent kinase inhibitor, 
dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE 12: e0172315. 
Liu, J., A. Ebrahimi, T. H. Low, K. Gao, C. E. Palme, C. Sydney, B. G. Ashford, N. G. Iyer, J. R. Clark and R. 
Gupta. (2018). Predictive value of the 8th edition american joint commission cancer (ajcc) nodal 
staging system for patients with cutaneous squamous cell carcinoma of the head and neck. Journal of 
Surgical Oncology 117: 765-772. 
Lukk, M., M. Kapushesky, J. Nikkilä, H. Parkinson, A. Goncalves, W. Huber, E. Ukkonen and A. Brazma. 
(2010). A global map of human gene expression. Nature Biotechnology 28: 322. 
Lupi, O. (2007). Correlations between the sonic hedgehog pathway and basal cell carcinoma. International 
Journal of Dermatology 46: 1113-1117. 
Madar, S., I. Goldstein and V. Rotter. (2013). ‘Cancer associated fibroblasts’ – more than meets the eye. Trends 
in Molecular Medicine 19: 447-453. 
Magrini, S. M., M. Buglione, R. Corvò, L. Pirtoli, F. Paiar, P. Ponticelli, A. Petrucci, A. Bacigalupo, M. 
Crociani, L. Lastrucci, S. Vecchio, P. Bonomo, N. Pasinetti, L. Triggiani, R. Cavagnini, L. Costa, S. 
Tonoli, M. Maddalo and S. Grisanti. (2016). Cetuximab and radiotherapy versus cisplatin and 
radiotherapy for locally advanced head and neck cancer: A randomized phase ii trial. Journal of 
Clinical Oncology 34: 427-435. 
Makki, F. M., A. I. Mendez, S. M. Taylor, J. Trites, M. Bullock, G. Flowerdew and R. D. Hart. (2013). 
Prognostic factors for metastatic cutaneous squamous cell carcinoma of the parotid. Journal of 
Otolaryngology - Head & Neck Surgery 42: 14. 
Maleki, M., F. Ghanbarvand, M. Reza Behvarz, M. Ejtemaei and E. Ghadirkhomi. (2014). Comparison of 
mesenchymal stem cell markers in multiple human adult stem cells. International journal of stem cells 
7: 118-126. 
Mani, S. A., W. Guo, M.-J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, 
M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang and R. A. Weinberg. (2008). The 
epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. 
Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, 
M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang and R. A. Weinberg. (2008). The 
epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. 
Marks, R. (1995). The epidemiology of non-melanoma skin cancer: Who, why and what can we do about it. The 
Journal of Dermatology 22: 853-857. 
Marks, R., G. Rennie and T. S. Selwood. (1988). Malignant transformation of solar keratoses to squamous cell 
carcinoma. Lancet 1: 795-797. 
Martincorena, I., A. Roshan, M. Gerstung, P. Ellis, P. Van Loo, S. McLaren, D. C. Wedge, A. Fullam, L. B. 
Alexandrov, J. M. Tubio, L. Stebbings, A. Menzies, S. Widaa, M. R. Stratton, P. H. Jones and P. J. 
Campbell. (2015). Tumor evolution. High burden and pervasive positive selection of somatic mutations 
in normal human skin. Science (New York, N.Y.) 348: 880-886. 
Massacesi, C., E. Di Tomaso, P. Urban, C. Germa, C. Quadt, L. Trandafir, P. Aimone, N. Fretault, B. Dharan, R. 
Tavorath and S. Hirawat. (2016). Pi3k inhibitors as new cancer therapeutics: Implications for clinical 
trial design. OncoTargets and therapy 9: 203-210. 
Mateus, C. (2014). Cutaneous squamous cell carcinoma. Rev Prat 64: 45-52. 
Matsumoto, T., J. Jiang, K. Kiguchi, L. Ruffino, S. Carbajal, L. Beltran, D. K. Bol, M. P. Rosenberg and J. 
DiGiovanni. (2003). Targeted expression of c-src in epidermal basal cells leads to enhanced skin tumor 
promotion, malignant progression, and metastasis. Cancer Research 63: 4819-4828. 
Mauretti, A., F. Rossi, N. A. M. Bax, C. Miano, F. Miraldi, M. J. Goumans, E. Messina, A. Giacomello, C. V. C. 
Bouten and C. Sahlgren. (2017). Spheroid three-dimensional culture enhances notch signaling in 
cardiac progenitor cells. MRS Communications 7: 496-501. 
McDonald, M., S. Corde, M. Lerch, A. Rosenfeld, M. Jackson and M. Tehei. (2018). First in vitro evidence of 
modulated electro-hyperthermia treatment performance in combination with megavoltage radiation by 
clonogenic assay. Scientific Reports 8: 16608-16608. 
 286 
 
Mebarki, S., R. Désert, L. Sulpice, M. Sicard, M. Desille, F. Canal, H. D.-P. Schneider, D. Bergeat, B. Turlin, P. 
Bellaud, E. Lavergne, R. L. Guével, A. Corlu, C. Perret, C. Coulouarn, B. Clément and O. Musso. 
(2016). De novo hapln1 expression hallmarks wnt-induced stem cell and fibrogenic networks leading to 
aggressive human hepatocellular carcinomas. Oncotarget 7: 39026-39043. 
Mekkawy, A. H., M. H. Pourgholami and D. L. Morris. (2014). Involvement of urokinase-type plasminogen 
activator system in cancer: An overview. Medicinal Research Reviews 34: 918-956. 
Menyhárt, O., H. Harami-Papp, S. Sukumar, R. Schäfer, L. Magnani, O. de Barrios and B. Győrffy. (2016). 
Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochimica et 
Biophysica Acta (BBA) - Reviews on Cancer 1866: 300-319. 
Migden, M. R., D. Rischin, C. D. Schmults, A. Guminski, A. Hauschild, K. D. Lewis, C. H. Chung, L. 
Hernandez-Aya, A. M. Lim, A. L. S. Chang, G. Rabinowits, A. A. Thai, L. A. Dunn, B. G. M. Hughes, 
N. I. Khushalani, B. Modi, D. Schadendorf, B. Gao, F. Seebach, S. Li, J. Li, M. Mathias, J. Booth, K. 
Mohan, E. Stankevich, H. M. Babiker, I. Brana, M. Gil-Martin, J. Homsi, M. L. Johnson, V. Moreno, J. 
Niu, T. K. Owonikoko, K. P. Papadopoulos, G. D. Yancopoulos, I. Lowy and M. G. Fury. (2018). Pd-1 
blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of 
Medicine 379: 341-351. 
Miller, D. M., B. E. Faulkner-Jones, J. R. Stone and R. E. Drews. (2017). Complete pathologic response of 
metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination 
immune checkpoint blockade. JAAD case reports 3: 412-415. 
Miller, S. J., P. J. Jensen, L. M. Dzubow and G. S. Lazarus. (1992). Urokinase plasminogen activator is 
immunocytochemically detectable in squamous cell but not basal cell carcinomas. Journal of 
Investigative Dermatology 98: 351-358. 
Mistry, I. N., M. Thomas, E. D. D. Calder, S. J. Conway and E. M. Hammond. (2017). Clinical advances of 
hypoxia-activated prodrugs in combination with radiation therapy. International Journal of Radiation 
Oncology 98: 1183-1196. 
Mitra, A., L. Mishra and S. Li. (2013). Technologies for deriving primary tumor cells for use in personalized 
cancer therapy. Trends in biotechnology 31: 347-354. 
Mitsudo, K., A. Jayakumar, Y. Henderson, M. J. Frederick, Y. Kang, M. Wang, A. K. El-Naggar and G. L. 
Clayman. (2003). Inhibition of serine proteinases plasmin, trypsin, subtilisin a, cathepsin g, and elastase 
by lekti: A kinetic analysis. Biochemistry 42: 3874-3881. 
Mitsui, H., M. Suárez-Fariñas, N. Gulati, K. R. Shah, M. V. Cannizzaro, I. Coats, D. Felsen, J. G. Krueger and J. 
A. Carucci. (2014). Gene expression profiling of the leading edge of cutaneous squamous cell 
carcinoma: Il-24-driven mmp-7. The Journal of Investigative Dermatology 134: 1418-1427. 
Moeckelmann, N., A. Ebrahimi, R. Dirven, J. Liu, T. H. Low, R. Gupta, B. Ashford, S. Ch'ng, C. E. Palme and J. 
R. Clark. (2018). Analysis and comparison of the 8th edition american joint committee on cancer (ajcc) 
nodal staging system in cutaneous and oral squamous cell cancer of the head and neck. Annals of 
Surgical Oncology 25: 1730-1736. 
Moeller, B. J. and M. W. Dewhirst. (2006). Hif-1 and tumour radiosensitivity. British Journal of Cancer 95: 1-5. 
Montuori, N., A. Pesapane, F. W. Rossi, V. Giudice, A. De Paulis, C. Selleri and P. Ragno. (2016). Urokinase 
type plasminogen activator receptor (upar) as a new therapeutic target in cancer. Transl Med UniSa 15: 
15-21. 
Morgillo, F., C. M. Della Corte, M. Fasano and F. Ciardiello. (2016). Mechanisms of resistance to egfr-targeted 
drugs: Lung cancer. ESMO Open 1. 
Morosin, T., B. Ashford, M. Ranson, K. Spring, R. Gupta, J. Clark and N. Gopalakrishna Iyer. (2016). 
Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: A pilot study. 
Oncotarget 7: 47111-47115. 
Mouriaux, F., K. Zaniolo, M.-A. Bergeron, C. Weidmann, A. De La Fouchardière, F. Fournier, A. Droit, M. W. 
Morcos, S. Landreville and S. L. Guérin. (2016). Effects of long-term serial passaging on the 
characteristics and properties of cell lines derived from uveal melanoma primary tumors. Investigative 
Ophthalmology & Visual Science 57: 5288-5301. 
Moussai, D., H. Mitsui, J. S. Pettersen, K. C. Pierson, K. R. Shah, M. Suárez-fariñas, I. R. Cardinale, M. J. 
Bluth, J. G. Krueger and J. A. Carucci. (2011). The human cutaneous squamous cell carcinoma 
microenvironment is characterized by increased lymphatic density and enhanced expression of 
macrophage-derived vegf-c. The Journal of Investigative Dermatology 131: 229-236. 
Mueller, S. A., M.-E. A. Gauthier, B. Ashford, R. Gupta, V. Gayevskiy, S. Ch’ng, C. E. Palme, K. Shannon, J. 
R. Clark, M. Ranson and M. J. Cowley. (2019). Mutational patterns in metastatic cutaneous squamous 
cell carcinoma. Journal of Investigative Dermatology. 
Munguía‐Calzada, P., I. Fernández-Vega, P. Martínez-Camblor, S. Díaz Coto, J. María García‐Pedrero, B. 
Vivanco, C. Galache Osuna, F. Vazquez‐Lopez, J. Rodrigo and J. Santos‐Juanes. (2018). Correlation of 
 287 
 
focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous 
squamous cell carcinoma. Head & Neck1-7. 
Nakamura, K., R. Okuyama, T. Saida and H. Uhara. (2013). Platinum and anthracycline therapy for advanced 
cutaneous squamous cell carcinoma. International Journal of Clinical Oncology 18: 506-509. 
Nam, S., W. Wen, A. Schroeder, A. Herrmann, H. Yu, X. Cheng, K.-H. Merz, G. Eisenbrand, H. Li, Y.-C. Yuan 
and R. Jove. (2013). Dual inhibition of janus and src family kinases by novel indirubin derivative 
blocks constitutively-activated stat3 signaling associated with apoptosis of human pancreatic cancer 
cells. Molecular Oncology 7: 369-378. 
Nelson, T. G. and R. E. Ashton. (2017). Low incidence of metastasis and recurrence from cutaneous squamous 
cell carcinoma found in a uk population: Do we need to adjust our thinking on this rare but potentially 
fatal event? Journal of Surgical Oncology 116: 783-788. 
Nie, X. J., W. M. Liu and L. Zhang. (2016). Association of vegf gene polymorphisms with the risk and prognosis 
of cutaneous squamous cell carcinoma. Med Sci Monit 22: 3658-3665. 
Nissinen, L., M. Farshchian, P. Riihilä and V.-M. Kähäri. (2016). New perspectives on role of tumor 
microenvironment in progression of cutaneous squamous cell carcinoma. Cell and Tissue Research 365: 
691-702. 
Niu, N. and L. Wang. (2015). In vitro human cell line models to predict clinical response to anticancer drugs. 
Pharmacogenomics 16: 273-285. 
Norris, W. D., J. G. Steele, G. Johnson and P. A. Underwood. (1990). Serum enhancement of human endothelial 
cell attachment to and spreading on collagens i and iv does not require serum fibronectin or vitronectin. 
Journal of Cell Science & Therapy 95 ( Pt 2): 255-262. 
Nunes, A. S., A. S. Barros, E. C. Costa, A. F. Moreira and I. J. Correia. (2019). 3d tumor spheroids as in vitro 
models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnology and 
Bioengineering 116: 206-226. 
Nuno-Gonzalez, A., F. J. Vicente-Martin, F. Pinedo-Moraleda and J. L. Lopez-Estebaranz. (2012). High-risk 
cutaneous squamous cell carcinoma. Actas Dermo-Sifiliograficas 103: 567-578. 
O'Brien, C. J. (2005). The parotid gland as a metastatic basin for cutaneous cancer. Archives of otolaryngology-
head & neck surgery 131: 551-555. 
Oddone, N., G. J. Morgan, C. E. Palme, L. Perera, J. Shannon, E. Wong, V. Gebski and M. J. Veness. (2009). 
Metastatic cutaneous squamous cell carcinoma of the head and neck. Cancer 115: 1883-1891. 
Ozsolak, F. and P. M. Milos. (2011). Rna sequencing: Advances, challenges and opportunities. Nature reviews. 
Genetics 12: 87-98. 
Pagliarini, R., W. Shao and W. R. Sellers. (2015). Oncogene addiction: Pathways of therapeutic response, 
resistance, and road maps toward a cure. EMBO Reports 16: 280-296. 
Pan, C., C. Kumar, S. Boh, U. Klingmueller and M. Mann. (2009). Comparative proteomic phenotyping of cell 
lines and primary cells to assess preservation of cell type-specific functions. Molecular & cellular 
proteomics 8: 443-450. 
Papathoma, A. S., C. Petraki, A. Grigorakis, H. Papakonstantinou, V. Karavana, S. Stefanakis, F. Sotsiou and A. 
Pintzas. (2000). Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. 
Anticancer Research 20: 2009-2013. 
Parker, J. S., M. Mullins, M. C. U. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, 
J. F. Quackenbush, I. J. Stijleman, J. Palazzo, J. S. Marron, A. B. Nobel, E. Mardis, T. O. Nielsen, M. J. 
Ellis, C. M. Perou and P. S. Bernard. (2009). Supervised risk predictor of breast cancer based on 
intrinsic subtypes. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 27: 1160-1167. 
Patel, P. G., S. Selvarajah, K. P. Guerard, J. M. S. Bartlett, J. Lapointe, D. M. Berman and J. B. A. Okello. 
(2017). Reliability and performance of commercial rna and DNA extraction kits for ffpe tissue cores.  
12. 
Pathak, A. P., D. Artemov, M. Neeman and Z. M. Bhujwalla. (2006). Lymph node metastasis in breast cancer 
xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and 
invasive phenotype. Cancer Research 66: 5151-5158. 
Pauli, C., B. D. Hopkins, D. Prandi, R. Shaw, T. Fedrizzi, A. Sboner, V. Sailer, M. Augello, L. Puca, R. Rosati, 
T. J. McNary, Y. Churakova, C. Cheung, J. Triscott, D. Pisapia, R. Rao, J. M. Mosquera, B. Robinson, 
B. M. Faltas, B. E. Emerling, V. K. Gadi, B. Bernard, O. Elemento, H. Beltran, F. Demichelis, C. J. 
Kemp, C. Grandori, L. C. Cantley and M. A. Rubin. (2017). Personalized in vitro and in vivo cancer 
models to guide precision medicine. Cancer Discovery 7: 462-477. 
Paver, K., K. Poyzer, N. Burry and M. Deakin. (1973). Letter: The incidence of basal cell carcinoma and their 
metastases in australia and new zealand. Australas J Dermatol 14: 53. 
 288 
 
Pearce, A. G., T. M. Segura, A. C. Rintala, N. D. Rintala-Maki and H. Lee. (2001). The generation and 
characterization of a radiation-resistant model system to study radioresistance in human breast cancer 
cells. Radiation Research 156: 739-750. 
Peat, B., P. Insull and R. Ayers. (2012). Risk stratification for metastasis from cutaneous squamous cell 
carcinoma of the head and neck. ANZ Journal of Surgery 82: 230-233. 
Pekkola-Heino, K., M. Jaakkola, J. Kulmala and R. Grenman. (1995). Comparison of cellular radiosensitivity 
between different localizations of head and neck squamous-cell carcinoma. Journal of Cancer Research 
and Clinical Oncology 121: 452-456. 
Pekkola-Heino, K., Kulmala, J., Grenman, R. (1992). Sublethal damage repair in squamous cell carcinoma cell 
lines. Head & Neck 14: 196-199. 
Peng, Q., L. Zhao, Y. Hou, Y. Sun, L. Wang, H. Luo, H. Peng and M. Liu. (2013). Biological characteristics and 
genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in 
human breast cancer. PLoS ONE 8. 
Perera, E., N. Gnaneswaran, C. Staines, A. K. Win and R. Sinclair. (2015). Incidence and prevalence of non-
melanoma skin cancer in australia: A systematic review. Australas J Dermatol 56: 258-267. 
Petter, G. and U. F. Haustein. (2000). Histologic subtyping and malignancy assessment of cutaneous squamous 
cell carcinoma. Dermatologic surgery : official publication for American Society for Dermatologic 
Surgery 26: 521-530. 
Phillips, T. M., W. H. McBride and F. Pajonk. (2006). The response of cd24(-/low)/cd44+ breast cancer-
initiating cells to radiation. Journal of the National Cancer Institute 98: 1777-1785. 
Pickering, C. R., J. H. Zhou, J. J. Lee, J. A. Drummond, S. A. Peng, R. E. Saade, K. Y. Tsai, J. L. Curry, M. T. 
Tetzlaff, S. Y. Lai, J. Yu, D. M. Muzny, H. Doddapaneni, E. Shinbrot, K. R. Covington, J. Zhang, S. 
Seth, C. Caulin, G. L. Clayman, A. K. El-Naggar, R. A. Gibbs, R. S. Weber, J. N. Myers, D. A. 
Wheeler and M. J. Frederick. (2014). Mutational landscape of aggressive cutaneous squamous cell 
carcinoma. Clinical Cancer Research 20: 6582-6592. 
Porceddu, S. V., M. Bressel, M. G. Poulsen, A. Stoneley, M. J. Veness, L. M. Kenny, C. Wratten, J. Corry, S. 
Cooper, G. B. Fogarty, M. Collins, M. K. Collins, A. M. J. Macann, C. G. Milross, M. G. Penniment, H. 
Y.-h. Liu, M. T. King, B. J. Panizza and D. Rischin. (2018). Postoperative concurrent 
chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma 
of the head and neck: The randomized phase iii trog 05.01 trial. Journal of Clinical Oncology 36: 1275-
1283. 
Pourreyron, C., K. J. Purdie, S. A. Watt and A. P. South. (2011). Feeder layers: Co-culture with nonneoplastic 
cells. Cancer cell culture: Methods and protocols. I. A. Cree. Totowa, NJ, Humana Press. 467-470. 
Prasad, N. B., A. C. Fischer, A. Y. Chuang, J. M. Wright, T. Yang, H.-L. Tsai, W. H. Westra, N. J. Liegeois, A. 
D. Hess and A. P. Tufaro. (2014). Differential expression of degradome components in cutaneous 
squamous cell carcinomas. Modern pathology: an official journal of the United States and Canadian 
Academy of Pathology, Inc 27: 945-957. 
Proby, C. M., K. J. Purdie, C. J. Sexton, P. Purkis, H. A. Navsaria, J. N. Stables and I. M. Leigh. (2000). 
Spontaneous keratinocyte cell lines representing early and advanced stages of malignant transformation 
of the epidermis. Experimental Dermatology 9: 104-117. 
Prokopec, S. D., J. D. Watson, D. M. Waggott, A. B. Smith, A. H. Wu, A. B. Okey, R. Pohjanvirta and P. C. 
Boutros. (2013). Systematic evaluation of medium-throughput mrna abundance platforms. RNA (New 
York, N.Y.) 19: 51-62. 
Purdie, K. J., C. Pourreyron and A. P. South. (2011). Isolation and culture of squamous cell carcinoma lines. 
Cancer cell culture: Methods and protocols. A. I. Cree. Totowa, NJ, Humana Press. 151-159. 
Qin, X., M. Yan, J. Zhang, Q. Xu, Z. Lv and W. Chen. (2016). Establishment of a highly metastatic buccal 
squamous cell carcinoma cell line from a sprague-dawley rat. Archives of Oral Biology 62: 1-9. 
Que, S. K. T., F. O. Zwald and C. D. Schmults. (2018). Cutaneous squamous cell carcinoma: Management of 
advanced and high-stage tumors. Journal of the American Academy of Dermatology 78: 249-261. 
Ra, S. H., X. Li and S. Binder. (2011). Molecular discrimination of cutaneous squamous cell carcinoma from 
actinic keratosis and normal skin. Modern Pathology 24: 963. 
Radisky, E. S., M. Raeeszadeh-Sarmazdeh and D. C. Radisky. (2017). Therapeutic potential of matrix 
metalloproteinase inhibition in breast cancer. Journal of cellular biochemistry 118: 3531-3548. 
Rasmussen, C., C. Thomas-Virnig and B. L. Allen-Hoffmann. (2013). Classical human epidermal keratinocyte 
cell culture. Epithelial cell culture protocols: Second edition. S. H. Randell and M. L. Fulcher. Totowa, 
NJ, Humana Press. 161-175. 
Ratushny, V., M. D. Gober, R. Hick, T. W. Ridky and J. T. Seykora. (2012). From keratinocyte to cancer: The 
pathogenesis and modeling of cutaneous squamous cell carcinoma. The Journal of Clinical 
Investigation 122: 464-472. 
 289 
 
Ravi, M., V. Paramesh, S. R. Kaviya, E. Anuradha and F. D. Solomon. (2015). 3d cell culture systems: 
Advantages and applications. Journal of Cellular Physiology 230: 16-26. 
Rege, T. A. and J. S. Hagood. (2006). Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon 
regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. The FASEB Journal 20: 1045-1054. 
Reule, R. B. (2009). Treatment of cutaneous squamous cell carcinoma with perineural invasion using mohs 
micrographic surgery report of two cases and review of the literature. Dermatologic Surgery 35: 1559-
1566. 
Reya, T., S. J. Morrison, M. F. Clarke and I. L. Weissman. (2001). Stem cells, cancer, and cancer stem cells. 
Nature 414: 105-111. 
Rheinwald, J. G. and H. Green. (1975). Serial cultivation of strains of human epidermal keratinocytes: The 
formation of keratinizing colonies from single cells. Cell 6: 331-343. 
Ribero, S., L. S. Stucci, G. A. Daniels and L. Borradori. (2017). Drug therapy of advanced cutaneous squamous 
cell carcinoma: Is there any evidence? Current Opinion in Oncology 29: 129-135. 
Rodewald, H. R. and T. N. Sato. (1996). Tie1, a receptor tyrosine kinase essential for vascular endothelial cell 
integrity, is not critical for the development of hematopoietic cells. Oncogene 12: 397-404. 
Rodríguez-Paredes, M., F. Bormann, G. Raddatz, J. Gutekunst, C. Lucena-Porcel, F. Köhler, E. Wurzer, K. 
Schmidt, S. Gallinat, H. Wenck, J. Röwert-Huber, E. Denisova, L. Feuerbach, J. Park, B. Brors, E. 
Herpel, I. Nindl, T. G. Hofmann, M. Winnefeld and F. Lyko. (2018). Methylation profiling identifies 
two subclasses of squamous cell carcinoma related to distinct cells of origin. Nature Communications 9: 
577. 
Rømer, J., C. Pyke, L. R. Lund, K. Danø and E. Ralfkiær. (2001). Cancer cell expression of urokinase-type 
plasminogen activator receptor mrna in squamous cell carcinomas of the skin. Journal of Investigative 
Dermatology 116: 353-358. 
Roy, R., J. Yang and M. A. Moses. (2009). Matrix metalloproteinases as novel biomarkers and potential 
therapeutic targets in human cancer. Journal of clinical oncology: official journal of the American 
Society of Clinical Oncology 27: 5287-5297. 
Ruzevick, J., A. Olivi and W. H. Westra. (2013). Metastatic squamous cell carcinoma to the brain: An 
unrecognized pattern of distant spread in patients with hpv-related head and neck cancer. Journal of 
Neuro-Oncology 112: 449-454. 
Rycaj, K. and D. G. Tang. (2014). Cancer stem cells and radioresistance. International Journal of Radiation 
Biology 90: 615-621. 
Sahlberg, S. H., D. Spiegelberg, B. Glimelius, B. Stenerlöw and M. Nestor. (2014). Evaluation of cancer stem 
cell markers cd133, cd44, cd24: Association with akt isoforms and radiation resistance in colon cancer 
cells. PLoS ONE 9: e94621. 
Saito, N., N. Hirai, K. Aoki, R. Suzuki, S. Fujita, H. Nakayama, M. Hayashi, K. Ito, T. Sakurai and S. Iwabuchi. 
(2019). The oncogene addiction switch from notch to pi3k requires simultaneous targeting of notch and 
pi3k pathway inhibition in glioblastoma. Cancers 11: 121. 
Samsanavicius, D., V. Kaikaris, A. Cepas, J. Ulrich, J. Makstiene and R. Rimdeika. (2018). Importance of 
sentinel lymphatic node biopsy in detection of early micrometastases in patients with cutaneous 
squamous cell carcinoma. Journal of Plastic, Reconstructive & Aesthetic Surgery 71: 597-603. 
Samstein, R. M., A. L. Ho, N. Y. Lee and C. A. Barker. (2014). Locally advanced and unresectable cutaneous 
squamous cell carcinoma: Outcomes of concurrent cetuximab and radiotherapy. Journal of Skin Cancer 
2014: 7. 
Sappino, A. P., D. Belin, J. Huarte, S. Hirschel-Scholz, J. H. Saurat and J. D. Vassalli. (1991). Differential 
protease expression by cutaneous squamous and basal cell carcinomas. The Journal of Clinical 
Investigation 88: 1073-1079. 
Sawaya, R. E., M. Yamamoto, Z. L. Gokaslan, S. W. Wang, S. Mohanam, G. N. Fuller, I. E. McCutcheon, W. G. 
Stetler-Stevenson, G. L. Nicolson and J. S. Rao. (1996). Expression and localization of 72 kda type iv 
collagenase (mmp-2) in human malignant gliomas in vivo. Clinical & Experimental Metastasis 14: 35-
42. 
Schipper, J. H., U. H. Frixen, J. Behrens, A. Unger, K. Jahnke and W. Birchmeier. (1991). E-cadherin expression 
in squamous cell carcinomas of head and neck: Inverse correlation with tumor dedifferentiation and 
lymph node metastasis. Cancer Research 51: 6328-6337. 
Sedlacek, H. H. (2001). Mechanisms of action of flavopiridol. Critical Reviews in Oncology/Hematology 38: 
139-170. 
Seyfried, T. N. and L. C. Huysentruyt. (2013). On the origin of cancer metastasis. Critical reviews in 
oncogenesis 18: 43-73. 
Shamir, E. R. and A. J. Ewald. (2014). Three-dimensional organotypic culture: Experimental models of 
mammalian biology and disease. Nat Rev Mol Cell Biol 15: 647-664. 
 290 
 
Sharma, S. V., D. A. Haber and J. Settleman. (2010). Cell line-based platforms to evaluate the therapeutic 
efficacy of candidate anticancer agents. Nature Reviews Cancer 10: 241. 
Shian, S. G., Y. R. Kao, F. Y. Wu and C. W. Wu. (2003). Inhibition of invasion and angiogenesis by zinc-
chelating agent disulfiram. Molecular Pharmacology 64: 1076-1084. 
Silva-Oliveira, R. J., M. Melendez, O. Martinho, M. F. Zanon, L. de Souza Viana, A. L. Carvalho and R. M. 
Reis. (2017). Akt can modulate the in vitro response of hnscc cells to irreversible egfr inhibitors. 
Oncotarget 8: 53288-53301. 
Silver, N., S. Best, J. Jiang and S. L. Thein. (2006). Selection of housekeeping genes for gene expression studies 
in human reticulocytes using real-time pcr. BMC Molecular Biology 7: 33. 
Simioni, C., A. Cani, A. M. Martelli, G. Zauli, A. A. M. Alameen, S. Ultimo, G. Tabellini, J. A. McCubrey, S. 
Capitani and L. M. Neri. (2015). The novel dual pi3k/mtor inhibitor nvp-bgt226 displays cytotoxic 
activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 6: 17147-17160. 
Slevin, M. L. (1991). The clinical pharmacology of etoposide. Cancer 67: 319-329. 
Sohn, B. S., Y. J. Yuh, H. S. Song, B.-S. Kim, K. H. Lee, J.-S. Jang and S. R. Kim. (2015). Triplet cytotoxic 
chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncology 
letters 10: 1204-1210. 
Somaiah, C., A. Kumar, D. Mawrie, A. Sharma, S. D. Patil, J. Bhattacharyya, R. Swaminathan and B. G. 
Jaganathan. (2015). Collagen promotes higher adhesion, survival and proliferation of mesenchymal 
stem cells. PLoS ONE 10: e0145068. 
Sondka, Z., S. Bamford, C. G. Cole, S. A. Ward, I. Dunham and S. A. Forbes. (2018). The cosmic cancer gene 
census: Describing genetic dysfunction across all human cancers. Nature Reviews Cancer 18: 696-705. 
South, A. P., K. J. Purdie, S. A. Watt, S. Haldenby, N. Y. den Breems, M. Dimon, S. T. Arron, M. J. Kluk, J. C. 
Aster, A. McHugh, D. J. Xue, J. H. Dayal, K. S. Robinson, S. M. Rizvi, C. M. Proby, C. A. Harwood 
and I. M. Leigh. (2014). Notch1 mutations occur early during cutaneous squamous cell carcinogenesis. 
The Journal of Investigative Dermatology 134: 2630-2638. 
Srikumar, T. and J. Padmanabhan. (2016). Potential use of flavopiridol in treatment of chronic diseases. Drug 
discovery from mother nature. S. C. Gupta, S. Prasad and B. B. Aggarwal. Cham, Springer International 
Publishing. 209-228. 
Staples, M. P., M. Elwood, R. C. Burton, J. L. Williams, R. Marks and G. G. Giles. (2006). Non-melanoma skin 
cancer in australia: The 2002 national survey and trends since 1985. Med J Aust 184: 6-10. 
Stark, H. J., M. Baur, D. Breitkreutz, N. Mirancea and N. E. Fusenig. (1999). Organotypic keratinocyte 
cocultures in defined medium with regular epidermal morphogenesis and differentiation. The Journal of 
Investigative Dermatology 112: 681-691. 
Stewart, G., J. Nanda, E. Katz, K. Bowman, J. G Christie, D. J. Gordon Brown, D. McLaren, A. Riddick, J. A 
Ross, G. Jones and F. Habib. (2010). DNA strand breaks and hypoxia response inhibition mediate the 
radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. 
Biochemical pharmacology 81: 203-210. 
Stillfried, G. E., D. N. Saunders and M. Ranson. (2007). Plasminogen binding and activation at the breast cancer 
cell surface: The integral role of urokinase activity. Breast Cancer Res 9: 14. 
Strassen, U., B. Hofauer, C. Jacobi and A. Knopf. (2017). Management of locoregional recurrence in cutaneous 
squamous cell carcinoma of the head and neck. European Archives of Oto-Rhino-Laryngology 274: 
501-506. 
Stratigos, A., C. Garbe, C. Lebbe, J. Malvehy, V. del Marmol, H. Pehamberger, K. Peris, J. C. Becker, I. 
Zalaudek, P. Saiag, M. R. Middleton, L. Bastholt, A. Testori and J.-J. Grob. (2015). Diagnosis and 
treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary 
guideline. European Journal of Cancer 51: 1989-2007. 
Su, S. C., C. W. Lin, W. E. Yang, W. L. Fan and S. F. Yang. (2016). The urokinase-type plasminogen activator 
(upa) system as a biomarker and therapeutic target in human malignancies. Expert Opinion on 
Therapeutic Targets 20: 551-566. 
Szabo, R., A. L. Rasmussen, A. B. Moyer, P. Kosa, J. M. Schafer, A. A. Molinolo, J. S. Gutkind and T. H. 
Bugge. (2011). C-met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. 
Oncogene 30: 2003. 
Tadokoro, A., N. Kanaji, D. Liu, H. Yokomise, R. Haba, T. Ishii, T. Takagi, N. Watanabe, N. Kita, N. Kadowaki 
and S. Bandoh. (2016). Vimentin regulates invasiveness and is a poor prognostic marker in non-small 
cell lung cancer. Anticancer Research 36: 1545-1551. 
Tanvetyanon, T., T. Padhya, J. McCaffrey, J. A. Kish, R. C. Deconti, A. Trotti and N. G. Rao. (2015). 
Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell 
carcinoma of the head and neck. Head & Neck 37: 840-845. 
Thiery, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. Nature Reviews Cancer 2: 442. 
 291 
 
Thiery, J. P., H. Acloque, R. Y. Huang and M. A. Nieto. (2009). Epithelial-mesenchymal transitions in 
development and disease. Cell 139: 871-890. 
Thoma, C. R., M. Zimmermann, I. Agarkova, J. M. Kelm and W. Krek. (2014). 3d cell culture systems modeling 
tumor growth determinants in cancer target discovery. Advanced Drug Delivery Reviews 69-70: 29-41. 
Thompson, A. K., B. F. Kelley, L. J. Prokop, M. H. Murad and C. L. Baum. (2016). Risk factors for cutaneous 
squamous cell carcinoma recurrence, metastasis, and disease-specific death: A systematic review and 
meta-analysis. JAMA Dermatol 152: 419-428. 
Tian, M., Y.-Z. Cui, G.-H. Song, M.-J. Zong, X.-Y. Zhou, Y. Chen and J.-X. Han. (2008). Proteomic analysis 
identifies mmp-9, dj-1 and a1bg as overexpressed proteins in pancreatic juice from pancreatic ductal 
adenocarcinoma patients. BMC cancer 8: 241-241. 
Timpson, P., E. J. McGhee, Z. Erami, M. Nobis, J. A. Quinn, M. Edward and K. I. Anderson. (2011). 
Organotypic collagen i assay: A malleable platform to assess cell behaviour in a 3-dimensional context. 
Journal of Visualized Experiments3089. 
Toll, A., P. Margalef, E. Masferrer, C. Ferrándiz-Pulido, J. Gimeno, R. M. Pujol, A. Bigas and L. Espinosa. 
(2015). Active nuclear ikk correlates with metastatic risk in cutaneous squamous cell carcinoma. 
Archives of Dermatological Research 307: 721-729. 
Toll, A., E. Masferrer, M. E. Hernández-Ruiz, C. Ferrandiz-Pulido, M. Yébenes, A. Jaka, A. Tuneu, A. Jucglà, J. 
Gimeno, T. Baró, B. Casado, A. Gandarillas, I. Costa, S. Mojal, R. Peña, A. G. de Herreros, V. García-
Patos, R. M. Pujol and I. Hernández-Muñoz. (2013). Epithelial to mesenchymal transition markers are 
associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are 
attenuated in lymph node metastases. Journal of Dermatological Science 72: 93-102. 
Torti, D. and L. Trusolino. (2011). Oncogene addiction as a foundational rationale for targeted anti-cancer 
therapy: Promises and perils. EMBO Molecular Medicine 3: 623-636. 
Trapnell, C., D. G. Hendrickson, M. Sauvageau, L. Goff, J. L. Rinn and L. Pachter. (2013). Differential analysis 
of gene regulation at transcript resolution with rna-seq. Nature Biotechnology 31: 46-53. 
Trapnell, C., A. Roberts, L. Goff, G. Pertea, D. Kim, D. R. Kelley, H. Pimentel, S. L. Salzberg, J. L. Rinn and L. 
Pachter. (2012). Differential gene and transcript expression analysis of rna-seq experiments with tophat 
and cufflinks. Nature Protocols 7: 562-578. 
Tripathi, B. K. and D. R. Lowy. (2017). Dlc1: A tumor suppressor that regulates rho signaling. Oncotarget 8: 
27674-27675. 
Trodello, C., J. P. Pepper, M. Wong and A. Wysong. (2017). Cisplatin and cetuximab treatment for metastatic 
cutaneous squamous cell carcinoma: A systematic review. Dermatologic Surgery 43: 40-49. 
Tsang, H.-F., V. W. Xue, S.-P. Koh, Y.-M. Chiu, L. P.-W. Ng and S.-C. C. Wong. (2017). Nanostring, a novel 
digital color-coded barcode technology: Current and future applications in molecular diagnostics. 
Expert Review of Molecular Diagnostics 17: 95-103. 
Tung, Y. C., A. Y. Hsiao, S. G. Allen, Y. S. Torisawa, M. Ho and S. Takayama. (2011). High-throughput 3d 
spheroid culture and drug testing using a 384 hanging drop array. Analyst 136: 473-478. 
Turin, I., R. Schiavo, M. Maestri, O. Luinetti, B. Bello, M. Paulli, P. Dionigi, M. Roccio, A. Spinillo, F. Ferulli, 
M. Tanzi, R. Maccario, D. Montagna and P. Pedrazzoli. (2014). In vitro efficient expansion of tumor 
cells deriving from different types of human tumor samples. Medical Sciences 2: 70. 
Tutton, M. G., M. L. George, S. A. Eccles, S. Burton, R. I. Swift and A. M. Abulafi. (2003). Use of plasma 
mmp-2 and mmp-9 levels as a surrogate for tumour expression in colorectal cancer patients. 
International Journal of Cancer 107: 541-550. 
Ulisse, S., E. Baldini, S. Sorrenti and M. D'Armiento. (2009). The urokinase plasminogen activator system: A 
target for anti-cancer therapy. Current Cancer Drug Targets 9: 32-71. 
Uribe, P. and S. Gonzalez. (2011). Epidermal growth factor receptor (egfr) and squamous cell carcinoma of the 
skin: Molecular bases for egfr-targeted therapy. Pathology - Research and Practice 207: 337-342. 
Van Haren, R., D. Feldman and A. A. Sinha. (2009). Systematic comparison of nonmelanoma skin cancer 
microarray datasets reveals lack of consensus genes. British Journal of Dermatology 161: 1278-1287. 
Vasconcelos, L., J. C. Melo, H. A. Miot, M. E. A. Marques and L. P. F. Abbade. (2014). Invasive head and neck 
cutaneous squamous cell carcinoma: Clinical and histopathological characteristics, frequency of local 
recurrence and metastasis. Anais Brasileiros de Dermatologia 89: 562-568. 
Veldman-Jones, M. H., R. Brant, C. Rooney, C. Geh, H. Emery, C. G. Harbron, M. Wappett, A. Sharpe, M. 
Dymond, J. C. Barrett, E. A. Harrington and G. Marshall. (2015). Evaluating robustness and sensitivity 
of the nanostring technologies ncounter platform to enable multiplexed gene expression analysis of 
clinical samples. Cancer Research 75: 2587-2593. 
Venables, Z., P. Autier, T. Nijsten, K. F. Wong, S. M. Langan, B. Rous, J. Broggio, C. Harwood, K. Henson, C. 
M. Proby, J. Rashbass and I. Leigh. (2018). Nationwide incidence of metastatic cutaneous squamous 
cell carcinoma in england. JAMA Dermatol 155: 298-306. 
 292 
 
Veness, M. and J. Howle. (2016). Management of nodal metastases. High-risk cutaneous squamous cell 
carcinoma: A practical guide for patient management. C. D. Schmults. Berlin, Heidelberg, Springer 
Berlin Heidelberg. 189-211. 
Veness, M. J., S. Porceddu, C. E. Palme and G. J. Morgan. (2007). Cutaneous head and neck squamous cell 
carcinoma metastatic to parotid and cervical lymph nodes. Head & Neck 29: 621-631. 
Verjans, E.-T., J. Doijen, W. Luyten, B. Landuyt and L. Schoofs. (2018). Three-dimensional cell culture models 
for anticancer drug screening: Worth the effort? Journal of Cellular Physiology 233: 2993-3003. 
Verschraegen, C. F., W. Hu, Y. Du, J. Mendoza, J. Early, M. Deavers, R. S. Freedman, R. C. Bast, A. P. 
Kudelka, J. J. Kavanagh and B. C. Giovanella. (2003). Establishment and characterization of cancer cell 
cultures and xenografts derived from primary or metastatic mullerian cancers. Clinical Cancer 
Research 9: 845-852. 
Verweij, J., M. Clavel and B. Chevalier. (1994). Paclitaxel (taxoltm) and docetaxel (taxoteretm): Not simply two 
of a kind. Japanese Society of Medical Oncology 5: 495-505. 
Verweij, J. and H. M. Pinedo. (1990). Mitomycin c: Mechanism of action, usefulness and limitations. Anticancer 
Drugs 1: 5-13. 
Vidimos, A. and T. Stultz. (2015). Evaluation for locoregional and distant metastases in cutaneous squamous cell 
and basal cell carcinoma. Uptodate. J. K. Robinson and R. Corona. UpToDate, Waltham, MA. 
(Accessed on March 22, 2016). 
Visentin, M., R. Zhao and I. D. Goldman. (2012). The antifolates. Hematology/oncology clinics of North 
America 26: 629. 
Wallden, B., J. Storhoff, T. Nielsen, N. Dowidar, C. Schaper, S. Ferree, S. Liu, S. Leung, G. Geiss, J. Snider, T. 
Vickery, S. R. Davies, E. R. Mardis, M. Gnant, I. Sestak, M. J. Ellis, C. M. Perou, P. S. Bernard and J. 
S. Parker. (2015). Development and verification of the pam50-based prosigna breast cancer gene 
signature assay. BMC Med Genomics 8: 54. 
Walter, M. N. M., K. T. Wright, H. R. Fuller, S. MacNeil and W. E. B. Johnson. (2010). Mesenchymal stem cell-
conditioned medium accelerates skin wound healing: An in vitro study of fibroblast and keratinocyte 
scratch assays. Experimental Cell Research 316: 1271-1281. 
Wang, H., C. Horbinski, H. Wu, Y. Liu, S. Sheng, J. Liu, H. Weiss, A. J. Stromberg and C. Wang. (2016). 
Nanostringdiff: A novel statistical method for differential expression analysis based on nanostring 
ncounter data. Nucleic Acids Research 44: 151. 
Wang, J. T., C. E. Palme, G. J. Morgan, V. Gebski, A. Y. Wang and M. J. Veness. (2012). Predictors of outcome 
in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph 
nodes: Improved survival with the addition of adjuvant radiotherapy. Head and Neck 34: 1524-1528. 
Wang, S. J., S. Asthana, A. van Zante, C. M. Heaton, J. Phuchareon, L. Stein, S. Higuchi, T. Kishimoto, C. Y. 
Chiu, A. B. Olshen, F. McCormick and O. Tetsu. (2017). Establishment and characterization of an oral 
tongue squamous cell carcinoma cell line from a never-smoking patient. Oral Oncology 69: 1-10. 
Wang, Z., Y. Wang, F. Farhangfar, M. Zimmer and Y. Zhang. (2012). Enhanced keratinocyte proliferation and 
migration in co-culture with fibroblasts. PLoS ONE 7: e40951. 
Ward, M. C., C. Shah, D. J. Adelstein, J. L. Geiger, J. A. Miller, S. A. Koyfman and M. E. Singer. (2017). Cost-
effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncology 74: 49-55. 
Warde-Farley, D., S. L. Donaldson, O. Comes, K. Zuberi, R. Badrawi, P. Chao, M. Franz, C. Grouios, F. Kazi, 
C. T. Lopes, A. Maitland, S. Mostafavi, J. Montojo, Q. Shao, G. Wright, G. D. Bader and Q. Morris. 
(2010). The genemania prediction server: Biological network integration for gene prioritization and 
predicting gene function. Nucleic Acids Research 38: 214-220. 
Wei, W., Y. Chen, J. Xu, Y. Zhou, X. Bai, M. Yang and J. Zhu. (2018). Identification of biomarker for 
cutaneous squamous cell carcinoma using microarray data analysis. Journal of Cancer 9: 400-406. 
Weigelt, B., C. M. Ghajar and M. J. Bissell. (2014). The need for complex 3d culture models to unravel novel 
pathways and identify accurate biomarkers in breast cancer. Advanced Drug Delivery Reviews42-51. 
Weinstein, I. B. and A. Joe. (2008). Oncogene addiction. Cancer Research 68: 3077-3080. 
Weinstein, J. N. (2012). Cell lines battle cancer. Nature 483: 544. 
Weis, S., I. C. Llenos, J. R. Dulay, M. Elashoff, F. Martínez-Murillo and C. L. Miller. (2007). Quality control for 
microarray analysis of human brain samples: The impact of postmortem factors, rna characteristics, and 
histopathology. Journal of Neuroscience Methods 165: 198-209. 
Wick, M. R. and J. L. Hornick. (2011). Chapter 4 - immunohistology of soft tissue and osseous neoplasms. 
Diagnostic immunohistochemistry (third edition). D. J. Dabbs. Philadelphia, W.B. Saunders. 83-136. 
Wigerup, C., S. Påhlman and D. Bexell. (2016). Therapeutic targeting of hypoxia and hypoxia-inducible factors 
in cancer. Pharmacology & Therapeutics 164: 152-169. 
Wiggins, H. L., J. M. Wymant, F. Solfa, S. E. Hiscox, K. M. Taylor, A. D. Westwell and A. T. Jones. (2015). 
Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. 
Biochemical pharmacology 93: 332-342. 
 293 
 
Wilding, J. L. and W. F. Bodmer. (2014). Cancer cell lines for drug discovery and development. Cancer 
Research 74: 2377-2384. 
Xu, J. and Y. Cao. (2014). Radiation-induced carotid artery stenosis: A comprehensive review of the literature. 
Interventional neurology 2: 183-192. 
Yanagi, T., S. Kitamura and H. Hata. (2018). Novel therapeutic targets in cutaneous squamous cell carcinoma. 
Frontiers in oncology 8: 79-79. 
Yanofsky, V. R., S. E. Mercer and R. G. Phelps. (2011). Histopathological variants of cutaneous squamous cell 
carcinoma: A review. Journal of Skin Cancer 2011: 210813. 
Yao, Z., R. Moy, T. Allen and B. Jansen. (2017). An adhesive patch-based skin biopsy device for molecular 
diagnostics and skin microbiome studies. Journal of drugs in dermatology 16: 979-986. 
Yap, T. A., A. Macklin-Doherty and S. Popat. (2017). Continuing egfr inhibition beyond progression in 
advanced non-small cell lung cancer. European Journal of Cancer 70: 12-21. 
Yesantharao, P., W. Wang, N. M. Ioannidis, S. Demehri, A. S. Whittemore and M. M. Asgari. (2017). Cutaneous 
squamous cell cancer (cscc) risk and the human leukocyte antigen (hla) system. Human immunology 78: 
327-335. 
Yoshimura, N., S. Kudoh, T. Kimura, S. Mitsuoka, K. Matsuura, K. Hirata, K. Matsui, S. Negoro, K. Nakagawa 
and M. Fukuoka. (2006). Ekb-569, a new irreversible epidermal growth factor receptor tyrosine kinase 
inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to 
gefitinib. Lung Cancer 51: 363-368. 
Zhang, B., X. Cao, Y. Liu, W. Cao, F. Zhang, S. Zhang, H. Li, L. Ning, L. Fu, Y. Niu, R. Niu, B. Sun and X. 
Hao. (2008). Tumor-derived matrix metalloproteinase-13 (mmp-13) correlates with poor prognoses of 
invasive breast cancer. BMC cancer 8: 83. 
Zhang, J., J. Jia, F. Zhu, X. Ma, B. Han, X. Wei, C. Tan, Y. Jiang and Y. Chen. (2012). Analysis of bypass 
signaling in egfr pathway and profiling of bypass genes for predicting response to anticancer egfr 
tyrosine kinase inhibitors. Molecular BioSystems 8: 2645-2656. 
Zhang, X., M. Zhang, Y. Hou, L. Xu, W. Li, Z. Zou, C. Liu, A. Xu and S. Wu. (2016). Single-cell analyses of 
transcriptional heterogeneity in squamous cell carcinoma of urinary bladder. Oncotarget 7: 66069-
66076. 
Zhang, Y. and T. Hunter. (2014). Roles of chk1 in cell biology and cancer therapy. International Journal of 
Cancer 134: 1013-1023. 
Zhao, B., L. Wang, H. Qiu, M. Zhang, L. Sun, P. Peng, Q. Yu and X. Yuan. (2017). Mechanisms of resistance to 
anti-egfr therapy in colorectal cancer. Oncotarget 8: 3980-4000. 
Zheng, C., Y.-h. Sun, X.-l. Ye, H.-q. Chen and H.-b. Ji. (2011). Establishment and characterization of primary 
lung cancer cell lines from chinese population. Acta Pharmacologica Sinica 32: 385-392. 
Zheng, L.-Q., R. Wang, S.-M. Chi and C.-X. Li. (2017). Matrix metalloproteinase 1: A better biomarker for 
squamous cell carcinoma by multiple microarray analyses. Giornale Italiano di Dermatologia e 
Venereologia. 
Zhou, J., D. Tao, Q. Xu, Z. Gao and D. Tang. (2015). Expression of e-cadherin and vimentin in oral squamous 
cell carcinoma. International journal of clinical and experimental pathology 8: 3150-3154. 
Zhu, J.-W., X.-J. Wu, Z.-F. Lu, D. Luo, S.-Q. Cai and M. Zheng. (2013). Role of vegf receptors in normal and 
psoriatic human keratinocytes: Evidence from irradiation with different uv sources. PLoS ONE 8: 
55463-55463. 
Zilberg, C., M. W. Lee, B. Yu, B. Ashford, S. Kraitsek, M. Ranson, K. Shannon, M. Cowley, N. G. Iyer, C. E. 
Palme, S. Ch'ng, T. H. Low, S. O'Toole, J. R. Clark and R. Gupta. (2017). Analysis of clinically 
relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Modern 
Pathology 31: 275-287. 
Zilberg, C., M. Weica-Lee, M. Gauthier, M. Cowley, S. Kraitsek, B. Ashford, M. Ranson, K. Shannon, N. G. 
Iyer, S. Ch’ng, T.-H. Low, C. Palme, J. Clark, B. Yu and R. Gupta. (2018). Cutaneous squamous cell 
carcinoma of the head and neck shows significant genetic diversity despite clinical and morphologic 
homogeneity. 
Zimmer, A. and P. S Steeg. (2014). Meaningful prevention of breast cancer metastasis: Candidate therapeutics, 
preclinical validation, and clinical trial concerns. Journal of Molecular Medicine (Berlin, Germany) 93. 
Zschenker, O., T. Streichert, S. Hehlgans and N. Cordes. (2012). Genome-wide gene expression analysis in 
cancer cells reveals 3d growth to affect ecm and processes associated with cell adhesion but not DNA 
repair. PLoS ONE 7: e34279. 
  
 294 
 
APPENDICES 
APPENDIX A: CULTURE MEDIA 
Table A-1 PDCC culture media ingredients.  
Media Components 
DMEM 
 
DMEM high-glucose (4,500 mg/mL) (ThermoFisher Scientific, USA) 
0-10 % FCS (Bovogen Biologicals, Australia) 
1 % penicillin and streptomycin (ThermoFisher Scientific, USA) 
Advanced Media 
(ADMEM) 
Advanced DMEM/F12 (ThermoFisher Scientific, USA) 
0.01 % (20 ng/mL) hEGF (ThermoFisher Scientific, USA) 
1 % penicillin and streptomycin (ThermoFisher Scientific, USA) 
1 % L-glutamine (Sigma-Aldrich, USA) 
0-5 % FCS (Bovogen Biologicals, Australia) 
Serum-free 
Spheroid Media 
Advanced DMEM/F12 (ThermoFisher Scientific, USA) 
1 % N2 (ThermoFisher Scientific, USA) 
0.02 % EGF (ThermoFisher Scientific, USA) 
0.01 % bFGF (ThermoFisher Scientific, USA) 
1 % penicillin and streptomycin (ThermoFisher Scientific, USA) 
1 % L-glutamine (Sigma-Aldrich, USA) 
0.01 % Hydrocortisone (Sigma-Aldrich, USA) 
 
 
 
 
 
 
 
  
 295 
 
APPENDIX B: GENETICIN TREATED CELLS 
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Figure B-1 Effect of different concentrations of G418 on early passage PDCCs after 72 hours. There was no 
obvious cell death attributed to the G418 at concentrations ≤ 50 µg/mL. Due to the squamous morphology of 
cSCC cells it was also not clear whether any reduced population was fibroblasts or carcinoma. As such, other 
methods of purification were implemented. 
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APPENDIX C: CLINOCOPATHOLOGIC CHARACTERISTICS OF TUMOURS INCLUDED IN THIS STUDY 
Table C-1 Clinicopathologic details of the tumours included in the study. FFPE = formalin-fixed, paraffin-embedded. The median age across the patients is 76 and mostly 
males. 
Sample Cohort 
Normal skin 
taken 
 % tumour 
cellularity 
Storage Primary location 
Age at  
resection 
Sex TNM 
Immuno- 
suppression 
SP08-10295 PRIMARY NO MET N na FFPE Forehead/cheek 84 M T2N0M0 N 
SP10-13718 PRIMARY NO MET N na FFPE Forehead 63 F TxN0M0 N 
SP11-011125 PRIMARY NO MET Y na FFPE Ear 74 M T2N0M0 N 
SP11-13104 PRIMARY NO MET Y na FFPE Pre-auricular 62 M T2N0M0 N 
SP-12-020061 PRIMARY NO MET N na FFPE na 58 M na Y 
SP12-14482 PRIMARY NO MET Y na FFPE Scalp 83 M T2N0M0 N 
SP12-15701 PRIMARY NO MET Y na FFPE Forehead 92 F T4N0M0 na 
SP13-06090 PRIMARY NO MET N na FFPE Nose 67 M T1N0M0 na 
SP14-07257 PRIMARY NO MET Y na FFPE Ear 76 M T2N0M0 Y 
SP-15-012970 PRIMARY NO MET N na FFPE Scalp 84 M T2N0M0 N 
SP-15-025623 PRIMARY NO MET N na FFPE Upper lip 65 M T2N0M0 N 
SP-17-027309 PRIMARY NO MET N na FFPE Ear 69 M T3N0M0 na 
SP-03-012507 PRIMARY MET N na FFPE Parotid 84 M na N 
SP-09-007323 PRIMARY MET N na FFPE Forehead 63 M Tx2bMx N 
SP-12-003231 PRIMARY MET N na FFPE Cheek 59 M T1N0M0 Y 
SP-13-004443 PRIMARY MET N na FFPE Ear 77 M T2N2bMx N 
SP-16-004706 PRIMARY MET N na FFPE Postauricular 62 M T2N1M0 N 
1748 LN MET N 50 Fresh-frozen na 90 M T0N2aM0 na 
183410 LN MET N na Fresh-frozen Lip 31 M TxN3bM0 N 
184577 LN MET N 95 Fresh-frozen Ear 78 M T0N3bMx N 
193958 LN MET N 70 Fresh-frozen na 73 M TxN3bM0 N 
  
 
2
9
7
 
200971 LN MET N 80 Fresh-frozen Lower lip 63 M TxN2cM0 N 
22743 LN MET N 95 Fresh-frozen Scalp 76 M T0N2bM0 N 
285248 LN MET N 65 Fresh-frozen na 66 M TxN1M0 na 
28611 LN MET N 60 Fresh-frozen Scalp, neck, cheek 81 M TxN2bM0 na 
296533 LN MET N 60 Fresh-frozen Ear 88 M T0N2bM0 na 
31537 LN MET Y 45 Fresh-frozen na 91 F TxN1M0 N 
321773 LN MET N 30 Fresh-frozen Ipsi forehead 77 M TxN2bM0 N 
33432 LN MET N 90 Fresh-frozen Cheek 69 M T0N3bM0 Y 
34366 LN MET N 70 Fresh-frozen na 87 M TxN2bM0 N 
34934 LN MET Y 60 Fresh-frozen na 87 M TxN3bM0 N 
35562 LN MET N na Fresh-frozen Forehead 66 M T2N3bM0 Y 
35649 LN MET N 70 Fresh-frozen Scalp 63 M T2N3bM0 N 
35818 LN MET N 80 Fresh-frozen na 69 M TxN3bM0 N 
38532 LN MET N na Fresh-frozen Nose 77 M TxN3bM0 N 
4699 LN MET N 70 Fresh-frozen Right pinna 77 M TxN3bM0 N 
48585 LN MET N 10 Fresh-frozen Cheek 78 F TxN3bM0 N 
658492 LN MET Y na Fresh-frozen na 86 M TxN2bM0 na 
9120 LN MET N 70 Fresh-frozen Left scalp 66 M TxN2bM0 N 
SP-12-11353 LN MET N na FFPE Ear 72 M T3N0M0 N 
SP-13-000340 LN MET N na FFPE Tempora 79 M T4N2bMx N 
SP-16-009972 LN MET N na FFPE Scalp 72 M T3N2bM0 N 
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APPENDIX D: INFLUENCE OF ATMOSPHERE ON CELL GROWTH 
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Figure D-1 Micrograph images of metastatic cSCC cell lines grown over 72 hours in normoxic and hypoxic 
conditions. Original seeding density was 4 × 104 cells/cm2. Cellular debris can be seen floating in normoxic 
treated samples, particularly with UW-CSCC1-R. 
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APPENDIX E: SPHEROID SEEDING OPTIMISATION 
 
Figure E-1 Optimisation of spheroid/aggregate seeding density. UW-CSCC1 spheroids and UW-CSCC-R aggregates grown in DMEM supplemented with 4,500 mg/mL 
glucose, 10 % FCS and 1 % penicillin and streptomycin. Cell lines were seeded at varying densities (cells/well) into low-attachment, round-bottomed 96-well plates, and 
imaged after 48 h at 10× objective. Representative images are shown of n=5. Image courtesy of Miss Gretel Major. 
 
 
Figure E-2 Optimisation of spheroid/aggregate seeding density. UW-CSCC2 cells grown in DMEM supplemented with 4,500 mg/mL glucose, 10 % FCS and 1 % penicillin 
and streptomycin. Cell lines were seeded at varying densities (cells/well) into low-attachment, round-bottomed 96-well plates, and imaged after 48 h at 10× objective. 
Representative images are shown of n=5. 
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APPENDIX F: COLLAGEN I PROTEIN DETERMINATION 
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Figure F-1 Standard curve of commercial collagen I (3 mg/mL) determined using a modified Lowry assay. 
Samples A, B and C represent extracted collagen I samples diluted 1/9, 1/6/ and 1/3 respectively. Derivations of 
concentration are shown below in Table F1. 
 
Table F-1 Concentration of extracted collagen I, as determined from extrapolating data from the commercial 
collagen I standard curve above (Figure F1).  
Sample 
(Dilution) 
Concentration 
(mg/mL) 
Dilution-corrected 
Concentration (mg/mL) 
Std Dev 
A (1/9) 0.516 4.6 ± 0.038 
B (1/6) 0.861 5.2 ± 0.039 
C (1/3) 1.674 5.0 ± 0.073 
 
 
Figure F-2 Concentrations of in-house collagen I were inferred from a separate protein determination assay. 
Lane 1, Precision Plus Protein Dual Colour Standards; Lane 2, commercial collagen I (30 ng); Lane 3, 
commercial collagen I (50 ng); Lane 4, In-house collagen I (~25 ng); Lane 5, In-house collagen (~42 ng); Lane 
6, In-house collagen I (~19 ng); Lane 7, In-house collagen I (~31 ng). Three distinct bands were observed in 
both the in-house derived collagen I as well as the commercial stock, corresponding with the collagen I 
monomers, alpha-1 chain and alpha-2 chain. As collagen I is a triple helix consisting of one alpha-2 chain and 
two alpha-1 chains, the third band is the dimeric form of alpha-1 (~270 kDa). 
Dimer 
α-1 chain 
α-2 chain 
A 
B 
C 
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APPENDIX G: QPCR KIT OPTIMISATION 
 
Figure G-1 A) Relative uPAR expression for the PDCC UW-CSCC1 was compared using SYBR green qPCR 
mixes from Biosystems, Bioline, and Sigma. Each target and reference reaction contained 20 ng and 2 ng of 
cDNA template, respectively. Samples were run in a LightCycler®480 (Roche, Switzerland) real-time PCR 
system and analysed using basic relative quantification. MDA-MB-231 cells and tumour tissue also shown were 
amplified using the Biosystems SYBR green qPCR mix. B) qPCR amplification curve of fluorescence vs cycle 
number. Standards were made from uPAR-positive MDA-MB-231 at 1:5 dilutions starting from 20 ng (shown in 
brown). UW-CSCC1 amplification shown in green. 
 
Figure G-2 Photograph of ethidium bromide stained agarose gel (2 %) run with qPCR products amplified via 
qPCR kits from Applied Biosystems, Bioline, or Sigma-Aldrich. Legend shown to the right of figure. RT refers to 
reverse transcriptase and the marker used was HyperLadder™III molecular marker. The Bioline kit appeared 
too sensitive, producing a strong series of bands in a negative control (lane 14), potentially amplifying a uPAR 
contaminant. 
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APPENDIX H: VOLCANO PLOTS SHOWING DIFFERENTIAL 
EXPRESSION BETWEEN CLINICAL COHORTS 
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 304 
 
 
 
Figure H-1 Volcano plots displaying each gene’s –log10(P-value) and log2 fold change with the selected 
covariate compared to the given baseline. Highly statistically significant genes fall at the top of the plot above 
the horizontal lines, and highly differentially expressed genes fall to either side. Horizontal lines indicate 
various P-value thresholds. Genes are coloured if the resulting P-value is below the given P-value threshold. 
The 40 most statistically significant genes are labelled in the plot. 
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APPENDIX I: 86-GENE PANEL TO DISTINGUISH BETWEEN CSCC 
COHORTS 
Table I-1 List of genes discriminatory between the cSCC cohorts and normal skin. Together, these 86 genes 
may help predict a patient’s risk of subsequent metastasis upon assessment of the primary tumour. 
Gene 
ACTG2 
AGR2 
ANGPTL4 
ASPN 
BMP5 
BMPR1B 
CAMK2A 
CAMK2B 
CCL11 
CCL7 
CD36 
CDKN2A 
CHI3L1 
CHP2 
CHRDL1 
CLEC3B 
CMA1 
COL1A2 
CTSG 
CXCL10 
CXCL11 
CXCL13 
EGF 
EMILIN1 
EMILIN3 
 
FBN2 
FBP1 
FGF18 
FN1 
FOXC2 
GATA4 
GDF5 
HAS1 
HKDC1 
PTGDS 
RBM47 
RORA 
SCNN1A 
SERPINE1 
SLC44A4 
SLPI 
SPINK5 
SPOCK3 
STAB2 
SULF1 
SV2B 
TF 
TIMP4 
TJP3 
TNMD 
 
TNXB 
TPSD1 
TSPAN1 
HOXB13 
HUNK 
IBSP 
IL11 
INHBA 
ISL1 
ISLR 
ITGA11 
ITGA5 
ITGA8 
ITGB7 
ITM2A 
KRT1 
LAMC2 
LRG1 
MGP 
MISP 
MMP1 
MMP10 
MMP12 
MMP13 
MMP3 
 
MYH11 
NAP1L3 
OCLN 
OGN 
PITX2 
PLA2G2A 
PLA2G2D 
POPDC3 
PPL 
PRELP 
PROM1 
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APPENDIX J: MUTATIONAL BURDEN AND FREQUENT VARIANTS 
IN CSCC 
 
 
Figure J-1 Mutation frequency in cSCC compared with other tumour types. Median value is shown and 
indicated by the horizontal line. Image courtesy of Dr Bruce Ashford. 
 
Figure J-2 High impact and frequency single variants across 14 metastatic cSCC. The right side of the panel 
shows the number of short variants per sample. Coloured tiles relate to variant type shown in the legend. 
Percentages on the top of the figure refer to the frequency of the variant occurring across the 14 samples. Image 
courtesy of Dr Bruce Ashford. 
cSCC 
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APPENDIX K: LIST OF POTENT COMPOUNDS FROM HTS SCREEN 
Table K-1 Top 40 compounds from anti-cancer library against UW-CSCC1. All tested at 1 µM. 
Compound UW-CSCC1 Pathway Target 
Flavopiridol (Alvocidib) 98.2 Cell Cycle CDK 
Daunorubicin HCl 97.61 DNA Damage Telomerase 
Elesclomol 97.6 Angiogenesis HSP 
MLN2238 97.18 Proteases Proteasome 
Bortezomib (Velcade) 97.15 Proteases Proteasome 
Topotecan HCl 96.98 DNA Damage Topoisomerase 
PIK-75 96.96 PI3K/Akt/mTOR DNA-PK, PI3K 
Flavopiridol (Alvocidib) HCl 96.69 Cell Cycle CDK 
MLN9708 96.66 Proteases Proteasome 
SNS-032 (BMS-387032) 96.53 Other CDK 
Doxorubicin (Adriamycin) 95.71 DNA Damage Topoisomerase 
Triptolide 95.48 Other Other 
Gemcitabine (Gemzar) 95.3 DNA Damage Other 
Clofarabine 94.78 DNA Damage DNA/RNA Synthesis 
Disulfiram (Antabuse) 94.68 Other Other 
Ganetespib (STA-9090) 94.52 Other HSP 
Romidepsin 94.32 Cytoskeletal Signalling HDAC 
Mitoxantrone HCl 94.23 Other Other 
MK-1775 94.09 Cell Cycle Wee1 
Mitoxantrone 94.03 Cell Cycle Topoisomerase 
HSP990 (NVP-HSP990) 93.8 Cytoskeletal Signalling HSP (e.g. HSP90) 
17-DMAG HCl  93.46 Other HSP 
AUY922 (NVP-AUY922) 93.16 Other HSP 
Teniposide (Vumon) 93.04 Other Other 
Vinorelbine Tartrate 92.76 Cytoskeletal Signalling Microtubule Associated 
AZD7762 92.63 Cell Cycle Chk 
JNJ-26481585 91.97 Other HDAC 
Geldanamycin 91.58 Cytoskeletal Signalling HSP 
BIIB021 90.39 Cytoskeletal Signalling HSP 
AT7519 HCl 90.34 Cell Cycle CDK 
Torin 2 89.92 PI3K/Akt/mTOR mTOR 
Vincristine 89.39 Cytoskeletal Signalling 
Autophagy, Microtubule 
Associated 
AT7519 89.29 Cell Cycle CDK 
Epothilone A 88.56 Cytoskeletal Signalling Microtubule Associated 
VER-50589 88.24 Cytoskeletal Signalling HSP (e.g. HSP90) 
Plinabulin (NPI-2358) 87.24 Angiogenesis VDA 
Obatoclax mesylate  87.09 Neuronal Signalling BclOther2 
KX2-391 87.07 Angiogenesis Src 
Docetaxel (Taxotere) 87.01 Other Microtubule Associated 
Trichostatin A (TSA) 86.88 Other HDAC 
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Table K-2 Top 40 compounds from anti-cancer library against UW-CSCC1-R. All tested at 1 µM. 
Compound UW-CSCC1-R Pathway Target 
Flavopiridol (Alvocidib) 98.32 Cell Cycle CDK 
MLN9708 98.28 Proteases Proteasome 
AZD7762 97.95 Cell Cycle Chk 
Daunorubicin HCl  97.89 DNA Damage Telomerase 
MLN2238 97.66 Proteases Proteasome 
PIK-75 97.55 PI3K/Akt/mTOR DNA-PK, PI3K 
Elesclomol 97.47 Angiogenesis HSP 
Bortezomib (Velcade) 97.41 Proteases Proteasome 
Clofarabine 97 DNA Damage DNA/RNA Synthesis 
Flavopiridol  HCl 96.96 Cell Cycle CDK 
Topotecan HCl 96.88 DNA Damage Topoisomerase 
Doxorubicin (Adriamycin) 96.84 DNA Damage Topoisomerase 
MK-1775 96.72 Cell Cycle Wee1 
Gemcitabine (Gemzar) 96.61 DNA Damage Other 
Vinorelbine Tartrate 95.99 Cytoskeletal Signalling Microtubule Associated 
LY2603618 (IC-83) 95.93 Cell Cycle Chk 
Teniposide (Vumon) 95.88 Other Other 
Mitoxantrone HCl 94.96 Other Other 
Triptolide 94.65 Other Other 
CYT997 (Lexibulin) 94.24 Cytoskeletal Signalling Microtubule Associated 
Mitoxantrone 94.06 Cell Cycle Topoisomerase 
SNS-032 (BMS-387032) 94.01 Other CDK 
SF1670 93.94 Other Other 
Romidepsin 93.74 Cytoskeletal Signalling HDAC 
JNJ-26481585 93.64 Other HDAC 
Torin 2 93.57 PI3K/Akt/mTOR mTOR 
Epothilone A 93.48 Cytoskeletal Signalling Microtubule Associated 
Ganetespib (STA-9090) 93.18 Other HSP 
BIIB021 92.58 Cytoskeletal Signalling HSP 
CH5138303 92.44 Cytoskeletal Signalling HSP (e.g. HSP90) 
Vincristine 92.32 Cytoskeletal Signalling 
Autophagy, Microtubule 
Associated 
PU-H71 92.1 Cytoskeletal Signalling HSP 
Voreloxin (SNS-595) 91.96 DNA Damage Topoisomerase 
17-DMAG HCl 91.88 Other HSP 
Obatoclax mesylate 91.67 Neuronal Signalling BclOther2 
Docetaxel (Taxotere) 91.47 Other Microtubule Associated 
KX2-391 91.28 Angiogenesis Src 
HSP990 (NVP-HSP990) 91.27 Cytoskeletal Signalling HSP (e.g. HSP90) 
Disulfiram (Antabuse) 90.85 Other Other 
Plinabulin (NPI-2358) 90.69 Angiogenesis VDA 
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Table K-3 Top 40 compounds from kinase-inhibitor library against UW-CSCC1. All tested at 1 µM. 
Compound UW-CSCC1 Pathway Target 
PIK-75 97.85 PI3K/Akt/mTOR DNA-PK, PI3K 
BGT226 (NVP-BGT226) 97.62 PI3K/Akt/mTOR mTOR, PI3K 
Dinaciclib (SCH727965) 96.02 Cell Cycle CDK 
SNS-032 (BMS-387032) 95.9 Other CDK 
Flavopiridol HCl 95.63 Cell Cycle CDK 
Staurosporine 94.9 TGFO-beta/Smad PKC 
CUDC-907 94.81 Cytoskeletal Signalling HDAC, PI3K 
Flavopiridol (Alvocidib) 93.6 Cell Cycle CDK 
AZD7762 89.55 Cell Cycle Chk 
KX2-391 88.63 Angiogenesis Src 
Torin 2 85.43 PI3K/Akt/mTOR mTOR 
Hesperadin 81.4 Cell Cycle Aurora Kinase 
CHIR-124 77.59 Cell Cycle Chk 
AT7519 77.38 Cell Cycle CDK 
VE-822 77.22 PI3K/Akt/mTOR ATM/ATR 
Rigosertib (ON-01910) 76.97 Cell Cycle PLK 
PHA-793887 74.79 Cell Cycle CDK 
FIIN-2 73.99 Protein Tyrosine Kinase FGFR 
JNK Inhibitor IX 72.68 MAPK JNK 
PF-3758309 72.26 Cytoskeletal Signalling PAK 
LY2603618 70.49 Cell Cycle Chk 
Mubritinib (TAK 165) 69.62 Protein Tyrosine Kinase HER2 
PF-477736 69.23 Cell Cycle Chk 
Ro3280 68.26 Cell Cycle PLK 
INK 128 (MLN0128) 66.91 PI3K/Akt/mTOR mTOR 
Tivantinib (ARQ 197) 66.52 Protein Tyrosine Kinase c-Met 
AZD8055 66.27 PI3K/Akt/mTOR mTOR 
ENMD-2076 65.96 Angiogenesis Aurora Kinase, Flt, VEGFR 
Trametinib 65.78 MAPK MEK 
GSK1059615 64.27 PI3K/Akt/mTOR mTOR, PI3K 
GSK461364 64.18 Cell Cycle PLK 
PF-04691502 61.01 PI3K/Akt/mTOR Akt, mTOR, PI3K 
PD173074 60.98 Angiogenesis FGFR, VEGFR 
CX-6258 HCl 60.63 JAK/STAT Pim 
AZD2014 60.27 PI3K/Akt/mTOR mTOR 
Tyrphostin 9 58.58 Protein Tyrosine Kinase EGFR 
WYE-125132  56.76 PI3K/Akt/mTOR mTOR 
Volasertib (BI 6727) 56.44 Cell Cycle PLK 
CCT137690 56.38 Cell Cycle Aurora Kinase 
Dasatinib 56.15 Angiogenesis Bcr-Abl, c-Kit, Src 
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Table K-4 Top 40 compounds from kinase-inhibitor library against UW-CSCC1-R. All tested at 1 µM. 
Compound UW-CSCC1-R Pathway Target 
PIK-75 98.43 PI3K/Akt/mTOR DNA-PK, PI3K 
SNS-032 (BMS-387032) 97.94 Other CDK 
BGT226 (NVP-BGT226) 97.84 PI3K/Akt/mTOR mTOR, PI3K 
VE-822 97.36 PI3K/Akt/mTOR ATM/ATR 
Dinaciclib (SCH727965) 97.17 Cell Cycle CDK 
LY2603618 97.07 Cell Cycle Chk 
CHIR-124 96.93 Cell Cycle Chk 
Flavopiridol HCl 96.75 Cell Cycle CDK 
AZD7762 96.64 Cell Cycle Chk 
Staurosporine 96.42 TGFO-beta/Smad PKC 
Flavopiridol (Alvocidib) 95.26 Cell Cycle CDK 
CUDC-907 95.15 Cytoskeletal Signalling HDAC, PI3K 
KX2-391 95.09 Angiogenesis Src 
PF-477736 94.94 Cell Cycle Chk 
MK-8776 (SCH 900776) 92.22 Cell Cycle CHK 
Torin 2 91.96 PI3K/Akt/mTOR mTOR 
AZ20 90.96 PI3K/Akt/mTOR ATM/ATR 
PF-3758309 90.13 Cytoskeletal Signalling PAK 
GSK461364 90 Cell Cycle PLK 
Ro3280 88.91 Cell Cycle PLK 
AP26113 88.61 Protein Tyrosine Kinase ALK 
Hesperadin 86.63 Cell Cycle Aurora Kinase 
JNK Inhibitor IX 85.9 MAPK JNK 
CX-6258 HCl 85.01 JAK/STAT Pim 
Tivantinib (ARQ 197) 83 Protein Tyrosine Kinase c-Met 
Rigosertib (ON-01910) 81.59 Cell Cycle PLK 
R428 (BGB324) 81.48 Protein Tyrosine Kinase Other 
BI 2536 78.72 Other PLK 
Volasertib (BI 6727) 76.4 Cell Cycle PLK 
Mubritinib (TAK 165) 75.15 Protein Tyrosine Kinase HER2 
Milciclib (PHA-848125) 74.7 Cell Cycle CDK 
AZ 960 72.11 JAK/STAT JAK 
INK 128 (MLN0128) 68 PI3K/Akt/mTOR mTOR 
GSK1059615 67.63 PI3K/Akt/mTOR mTOR, PI3K 
Tyrphostin 9 66.39 Protein Tyrosine Kinase EGFR 
AZD6738 66.15 PI3K/Akt/mTOR ATM/ATR 
Pelitinib (EKB-569) 65.6 Protein Tyrosine Kinase EGFR 
AZD8055 59.52 PI3K/Akt/mTOR mTOR 
PF-04691502 58.26 PI3K/Akt/mTOR Akt, mTOR, PI3K 
SNS-314 Mesylate 58.16 Other Aurora Kinase 
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APPENDIX L: OPTIMISED 3D DRUG SCREENING METHOD FOR 
DETERMINATION OF VIABILITY 
 
Figure L-1 Representative fluorescence microscopy images (n=4 spheroids) of calcein AM/PI stained UW-
CSCC1 spheroids and UW-CSCC1-R aggregates treated with A) 5-fluorouracil and B) cisplatin. 
Spheroid/aggregates were allowed to form for 48 h prior to drug addition. At 72 hours post treatment the cells 
were incubated with calcein AM and PI for 20 min, washed and then and imaged at 20× objective. 
Overexposure of some images is due to fluorescence exposure being kept constant across cell lines and all 
experiments. These experiments were conducted by Miss Gretel Major in fulfilment of her honours project, 2018. 
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APPENDIX M: CYTOTOXIC SCREENING OF ANTI-UPA/NHE1 
AMILORIDE DERIVATIVES 
 
 
Figure M-1 UW-CSCC1 cell survival following 72 hour exposure to anti-uPA/NHE1 drugs, BB2-30F and HM2-
74. Response to vehicle control is also shown for comparison. HM2-74 resulted in complete cell death at a 
concentration of 100 µM whilst BB2-30F remained non-cytotoxic. A concentration of 10 µM produced no 
notable cytotoxicity with any of the treatments. 
 
 
 
 
 
